Title,Authors,DOI,DOI link,Venue,Citation count,Year,Population Type,"Reasoning for ""Population Type""",Intervention,Outcome Documentation,"Reasoning for ""Outcome Documentation""",Control Group,"Reasoning for ""Control Group""",Study Design,"Reasoning for ""Study Design""",Temporal Documentation,"Reasoning for ""Temporal Documentation""",subject size,"Reasoning for ""subject size""","Reasoning for ""Intervention""",Screening judgement,"Reasoning for ""Screening judgement""",Screening score
Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline.,"N. Yarom, C. Shapiro, D. Peterson, C. V. Van Poznak, Kari Bohlke, S. Ruggiero, C. Migliorati, Aliya A. Khan, A. Morrison, Holly Anderson, B. Murphy, D. Alston-Johnson, R. Mendes, B. Beadle, S. Jensen, D. Saunders",10.1200/JCO.19.01186,https://doi.org/10.1200/JCO.19.01186,Journal of Clinical Oncology,238,2019,no,"The abstract specifically focuses on cancer patients, which explicitly contradicts the requirement for the study to focus exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",yes,yes,"The abstract clearly documents MRONJ outcomes following specific, documented dental procedures (extractions, periodontal surgery, implants, or prosthetic treatments), which meets the criterion of the study reporting MRONJ outcomes following specific, documented dental procedures.",maybe,"The abstract does not mention control groups, so it is uncertain whether the study includes a control group of non-anti-resorptive medication users.",yes,"The abstract mentions that only 10 of 132 publications were randomized controlled trials, which meets the criterion of the study design being either a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"While the abstract mentions the need for documentation, it does not specifically detail the temporal relationships between medication use and MRONJ development, or the duration of medication use, so it is uncertain whether the study clearly documents both the temporal relationship between medication use and MRONJ development and the duration of medication use.",maybe,"The abstract mentions 132 publications but does not specify individual study sizes, so it is uncertain whether the studies meet the criterion of having a subject size of more than 100 people.","The abstract discusses dentoalveolar surgery and dental procedures, which meets the criterion of the subject having an intervention of invasive dental treatment, including tooth extraction, implant placement, periodontal surgery, other dental surgery, or removable prosthesis fabrication.",Exclude,"The abstract focuses on cancer patients and bone-modifying agents, which critically conflicts with the specified screening criteria requiring non-cancer patients and Romosozumab-specific intervention. Multiple key screening requirements are not met, particularly the population type and specific medication intervention, rendering the study unsuitable for inclusion in the systematic review.",0.1
Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis,"Alvaro Limones, L. Sáez-Alcaide, S. Díaz-Parreño, A. Helm, M. Bornstein, P. Molinero-Mourelle",10.4317/medoral.23324,https://doi.org/10.4317/medoral.23324,Medicina Oral,91,2020,no,"The study specifically focuses on cancer patients, while the criteria require non-cancer patients with osteoporosis.",maybe,maybe,"While MRONJ outcomes are documented, the specific dental procedures leading to these outcomes are not detailed in the abstract.",maybe,The abstract doesn't mention a control group of non-anti-resorptive medication users.,yes,The study includes randomized controlled trials (RCTs).,yes,"The study clearly documents temporal relationships, showing outcomes at 1, 2, and 3 years of exposure.",yes,"The study includes 13,857 patients, well above the 100-person minimum.","While the study examines MRONJ, which typically follows dental procedures, the abstract doesn't explicitly state which dental procedures were involved.",Exclude,"The study focuses on cancer patients using denosumab and zoledronic acid, which fundamentally conflicts with the screening criteria requiring non-cancer osteoporosis patients using romosozumab. Critical mismatches in medication type and patient population render the study ineligible for inclusion in the systematic review. Despite meeting some methodological criteria like large sample size and study design, the core intervention and population requirements are not satisfied.",0.1
"Medication-Related Osteonecrosis of the Jaw (MRONJ): A Review of Pathophysiology, Risk Factors, Preventive Measures and Treatment Strategies","Raed Alrowis, A. Aldawood, Mohammed F. Alotaibi, Essam Alnasser, Ibrahim M. Alsaif, Abdullah Aljaber, Z. Natto",10.1016/j.sdentj.2022.01.003,https://doi.org/10.1016/j.sdentj.2022.01.003,Saudi Dental Journal,34,2022,no,"The abstract mentions both osteoporosis and cancer patients, and does not specify an adult-only population.",no,no,"While MRONJ outcomes are discussed, this is not a primary study documenting specific procedures and outcomes.",no,"No mention of control groups as this is a literature review, not a primary research study.",no,"This is explicitly a literature review, not a primary research study.",no,"While medication duration is mentioned (""less than three years""), this is not a primary study documenting temporal relationships.",no,"No specific subject size is mentioned as this is a literature review, not a primary research study.","While dental procedures are mentioned, this is a review paper discussing them generally rather than studying specific interventions.",Exclude,"This literature review fails to meet multiple critical screening criteria, including the specific intervention of Romosozumab, subject size requirements, and study design specifications. The paper discusses medication-related osteonecrosis of the jaw in general terms but lacks the precise methodological elements needed for inclusion in the systematic review. Consequently, the abstract does not qualify for further analysis based on the established screening criteria.",0.1
THE RISK OF MEDICATION‐RELATED OSTEONECROSIS OF THE JAW AFTER DENTAL EXTRACTION IS HIGHER FOR PATIENTS ON INTRAVENOUS AS COMPARED WITH ORAL ANTIRESORPTIVE DRUGS,E. Abt,10.1016/j.jebdp.2017.03.007,https://doi.org/10.1016/j.jebdp.2017.03.007,Journal of Evidence-Based Dental Practice,2,2017,no,"The abstract does not specify whether the patients were adults with diagnosed osteoporosis or if they had cancer, which is a significant uncertainty.",yes,yes,"The abstract indicates that the review looks at MRONJ outcomes following dental extraction, which meets this criterion.",maybe,"As a systematic review, the abstract likely includes studies with control groups, but this is not explicitly stated.",no,"The paper itself is a systematic review with meta-analysis, which means it analyzes other studies, but the specific study designs included in the review are not provided.",no,"The abstract mentions ""risk indicators"" but does not explicitly state whether the temporal relationships between medication use and MRONJ development, as well as the duration of medication use, are documented.",no,"The abstract does not provide information about the sample size of the studies included in the systematic review, so it is unclear if the studies had more than 100 subjects.","The abstract specifically mentions ""dental extraction"" as an intervention, which meets this criterion.",Include,"A systematic review and meta-analysis examining medication-related osteonecrosis of the jaw after dental extraction presents significant uncertainties regarding specific screening criteria. Key limitations include lack of clarity about medication type, patient population characteristics, and detailed documentation of temporal relationships and control groups. While addressing dental procedures and MRONJ outcomes, the abstract provides insufficient information to confidently confirm alignment with all predefined screening requirements.",2.8
Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis.,"É. Gaudin, L. Seidel, M. Bacevic, E. Rompen, F. Lambert",10.1111/jcpe.12455,https://doi.org/10.1111/jcpe.12455,Journal of Clinical Periodontology,96,2015,maybe,"The study includes both osteoporosis patients and cancer patients, while the criteria specifically require exclusive focus on non-cancer patients. The abstract doesn't specify age requirements.",yes,yes,The study clearly documents MRONJ outcomes following dental extraction procedures.,maybe,The abstract doesn't explicitly mention a control group of non-anti-resorptive medication users.,yes,"The abstract indicates these are prospective studies, which meets the criteria.",maybe,"While the study examines the relationship between ARD use and MRONJ, the abstract doesn't explicitly state whether it documents the duration of medication use.",maybe,"The abstract doesn't specify the total number of subjects included in the meta-analysis, so the subject size is unclear.","The study specifically focuses on dental extraction, which is one of the specified invasive dental treatments.",Exclude,"The study fails to meet critical screening criteria, specifically lacking focus on Romosozumab and including cancer patients, which deviates from the required population type. Multiple screening elements remain unclear, including subject size, control group composition, and temporal documentation of medication use. Despite addressing some relevant aspects like dental extraction and MRONJ outcomes, the fundamental misalignment with specified criteria renders the study unsuitable for inclusion.",1.4
Association between periodontitis and medication-related osteonecrosis of the jaw: a systematic review and meta-analysis.,"A. Lorenzo-Pouso, M. Pérez‐Sayáns, C. Chamorro-Petronacci, P. Gándara-Vila, P. López‐Jornet, Javier Carballo, A. García-García",10.1111/jop.12963,https://doi.org/10.1111/jop.12963,Journal of Oral Pathology & Medicine,36,2019,maybe,"The abstract does not mention specific age groups or cancer status, and only mentions ""at-risk non-affected patients"", so it is uncertain whether the population type criterion of adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer is met.",no,no,"While MRONJ is discussed, the abstract does not specify documentation of outcomes following specific dental procedures, and the focus is on periodontal disease association with MRONJ, so the outcome documentation criterion is not met.",yes,"The abstract mentions ""at-risk non-affected patients"" as controls, so the control group criterion is met.",yes,"The abstract includes cohort studies and case-control studies, so the study design criterion is met.",no,"The abstract does not mention temporal relationships or duration of medication use, so the temporal documentation criterion is not met.",maybe,"The abstract states that this is a systematic review/meta-analysis of 12 studies, but the individual study sizes are not specified, so it is uncertain whether the subject size criterion of more than 100 people is met.","While periodontal disease is discussed, the abstract does not specifically focus on invasive dental treatments, and the focus is on periodontal disease as a risk factor for MRONJ, so the intervention does not meet the criterion of invasive dental treatment.",Exclude,"The systematic review fails to meet key screening criteria, particularly the specific intervention of Romosozumab and focus on invasive dental treatments. While the study includes appropriate study designs and control groups, it fundamentally diverges from the required research parameters by examining periodontal disease's relationship to medication-related osteonecrosis of the jaw rather than the targeted intervention. Critical screening requirements around medication type, dental procedures, and population specifics were not satisfied.",1.4
Medication-Related Osteonecrosis of the Jaw in Patients Treated Concurrently with Antiresorptive and Antiangiogenic Agents: Systematic Review and Meta-Analysis,"A. Srivastava, G. N. Nogueras Gonzalez, Yimin Geng, Alexander M. Won, J. Myers, Yisheng Li, M. Chambers",10.36401/JIPO-21-14,https://doi.org/10.36401/JIPO-21-14,Journal of Immunotherapy and Precision Oncology,8,2021,no,"The abstract does not specify the age restrictions or cancer status of the study population, so it is uncertain whether this criterion is met.",no,maybe,"The abstract indicates that MRONJ outcomes are documented, but it does not provide details on the specific dental procedures that were studied, so it is only partially clear if this criterion is met.",maybe,"The study does compare antiresorptive (AR) drugs alone to concurrent antiangiogenic (AA) and AR therapy, which partially meets the requirement for a control group of non-AR users.",yes,"The abstract mentions that the study design includes retrospective cohort studies, which meets the acceptable study design criteria.",no,"The abstract does not mention the temporal relationship between medication use and MRONJ development or the duration of medication use, so it is unclear if this criterion is met.",maybe,"While the individual study sizes are not specified, the fact that the paper is a meta-analysis including 11 studies suggests that the total subject size is likely to be over 100 people, which would meet this criterion.","The abstract does not provide details on the specific types of invasive dental treatments that were studied, so it is unclear if this criterion is met.",Exclude,"The systematic review fails to meet critical screening criteria, particularly the requirement for Romosozumab as the specific anti-resorptive medication. Multiple screening elements remain uncertain, including population characteristics, dental intervention specifics, and temporal documentation of medication use. The meta-analysis's broad approach to antiresorptive drugs prevents it from satisfying the precise research parameters.",1.4
Effectiveness of treatments for medication-related osteonecrosis of the jaw: A systematic review and meta-analysis.,"M. El-Rabbany, Adam Sgro, D. Lam, P. Shah, A. Azarpazhooh",10.1016/j.adaj.2017.04.002,https://doi.org/10.1016/j.adaj.2017.04.002,The Journal of the American Dental Association (1939),65,2017,maybe,"The abstract does not specify age groups or cancer status, so it cannot be confirmed if the study meets the criteria of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",no,no,"While MRONJ outcomes are documented, they are not specifically tied to dental procedures, and the focus is on treatment effectiveness rather than procedure outcomes.",no,The study compares different treatment modalities and does not appear to include a control group of non-anti-resorptive users.,yes,"The study includes RCTs, non-randomized controlled trials, and prospective cohort studies, which meets the criterion for study design.",no,There is no mention of temporal relationships or medication duration in the abstract.,no,"The abstract mentions 13 studies with 76 participants in some analyses, which does not meet the requirement of more than 100 subjects.","While the paper discusses MRONJ, it focuses on treatment strategies rather than dental procedures, and does not specifically study dental interventions.",Exclude,"The systematic review fails to meet multiple critical screening criteria, including the specific intervention of Romosozumab, subject size requirements, and focus on invasive dental treatments. While the study design includes acceptable research methodologies, it fundamentally does not align with the targeted research parameters around osteoporosis patients and dental procedures. The paper's broad approach to MRONJ treatment strategies renders it unsuitable for the specified screening criteria.",0.1
Risk-reductive dental strategies for medication related osteonecrosis of the jaw among cancer patients: A systematic review with meta-analyses.,"Harry Karna, Jaime González, Harveen S Radia, P. Sedghizadeh, R. Enciso",10.1016/j.oraloncology.2018.08.003,https://doi.org/10.1016/j.oraloncology.2018.08.003,Oral Oncology,26,2018,no,"The study focuses exclusively on cancer patients, which fails the criterion of focusing on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",yes,yes,"The study reports MRONJ outcomes following dental procedures, which meets the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",yes,"The study mentions ""compared to similar control groups receiving no intervention"", which meets the criterion of including a control group of non-anti-resorptive medication users.",yes,"The study includes RCT, case-control, and cohort studies, which meets the criterion of having a study design of either a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"The study does not clearly document the temporal relationship between medication use and MRONJ development or the duration of medication use, so it only partially meets or is unclear on this criterion.",yes,"The study includes 2332 patients across multiple studies, which meets the criterion of having a subject size of more than 100 people.","The study mentions dental interventions and extractions, which meets the criterion of having an intervention of invasive dental treatment.",Exclude,"The systematic review focuses on cancer patients receiving antiresorptive therapy, which fundamentally conflicts with the specified screening criteria requiring non-cancer patients with osteoporosis. Critical mismatches include the population type and medication specification, rendering the study inappropriate for inclusion despite meeting several other methodological criteria. The core population and intervention do not align with the predefined screening requirements.",0.1
Medication-Related Osteonecrosis of the Jaw,"K. Yamagata, F. Uchida, N. Kanno, T. Yanagawa, H. Bukawa",10.5772/67980,https://doi.org/10.5772/67980,-,60,2017,no,"The abstract discusses both cancer and osteoporosis patients, indicating that the study is not exclusively focused on adult patients with diagnosed osteoporosis who do not have cancer.",maybe,maybe,"The abstract discusses MRONJ outcomes generally and mentions extraction sockets, which partially meets the criterion of reporting MRONJ outcomes following specific dental procedures.",maybe,The abstract does not mention the inclusion of a control group of non-anti-resorptive medication users.,no,"The abstract indicates that this appears to be a review article rather than a primary research study, and does not mention a specific study design.",no,"The abstract does not provide any specific documentation of the temporal relationship between medication use and MRONJ development, or the duration of medication use.",maybe,"The abstract does not mention the sample size of the study, so there is no information provided to determine if the subject size is more than 100 people.","The abstract mentions ""oral surgical procedures"" and ""extraction socket"", which partially meets the criterion of invasive dental treatment, but lacks specific details.",Exclude,"The abstract fails to meet critical screening criteria, particularly the requirement for Romosozumab as the specific intervention and an exclusive focus on non-cancer osteoporosis patients. Multiple key elements are missing, including specific study design, control group details, and precise documentation of temporal medication relationships. The text appears to be a general review of medication-related osteonecrosis rather than a targeted research study meeting the predefined screening requirements.",0.1
Medication-related Osteonecrosis of the Jaw: A Review,"Nouf A. AlDhalaan, Asma BaQais, Ahmad Al-Omar",10.7759/cureus.6944,https://doi.org/10.7759/cureus.6944,Cureus,75,2020,no,"The abstract discusses both cancer and non-cancer patients, and is not focused exclusively on adult osteoporosis patients.",no,no,"While MRONJ outcomes are discussed, this is not a primary study documenting specific procedures.",no,"No mention of control groups, as this is a review article, not an interventional study.",no,"This is explicitly a review article, not a RCT, cohort study, or case-control study.",no,"While the abstract mentions that risk can be ""dose-time dependent,"" this is not a primary study documenting temporal relationships.",no,"This is a review article, not a primary study, and no specific subject size is mentioned.","While dental procedures are mentioned, this is a review of MRONJ in general, and no specific intervention study is described.",Exclude,"This review article on medication-related osteonecrosis of the jaw fails to meet the specified screening criteria, particularly lacking focus on Romosozumab, specific patient populations, and primary research design. The manuscript provides a general overview of MRONJ but does not constitute an interventional study with the required methodological and population characteristics. Consequently, it does not align with the predefined screening requirements for inclusion.",0.1
The Prevention of Medication-related Osteonecrosis of the Jaw.,"P. Poxleitner, M. Engelhardt, R. Schmelzeisen, P. Voss",10.3238/arztebl.2017.0063,https://doi.org/10.3238/arztebl.2017.0063,Deutsches Ärzteblatt International,45,2017,no,"The abstract primarily focuses on patients with cancer (multiple myeloma) and bone metastases, though it briefly mentions osteoporosis patients. This is another critical failure as the population must be adults with osteoporosis and no cancer.",yes,yes,"The abstract discusses MRONJ outcomes following dental procedures, particularly tooth extraction.",maybe,"As this is a systematic review, it's not clear if the included studies had control groups.",no,"This is a systematic review of other publications, not a primary research study of the required design types.",maybe,"While the abstract mentions that bisphosphonates can persist in bone for over 15 years, it doesn't clearly document temporal relationships for specific cases.",maybe,"The abstract mentions one case series of over 1200 patients, but this is not the main study being discussed. The main study appears to be a systematic review of other publications, so the subject size is unclear.","The abstract discusses tooth extraction and mentions other dental procedures, though as part of a review rather than primary research.",Exclude,"The systematic review fails to meet critical screening criteria, specifically lacking focus on Romosozumab and primarily discussing cancer patients instead of osteoporosis patients. Multiple key requirements were not satisfied, including intervention type, population characteristics, and study design, rendering the paper unsuitable for inclusion in the systematic review.",0.1
Declining Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Cancer.,"Ie-Wen Sim, K. Sanders, G. Borromeo, J. Seymour, P. Ebeling",10.1210/jc.2015-1794,https://doi.org/10.1210/jc.2015-1794,Journal of Clinical Endocrinology and Metabolism,52,2015,no,"The study was conducted at a ""specialized cancer center"" and appears to focus on cancer patients, which is explicitly excluded in the criteria.",maybe,yes,The study clearly documents MRONJ outcomes following dental procedures.,maybe,"The study compares before and after implementation of dental intervention, but does not explicitly mention a control group of non-anti-resorptive medication users.",yes,"This appears to be a retrospective cohort study, which meets the criteria.",yes,"The study documents temporal relationships between medication use and MRONJ development, with clear time periods (2003-2013) and before/after intervention analysis.",yes,"The study includes 1,243 patients, which is well above the minimum requirement of 100.","While the study mentions ""active dental intervention,"" it does not specifically detail the types of procedures, such as tooth extraction, implant placement, periodontal surgery, or removable prosthesis fabrication.",Exclude,"The study fails key screening criteria by focusing on cancer patients and not specifying Romosozumab as the anti-resorptive medication. While the research demonstrates a robust sample size and clear documentation of MRONJ outcomes, the population type and medication specificity disqualify it from meeting the systematic review requirements. Critical exclusion factors include the cancer patient population and lack of precise medication identification.",1.4
Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review,"Mampei Kawahara, S. Kuroshima, T. Sawase",10.1186/s40729-021-00323-0,https://doi.org/10.1186/s40729-021-00323-0,International Journal of Implant Dentistry,67,2021,no,"While the paper mentions osteoporosis patients, it also discusses cancer patients, and is not exclusively focused on adult osteoporosis patients without cancer. Therefore, the paper does not meet the criterion of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",no,no,"While MRONJ outcomes are discussed, this is in the context of reviewing other studies, and the paper does not report specific outcomes from original research. Therefore, the paper does not meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"As a review paper, the paper does not include a control group of non-anti-resorptive medication users. Therefore, the paper does not meet the criterion of including a control group.",no,"This is a literature review, not a primary research study, and therefore does not meet the criterion of having a study design of a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The paper does not document temporal relationships or medication duration in a study population. Therefore, the paper does not meet the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",no,"This is a literature review/meta-analysis, not a primary study, and no specific subject size is mentioned. Therefore, the paper does not meet the criterion of having a subject size of more than 100 people.","The paper discusses dental treatment in general but as a review of recommendations, and does not report on specific interventions in a study population. Therefore, the paper does not meet the criterion of having an intervention of invasive dental treatment, including tooth extraction, implant placement, periodontal surgery, other dental surgery, or removable prosthesis fabrication.",Exclude,"This literature review fails to meet multiple screening criteria, including specific intervention type, subject size, population focus, and study design requirements. The paper provides a comprehensive overview of medication-related osteonecrosis of the jaw but does not constitute a primary research study with the specified parameters. Consequently, it would be excluded from a systematic review targeting specific research characteristics.",0.1
Risk of medication-related osteonecrosis of the jaw after dental extractions in patients receiving antiresorptive agents - A retrospective study of 240 patients.,"R. Coropciuc, R. Coopman, M. Garip, E. Gielen, C. Politis, T. Van den Wyngaert, B. Beuselinck",10.1016/j.bone.2023.116722,https://doi.org/10.1016/j.bone.2023.116722,Bone,13,2023,maybe,"While the study includes adult patients with osteoporosis, it also includes patients with bone metastases (cancer). The osteoporosis cohort is separate but not exclusively studied.",yes,yes,"The study clearly documents MRONJ outcomes following dental extractions, including specific stages and healing outcomes.",no,The abstract does not mention a control group of non-anti-resorptive medication users.,yes,"This is a retrospective cohort study, which meets the criteria.",yes,"The study documents temporal relationships, including median drug exposure of 43 months and specific timing of medication use (e.g., ""interval since last administration of at least 3 months"").",yes,"The study includes 240 patients (126 with osteoporosis, 114 with bone metastases), which is well above the 100-person requirement.","The study specifically focuses on dental extractions, which is one of the specified invasive dental treatments.",Include,"The study fails to meet critical screening criteria, specifically lacking confirmation of Romosozumab use and including patients with bone metastases alongside osteoporosis patients. While demonstrating robust methodology with a large sample size and clear documentation of dental extraction outcomes, the absence of a control group and non-specific antiresorptive agent classification prevent systematic review inclusion. The research provides valuable insights into medication-related osteonecrosis of the jaw but does not align with the precise screening requirements.",2.5
Interventions for managing medication-related osteonecrosis of the jaw.,"Natalie H Beth-Tasdogan, B. Mayer, H. Hussein, O. Zolk",10.1002/14651858.CD012432.pub2,https://doi.org/10.1002/14651858.CD012432.pub2,Cochrane Database of Systematic Reviews,197,2017,no,"The paper includes both cancer and non-cancer patients, and is not exclusively focused on adult osteoporosis patients without cancer, which does not meet the population type criterion.",yes,yes,"The paper clearly documents MRONJ outcomes following dental procedures, which meets the outcome documentation criterion.",maybe,"The paper includes control groups in the RCTs, but these are not specifically comparing anti-resorptive medication users vs non-users, so the criterion is only partially met.",no,"The paper is a systematic review of RCTs, which is not a primary study, so it does not meet the study design criterion.",maybe,"While the paper discusses medication use and MRONJ, it does not clearly document the temporal relationships or the duration of medication use, so the criterion is only partially met.",yes,"The paper includes 5 RCTs with 1218 total participants, which clearly meets the >100 subjects requirement.","The paper discusses dental extractions, dentoalveolar surgery, and other dental procedures, which meets the criterion for invasive dental treatment.",Exclude,"The systematic review fails to meet critical screening criteria, specifically using the wrong intervention (bisphosphonates/denosumab instead of Romosozumab) and including cancer patients in the study population. While the paper demonstrates methodological rigor with multiple RCTs and comprehensive outcome documentation, these fundamental deviations from the specified screening requirements necessitate exclusion from the systematic review.",0.1
Medication-related osteonecrosis of the jaw-like lesions in rodents: A comprehensive systematic review and meta-analysis.,"S. Kuroshima, Muneteru Sasaki, H. Murata, T. Sawase",10.1111/ger.12416,https://doi.org/10.1111/ger.12416,Gerodontology,18,2019,no,"The study focuses on rodents, not human patients, so it does not meet the criterion of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",no,no,"While MRONJ outcomes are discussed, they are in rodent models, not human patients, so it does not meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"While the study likely included controls (as it's a systematic review), it's not relevant as it's in rodents, not human patients.",no,"This is a systematic review and meta-analysis of animal studies, not a primary study of the required design types (randomized controlled trial, prospective/retrospective cohort study, or case-control study).",no,"The abstract does not discuss temporal relationships in human patients, so it does not meet the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",no,"This is a systematic review of rodent studies, not human subjects, so it does not meet the requirement of having a subject size of more than 100 people.","The abstract does not discuss specific dental procedures, so it does not meet the criterion of having an intervention of invasive dental treatment.",Exclude,"This systematic review of rodent studies fails to meet multiple critical screening criteria, including the requirement for human subjects, Romosozumab intervention, and specific dental treatment outcomes. The research focuses on animal models of medication-related osteonecrosis of the jaw, which fundamentally differs from the desired human clinical study parameters. Consequently, the paper does not qualify for inclusion in the systematic review.",0.1
"Prevalence, Incidence Rate, and Risk Factors of Medication-Related Osteonecrosis of the Jaw in Patients With Osteoporosis and Cancer: A Nationwide Population-Based Study in Japan.","M. Ishimaru, S. Ono, K. Morita, H. Matsui, Y. Hagiwara, H. Yasunaga",10.1016/j.joms.2021.12.007,https://doi.org/10.1016/j.joms.2021.12.007,Journal of oral and maxillofacial surgery,33,2021,maybe,"While the study includes adult patients with osteoporosis (2,664,104), it also includes cancer patients (155,206). The abstract does not specify age requirements, though it is likely these are adults given the context.",maybe,maybe,"While MRONJ outcomes are documented, the specific dental procedures leading to MRONJ are not clearly detailed in the abstract.",no,The abstract does not mention a control group of non-antiresorptive medication users.,yes,"This is a retrospective cohort study using a national database, which meets the criteria.",maybe,"While the study period is mentioned (2015-2018), the abstract does not clearly document the temporal relationship between medication use and MRONJ development or the duration of medication use.",yes,"The study includes 2,819,310 patients, far exceeding the minimum requirement of 100.","The abstract mentions ""tooth extraction"" and ""poor oral conditions"" as risk factors, but does not clearly specify that the study focuses on patients who underwent these procedures. It is more of an observational study of general antiresorptive drug users.",Include,"The study fails to meet critical screening criteria, particularly the requirement for Romosozumab as the specific antiresorptive medication. While the research includes a large patient population and uses a retrospective cohort design, it lacks specificity in dental intervention documentation and includes cancer patients, which deviates from the targeted review parameters. The broad approach to antiresorptive drugs and mixed patient population prevents alignment with the precise screening requirements.",2.5
Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates.,"Yong-Dae Kwon, D. Kim",10.1016/j.oraloncology.2008.11.010,https://doi.org/10.1016/j.oraloncology.2008.11.010,Oral Oncology,63,2009,maybe,"The study focuses on osteoporotic patients with a mean age of 69.7 years (adults), but it's unclear if cancer patients were excluded.",yes,yes,The study reports MRONJ outcomes following specific dental procedures.,maybe,The abstract doesn't mention whether there was a control group of non-anti-resorptive medication users.,maybe,"This is actually a systematic review of other studies, not a primary research study of the types specified in the criteria.",yes,The study documents duration of medication use (mean 50.4 ± 19 months) and temporal relationship with MRONJ development.,yes,"The study includes 680 MRONJ cases, well above the 100-person threshold.","The abstract mentions dental procedures including ""extraction"" and ""dentoalveolar surgery"" as preceding events.",Exclude,"The systematic review fails to meet key screening criteria, particularly the requirement for Romosozumab as the specific anti-resorptive medication and the need for a primary research study design. While the study provides valuable insights into medication-related osteonecrosis of the jaw, it does not align with the specified research parameters, rendering it unsuitable for inclusion based on the established screening criteria.",1.4
What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review.,"Suad Aljohani, Riham Fliefel, J. Ihbe, J. Kühnisch, M. Ehrenfeld, S. Otto",10.1016/j.jcms.2017.05.028,https://doi.org/10.1016/j.jcms.2017.05.028,Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,96,2017,maybe,"The study focuses on osteoporotic patients with mean age 69.7 years (adults), but it doesn't explicitly state whether cancer patients were excluded.",yes,yes,The study reports MRONJ outcomes following specific dental procedures (extractions and dentoalveolar surgery).,no,The abstract doesn't mention a control group of non-anti-resorptive medication users.,maybe,"This is a systematic review of 44 studies, but the design of the included studies isn't specified.",yes,The study documents duration of medication use (mean 50.4 ± 19 months) and temporal relationship with MRONJ development.,yes,"The study includes 680 MRONJ cases, well above the 100-person threshold.","The abstract mentions extraction and dentoalveolar surgery as preceding events, indicating the study includes invasive dental treatment.",Exclude,"The systematic review fails to meet the specific screening criteria, particularly the requirement for Romosozumab as the intervention medication. While the study provides comprehensive insights into medication-related osteonecrosis of the jaw in osteoporosis patients, it does not align with the precise research parameters. Multiple screening criteria remain unclear or unmet, rendering the study unsuitable for the intended research focus.",1.4
"Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.","S. Otto, C. Pautke, T. Van den Wyngaert, D. Niepel, M. Schiødt",10.1016/j.ctrv.2018.06.007,https://doi.org/10.1016/j.ctrv.2018.06.007,Cancer Treatment Reviews,219,2018,no,"The abstract primarily focuses on cancer patients with bone metastases, and does not focus on non-cancer osteoporosis patients, which is a clear failure of a critical criterion.",maybe,no,"While MRONJ outcomes are discussed, they are not documented in relation to specific dental procedures, as this is a general review rather than documentation of specific outcomes.",maybe,"There is no mention of control groups, and this is a review article rather than a comparative study, so it cannot be confirmed if this criterion is met.",no,"This is a ""critical review"" based on ""best-evidence review"", not a primary research study (RCT, cohort, or case-control), which is a clear failure of a critical criterion.",no,"No specific temporal relationships or medication durations are documented, as this is a general review rather than a study with specific temporal documentation.",maybe,"The abstract does not specify any subject size, and this is a review article rather than a primary study, so it cannot be confirmed if this criterion is met.","The abstract discusses dental procedures and treatments in general, mentioning ""avoiding bone trauma"" and dental infections, but this is a review of general principles rather than a study of specific interventions.",Exclude,"The abstract focuses on denosumab and bisphosphonates in cancer patients, which fundamentally differs from the required criteria of Romosozumab in non-cancer osteoporosis patients. Multiple critical screening requirements are not met, including medication type, population focus, and study design, rendering the paper unsuitable for inclusion. The review's general nature and lack of specific intervention documentation further disqualify it from meeting the established screening criteria.",0.1
The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.,T. Dodson,10.1016/j.coms.2015.06.003,https://doi.org/10.1016/j.coms.2015.06.003,Oral and Maxillofacial Surgery Clinics of North America,92,2015,no,"The abstract mentions both cancer and osteoporosis patients, so it's not exclusively focused on osteoporosis patients, which is a failure.",maybe,maybe,"While MRONJ is the focus, specific dental procedures and outcomes are not detailed, so the outcome documentation is unclear.",no,"There is no mention of control groups, so the control group is unclear or fails.",no,"This appears to be a review article, not a primary research study, so it does not meet the required study design criteria, which is a failure.",maybe,"No specific temporal relationships or medication duration details are provided, so the temporal documentation is unclear.",no,"The abstract doesn't specify the sample size, and this is a review article rather than a primary study, so the subject size is unclear or fails.","While MRONJ is discussed, specific dental procedures are not detailed, so the intervention is unclear.",Exclude,"The abstract fails to meet multiple critical screening criteria, including the specific medication (Romosozumab), study design, and population type. It is a review article that discusses medication-related osteonecrosis of the jaw across different patient populations, rather than a focused primary research study on osteoporosis patients using Romosozumab. Consequently, the paper does not align with the required systematic review parameters.",0.1
Medication-Related Osteonecrosis of the Jaw: An Overview,"M. Blašković, D. Blašković",10.5772/INTECHOPEN.86241,https://doi.org/10.5772/INTECHOPEN.86241,Maxillofacial Surgery and Craniofacial Deformity - Practices and Updates,1,2019,maybe,"The abstract discusses both cancer and osteoporosis patients, and is not exclusively focused on adult osteoporosis patients without cancer, so it only partially meets this criterion.",yes,yes,"The abstract mentions MRONJ outcomes and dental procedures, indicating that the study reports the required outcome documentation.",maybe,"The abstract does not mention any control groups, so it is uncertain whether the study includes a control group of non-anti-resorptive medication users.",no,"The abstract indicates that this appears to be a review article rather than a primary research study, so it fails this criterion.",no,"The abstract does not provide any specific documentation of the temporal relationship between medication use and MRONJ development or the duration of medication use, so it fails this criterion.",maybe,"The abstract mentions ""15,000 cases"" in literature but does not specify the size of any particular study, so the subject size is uncertain.","The abstract mentions tooth extraction and other dental procedures, indicating that the study includes the required intervention of invasive dental treatment.",Exclude,"The abstract discusses medication-related osteonecrosis of the jaw across multiple medication types, but fails to meet key screening criteria including specific focus on romosozumab, exclusive osteoporosis patient population, and primary research design. Multiple critical screening requirements were not satisfied, rendering the study unsuitable for inclusion in the systematic review.",0.1
Evaluation of the Treatment Strategies for Medication‐Related Osteonecrosis of the Jaws (MRONJ) and the Factors Affecting Treatment Outcome: A Multicenter Retrospective Study with Propensity Score Matching Analysis,"S. Hayashida, S. Soutome, S. Yanamoto, S. Fujita, T. Hasegawa, T. Komori, Y. Kojima, H. Miyamoto, Y. Shibuya, N. Ueda, T. Kirita, H. Nakahara, M. Shinohara, M. Umeda",10.1002/jbmr.3191,https://doi.org/10.1002/jbmr.3191,Journal of Bone and Mineral Research,147,2017,maybe,"The abstract does not specify whether all patients were adults (≥18) or whether they had cancer. It only mentions ""patients with MRONJ.""",maybe,maybe,"While MRONJ outcomes are documented, the abstract does not specify which dental procedures led to these outcomes.",no,The study compares different treatment methods (surgical vs. nonsurgical) but does not mention a control group of non-anti-resorptive medication users.,yes,"The study is described as a ""multicenter retrospective study,"" which fits within the acceptable study designs.",maybe,"The abstract mentions ""low-dose administration"" but does not clearly document the temporal relationship between medication use and MRONJ development or the duration of medication use.",yes,"The study includes 361 patients, which is well above the 100-person minimum requirement.","While the study focuses on MRONJ, which typically follows dental procedures, the abstract does not explicitly state which dental procedures were involved in the cases studied.",Exclude,"The study fails to meet critical screening criteria, particularly the requirement for Romosozumab as the specific anti-resorptive medication. While the research includes a large patient sample and uses a retrospective design, it lacks specificity about medication type, patient population characteristics, and dental procedure details. Multiple screening criteria remain unmet or unclear, significantly reducing the study's potential for inclusion.",1.4
Risk factors for medication-related osteonecrosis of the jaws: A systematic review.,"K. McGowan, T. McGowan, Saso Ivanovski",10.1111/odi.12708,https://doi.org/10.1111/odi.12708,Oral Diseases,169,2018,maybe,"The abstract mentions ""39 different systemic diseases"" were implicated, but does not specify a focus on osteoporosis patients or age restrictions.",maybe,maybe,"While MRONJ outcomes are discussed, the abstract does not specify documentation of outcomes following specific dental procedures.",no,There is no mention of control groups in the abstract.,no,"This appears to be a systematic review/meta-analysis, not a primary study.",no,There is no mention of temporal relationships or medication duration in the abstract.,yes,"The study includes 4106 patients, which exceeds the minimum requirement of 100 subjects.","While dental procedures are implied as risk factors, the abstract does not specify which procedures were studied.",Exclude,"The systematic review fails to meet multiple critical screening criteria, including specific intervention with Romosozumab, control group requirements, and precise documentation of dental procedures and temporal medication relationships. While the study includes a large patient population, its broad scope and lack of focused methodology disqualify it from meeting the predefined screening standards. The research appears to be a general exploration of MRONJ risk factors rather than a targeted investigation of the specified parameters.",1.4
"Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment.","O. Nicolatou‐Galitis, M. Schiødt, R. Mendes, C. Ripamonti, S. Hope, L. Drudge-Coates, D. Niepel, T. Van den Wyngaert",10.1016/j.oooo.2018.09.008,https://doi.org/10.1016/j.oooo.2018.09.008,"Oral surgery, oral medicine, oral pathology and oral radiology",235,2019,no,"The abstract mentions both osteoporosis and cancer patients, and does not focus exclusively on adult osteoporosis patients without cancer, which is another critical failure.",no,no,"While MRONJ is discussed, this is not a study documenting specific outcomes, and no specific dental procedures and outcomes are reported.",no,"No mention of control groups, as this is a review article rather than an interventional study.",no,"This is explicitly a review article, not a RCT, cohort study, or case-control study, and therefore fails to meet this criterion.",no,"No specific temporal relationships or medication durations are documented, as this is a general review rather than a study with documented temporal relationships.",no,"The abstract does not mention any specific study size, and this is a review article rather than a primary research study.","While dental procedures are mentioned, this is a review of MRONJ in general, and no specific intervention study is described.",Exclude,"This review article fails multiple critical screening criteria, including the absence of Romosozumab as the intervention and the inclusion of cancer patients alongside osteoporosis patients. The paper is a general review of medication-related osteonecrosis of the jaw, not a primary research study with specific interventions, control groups, or documented outcomes, rendering it ineligible for the systematic review.",0.1
Bisphosphonate and Medication-Related Osteonecrosis of the Jaw: A Review,"T. Mücke, C. Krestan, D. Mitchell, J. Kirschke, A. Wutzl",10.1055/s-0036-1592367,https://doi.org/10.1055/s-0036-1592367,Seminars in Musculoskeletal Radiology,66,2016,no,"The abstract discusses both cancer patients and osteoporosis patients, and is not focused exclusively on adult osteoporosis patients without cancer, which fails this criterion.",yes,maybe,"The abstract discusses MRONJ outcomes following dental procedures, but it's not clear if these are documented in a systematic way, so this criterion is only partially met.",maybe,"There is no mention of control groups, so it cannot be determined if this criterion is met.",no,"The abstract appears to be a review article rather than a primary research study, and does not specify any of the required study designs, which fails this criterion.",no,"There is no clear documentation of temporal relationships or medication duration, so this criterion fails.",maybe,"The abstract does not specify the study size, so it cannot be determined if it meets the >100 subjects requirement.","The abstract discusses invasive dental procedures and dental implants, which meets this criterion.",Exclude,"The abstract fails key screening criteria by discussing bisphosphonates and denosumab instead of Romosozumab, and including cancer patients alongside osteoporosis patients. Multiple critical requirements are not met, including study design, population specificity, and intervention details, rendering the paper unsuitable for the specified research parameters.",1.4
Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS,"A. Anastasilakis, J. Pepe, N. Napoli, A. Palermo, C. Magopoulos, Aliya A. Khan, M. C. Zillikens, J. Body",10.1210/clinem/dgab888,https://doi.org/10.1210/clinem/dgab888,Journal of Clinical Endocrinology and Metabolism,46,2021,no,"The paper includes both cancer and non-cancer patients, specifically mentioning ""patients with benign bone disease"" and ""cancer patients with BM"", and does not focus exclusively on non-cancer patients.",no,no,"While MRONJ is discussed, the paper does not report specific outcomes following dental procedures, and it focuses on general risk factors and management.",no,"As a review paper, it does not include a control group, and it discusses risk factors and management rather than comparing groups.",no,"This is a literature review, not a primary research study, and does not match any of the required study designs.",no,"The paper does not document specific temporal relationships or medication durations, and it provides general information about risk factors.",maybe,"The abstract does not specify any sample size, and this is a review paper rather than a primary study, so the subject size cannot be determined.","While the paper discusses MRONJ, it does not specifically study dental procedures, and it appears to be a review of MRONJ risk factors and management rather than a study of invasive dental treatment.",Exclude,"This literature review fails multiple critical screening criteria, including the specific intervention of Romosozumab, study design requirements, and population specifications. The paper discusses medication-related osteonecrosis of the jaw across different patient populations but does not meet the systematic review's precise methodological and intervention-focused parameters. Consequently, the abstract does not qualify for inclusion in the systematic review.",0.1
Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs.,"J. Hellstein, R. Adler, B. Edwards, P. Jacobsen, J. Kalmar, S. Koka, C. Migliorati, H. Ristic",10.14219/JADA.ARCHIVE.2011.0108,https://doi.org/10.14219/JADA.ARCHIVE.2011.0108,The Journal of the American Dental Association (1939),350,2011,maybe,"The paper mentions ""patients with low bone mass"" and osteoporosis, but does not specify age restrictions or cancer exclusion, so it partially meets this criterion.",yes,no,"The paper discusses ARONJ outcomes but as a general review rather than specific documented cases, so it fails this criterion.",no,"As a narrative review, the paper does not include a control group, so it fails this criterion.",no,"This is a narrative review, not a RCT, cohort study, or case-control study, so it fails this criterion.",no,"The paper does not provide any specific temporal relationships or medication duration documentation, so it fails this criterion.",no,"This is a narrative review, not a primary study, and no specific subject size is mentioned, so the paper does not meet this criterion.","The paper discusses various dental procedures including ""implant placement and maintenance; oral and maxillofacial surgery"", so it meets this criterion.",Exclude,"This narrative review fails to meet multiple critical screening criteria, including specific intervention type, subject size, study design, and outcome documentation. While addressing dental procedures and osteoporosis, the paper lacks the precise methodological requirements for systematic review inclusion, particularly regarding Romosozumab and controlled research design. The broad, review-based approach prevents it from satisfying the detailed screening requirements.",0.1
Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.,"Makoto Kajizono, Hikaru Sada, Y. Sugiura, Y. Soga, Y. Kitamura, J. Matsuoka, T. Sendo",10.1248/bpb.b15-00385,https://doi.org/10.1248/bpb.b15-00385,Biological and Pharmaceutical Bulletin,62,2015,no,"The study specifically focuses on patients with ""advanced cancer,"" which explicitly violates the criterion requiring patients without cancer.",maybe,maybe,"While MRONJ outcomes are documented, the specific dental procedures leading to these outcomes are not clearly detailed in the abstract.",no,The abstract doesn't mention a control group of non-anti-resorptive medication users.,yes,"While not explicitly stated, this appears to be a retrospective cohort study based on the methodology described.",yes,"The study clearly documents the temporal relationship between medication use and MRONJ development, including duration of therapy.",yes,"The study includes 155 patients, which exceeds the minimum requirement of 100 subjects.","While the study mentions ""periodical dentistry maintenance"" and discusses MRONJ, it doesn't clearly specify the types of invasive dental treatments performed.",Exclude,"The study focuses on cancer patients using zoledronic acid and denosumab, which fundamentally conflicts with the screening criteria requiring non-cancer osteoporosis patients using romosozumab. Critical mismatches include the wrong medication, patient population, and absence of a control group, rendering the study ineligible for inclusion in the systematic review. Despite meeting some secondary criteria like sample size and study design, the primary disqualifying factors necessitate exclusion.",0.1
Medication-related osteonecrosis of the jaw: A literature review.,"S. Kuroshima, Muneteru Sasaki, T. Sawase",10.1016/j.job.2019.03.005,https://doi.org/10.1016/j.job.2019.03.005,Journal of Oral Biosciences,84,2019,maybe,"The paper mentions an aging population but does not specify that the subjects are adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer. Therefore, it only partially meets this criterion.",maybe,maybe,"The paper discusses MRONJ outcomes in general and mentions dental procedures, but not in a primary study context. Therefore, it only partially meets this criterion.",no,"As a literature review, the paper does not include its own control group of non-anti-resorptive medication users, and therefore fails this criterion.",no,"This is a literature review, not a primary study design, and therefore fails the criterion of being a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"The paper mentions the administration duration of bisphosphonates, but not in a primary study context. Therefore, it only partially meets this criterion.",no,"This is a literature review, not a primary study, and no specific subject size is mentioned. Therefore, the study does not meet the criterion of having a subject size of more than 100 people.","The paper mentions dental implant therapy and peri-implantitis, and discusses dental treatment in general, which partially meets the criterion of having an intervention of invasive dental treatment.",Exclude,"This literature review fails to meet multiple critical screening criteria, including the specific focus on Romosozumab, lack of a primary study design, and absence of a defined subject population. While discussing medication-related osteonecrosis of the jaw, the paper does not provide the required primary research elements such as a control group, specific subject size, or direct documentation of outcomes. The review's broad approach and lack of precise methodological details render it unsuitable for the specified screening requirements.",1.4
The Effect of Antiresorptive Drug Holidays on Medication-Related Osteonecrosis of the Jaw: A Systematic Review and Meta-Analysis,"Ali Aboalela, F. Farook, A. Alqahtani, Mandlin Almousa, R. Alanazi, Duaa Almohammadi",10.7759/cureus.30485,https://doi.org/10.7759/cureus.30485,Cureus,9,2022,maybe,"While the study involves patients receiving antiresorptive medications, it doesn't explicitly state they have diagnosed osteoporosis or specify age requirements. The cancer status is also not mentioned.",yes,yes,The study specifically reports MRONJ outcomes following dental procedures.,yes,"The study includes a control group (non-drug holiday group) with 1,961 subjects.",yes,"The abstract indicates this is a systematic review including ""observational and interventional studies,"" which would include the required study designs.",maybe,"While the study examines the relationship between medication use and MRONJ, the specific duration of medication use is not clearly documented in the abstract.",yes,"The study includes 6,808 subjects, well above the 100-person minimum.","The study specifically focuses on ""dentoalveolar surgery or tooth extractions,"" which meets the requirement for invasive dental treatment.",Include,"The systematic review fails to meet the critical screening criterion of focusing specifically on Romosozumab, instead examining antiresorptive therapy more broadly. While the study includes a large sample size and addresses dental interventions and MRONJ outcomes, the lack of specificity regarding the medication type represents a fundamental disqualification from the screening requirements. Uncertainty also exists regarding the precise patient population characteristics and temporal documentation of medication use.",2.5
Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): A systematic review,"C. Ottesen, M. Schiødt, K. Gotfredsen",10.1016/j.heliyon.2020.e03795,https://doi.org/10.1016/j.heliyon.2020.e03795,Heliyon,68,2020,no,"The abstract specifically focuses on ""patients with cancer"" which directly contradicts the criterion of the study focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do NOT have cancer.",yes,yes,"The study specifically looks at MRONJ outcomes following dental procedures, indicating that it reports MRONJ outcomes following specific, documented dental procedures.",yes,"The abstract mentions one study with a control group, indicating that the study includes a control group of non-anti-resorptive medication users.",yes,"The study includes RCTs, cohort studies, and case reports, which are considered appropriate study designs.",maybe,"While the study discusses drug holidays and timing of procedures, it is not clear if it documents the duration of medication use.",maybe,"The abstract mentions ""more than five patients"" in their inclusion criteria, but does not specify the actual number of patients in the included studies. Therefore, it is unclear if the study has a subject size of more than 100 people.","The study focuses on tooth extraction and dentoalveolar surgery, which are considered invasive dental treatments.",Exclude,"The systematic review focuses on antiresorptive medication and dental procedures, but critically fails key screening criteria by examining cancer patients instead of osteoporosis patients and not using Romosozumab. Multiple methodological elements align with screening requirements, such as dental intervention types and study design, but fundamental population and intervention mismatches disqualify the study from inclusion.",1.4
Medication-Related Osteonecrosis of the Jaws (MRONJ) in Children and Young Patients—A Systematic Review,"H. Rosales, Henry García Guevara, Stefanía Requejo, Maria Dianella Jensen, Julio Acero, S. Olate",10.3390/jcm12041416,https://doi.org/10.3390/jcm12041416,Journal of Clinical Medicine,10,2023,no,"The study focuses on children and young patients (average age 11.56 years) and explicitly includes patients with conditions other than osteoporosis (OI, MAS, etc.), which does not meet the requirement of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",yes,yes,"The study reports MRONJ outcomes following dental procedures, which meets the requirement of reporting MRONJ outcomes following specific, documented dental procedures.",no,"There is no mention of a control group of non-anti-resorptive medication users, which does not meet the requirement of including a control group.",yes,"The study includes ""randomized and non-randomized clinical trials, prospective and retrospective cohort studies, cases and controls studies"", which meets the requirement of having a study design of either a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"The study mentions average therapy time (4.21 years) and number of doses, which partially meets the requirement of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use, but the temporal relationship to MRONJ development is not clearly documented.",yes,"The study includes 1,192 patients total, which meets the requirement of having a subject size of more than 100 people.","The abstract mentions oral surgery in 216 subjects, which meets the requirement of having an intervention of invasive dental treatment, including tooth extraction, implant placement, periodontal surgery, other dental surgery, or removable prosthesis fabrication.",Exclude,"The systematic review focuses on medication-related osteonecrosis of the jaw in children and young patients, examining antiresorptive medications like bisphosphonates and denosumab, not romosozumab. The study includes a large patient population with diverse medical conditions, involving oral surgery and MRONJ outcomes, but fails to meet key screening criteria related to medication type, population age, and control group requirements. Consequently, the research does not align with the specified screening parameters for inclusion.",0.1
Emerging antiresorptive medications and their potential implications for dental surgeries.,"A. Aminoshariae, M. Donaldson, M. Horan, Scott A. Mackey, J. Kulild, D. Baur",10.1016/j.adaj.2021.12.008,https://doi.org/10.1016/j.adaj.2021.12.008,The Journal of the American Dental Association (1939),4,2022,no,"The abstract discusses both cancer and osteoporosis patients, and does not focus exclusively on adult osteoporosis patients without cancer.",yes,no,"While MRONJ outcomes are discussed, this is a review of existing literature rather than reporting specific outcomes from primary research.",no,"As a review article, the paper does not include its own control group of non-anti-resorptive medication users.",no,"The paper is a literature review, not a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The paper discusses medication use and MRONJ, but as a review article, it does not document the temporal relationship between medication use and MRONJ development or the duration of medication use.",no,"As this is a review article rather than a primary study, the subject size is not specified and cannot be determined.","The abstract discusses dental procedures and surgeries in general, which aligns with the criterion of invasive dental treatment.",Exclude,"This review article fails to meet multiple critical screening criteria, including specific focus on Romosozumab, subject size requirements, and primary research design. The paper discusses antiresorptive medications and MRONJ broadly but lacks the precise methodological and population specifications needed for inclusion. Consequently, the abstract does not satisfy the established screening requirements for the intended research study.",0.1
"Location and Gender Differences in Osteonecrosis of the Jaws in Patients Treated with Antiresorptive and Antineoplastic Drugs Undergoing Dentoalveolar Surgical, Systematic Review with Meta-Analysis and Trial Sequential Analysis","M. Dioguardi, F. Spirito, M. Alovisi, R. Aiuto, Daniele Garcovich, V. Crincoli, A. Ballini, G. A. Caloro, L. Lo Muzio",10.3390/jcm12093299,https://doi.org/10.3390/jcm12093299,Journal of Clinical Medicine,5,2023,maybe,"While the study includes adult patients with osteoporosis, it also includes patients with neoplastic diseases, which violates the criterion of focusing exclusively on non-cancer patients.",yes,yes,"The study clearly documents MRONJ outcomes following dental procedures, specifically extractions, meeting the criterion for outcome documentation.",maybe,"The abstract doesn't explicitly mention a control group of non-anti-resorptive medication users, so the presence of a control group is unclear.",yes,"This is a systematic review and meta-analysis, which includes analysis of multiple study types, meeting the criterion for study design.",maybe,"The abstract doesn't clearly document the temporal relationship between medication use and MRONJ development or the duration of medication use, so the temporal documentation is unclear.",maybe,"The abstract mentions analyzing 24 studies but doesn't specify the total number of subjects included, so the subject size is unclear.","The study focuses on dentoalveolar surgical procedures, specifically tooth extractions, which meets the criterion for invasive dental treatment.",Exclude,"The systematic review fails to meet critical screening criteria, specifically lacking focus on Romosozumab and including patients with neoplastic diseases. While the study addresses dental procedures and MRONJ outcomes, fundamental deviations from the specified intervention and population requirements disqualify it from meeting the established screening standards. Multiple unclear elements regarding control groups and temporal documentation further compromise the study's alignment with the predefined criteria.",1.4
Clinical characteristics and recurrence-related factors of medication-related osteonecrosis of the jaw,"Mong-Hun Kang, Dong-Keon Lee, Chang-Woo Kim, In-Seok Song, S. Jun",10.5125/jkaoms.2018.44.5.225,https://doi.org/10.5125/jkaoms.2018.44.5.225,Journal of the Korean Association of Oral and Maxillofacial Surgeons,24,2018,maybe,"While the study appears to focus on adult patients with osteoporosis, the abstract doesn't explicitly state the age range or confirm that patients don't have cancer.",yes,yes,"The study clearly documents MRONJ outcomes following specific dental procedures, particularly tooth extractions.",no,The abstract doesn't mention any control group of non-anti-resorptive medication users.,yes,"This is a retrospective cohort study, which meets the criteria.",yes,The study documents both the temporal relationship (MRONJ development after dental treatment) and duration of medication use (mean 61.1±42.9 months).,no,"The study includes only 51 patients, which is below the required minimum of 100 subjects.","The study clearly includes invasive dental treatments, specifically mentioning tooth extraction (69.6% of cases) and other dental procedures.",Exclude,"The study fails key screening criteria due to using different anti-resorptive medications instead of romosozumab, having a sample size below 100 patients, and lacking a control group. Despite meeting some methodological requirements like documenting dental procedures and MRONJ outcomes, these critical shortcomings disqualify the study from inclusion in the systematic review.",0.1
An Update on Medication-Related Osteonecrosis of the Jaw in Patients with Osteoporosis,"B. Bennett, H. Tahir, K. Solanki, N. Ali",10.33590/emjrheumatol/10300262,https://doi.org/10.33590/emjrheumatol/10300262,EMJ Rheumatology,2,2023,maybe,"The paper focuses on adult osteoporosis patients without cancer, but this appears to be a review rather than a primary study.",maybe,maybe,"While MRONJ outcomes are discussed, this is in the context of a review rather than documenting specific outcomes from primary research.",no,No mention of control groups in the abstract.,no,"This appears to be a review paper rather than a primary research study (RCT, cohort, or case-control).",maybe,"While the paper discusses timing of procedures and medication use, it's doing so in a review context rather than documenting specific temporal relationships in a primary study.",no,The abstract does not specify the number of subjects studied.,"The abstract mentions tooth extraction and discusses dental procedures, but this appears to be a review paper rather than a primary study of specific interventions.",Exclude,"The abstract represents a review paper discussing medication-related osteonecrosis of the jaw in osteoporosis patients, which fails to meet multiple screening criteria including specific intervention type, study design, and subject size requirements. Key disqualifying factors include the lack of a primary research study design, absence of Romosozumab as the specific intervention, and no clear documentation of a defined subject population or control group. Consequently, the paper does not satisfy the established screening criteria for inclusion in the systematic review.",1.4
The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention,"O. D. Fede, V. Panzarella, R. Mauceri, V. Fusco, A. Bedogni, L. Muzio, Sipmo Onj Board, G. Campisi",10.1155/2018/2684924,https://doi.org/10.1155/2018/2684924,BioMed Research International,127,2018,no,"The abstract discusses both cancer and non-cancer patients, and does not focus exclusively on non-cancer patients. Therefore, the study fails to meet the criterion of focusing on adult patients with diagnosed osteoporosis who do not have cancer.",maybe,no,"While MRONJ is discussed, this paper appears to be about prevention protocols rather than documenting specific outcomes. Therefore, the study fails to meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",maybe,"The abstract does not mention any control groups, so it is uncertain whether the study meets the criterion of including a control group of non-anti-resorptive medication users.",no,"This appears to be a review/protocol paper rather than a primary research study, and does not describe any specific study design. Therefore, the study fails to meet the criterion of having a study design of a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"While timing of dental treatments is mentioned, this is in the context of prevention protocols rather than documenting specific temporal relationships. Therefore, the study fails to meet the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",maybe,"The abstract does not mention any specific study size, so it is uncertain whether the study meets the criterion of having a subject size of more than 100 people.","The abstract mentions dental treatments but as a general concept, and does not describe specific study interventions. Therefore, it is uncertain whether the study meets the criterion of having an intervention of invasive dental treatment.",Exclude,"The abstract describes a protocol for medication-related osteonecrosis of the jaw prevention, but fails to meet multiple critical screening criteria including specific intervention type, population focus, and study design. Key shortcomings include lack of Romosozumab as the primary medication, absence of a clear research methodology, and no documentation of specific MRONJ outcomes or temporal relationships. The document appears to be a guidance paper rather than a primary research study meeting the predefined screening requirements.",0.1
Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials.,"A. Boquete-Castro, G. Gómez-Moreno, J. Calvo-Guirado, A. Aguilar-Salvatierra, R. Delgado-Ruiz",10.1111/clr.12556,https://doi.org/10.1111/clr.12556,Clinical Oral Implants Research,148,2016,no,"The study specifically focuses on patients with solid tumors/cancer, which is explicitly excluded in the screening criteria.",maybe,maybe,"While ONJ outcomes are documented, the specific dental procedures leading to these outcomes are not clearly detailed in the abstract.",yes,The study includes control groups (bisphosphonates/placebo treatment).,yes,The study includes randomized controlled trials (RCTs).,maybe,"The abstract mentions ""first event apparition"" but doesn't clearly document the temporal relationship or duration of medication use.",yes,"The study includes 8,963 patients, which is well above the 100-person minimum.","While dental procedures are mentioned (dental extraction, removable apparatus), they are not the primary focus of the study but rather mentioned as risk factors.",Exclude,"The study focuses on denosumab in cancer patients, which fundamentally conflicts with the screening criteria requiring romosozumab in non-cancer osteoporosis patients. Critical mismatches in medication type and patient population render the study ineligible for inclusion, despite meeting some secondary screening requirements. The core exclusion criteria definitively disqualify this research from the systematic review.",0.1
Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.,"A. Owosho, See Toh Yoong Liang, Adi Z. Sax, Kant Wu, S. Yom, J. Huryn, C. Estilo",10.1016/j.oooo.2018.02.003,https://doi.org/10.1016/j.oooo.2018.02.003,"Oral surgery, oral medicine, oral pathology and oral radiology",47,2018,no,"The study appears to focus on cancer patients (Memorial Sloan Kettering Cancer Center), which explicitly violates the criterion of excluding cancer patients.",maybe,yes,The study clearly documents MRONJ outcomes and their relationship to dental procedures.,maybe,"While there are two groups (pre- and post-medication), these are not exactly control groups of non-users.",yes,This appears to be a retrospective cohort study based on database review.,yes,"The study documents temporal relationships between medication use and MRONJ development, including onset doses.",maybe,"The abstract does not specify the total number of subjects, though being from a major cancer center over a 10-year period suggests it likely exceeds 100.","While the study mentions ""dentoalveolar trauma"" and dental evaluation, it does not specifically detail the types of invasive dental procedures performed.",Exclude,"The study fails key screening criteria by focusing on cancer patients and using medications other than Romosozumab, which immediately disqualifies it from the systematic review. While the research demonstrates methodological rigor in examining medication-related osteonecrosis of the jaw, it does not meet the specific population and intervention requirements. Uncertainties around subject size and control group structure further complicate its potential inclusion.",0.1
Surgical Management of Medication-Related Osteonecrosis of the Jaw Is Associated With Improved Disease Resolution: A Retrospective Cohort Study.,"M. El-Rabbany, D. Lam, P. Shah, A. Azarpazhooh",10.1016/j.joms.2019.03.040,https://doi.org/10.1016/j.joms.2019.03.040,Journal of oral and maxillofacial surgery,27,2019,maybe,"The abstract mentions patients with osteoporosis (46 in surgical group, 20 in nonsurgical), but also includes patients with cancer (mentioned in the multivariate analysis). The age criterion isn't explicitly stated.",maybe,yes,The study clearly documents MRONJ outcomes and their resolution.,no,"The study compares surgical vs. nonsurgical treatment approaches, not anti-resorptive medication users vs. non-users.",yes,"This is a retrospective review, which fits within the acceptable study designs.",maybe,"While the study documents follow-up periods (median 15.5 months surgical, 11 months nonsurgical), it doesn't clearly specify the temporal relationship between medication use and MRONJ development.",no,"The study includes only 78 patients, which is below the required minimum of 100 subjects.","While the study deals with MRONJ, which typically follows dental procedures, the abstract doesn't explicitly state which dental procedures were performed. However, it's likely these were included given the MRONJ diagnosis.",Exclude,"The study fails to meet critical screening criteria, including the specific requirement for Romosozumab intervention and a minimum sample size of 100 patients. Multiple key elements are misaligned with the systematic review's requirements, particularly the intervention type, population composition, and control group design. These fundamental discrepancies render the study unsuitable for inclusion in the review.",1.4
Medication-related osteonecrosis of the jaw after tooth extraction in patients receiving pharmaceutical treatment for osteoporosis: A retrospective cohort study,"Keisuke Seki, T. Kaneko, Atsushi Kamimoto, M. Wada, Yoshimasa Takeuchi, Mika Furuchi, T. Iinuma",10.1016/j.jds.2022.03.014,https://doi.org/10.1016/j.jds.2022.03.014,Journal of Dental Sciences,11,2022,maybe,"While the study involves patients with osteoporosis, the abstract doesn't explicitly state that all patients are adults (≥18 years) or confirm the absence of cancer patients.",yes,yes,The study clearly documents MRONJ outcomes following tooth extraction procedures.,no,The abstract doesn't mention a control group of non-anti-resorptive medication users.,yes,"This is a retrospective cohort study, which meets the criterion.",yes,The study documents both the temporal relationship (mean duration of medication use was 40.4 months) and duration of medication use.,no,"The study only includes 40 patients (70 teeth), which is well below the required 100 subjects.","The study specifically focuses on tooth extraction procedures, which meets this criterion.",Exclude,"The study fails key screening criteria due to using bisphosphonates and denosumab instead of romosozumab, and having a sample size of only 40 patients, which is significantly below the required 100 subjects. While the research addresses dental extraction and MRONJ outcomes, critical methodological requirements are not met, rendering the study ineligible for inclusion in the systematic review.",1.4
Incidence and risk factors for medication‐related osteonecrosis after tooth extraction in cancer patients—A systematic review,"Nurda Schwech, J. Nilsson, P. Gabre",10.1002/cre2.698,https://doi.org/10.1002/cre2.698,Clinical and Experimental Dental Research,20,2022,no,"The abstract explicitly states the study focuses on ""cancer patients"", which does not meet the population type criterion that requires non-cancer patients.",yes,yes,"The abstract mentions MRONJ outcomes following tooth extractions, which meets the outcome documentation criterion.",maybe,"The abstract does not mention a control group, so it is not possible to determine if the study meets this criterion.",no,"The abstract indicates this is a systematic review, not a primary study, which does not meet the study design criterion.",maybe,"The abstract does not provide information about temporal relationships or duration of medication use, so it is not possible to determine if the study meets this criterion.",maybe,"The abstract does not specify the sample size, so it is not possible to determine if the study meets the subject size criterion.","The abstract specifically mentions tooth extractions, which is an invasive dental treatment as required by the criterion.",Exclude,"The systematic review focuses on cancer patients using bisphosphonates and denosumab, which fundamentally conflicts with the specified screening criteria requiring non-cancer patients and Romosozumab. Critical deviations include the wrong medication type, population, and study design, rendering the abstract incompatible with the predefined inclusion requirements.",0.1
Interventions for managing medication-related osteonecrosis of the jaw.,"Natalie H Beth-Tasdogan, B. Mayer, H. Hussein, O. Zolk, Jens-Uwe Peter",10.1002/14651858.cd012432,https://doi.org/10.1002/14651858.cd012432,Cochrane Database of Systematic Reviews,4,2022,maybe,"While the study includes patients with osteoporosis, it also includes cancer patients. The abstract doesn't clearly separate these populations in the results.",yes,yes,The study clearly documents MRONJ outcomes following specific dental procedures.,yes,"The studies described include control groups (standard care, placebo, or active control).",yes,The paper explicitly states it includes randomized controlled trials (RCTs).,maybe,"While the abstract mentions ""duration of exposure"" in the background, it doesn't clearly document temporal relationships between medication use and MRONJ development in the results.",yes,"The review includes 13 RCTs with 1668 total participants, well above the 100-person threshold.","The abstract discusses various dental procedures including dentoalveolar surgery, tooth extractions, and surgical interventions, which meet the intervention criteria.",Exclude,"The systematic review fails to meet key screening criteria, specifically the requirement for Romosozumab as the intervention medication. While the study includes multiple randomized controlled trials with a large sample size and documents dental procedures and MRONJ outcomes, the population includes both cancer and osteoporosis patients, and the intervention does not match the specified medication. These critical deviations from the screening criteria render the study unsuitable for inclusion.",1.4
Proposal for a preventive protocol for medication-related osteonecrosis of the jaw,"M. M. Romero-Ruiz, Marta Romero-Serrano, Ascensión Serrano-González, M. Serrera-Figallo, J. Gutierrez-Perez, D. Torres-Lagares",10.4317/medoral.24197,https://doi.org/10.4317/medoral.24197,Medicina Oral,18,2020,no,"The paper includes both osteoporosis and cancer patients, and does not focus exclusively on adult osteoporosis patients without cancer.",no,no,"While MRONJ is discussed, this paper does not report actual outcomes. It focuses on developing preventive protocols rather than documenting outcomes.",no,"This is not an interventional study, and no control group is mentioned.",no,"This is a literature review/protocol development paper, and does not match any of the required study designs (RCT, cohort, or case-control).",no,"While the paper mentions duration of drug application as a variable, it does not document actual temporal relationships. This is a protocol paper, not an outcomes study.",no,"This is a protocol development paper based on literature review, and no specific subject size is mentioned.","The paper discusses dental implant treatment and preventive measures, but this is a protocol paper, not a study of actual treatments.",Exclude,"This protocol development paper fails to meet multiple screening criteria, including specific medication use, subject size, intervention type, and study design. The literature review focuses on developing preventive protocols for medication-related osteonecrosis of the jaw, but does not constitute an interventional study with documented outcomes. Consequently, the paper does not align with the required research parameters for inclusion.",0.1
Medication-related osteonecrosis of the jaw: Clinical and practical guidelines,"D. Rosella, P. Papi, R. Giardino, E. Cicalini, L. Piccoli, G. Pompa",10.4103/2231-0762.178742,https://doi.org/10.4103/2231-0762.178742,Journal of International Society of Preventive and Community Dentistry,152,2016,maybe,"The abstract mentions patients with MRONJ but does not specify age groups, and there is no clear distinction between cancer and non-cancer patients.",no,no,"While MRONJ outcomes are discussed, this is not a study documenting specific outcomes, and no specific dental procedures and their outcomes are reported.",no,"No mention of control groups, as this appears to be a review rather than a comparative study.",no,"This is clearly a review paper, not a primary research study, and does not match any of the required study designs.",no,"No specific temporal relationships or medication durations are documented, as this is a general review of MRONJ.",no,"The abstract does not mention any specific study size, and this appears to be a review paper rather than a primary research study.","While dental procedures are mentioned, this is a general review of MRONJ, and no specific intervention study is described.",Exclude,"This review article on medication-related osteonecrosis of the jaw fails to meet the specified screening criteria, lacking specific details about Romosozumab, subject size, intervention specifics, population characteristics, control groups, study design, outcome documentation, and temporal relationships. The paper provides a general overview of MRONJ pathophysiology and management strategies but does not constitute a primary research study that would satisfy the required screening parameters.",0.1
Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score–matched analysis,"H. Ikesue, Kohei Doi, M. Morimoto, M. Hirabatake, Nobuyuki Muroi, S. Yamamoto, T. Takenobu, T. Hashida",10.1007/s00520-021-06634-7,https://doi.org/10.1007/s00520-021-06634-7,Supportive Care in Cancer,14,2021,no,"The study specifically focuses on patients with cancer who received treatment for bone metastasis, which explicitly violates the criterion requiring non-cancer patients.",yes,yes,"The study clearly documents MRONJ outcomes following dental procedures, particularly tooth extraction.",maybe,"While there is a comparison between two treatment groups (denosumab vs. zoledronic acid), this doesn't meet the specific requirement for a control group of non-anti-resorptive medication users.",yes,"This is a retrospective cohort study, which meets the acceptable study design criteria.",yes,"The study appears to document the temporal relationship between medication use and MRONJ development, as evidenced by the analysis of risk factors and timing of tooth extraction.",yes,"The study includes 799 patients, well above the minimum requirement of 100.","The study mentions tooth extraction and dental procedures, though specific details are limited in the abstract.",Exclude,"The study fails key screening criteria by focusing on cancer patients and using denosumab and zoledronic acid instead of the specified romosozumab medication. While the research demonstrates methodological rigor with a large sample size and clear outcome documentation, critical population and intervention mismatches disqualify it from meeting the systematic review's requirements.",0.1
Prediction of medication-related osteonecrosis of the jaw (MRONJ) using automated machine learning in patients with osteoporosis associated with dental extraction and implantation: a retrospective study,"Dahui Kwack, S. Park",10.5125/jkaoms.2023.49.3.135,https://doi.org/10.5125/jkaoms.2023.49.3.135,Journal of the Korean Association of Oral and Maxillofacial Surgeons,6,2023,maybe,"The study includes adult patients (≥55 years) with osteoporosis, but doesn't explicitly state they don't have cancer. However, the focus appears to be on osteoporosis patients without mention of cancer.",yes,yes,The study specifically documents MRONJ outcomes following dental procedures (extractions and implantation).,no,The abstract doesn't mention a control group of non-anti-resorptive medication users. The study appears to focus only on patients receiving antiresorptive therapy.,yes,"This is a retrospective chart review, which falls under the acceptable study designs.",yes,"The study considers ""medication administration and duration"" and appears to document the temporal relationship between medication use and MRONJ development.",yes,"The study includes 340 patients, well above the minimum requirement of 100.","The study explicitly includes patients undergoing ""tooth extraction or implantation,"" which meets the criterion for invasive dental treatment.",Include,"A retrospective study of 340 osteoporosis patients undergoing dental procedures reveals machine learning models for predicting medication-related osteonecrosis of the jaw, with comprehensive documentation of intervention and outcomes. While meeting most screening criteria, the study critically fails to specify Romosozumab as the anti-resorptive medication and lacks a control group of non-medication users. The research provides insights into MRONJ prediction but does not fully align with the precise screening requirements.",2.5
"Is the prevalence of the medication-related osteonecrosis of the jaws underestimated, evaluation in oncological and non-oncological disease.","B. Gális, J. Zajko, D. Hirjak, L. Vanko, I. Kupcová, J. Jurkemík, P. Gengelova, K. Mikušková, K. Halmova, M. Riznic, L. Czako",10.4149/BLL_2017_137,https://doi.org/10.4149/BLL_2017_137,Bratislava Medical Journal,20,2017,no,"The study includes both oncologic and non-oncologic patients, specifically mentioning breast cancer, prostate cancer, and multiple myeloma patients, so it is not exclusively focused on non-cancer patients and does not meet this criterion.",no,no,"The study reports MRONJ outcomes but does not specify the dental procedures leading to MRONJ, so it does not meet this criterion.",no,"There is no mention of a control group, and the study appears to be prevalence-based rather than comparative, so it does not meet this criterion.",no,"The study appears to be a multi-centric prevalence study, which does not match the required study designs (RCT, cohort, or case-control), so it does not meet this criterion.",no,"There is no clear documentation of the temporal relationship between medication use and MRONJ, and no mention of medication duration, so the study does not meet this criterion.",yes,"The study includes 1166 MRONJ patients, which meets the subject size criterion.","There is no specific mention of dental procedures, and the focus is on MRONJ prevalence rather than specific dental interventions, so the study does not meet this criterion.",Exclude,"The study fails to meet multiple critical screening criteria, including specific medication type, dental intervention details, population exclusivity, and study design requirements. While the research provides a comprehensive prevalence analysis of medication-related osteonecrosis of the jaw, it does not align with the precise methodological and population specifications sought in the screening protocol. Consequently, the abstract does not qualify for inclusion based on the established criteria.",1.4
Management von medikamentenassoziierten Kiefernekrosen – Ergebnisse einer Literaturanalyse neuester Studien im Vergleich zu bewährten Strategien,"M. Tröltzsch, M. Tröltzsch, C. Pautke, S. Otto",10.1007/s00106-021-01130-0,https://doi.org/10.1007/s00106-021-01130-0,HNO (Berlin. Print),5,2022,maybe,"The abstract mentions both oncological and osteological (osteoporosis) patients, and it does not explicitly state that cancer patients are excluded. Age criteria are also not specified.",maybe,maybe,"MRONJ outcomes are discussed generally, but specific dental procedures and their outcomes are not detailed.",maybe,"No mention of control groups in the abstract, and this is a systematic review rather than a primary study.",no,"This is a systematic review, not a primary study of the required design types, and while it reviews such studies, it doesn't match the required study designs itself.",no,No specific temporal relationships or medication duration are mentioned.,maybe,"The abstract does not specify the number of subjects in the studies reviewed, and since this is a systematic review of multiple studies, individual study sizes are not mentioned.","The abstract discusses MRONJ in relation to dental procedures but doesn't specify which procedures, so while dental procedures are implied, specific interventions are not detailed.",Exclude,"The systematic review fails to meet critical screening criteria, particularly the specific requirement for Romosozumab intervention and the need for a primary study design. Multiple key elements are either partially met or completely unaddressed, including subject size, population type, control group, and temporal documentation of medication use and outcomes. The broad nature of the review and lack of specificity in key areas render it unsuitable for the defined screening requirements.",1.4
A systematic review assessing occurrence of medication-related osteonecrosis of the jaw following dental procedures,"Shimelly Monteiro de Castro Lara, F. Muniz, Ana C. R. Geronimo, Cinthia Studzinski dos Santos, Thayanne Brasil Barbosa Calcia",10.20396/bjos.v21i00.8666585,https://doi.org/10.20396/bjos.v21i00.8666585,Brazilian Journal of Oral Sciences,1,2022,maybe,"The study includes adults (mean age 64 years) but also includes cancer patients, which is explicitly excluded in the criteria. The abstract doesn't specify if non-cancer patients were included.",yes,yes,"The study clearly documents MRONJ outcomes following dental procedures, particularly tooth extractions.",maybe,"As a systematic review, it likely includes studies with control groups, but this isn't explicitly stated in the abstract.",maybe,The abstract doesn't specify the study designs of the included papers.,maybe,"While the study examines the relationship between dental procedures and MRONJ, the abstract doesn't specify if it documents the temporal relationship and duration of medication use.",maybe,"The abstract does not explicitly state the total subject size, so it is unclear if the study meets the requirement of having more than 100 participants.","The study explicitly focuses on dental procedures including tooth extractions and periodontal therapy, which meets the intervention criterion.",Exclude,"The systematic review fails to meet critical screening criteria, specifically the requirement for Romosozumab as the intervention medication. While the study addresses dental procedures and MRONJ outcomes, the inclusion of cancer patients and use of different bone-modifying drugs disqualifies it from meeting the specified screening requirements. Multiple key criteria remain unclear, further compromising the study's alignment with the predefined screening standards.",1.4
Dental Implant Placement in Patients with a History of Medications Related to Osteonecrosis of the Jaws: A Systematic Review.,"J. Sher, K. Kirkham-Ali, Denny Luo, Catherine M Miller, D. Sharma",10.1563/aaid-joi-d-19-00351,https://doi.org/10.1563/aaid-joi-d-19-00351,Journal of Oral Implantology,32,2020,maybe,"While the study includes patients with osteoporosis, it also includes patients with malignancy, which is explicitly excluded in the criteria. The age criterion is not explicitly stated.",yes,yes,The study specifically documents MRONJ outcomes following dental procedures (implant placement).,maybe,"The abstract does not explicitly mention control groups, though the inclusion of case-control studies suggests some studies may have had controls.",yes,"The abstract includes cohort studies, case-control studies, and case series, which meet the criteria for study design.",maybe,"While the abstract mentions ""history of"" drug therapy, it does not clearly document the temporal relationship or duration of medication use.",maybe,"The abstract does not specify the total number of subjects across the included studies, so it is unclear if the subject size exceeds 100 people.","The study specifically focuses on dental implant placement, which is one of the specified invasive dental treatments.",Exclude,"The systematic review fails to meet critical screening criteria, specifically the requirement for Romosozumab as the intervention medication. While the study addresses dental implant placement and includes various study designs, it includes cancer patients and does not focus exclusively on osteoporosis patients using the specified medication. Multiple screening criteria remain partially or completely unmet, rendering the study non-compliant with the established requirements.",1.4
The role of antiresorptive drugs and medication-related osteonecrosis of the jaw in nononcologic immunosuppressed patients: A systematic review,"R. Sacco, Julian Woolley, J. Yates, M. Calasans-Maia, O. Akintola, V. Patel",10.4103/JRMS.JRMS_794_20,https://doi.org/10.4103/JRMS.JRMS_794_20,Journal of Research in Medical Sciences,5,2021,no,"The study focuses on immunosuppressed patients, not specifically osteoporosis patients, and there is no mention of age restrictions. This indicates that the study does not meet the criterion of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",yes,yes,"The study clearly documents MRONJ outcomes following dental procedures, which meets the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"There is no mention of a control group in the study, which means it does not meet the criterion of including a control group of non-anti-resorptive medication users.",no,"The study is a systematic review, not a primary study, which means it does not meet the criterion of having a study design of a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"There is no clear documentation of the temporal relationship between medication use and MRONJ development, or the duration of medication use, which means the study does not meet the criterion of clearly documenting both the temporal relationship and duration of medication use.",yes,"The study includes a total of 206 patients, which meets the criterion of having a subject size of more than 100 people.","The study clearly includes dental extractions (n=197) as an intervention, which meets the criterion of having an intervention of invasive dental treatment.",Exclude,"The systematic review fails to meet critical screening criteria, particularly the specific intervention of Romosozumab and the required population of osteoporosis patients. Multiple key requirements were not satisfied, including study design, control group presence, and precise population characteristics. Consequently, the study does not align with the predefined screening parameters and would be excluded from further review.",0.1
Pharmacogenetics of medication-related osteonecrosis of the jaw: a systematic review and meta-analysis.,"Z. Guo, W. Cui, L. Que, C. Li, Xiu-fa Tang, J. Liu",10.1016/j.ijom.2019.07.016,https://doi.org/10.1016/j.ijom.2019.07.016,International Journal of Oral & Maxillofacial Surgery,20,2020,no,"The study includes multiple myeloma patients, which violates the criterion of excluding cancer patients. The age range is also not specified, so this criterion is not met.",no,no,"While MRONJ is the outcome, the abstract doesn't specify documentation of dental procedures, so this criterion is not met.",maybe,"The study appears to compare MRONJ vs non-MRONJ groups, but it's unclear if these are specifically non-anti-resorptive medication users, so this criterion is uncertain.",no,"This is a systematic review, not a primary study of the required designs, so this criterion is not met.",no,"The abstract doesn't mention temporal relationships or duration of medication use, so this criterion is not met.",yes,"The study includes 1515 participants, which exceeds the minimum requirement of 100, so this criterion is met.","The abstract does not specify any dental procedures or interventions, which is a critical missing element.",Exclude,"The systematic review fails to meet multiple critical screening criteria, including the specific medication requirement, population type, and study design. Key deficiencies include the use of bisphosphonates instead of Romosozumab, inclusion of cancer patients, and lack of documentation for dental interventions and temporal medication use. These fundamental deviations from the screening criteria render the study unsuitable for inclusion in the systematic review.",0.1
Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab,"A. Wick, Philipp Bankosegger, S. Otto, B. Hohlweg-Majert, T. Steiner, F. Probst, O. Ristow, C. Pautke",10.1007/s00784-021-04261-4,https://doi.org/10.1007/s00784-021-04261-4,Clinical Oral Investigations,19,2021,no,"The study includes patients with cancer (specifically mentions breast cancer), which is explicitly excluded in the criteria. While it includes osteoporosis patients, the mixed population doesn't meet the criteria.",maybe,maybe,"While MRONJ outcomes are documented, the abstract doesn't clearly specify which dental procedures were performed in relation to MRONJ development.",yes,"The study includes a control group (Group I, n=40) of patients receiving DNO without MRONJ.",yes,"The study is described as a ""retrospective single-center cohort study,"" which meets the acceptable study design criteria.",maybe,The abstract doesn't explicitly document the temporal relationship between medication use and MRONJ development or the duration of medication use.,yes,"The study includes 128 patients, which exceeds the minimum requirement of 100 subjects.","While the abstract mentions ""trauma"" and ""oral inflammation"" as risk factors, it doesn't explicitly state that all subjects underwent invasive dental procedures. However, it does mention denture use as a risk factor.",Exclude,"The study focuses on Denosumab rather than Romosozumab, and includes cancer patients, which immediately disqualifies it from meeting the specified screening criteria. While the research demonstrates methodological rigor with a robust sample size and control group, critical deviations from the required intervention and population type render the study non-compliant with the predefined screening requirements.",1.4
A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients,"Seoyeon Jung, Jaeyeon Kim, Jin Hoo Park, Kiyomi Kim, Hyung Jun Kim, Wonse Park",10.1038/s41598-022-11615-9,https://doi.org/10.1038/s41598-022-11615-9,Scientific Reports,13,2022,maybe,"While the study involves osteoporotic patients, the abstract doesn't explicitly state that all patients are adults (≥18 years) or confirm the absence of cancer patients.",yes,yes,The study clearly documents MRONJ outcomes following specific dental procedures (tooth extraction).,no,"The study compares two groups of denosumab users (one with prior bisphosphonate use), but does not include a control group of non-anti-resorptive medication users.",maybe,"The study design is not explicitly stated in the abstract, though it appears to be a retrospective cohort study based on the methodology described.",yes,"The study documents the temporal relationship between medication use and MRONJ development, including cases that developed MRONJ before and after tooth extraction.",yes,"The study includes 98 patients, which exceeds the minimum requirement of 100, though it is very close to the threshold.","The study explicitly focuses on invasive dental treatment, specifically tooth extraction.",Exclude,"The study focuses on denosumab for osteoporosis patients, which fundamentally differs from the specified romosozumab intervention, representing a critical screening criterion mismatch. While the research meets several other criteria such as subject size, dental intervention, and outcome documentation, the primary intervention deviation disqualifies the study from meeting the core screening requirements.",1.4
"A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit.","U. Disel, A. Besen, Ö. Özyi̇lkan, E. Er, T. Canpolat",10.1016/j.oraloncology.2011.07.030,https://doi.org/10.1016/j.oraloncology.2011.07.030,Oral Oncology,38,2012,no,"The abstract does not specify the age range of the patients and focuses on patients with cancer, which is explicitly excluded in the criteria.",maybe,maybe,"The abstract does document MRONJ outcomes, but the specific dental procedures are not clearly documented.",no,"The abstract does not mention a control group, and the study appears to be a review of cases rather than a comparative study.",no,"The paper is a review article, not a primary research study, and does not match any of the required study designs.",no,The abstract does not provide clear documentation of the temporal relationships or duration of medication use.,no,"The total number of patients included in the study was 36, which is well below the required minimum of 100 subjects.","The abstract mentions ""invasive dental procedures"" as triggers for MRONJ, but does not provide details on the specific procedures.",Exclude,"The study fails multiple critical screening criteria, including using the wrong medication, having an insufficient sample size, focusing on cancer patients, and being a review rather than a primary research study. Specifically, the research does not involve Romosozumab, lacks a control group, and does not meet the required study design or population specifications. These fundamental deviations from the screening requirements render the paper unsuitable for inclusion in the systematic review.",0.1
Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-Naïve Patient: A Comprehensive Review of the Literature,"Kununya Pimolbutr, S. Porter, S. Fedele",10.1155/2018/8071579,https://doi.org/10.1155/2018/8071579,BioMed Research International,62,2018,no,"The study includes patients with cancer (specifically mentions metastatic renal cell cancer as the most common underlying disease), which is explicitly excluded in the criteria.",maybe,maybe,"While MRONJ outcomes are documented, they're not specifically tied to the dental procedures in a systematic way.",no,The abstract doesn't mention a control group of non-anti-resorptive medication users.,no,"This appears to be a literature review rather than a primary research study (RCT, cohort, or case-control study).",maybe,"The abstract mentions duration of antiangiogenic therapy before MRONJ development (6.5 and 16.72 months), but this isn't for the specific medication of interest (Romosozumab).",no,"The study reports on only 35 patients, which is well below the required minimum of 100 subjects.","The abstract mentions dental extraction as a risk factor (37.14% of cases), but this isn't the primary focus of the study.",Exclude,"The study fails to meet multiple critical screening criteria, including the wrong intervention type, insufficient sample size, and inclusion of cancer patients. Fundamental differences in medication focus, study design, and population characteristics render this paper unsuitable for the systematic review. The abstract describes a literature review on antiangiogenics in antiresorptive-naïve patients, which diverges significantly from the specified research parameters.",0.1
Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.,"G. Ghidini, M. Manfredi, I. Giovannacci, G. Mergoni, A. Sarraj, Maura Mureddu, G. Giunta, M. Bonanini, M. Meleti, P. Vescovi",10.23736/S0026-4970.17.04056-0,https://doi.org/10.23736/S0026-4970.17.04056-0,Minerva Stomatologica,19,2017,no,"The study explicitly mentions patients with oncologic disease, which is specifically excluded in the criteria. The abstract doesn't clearly indicate if any patients had non-cancer osteoporosis.",yes,yes,The study clearly documents MRONJ outcomes following specific dental procedures.,no,No mention of a control group of non-anti-resorptive medication users. The comparison is between different types of anti-resorptive medication users.,yes,"This is a retrospective cohort study, which meets the criteria.",maybe,"While the study period is documented (2004-2016), the abstract doesn't clearly specify the temporal relationship between medication use and MRONJ development or the duration of medication use.",yes,"The study includes 303 patients, well above the minimum requirement of 100.","The study mentions dental extraction, bone surgery, and other dental procedures as triggers for MRONJ.",Exclude,"The study fails key screening criteria by focusing on bisphosphonates and antiresorptive-antiangiogenic drugs instead of Romosozumab, and by including cancer patients which are explicitly excluded. While the research demonstrates a robust sample size and appropriate study design, critical mismatches with the specified intervention and population type render the study non-compliant with the established screening requirements.",1.4
Medication-related osteonecrosis of the jaw (MRONJ) stage III: Conservative and conservative surgical approaches versus an aggressive surgical intervention: A systematic review.,"V. Jasper, V. Laurence, Smeets Maximiliaan, J. Ferri, R. Nicot, P. Constantinus",10.1016/j.jcms.2020.02.017,https://doi.org/10.1016/j.jcms.2020.02.017,Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,42,2020,maybe,"The abstract doesn't specify if patients are adults or if they have cancer. It only mentions they received zoledronic acid, which is often used in cancer treatment.",maybe,maybe,"While MRONJ outcomes are documented, the specific dental procedures leading to MRONJ are not clearly described in the abstract.",no,No control group is mentioned in the abstract.,yes,"The study is described as a retrospective cohort study, which meets the criteria.",yes,The study documents medication duration (specifically mentioning >18 months) and its relationship to outcomes.,no,"The study includes only 58 patients, which is below the required minimum of 100 subjects.","While the study deals with MRONJ, which typically follows dental procedures, the abstract doesn't explicitly state what dental procedures were performed.",Exclude,"The study fails key screening criteria by using zoledronic acid instead of romosozumab, having a small sample size of 58 patients, and lacking a control group. Multiple critical elements are either missing or unclear, including specific dental procedures, patient population characteristics, and comprehensive outcome documentation. These significant deviations from the required screening parameters render the study non-compliant with the established inclusion criteria.",1.4
Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases,"H. Ikesue, Moe Mouri, H. Tomita, M. Hirabatake, M. Ikemura, Nobuyuki Muroi, S. Yamamoto, T. Takenobu, K. Tomii, M. Kawakita, Hironori Katoh, T. Ishikawa, H. Yasui, T. Hashida",10.1007/s00520-021-06018-x,https://doi.org/10.1007/s00520-021-06018-x,Supportive Care in Cancer,28,2021,no,"The study specifically focuses on patients with cancer and bone metastases, which is explicitly excluded in the criteria. The population is also not exclusively osteoporosis patients.",yes,yes,"The study clearly documents MRONJ outcomes following dental procedures, particularly tooth extraction.",no,The study compares two different anti-resorptive medications (denosumab vs zoledronic acid) but does not include a control group of non-users.,yes,"This is a retrospective cohort study, which meets the acceptable study design criteria.",yes,"The study appears to document temporal relationships between medication use and MRONJ development, with clear timing information provided.",yes,"The study includes 374 patients, well above the minimum requirement of 100.","The study includes tooth extraction and mentions dental procedures, though specific details are limited in the abstract.",Exclude,"The study focuses on cancer patients receiving denosumab or zoledronic acid, which fundamentally differs from the required osteoporosis patient population using romosozumab. Critical screening criteria were not met, including the specific medication, patient population, and control group requirements. These significant deviations render the study ineligible for inclusion in the systematic review.",0.1
Medication-Related Osteonecrosis of the Jaw in Dental Practice: A Retrospective Analysis of Data from the Milan Cohort,"Cristina Mirelli, S. Marino, A. Bovio, Sara Pederielli, C. Dall’Agnola, A. Giannì, R. Biagi",10.3390/dj10050089,https://doi.org/10.3390/dj10050089,Dental journal,5,2022,maybe,"The study includes both osteoporotic and cancer patients, while the criteria specifically require exclusively osteoporotic patients without cancer. The abstract doesn't separate the results between these groups.",maybe,maybe,"While MRONJ outcomes are mentioned, the abstract doesn't clearly document specific dental procedures leading to MRONJ.",no,The abstract doesn't mention a control group of non-anti-resorptive medication users.,yes,"It's a retrospective analysis, which falls under the acceptable study designs.",maybe,"The study mentions ""duration of treatment"" as a collected variable, but doesn't clearly document the temporal relationship between medication use and MRONJ development.",yes,"The study includes 434 patients, well above the minimum requirement of 100.","While dental treatments are mentioned, the abstract doesn't clearly specify which invasive procedures were performed. It only mentions ""dental extractions"" as a risk factor.",Include,"The study fails to meet critical screening criteria, particularly the specific requirement for Romosozumab as the intervention medication. While the research includes a substantial patient sample and appropriate study design, it lacks precise documentation of dental procedures and includes cancer patients, which deviates from the specified population requirements. Multiple screening criteria were only partially met or not met at all, rendering the study unsuitable for inclusion.",2.7
Cancer Patients at Risk for Medication-Related Osteonecrosis of the Jaw. A Case and Control Study Analyzing Predictors of MRONJ Onset,"A. Marcianó, Y. Ingrasciotta, Valentina Isgró, L. L'Abbate, S. S. Foti, A. Picone, M. Peditto, G. Guzzo, A. Alibrandi, G. Oteri",10.3390/jcm10204762,https://doi.org/10.3390/jcm10204762,Journal of Clinical Medicine,8,2021,no,"The study explicitly focuses on cancer patients, which directly contradicts the criterion requiring non-cancer patients, and is another clear failure of a critical criterion.",no,no,"While MRONJ is the outcome of interest, the abstract does not specify documentation of dental procedures, so this criterion is not clearly met.",no,"The study appears to be analyzing risk factors within a cohort of patients already on medication, and there is no clear mention of a control group of non-users, so this criterion is not met.",yes,"The study appears to be a cohort study with propensity score matching, which would meet the criterion.",maybe,"The study does document medication use (number of doses), but the temporal relationship with MRONJ development is not clearly specified.",maybe,"The abstract does not explicitly state the sample size, creating uncertainty, though the study appears to be a substantial cohort study.","The abstract does not mention any specific dental procedures, which is a significant missing element.",Exclude,"The study focuses on cancer patients using zoledronic acid and denosumab, which fundamentally conflicts with the screening criteria requiring non-cancer patients and Romosozumab. Multiple critical screening requirements are unmet, including medication type, population characteristics, and lack of clear dental intervention documentation. These significant deviations render the study ineligible for inclusion in the systematic review.",0.1
Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab-a review.,"Rebecca King, N. Tanna, V. Patel",10.1016/j.oooo.2018.11.012,https://doi.org/10.1016/j.oooo.2018.11.012,"Oral surgery, oral medicine, oral pathology and oral radiology",64,2019,no,"The abstract discusses both cancer and non-cancer patients, and does not focus exclusively on adult osteoporosis patients. This suggests that the study does not meet the criterion of focusing on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",no,no,"While MRONJ is discussed, the paper does not report specific outcomes following dental procedures. It is a general review of medications associated with MRONJ, rather than a study of specific outcomes. This indicates that the study does not meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"The abstract does not mention any control groups, and the paper is a review article rather than a comparative study. This indicates that the study does not meet the criterion of including a control group of non-anti-resorptive medication users.",no,"The paper appears to be a narrative review article, and does not match any of the required study designs (RCT, cohort, or case-control). This suggests that the study does not meet the criterion of having a study design of a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,The abstract does not document any specific temporal relationships or medication durations. This suggests that the study does not meet the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.,no,"The abstract does not mention any specific study size, and the paper appears to be a review article rather than a primary research study. This suggests that the study does not meet the criterion of having a subject size of more than 100 people.","While the abstract discusses MRONJ, it does not specifically study dental procedures. The paper is a review of medications associated with MRONJ rather than a study of dental interventions. This indicates that the study does not meet the criterion of having an intervention of invasive dental treatment.",Exclude,"This narrative review article fails to meet multiple critical screening criteria, including specific intervention type, subject size, population focus, and study design. The paper discusses medication-related osteonecrosis of the jaw across various drug classes but does not align with the required research parameters for the systematic review. Consequently, the abstract does not qualify for inclusion based on the predefined screening requirements.",0.1
Clinical features of peri-implant medication-related osteonecrosis of the jaw: Is there an association to peri-implantitis?,"M. Troeltzsch, D. Cagna, Philip Stähler, F. Probst, G. Kaeppler, M. Troeltzsch, M. Ehrenfeld, S. Otto",10.1016/j.jcms.2016.09.018,https://doi.org/10.1016/j.jcms.2016.09.018,Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,47,2016,no,"The abstract indicates that ""the majority of whom had received antiresorptive drug therapy within oncologic treatment protocols,"" suggesting these are cancer patients, which is explicitly excluded by the criteria.",yes,yes,The study clearly documents MRONJ outcomes following dental procedures (specifically implants).,no,No control group of non-anti-resorptive medication users is mentioned in the abstract.,yes,"The study is described as a retrospective study, which meets the criteria.",maybe,"While the study period (2010-2016) is mentioned, the abstract doesn't clearly document the temporal relationship between medication use and MRONJ development or the duration of medication use.",no,"The study includes only 34 patients, which is well below the required minimum of 100 subjects.","The study focuses on dental implants, which is one of the specified invasive dental treatments.",Exclude,"The study fails key screening criteria due to its small sample size of 34 patients, focus on cancer patients receiving antiresorptive drugs, and lack of a control group. While the research examines dental implants and MRONJ, it does not meet the specified requirements for medication type, population, and study design. Consequently, the paper would be excluded from the systematic review.",0.1
Medication-Related Osteonecrosis of the Jaw – 2022 Update,S. Ruggiero,-,-,-,221,2022,no,"No specific population characteristics are mentioned in the abstract, and this is a general guidance document. Therefore, the population type does not meet the criterion of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",no,no,"While MRONJ is discussed, this is not a study documenting specific outcomes. Therefore, the study does not meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"No control group is mentioned in the abstract, and this is not a comparative study. Therefore, the study does not meet the criterion of including a control group of non-anti-resorptive medication users.",no,"This is a position paper/guidance document, not a primary research study, and does not meet any of the required study designs (randomized controlled trial, prospective/retrospective cohort study, or case-control study).",no,"No temporal relationships or medication durations are documented in the abstract. Therefore, the study does not meet the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",no,"No specific subject size is mentioned in the abstract, and this is a position paper/review rather than a primary research study. Therefore, the subject size does not meet the criterion of having more than 100 people.","While dental procedures are implied as part of MRONJ management, this is not a study of specific interventions. Therefore, the intervention does not meet the criterion of having an intervention of invasive dental treatment.",Exclude,"This position paper fails to meet the screening criteria for a research study, lacking specific details about patient population, intervention, control group, and study design. The document provides clinical guidance on medication-related osteonecrosis of the jaw but does not constitute a primary research investigation with the required methodological elements. Consequently, it does not qualify for inclusion based on the predefined screening requirements.",0.1
Medication-Related Osteonecrosis of the Jaws: Considerations on a New Antiresorptive Therapy (Denosumab) and Treatment Outcome after a 13-Year Experience,"G. Favia, A. Tempesta, L. Limongelli, V. Crincoli, E. Maiorano",10.1155/2016/1801676,https://doi.org/10.1155/2016/1801676,International Journal of Dentistry,27,2016,maybe,"The study includes patients with osteoporosis, but also includes patients with ""bone neoplastic localizations"" (cancer). The abstract doesn't separate these populations in the results.",maybe,yes,"The study clearly documents MRONJ outcomes and their treatment, including staging and follow-up.",no,No control group is mentioned in the abstract.,yes,This appears to be a retrospective cohort study following patients from 2003 to 2015.,maybe,"While the study documents follow-up (up to 13 years), it doesn't clearly specify the temporal relationship between medication use and MRONJ development.",yes,"The study includes 244 patients, well above the minimum requirement of 100.","While the study discusses surgical treatment of MRONJ, it doesn't explicitly state whether these were triggered by dental procedures. The abstract doesn't specify the initial dental interventions that led to MRONJ.",Exclude,"The study focuses on denosumab-related MRONJ, which fundamentally differs from the specified romosozumab intervention, rendering it non-compliant with the primary screening criteria. Additional limitations include a mixed patient population with cancer patients, absence of a control group, and unclear documentation of initial dental interventions. These significant deviations from the required screening parameters suggest the study does not meet the established inclusion criteria.",1.4
"Medication-related osteonecrosis of the jaw: A review about etiology, risk factors, pathophysiology, and treatment","Sheetal Singar, A. Parihar, P. Reddy, A. Maurya, Vishal Bamaniya",10.4103/jiaomr.jiaomr_206_19,https://doi.org/10.4103/jiaomr.jiaomr_206_19,Journal of Indian Academy of Oral Medicine and Radiology,3,2020,maybe,"The abstract does not provide any specific information about the age groups or whether the study focuses exclusively on adult patients with diagnosed osteoporosis who do not have cancer. Therefore, it is uncertain whether the population type meets the requirements.",maybe,maybe,"The abstract discusses MRONJ outcomes generally and mentions extraction as a risk factor, which partially meets the requirement of reporting MRONJ outcomes following specific, documented dental procedures.",no,"The abstract does not mention any control groups or comparisons between medication users and non-users, so it fails to meet the requirement of including a control group.",no,"The abstract appears to be a review or commentary rather than an original research study, and does not mention any specific study design. Therefore, it fails to meet the requirement of having a randomized controlled trial, prospective/retrospective cohort study, or case-control study design.",no,"The abstract does not provide any specific documentation of the temporal relationship between medication use and MRONJ development, or the duration of medication use. Therefore, it fails to meet the requirement of clearly documenting both the temporal relationship and the duration of medication use.",maybe,"The abstract does not mention the sample size, so it is uncertain whether the study meets the requirement of having more than 100 subjects.","The abstract mentions ""dentoalveolar trauma and extraction"" as risk factors, and discusses dental evaluation and treatment, which partially meets the requirement of having an intervention of invasive dental treatment.",Exclude,"The abstract fails to meet multiple critical screening criteria, including specific intervention details, study design requirements, and control group specifications. While discussing medication-related osteonecrosis of the jaw, the text lacks the precise methodological and population characteristics needed for systematic review inclusion. Key elements such as Romosozumab use, subject size, and temporal documentation are absent or insufficiently addressed.",1.4
Medication-Related Osteonecrosis of the Jaw: A Review,"Nandita Gautam, Sheena Kaur Samagh",10.47363/jmhc/2022(4)212,https://doi.org/10.47363/jmhc/2022(4)212,Journal of Medicine and HealthCare,1,2022,maybe,"The paper mentions patients with osteoclastic bone disease and osteoporosis, but does not specify that the study focuses exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",no,no,"While MRONJ is discussed, the paper does not report specific MRONJ outcomes following documented dental procedures (extractions, periodontal surgery, implants, or prosthetic treatments).",no,There is no mention of a control group of non-anti-resorptive medication users in the paper.,no,"The paper is described as an ""analysis"" to ""pinpoint all potential causes"", indicating that it is a review paper rather than a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The paper does not clearly document the temporal relationship between medication use and MRONJ development, nor the duration of medication use.",no,"No specific subject size is mentioned, and the paper appears to be a review/analysis rather than a primary study. This suggests that the study does not have a subject size of more than 100 people.","While dental procedures are mentioned, this is a general review of MRONJ rather than a specific intervention study. The paper does not describe a study with an intervention of invasive dental treatment, including tooth extraction, implant placement, periodontal surgery, other dental surgery, or removable prosthesis fabrication.",Exclude,"This review paper fails to meet multiple critical screening criteria, particularly the requirement for a study on Romosozumab, with no specific intervention, subject size, or control group documented. The abstract represents a general analysis of medication-related osteonecrosis of the jaw rather than a focused research study meeting the predefined systematic review parameters. Consequently, the paper does not qualify for inclusion in the systematic review.",0.1
Incidence and severity of medication-related osteonecrosis of the jaw in patients with osteoporosis using data from a Korean nationwide sample cohort in 2002 to 2019: a retrospective study,"Su-Youn Ko, Tae-Yoon Hwang, Kiook Baek, Chulyong Park",10.12701/jyms.2023.01116,https://doi.org/10.12701/jyms.2023.01116,Journal of Yeungnam Medical Science,0,2024,yes,"The study focuses on adult patients (≥40 years) with diagnosed osteoporosis, and there's no mention of cancer patients.",maybe,maybe,"While MRONJ outcomes are documented, the specific dental procedures leading to MRONJ are not clearly detailed in the abstract.",maybe,The abstract doesn't explicitly mention a control group of non-anti-resorptive medication users.,yes,This appears to be a retrospective cohort study using national health insurance data.,maybe,"The abstract mentions ""duration of use"" but doesn't clearly document the temporal relationship between medication use and MRONJ development.",yes,"The study uses a large national database cohort, which would certainly exceed 100 subjects.","The abstract mentions ""invasive treatment"" but doesn't specify the types of dental procedures, only that 71.3% underwent invasive treatment.",Exclude,"The study fails to meet the primary screening criterion of using Romosozumab as the intervention, rendering it ineligible for inclusion. While the research demonstrates methodological rigor and addresses several other screening requirements, the absence of the specified medication disqualifies it from further consideration. Multiple partial or unclear criteria further complicate its potential suitability.",0.1
Treatment of medication-related osteonecrosis of the jaw (MRONJ). A systematic review.,"F. Goker, E. Grecchi, F. Grecchi, L. Francetti, M. Del Fabbro",10.26355/eurrev_202103_25430,https://doi.org/10.26355/eurrev_202103_25430,European Review for Medical and Pharmacological Sciences,21,2021,maybe,"The abstract does not specify age restrictions or cancer status, and only mentions ""patients under current or previous treatment with antiresorptive agents"", which is insufficient information to confirm this criterion.",no,no,"While MRONJ outcomes are discussed, this is a review of treatment options, and does not document specific dental procedures and outcomes, so it does not meet this criterion.",no,"There is no mention of control groups, and this is a review of treatment options rather than a comparative study, so it does not meet this criterion.",no,"This is a systematic review, not a primary research study, and does not meet the required study design criteria.",no,"There is no specific documentation of temporal relationships or medication duration, so it does not meet this criterion.",no,"The abstract mentions ""at least 3 cases"" as inclusion criteria, which is much lower than the required 100 subjects, and is another critical failure.","The abstract discusses various treatments including surgical procedures, but this is a review of treatment options rather than a study of dental procedures, so it does not meet this criterion.",Exclude,"The systematic review fails to meet multiple critical screening criteria, including specific intervention with Romosozumab, required subject size, and appropriate study design. Key deficiencies include lack of focus on Romosozumab, insufficient subject numbers, and absence of a primary research approach with clear control groups and temporal documentation. The paper represents a broad review of MRONJ treatment options rather than a targeted study meeting the specified screening requirements.",0.1
The effect of antiresorptive drugs on implant therapy: Systematic review and meta‐analysis,"A. Stavropoulos, K. Bertl, P. Pietschmann, N. Pandis, M. Schiødt, B. Klinge",10.1111/clr.13282,https://doi.org/10.1111/clr.13282,Clinical Oral Implants Research,93,2018,maybe,"The study includes adult patients with osteoporosis, but also includes cancer patients. The abstract doesn't clearly separate these populations in all analyses, which is a partial match with the population type criterion.",yes,yes,"The study reports MRONJ outcomes following specific dental procedures (implant therapy), which meets the outcome documentation criterion.",yes,"The abstract explicitly mentions including controls not taking the medication, which meets the control group criterion.",yes,"The study includes case series, cohort studies, case-control studies, and controlled/ randomized controlled clinical trials, which meets the study design criterion.",yes,"The study documents temporal relationships, noting that MRONJ appeared in 70% of cases >36 months after BP intake for osteoporosis patients, which meets the temporal documentation criterion.",yes,"The study includes multiple studies with >10 patients, and the meta-analysis includes data from 24 studies on bisphosphonates and 7 on HRT, which meets the subject size criterion.","The study specifically focuses on implant therapy and associated bone grafting procedures, which meets the criterion for invasive dental treatment.",Exclude,"The study primarily focuses on bisphosphonates and hormone replacement therapy, not Romosozumab, which critically disqualifies it from meeting the intervention screening criterion. While the research demonstrates robust methodology and includes multiple relevant dental intervention parameters, the fundamental mismatch with the specified medication type renders the study non-compliant with the core screening requirements. The inclusion of cancer patients further complicates its alignment with the predefined population criteria.",1.4
In Vitro Cytotoxicity of Antiresorptive and Antiangiogenic Compounds on Oral Tissues Contributing to MRONJ: Systematic Review,"R. H. Guirguis, L. Tan, Rebecca M. Hicks, Aniqa Hasan, Tina D. Duong, Xia Hu, Jordan Y. S. Hng, M. H. Hadi, Henry C. Owuama, Tamara Matthyssen, M. McCullough, Federica Canfora, R. Paolini, A. Celentano",10.3390/biom13060973,https://doi.org/10.3390/biom13060973,Biomolecules,6,2023,no,"The study focuses on cell cultures (gingival fibroblasts, oral keratinocytes, alveolar osteoblasts), not a study of adult patients with osteoporosis, so it does not meet the population type criterion.",no,no,"While MRONJ is mentioned, the outcomes measured are cellular responses (proliferation, viability, migration), not documenting clinical MRONJ outcomes, so it does not meet the outcome documentation criterion.",no,"As an in vitro study review, this does not include human control groups, so it does not meet the control group criterion.",no,"This is a systematic review of in vitro studies, which does not match the required study designs (RCT, cohort, or case-control), so it does not meet the study design criterion.",no,"There is no documentation of temporal relationships or medication duration in patients, so it does not meet the temporal documentation criterion.",no,"This is a review of in vitro studies, not clinical studies with human subjects, so it does not meet the criterion of having a subject size of more than 100 people.","While the abstract mentions ""invasive dental treatment,"" this is in the context of background information, and the actual studies reviewed are in vitro studies, not clinical interventions. Therefore, the study does not meet the criterion of having an intervention of invasive dental treatment.",Exclude,"This in vitro study review of cellular responses to antiresorptive drugs fails to meet any of the specified screening criteria for a clinical study on Romosozumab and MRONJ. The research focuses on laboratory cell cultures examining drug mechanisms, not patient outcomes, and lacks the required clinical parameters such as patient population, intervention type, and outcome documentation.",0.1
Prophylaxis and antibiotic therapy in management protocols of patients treated with oral and intravenous bisphosphonates,"Elena-Beatriz Bermúdez-Bejarano, M. Serrera-Figallo, Aida Gutiérrez-Corrales, Manuel-María Romero-Ruíz, Raquel Castillo-de-Oyagüe, J. Gutierrez-Perez, D. Torres-Lagares",10.4317/jced.53372,https://doi.org/10.4317/jced.53372,Journal of Clinical and Experimental Dentistry,41,2017,maybe,"The abstract mentions patients with bisphosphonate treatment, which includes both cancer and non-cancer patients, and does not specify age restrictions, so it only partially meets the population type criterion.",yes,maybe,"The abstract discusses MRONJ outcomes following dental procedures, but this is in the context of a review rather than primary documentation, so it only partially meets the outcome documentation criterion.",no,"There is no mention of a control group, and this is a literature review rather than a comparative study, so it fails to meet the control group criterion.",no,"This is a literature review, not a primary research study, so it does not meet the required study design criteria.",no,"There is no clear documentation of temporal relationships or duration of medication use, as this is a review rather than a primary study, so it fails to meet the temporal documentation criterion.",no,"The abstract does not specify the number of subjects, and this is a literature review rather than a primary study, so the subject size is unclear.","The abstract discusses oral surgery and tooth extraction, which meets the criterion for invasive dental treatment.",Exclude,"The study focuses on bisphosphonates rather than Romosozumab, immediately disqualifying it from the systematic review. Multiple screening criteria were not met, including the required study design, control group, and specific population parameters. The literature review's methodology and focus fundamentally differ from the targeted research requirements.",0.1
Tooth extractions in patients with cancer receiving high-dose antiresorptive medication: a randomized clinical feasibility trial of drug holiday versus drug continuation.,"C. Ottesen, M. Schiødt, S. S. Jensen, T. Kofod, K. Gotfredsen",10.1016/j.oooo.2021.06.003,https://doi.org/10.1016/j.oooo.2021.06.003,"Oral surgery, oral medicine, oral pathology and oral radiology",33,2021,no,"The study specifically focuses on cancer patients receiving high-dose antiresorptive medication, which explicitly fails the criterion as it includes cancer patients instead of the required population of adults with osteoporosis.",yes,yes,"The study clearly documents MRONJ outcomes following tooth extraction, which meets the criterion.",no,"The study compares drug holiday vs. drug continuation groups, but does not include a control group of non-anti-resorptive medication users.",yes,"The study is a randomized controlled trial, which meets the criterion for study design.",yes,"The study documents the temporal relationship between medication use and MRONJ development (1 month before to 3 months after extraction) and the duration of medication use (median 9 and 17.5 months), which meets the criterion.",no,"The study included only 23 patients, which fails to meet the minimum requirement of 100 subjects.","The study includes surgical tooth extraction, which meets the criterion for invasive dental treatment.",Exclude,"The study fails critical screening criteria by using denosumab and bisphosphonates instead of Romosozumab, having a small sample size of 23 patients, and focusing on cancer patients rather than osteoporosis patients. Despite meeting some methodological criteria like study design and outcome documentation, the fundamental deviations from the required intervention and population type necessitate exclusion from the systematic review.",0.1
Success rate and safety of dental implantology in patients treated with antiresorptive medication: A systematic review.,"I. Papadakis, A. Spanou, D. Kalyvas",10.1563/aaid-joi-d-19-00088,https://doi.org/10.1563/aaid-joi-d-19-00088,Journal of Oral Implantology,11,2020,maybe,"While the study involves patients receiving antiresorptive medication, it doesn't explicitly state that all patients are adults (≥18) or specify that cancer patients are excluded.",yes,yes,The study reports MRONJ outcomes following dental procedures (specifically implants).,maybe,The abstract doesn't explicitly mention a control group of non-antiresorptive medication users.,no,"This is a systematic review, not a primary research study of the specified designs (RCT, cohort, or case-control).",maybe,"While the abstract mentions ""early or late complications,"" it doesn't clearly indicate whether the temporal relationship between medication use and MRONJ development is documented.",yes,"The study includes 5,221 patients, which is well above the 100-person threshold specified in the criteria.","The study specifically focuses on dental implants, which is one of the specified invasive dental treatments.",Exclude,"The systematic review fails to meet key screening criteria, particularly the requirement for a primary research study focusing on Romosozumab and a specific patient population. While the study includes a large sample size and examines dental implant outcomes, it lacks the precise intervention and study design specifications needed for inclusion. Multiple screening criteria remain unclear or unmet, significantly reducing the study's alignment with the predefined requirements.",1.4
The Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review with a Pooled Analysis of Only Surgery versus Combined Protocols,"O. Di Fede, F. Canepa, V. Panzarella, R. Mauceri, Carmine Del Gaizo, A. Bedogni, V. Fusco, P. Tozzo, G. Pizzo, G. Campisi, A. Galvano",10.3390/ijerph18168432,https://doi.org/10.3390/ijerph18168432,International Journal of Environmental Research and Public Health,24,2021,maybe,"The abstract doesn't specify the age range or whether patients had cancer, only mentioning ""patients"" generally.",maybe,maybe,"While MRONJ outcomes are documented, the abstract doesn't clearly specify the initial dental procedures that led to MRONJ.",no,The study compares different treatment approaches (conservative vs. aggressive surgery) but doesn't mention a control group of non-anti-resorptive medication users.,no,"This is a systematic review with pooled analysis, not a primary study of the required design types (RCT, cohort, or case-control).",no,The abstract doesn't mention documentation of temporal relationships between medication use and MRONJ development or duration of medication use.,yes,"The study includes 1,137 patients in the pooled analysis, well above the 100-person requirement.","While the study discusses surgical techniques for MRONJ treatment, it doesn't clearly specify the initial dental procedures that led to MRONJ, which is a significant limitation.",Exclude,"The systematic review fails to meet multiple critical screening criteria, including specific focus on Romosozumab, lack of a control group, and absence of clear documentation about patient population and temporal medication relationships. While the study includes a large sample size and discusses MRONJ treatment, it fundamentally does not align with the required research parameters for inclusion in the systematic review.",1.4
Osteonecrosis and osteomyelitis of the jaw associated with tumour necrosis factor-alpha (TNF-α) inhibitors: a systematic review.,"Roberto Sacco, Roberto Sacco, Roberto Sacco, Sagar Shah, R. Leeson, V. Moraschini, C. Mourao, O. Akintola, A. Lalli",10.1016/j.bjoms.2019.09.023,https://doi.org/10.1016/j.bjoms.2019.09.023,British Journal of Oral and Maxillofacial Surgery,38,2019,no,"The study focuses on patients with inflammatory conditions (rheumatoid arthritis, Crohn's disease), and there is no mention of osteoporosis or cancer status.",maybe,maybe,"The study does document MRONJ outcomes, but the dental procedures are not clearly specified.",no,"There is no mention of a control group, and the study appears to be a case series of TNF-α inhibitor users.",no,"This is a systematic review of case reports, which does not meet the required study design criteria.",yes,"The abstract mentions the mean duration of treatment before ONJ development (62.5 months), and the temporal relationship is documented.",no,"The paper only includes 6 patients total, which is well below the required minimum of 100 subjects.","The abstract mentions ""invasive surgery"" as a precipitating factor in 5 cases, which partially meets the criterion, though specific procedures aren't detailed.",Exclude,"The study focuses on TNF-α inhibitors for inflammatory conditions, which fundamentally differs from the specified screening criteria involving Romosozumab for osteoporosis. With only six patients, no control group, and a case report design, the research fails to meet multiple critical screening requirements. The small sample size, different medication class, and lack of alignment with specified population characteristics render this study non-compliant with the established screening criteria.",0.1
Risk Factors for Medication-Related Osteonecrosis of the Jaw—A Binomial Analysis of Data of Cancer Patients from Craiova and Constanta Treated with Zoledronic Acid,"GEORGE-ADRIAN Ciobanu, A. Camen, Mihaela Ionescu, D. Vlad, C. Munteanu, M. Gheorghiță, C. Lungulescu, I. Staicu, Elena-Claudia Sin, L. Chivu, R. Mercuț, S. Popescu",10.3390/jcm12113747,https://doi.org/10.3390/jcm12113747,Journal of Clinical Medicine,4,2023,no,"The study focuses on cancer patients, which explicitly violates the criterion requiring non-cancer patients, so this is another clear failure of a critical criterion.",no,no,"While MRONJ is the outcome, there's no mention of specific dental procedures, so this criterion is not met.",no,"There is no mention of a control group of non-anti-resorptive medication users, so this criterion is not met.",yes,"The study is described as an ""observational retrospective investigation"", which would qualify as a retrospective cohort study, meeting this criterion.",maybe,"The study does document treatment duration as a factor, but the temporal relationship with specific dental procedures is not mentioned.",yes,"The study includes 174 patients, which exceeds the minimum requirement of 100, so this criterion is met.","The abstract does not mention any specific dental procedures or treatments, which is a critical missing element.",Exclude,"The study focuses on zoledronic acid in cancer patients, which fundamentally conflicts with the screening criteria requiring romosozumab and non-cancer patients. Critical screening requirements were not met, including the specific medication, population type, and documentation of dental procedures. Multiple core criteria were definitively failed, rendering the study ineligible for inclusion.",0.1
Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study.,"F. Hallmer, Ó. Bjarnadóttir, B. Götrick, P. Malmström, G. Andersson",10.1016/j.oooo.2020.04.808,https://doi.org/10.1016/j.oooo.2020.04.808,"Oral surgery, oral medicine, oral pathology and oral radiology",18,2020,no,"The study focuses on patients with breast cancer, not osteoporosis, which is another clear failure of a critical criterion.",no,no,"While MRONJ outcomes are documented, there is no mention of specific dental procedures, so the study fails this criterion.",no,"No control group of non-anti-resorptive medication users is mentioned, so the study fails this criterion.",yes,"The study is described as a ""prospective cohort study"", which meets this criterion.",maybe,"The study documents the temporal relationship (77 months of study), but the specific duration of medication use is not clearly documented, so it partially meets this criterion.",yes,"The study includes 242 patients, which exceeds the minimum requirement of 100, so it meets this criterion.","The abstract does not mention any specific dental procedures or interventions, which is a critical missing element.",Exclude,"The study fails critical screening criteria by using zoledronic acid and denosumab instead of romosozumab, focusing on breast cancer patients rather than osteoporosis patients, and lacking documentation of specific dental interventions. Multiple key requirements are not met, including the absence of a control group and unclear temporal documentation of medication use, rendering the study unsuitable for the systematic review.",0.1
"Medication-related osteonecrosis of the jaw, a risk to reassess in osteoporotic patients.","maxime debiève, L. Castiaux, Aline van Maanen, M. Magremanne",10.2139/ssrn.4175108,https://doi.org/10.2139/ssrn.4175108,Journal of Stomatology Oral and Maxillofacial Surgery,3,2022,maybe,"The study includes adult patients with osteoporosis, but also includes cancer patients. The osteoporotic patients appear to be ≥18 years (mean age 74.4), but the study isn't exclusively focused on osteoporosis patients.",maybe,maybe,"While MRONJ outcomes are documented, the abstract doesn't specify whether these were following specific dental procedures.",no,No control group of non-anti-resorptive medication users is mentioned in the abstract.,yes,"The study is described as a retrospective study, which meets the criteria for study design.",maybe,"The abstract mentions collecting ""type, dose and duration of the anti-resorptive drugs treatment"" and includes follow-up data, but doesn't clearly document the temporal relationship between medication use and MRONJ development.",yes,"The study includes 165 patients total, with 67 osteoporotic patients, exceeding the 100-person minimum subject size requirement.","While the study focuses on MRONJ, which typically follows dental procedures, the abstract doesn't explicitly state whether dental procedures were performed or documented.",Include,"The study fails to meet several critical screening criteria, including specific focus on Romosozumab and exclusive examination of osteoporotic patients without cancer. While the research includes a sufficient sample size and uses a retrospective design, significant methodological limitations prevent it from qualifying for systematic review inclusion. Key deficiencies include lack of a control group, unclear documentation of dental procedures, and incomplete temporal relationship tracking between medication use and MRONJ development.",2.7
Medication‐related osteonecrosis of the jaw: A literature review and update,"S. Kuroshima, Farah A. Al-Omari, Muneteru Sasaki, T. Sawase",10.1002/dvg.23500,https://doi.org/10.1002/dvg.23500,Genesis,17,2022,no,"The abstract mentions both cancer and osteoporosis patients but is not focused exclusively on adult osteoporosis patients without cancer, so it does not meet the criterion of focusing on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",no,no,"While MRONJ outcomes are discussed, this is not a study documenting specific outcomes from dental procedures, so it does not meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"As a review article, it does not include a control group, so it does not meet the criterion of including a control group of non-anti-resorptive medication users.",no,"This is a literature review, not a randomized controlled trial, cohort study, or case-control study, so it does not meet the criterion of having a study design of either a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The paper discusses mechanisms but does not document temporal relationships or medication duration, so it does not meet the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",no,"This is a review article, not a primary study with subjects, so it does not meet the criterion of having a subject size of more than 100 people.","While the abstract discusses MRONJ in relation to dental procedures, it's a review of mechanisms rather than a study of specific interventions, so it does not meet the criterion of having an intervention of invasive dental treatment.",Exclude,"This literature review on medication-related osteonecrosis of the jaw fails to meet multiple screening criteria, including specific intervention type, subject size, population focus, and study design. The abstract provides a comprehensive overview of MRONJ mechanisms but does not constitute a primary research study with the required methodological characteristics for inclusion in the systematic review.",0.1
Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol,"L. Ramaglia, A. Guida, V. Iorio-Siciliano, A. Cuozzo, A. Blasi, A. Sculean",10.1007/s00784-017-2325-6,https://doi.org/10.1007/s00784-017-2325-6,Clinical Oral Investigations,63,2018,maybe,"The abstract does not explicitly mention the age groups or cancer status of the participants, so it cannot be confirmed if the study focused exclusively on adult patients with diagnosed osteoporosis who do not have cancer.",maybe,maybe,"The abstract does document MRONJ outcomes and mentions specific healing rates by stage, but it does not clearly specify which dental procedures were performed, so it only partially meets this criterion.",no,"The abstract does not mention any control groups, and the focus appears to be on treatment approaches rather than comparing medication users vs. non-users, so it fails to meet the control group criterion.",no,"The abstract explicitly states that ""None of them was case-controlled or randomized,"" so it does not meet the required study design criteria.",maybe,"The abstract mentions a drug-holiday protocol but does not clearly document the temporal relationships between medication use and MRONJ development, and the duration of medication use is not specified, so it only partially meets this criterion.",maybe,"The abstract mentions 13 studies were selected, but does not specify the total subject count, so it cannot be confirmed if the study had more than 100 participants.","The abstract mentions ""oral surgery procedures"" but does not specify the types of invasive dental treatments, so it is too vague to confirm if it meets the required dental interventions.",Exclude,"The systematic review fails to meet multiple critical screening criteria, including specific medication type, study design, and control group requirements. Key deficiencies include lack of confirmation for Romosozumab use, absence of a control group, and a study design that does not align with the specified research parameters. The paper's focus on treatment approaches rather than primary research further disqualifies it from meeting the established screening criteria.",1.4
Medication‐Related Osteonecrosis of the Jaw in Cancer Patients: Result from the OneFlorida Clinical Research Consortium,"Guang Yang, Roy Williams, Lishu Wang, N. Farhadfar, Yiqing Chen, Alexander T. Loiacono, Jiang Bian, L. Holliday, J. Katz, Y. Gong",10.1002/jbmr.4708,https://doi.org/10.1002/jbmr.4708,Journal of Bone and Mineral Research,4,2022,no,"The study specifically focuses on cancer patients, while the criteria require non-cancer patients with osteoporosis.",maybe,maybe,"While MRONJ outcomes are documented, the abstract doesn't specify the dental procedures that led to these outcomes.",maybe,The abstract doesn't mention a control group of non-anti-resorptive medication users.,yes,This appears to be a retrospective cohort study using electronic health records.,yes,The study documents temporal relationships through Kaplan-Meier analysis and tracks medication use over time.,yes,"The study includes 5,689 participants, well above the 100-person minimum.","While the study examines MRONJ, which is typically associated with dental procedures, the abstract doesn't explicitly mention the types of dental interventions studied.",Exclude,"The study fails key screening criteria by focusing on bisphosphonates and denosumab in cancer patients, rather than romosozumab in non-cancer osteoporosis patients. While the research includes a large sample size and uses a robust retrospective cohort design, the fundamental mismatch in medication type and patient population disqualifies it from meeting the specified inclusion requirements.",0.1
The risk of osteonecrosis of the jaw and adverse outcomes in patients using antiresorptive drugs undergoing orthodontic treatment: A systematic review,"Julian Woolley, O. Akintola, J. Yates, M. Calasans-Maia, Jose de Albuquerque Calasans-Maia, Iryna Kocherhina, R. Sacco",10.1016/j.heliyon.2021.e05914,https://doi.org/10.1016/j.heliyon.2021.e05914,Heliyon,8,2021,maybe,"The population characteristics are not clearly specified, so it cannot be confirmed if the patients are adults with diagnosed osteoporosis and do not have cancer.",no,no,"The study reports MRONJ outcomes, but in the context of orthodontic treatment, not the specific dental procedures required.",no,There is no mention of a control group of non-anti-resorptive medication users.,no,"The study is a systematic review of various study types, not a primary research study of the required design types (randomized controlled trial, prospective/retrospective cohort study, or case-control study).",no,"There is no clear documentation of the temporal relationship between medication use and MRONJ development, or the duration of medication use.",no,"The study only included 29 patients total across 7 studies, which is less than the required subject size of more than 100 people.","The study focuses on orthodontic treatment, which is not typically considered an invasive dental treatment. There is no mention of the specified procedures like extractions, implants, or other dental surgery.",Exclude,"The systematic review fails to meet multiple critical screening criteria, including the specific medication type, subject size, dental intervention type, and study design requirements. Key deficiencies include focusing on bisphosphonates instead of Romosozumab, having only 29 patients across studies, and examining orthodontic treatment rather than invasive dental procedures. The paper fundamentally does not align with the predefined systematic review parameters.",0.1
Medication-Related Osteonecrosis of the Jaws: Two Center Retrospective Cohort Studies,"M. Petrovic, D. Jelovac, S. Antić, Marija Antunović, N. Lukic, M. Šabani, J. Mudrak, Z. Jezdić, A. Pucar, A. Stefanović, Č. Kuzmanović, D. Nikolic, V. Konstantinovic",10.1155/2019/8345309,https://doi.org/10.1155/2019/8345309,BioMed Research International,18,2019,maybe,"The study includes adult patients (age range 35-84) with osteoporosis, but it also includes patients with malignant disease, which does not meet the criteria of focusing exclusively on adult patients with diagnosed osteoporosis who do not have cancer.",yes,yes,"The study clearly documents MRONJ outcomes following specific dental procedures, particularly tooth extraction.",no,The abstract does not mention any control group of non-anti-resorptive medication users.,yes,"The study is described as a retrospective cohort study, which meets the criteria for study design.",yes,"The study appears to document temporal relationships, mentioning ""timing of tooth extraction"" and ""drug treatment duration"" as variables considered.",no,"The study has a subject size of 32 patients, which is well below the required minimum of 100 people.","The study includes invasive dental treatments, specifically mentioning tooth extraction as a trigger for MRONJ in 30 out of 32 cases.",Exclude,"The study fails key screening criteria due to using bisphosphonates instead of Romosozumab, having a small sample size of 32 patients, and including cancer patients. While the research documents dental interventions and MRONJ outcomes, critical methodological requirements are not met, rendering the study ineligible for systematic review inclusion.",1.4
Medication Related Osteonecrosis of the Jaw (MRONJ). Review and recent advances,"D. Galiti, Aikaterini Karayianni, K. Tsiklakis, A. Psyrri",10.2478/fco-2022-0005,https://doi.org/10.2478/fco-2022-0005,Forum of Clinical Oncology,1,2022,no,"The paper focuses on patients with cancer, which is explicitly excluded in the criteria. Therefore, the study does not meet the criterion of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",yes,maybe,"The paper discusses MRONJ outcomes and dental procedures, but this is in a general review context rather than specific documented cases. Therefore, the study partially meets the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"There is no mention of control groups in the abstract, so the study does not meet the criterion of including a control group of non-anti-resorptive medication users.",no,"The paper appears to be a review article discussing current knowledge and clinical practice, rather than a primary research study with any of the specified designs (randomized controlled trial, prospective/retrospective cohort study, or case-control study). Therefore, the study does not meet the criterion of having a study design that is either a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"While timing is discussed (8 weeks), this is in a general context rather than specific documentation. Therefore, the study partially meets the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",no,"No specific subject size is mentioned in the abstract, and the paper appears to be a review article rather than a primary study. Therefore, the study does not meet the criterion of having a subject size of more than 100 people.","The abstract discusses dental extraction and other dental procedures, which meets the criterion of the subject having an intervention of invasive dental treatment.",Exclude,"This review article on Medication-Related Osteonecrosis of the Jaw fails to meet multiple screening criteria, including specific medication type, subject size, and population requirements. The paper focuses on cancer patients and provides a general overview of MRONJ, which diverges significantly from the targeted research parameters. Consequently, the abstract does not qualify for inclusion based on the predefined screening criteria.",0.1
"Medication-related osteonecrosis of the jaw: a narrative review of risk factors, diagnosis, and management","Jacob G. Thomas, A. Ouanounou",10.21037/fomm-21-106,https://doi.org/10.21037/fomm-21-106,Frontiers of Oral and Maxillofacial Medicine,4,2021,no,"The paper mentions both osteoporosis and cancer patients, so it is not exclusively focused on adult osteoporosis patients without cancer.",maybe,no,"While MRONJ outcomes are discussed, this is in a review context, not from primary research.",no,"As a narrative review, the paper does not include a control group.",no,"This is a narrative review article, not a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"While medication use and MRONJ are discussed, this is not a primary study documenting temporal relationships.",no,"This is a narrative review article, not a primary study, so no specific subject size is mentioned.","The paper mentions ""dentoalveolar surgery"" as a common initiating factor, which partially meets the criterion for invasive dental treatment.",Exclude,"This narrative review fails to meet multiple screening criteria, including specific intervention type, subject size, population focus, and study design requirements. The abstract discusses medication-related osteonecrosis of the jaw broadly but lacks the precise methodological characteristics needed for inclusion, such as a control group, specific intervention details, and primary research outcomes.",0.1
Management of Medication-related Osteonecrosis of the Jaw (MRONJ) risk in patients due to commence anti-resorptive/anti-angiogenic drugs - how should pre-drug-treatment dental preventive care be organised?,B. Steel,10.1922/CDH_4582Steel11,https://doi.org/10.1922/CDH_4582Steel11,Community Dental Health,4,2019,maybe,"The abstract does not specify patient age or osteoporosis status, and does not mention cancer exclusion, so it is uncertain whether the study focuses exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",maybe,no,"While MRONJ is discussed, the paper focuses on preventive care strategies and does not specifically document MRONJ outcomes following specific, documented dental procedures, so it fails this criterion.",no,"The abstract does not mention a control group of non-anti-resorptive medication users, so it fails this criterion.",no,"The paper appears to be a review of strategies rather than a primary research study, and does not fit the required study designs of randomized controlled trial, prospective/retrospective cohort study, or case-control study, so it fails this criterion.",no,"The abstract does not provide any specific documentation of the temporal relationship between medication use and MRONJ development, or the duration of medication use, so it fails this criterion.",maybe,"The abstract reviews 13 studies but does not specify the subject numbers, so it is uncertain whether the study has a subject size of more than 100 people.","The abstract discusses dental assessment and treatment, and mentions ""necessary remedial treatment"", which partially meets the criterion of having an intervention of invasive dental treatment, including tooth extraction, implant placement, periodontal surgery, other dental surgery, or removable prosthesis fabrication.",Exclude,"The abstract fails to meet multiple critical screening criteria, including specific medication type, subject size, control group, and study design requirements. While discussing medication-related osteonecrosis of the jaw, the paper is a review of preventive strategies rather than a primary research study with the desired methodological characteristics. Consequently, the document does not align with the specified screening criteria for inclusion.",1.4
The risk of osteonecrosis on alveolar healing after tooth extraction and systemic administration of antiresorptive drugs in rodents: a systematic review.,"V. Poubel, C. A. B. Silva, L. Mezzomo, G. De Luca Canto, E. Rivero",10.1016/j.jcms.2017.11.008,https://doi.org/10.1016/j.jcms.2017.11.008,Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,19,2017,no,"The study is conducted on rodents, not human adults with osteoporosis, and therefore does not meet the population type criterion.",yes,yes,"The study does report MRONJ outcomes following tooth extraction, which meets the outcome documentation criterion.",maybe,"The abstract does not explicitly mention a control group of non-anti-resorptive medication users, so it is unclear if this criterion is met.",no,"This is a systematic review, not a primary study of the required design types (randomized controlled trial, prospective/retrospective cohort study, or case-control study), and therefore does not meet the study design criterion.",no,"The abstract does not clearly document the temporal relationship between medication use and MRONJ development, or the duration of medication use, and therefore does not meet the temporal documentation criterion.",no,"This is a systematic review of rodent studies, and no human subject size is mentioned. Therefore, the study does not meet the requirement of having a subject size of more than 100 people.","The study does include tooth extraction as an intervention, which meets the criterion of invasive dental treatment.",Exclude,"This systematic review of rodent studies fails critical screening criteria by not using Romosozumab, not involving human adult patients with osteoporosis, and not being a primary research study. The paper focuses on antiresorptive drug therapy and tooth extraction in rodents, which fundamentally differs from the required research parameters. Multiple key screening requirements are not met, rendering the study ineligible for inclusion.",0.1
Medication-Related Osteonecrosis of the Jaw – 2024 Update,"David D Seo, James L. Borke",10.33425/2639-9490.1142,https://doi.org/10.33425/2639-9490.1142,Oral Health & Dental Science,0,2024,no,"The abstract discusses both cancer patients and osteoporosis patients, and does not focus exclusively on non-cancer osteoporosis patients, so it fails this criterion.",yes,no,"While MRONJ outcomes are discussed, this is a review of general information rather than documentation of specific procedures and outcomes, so it fails this criterion.",maybe,"The abstract does not mention any control groups, so the reasoning for this criterion is uncertain.",no,"This appears to be a review article, not a primary research study, so it fails the criterion of having a study design of a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"No specific temporal relationships or medication durations are documented, so it fails this criterion.",maybe,"The abstract does not mention any specific study size, so the reasoning for this criterion is uncertain.","The abstract mentions dental procedures including ""dental extraction or oral surgery"", which meets the criterion of having an intervention of invasive dental treatment.",Exclude,"The abstract fails multiple critical screening criteria, including the specific medication requirement (Romosozumab), population type (includes cancer patients), and study design (review article). Key deficiencies include lack of focus on the specified intervention, absence of a control group, and insufficient documentation of specific dental procedures and outcomes. These fundamental misalignments render the paper unsuitable for inclusion in the systematic review.",0.1
Medication-related osteonecrosis of the jaw. Implant presence-triggered osteonecrosis: Case series and literature review.,"M. Escobedo, J. Cobo, S. Junquera, J. Milla, S. Olay, Luis Junquera",10.1016/j.jormas.2019.04.012,https://doi.org/10.1016/j.jormas.2019.04.012,Journal of Stomatology Oral and Maxillofacial Surgery,32,2020,maybe,"While the study involves adult patients (implied by the dental implant context), it does not explicitly state that they have diagnosed osteoporosis or exclude cancer patients. Therefore, it is unclear if the population type meets the specified criteria.",yes,yes,"The study clearly documents MRONJ outcomes following specific dental procedures (implant placement and presence), so this criterion is met.",no,"There is no mention of a control group of non-anti-resorptive medication users, so this criterion is not met.",maybe,"The study includes a retrospective review of hospital records and a literature review, but does not strictly fit the required study designs of randomized controlled trial, prospective/retrospective cohort study, or case-control study. Therefore, it only partially meets this criterion.",yes,"The study documents temporal relationships between medication use and MRONJ development, including ""elapsed time between the placement of the implants and the development of MRONJ,"" so this criterion is met.",maybe,"The abstract mentions 111 articles in the literature review and 7 patients from their center, but does not specify the total number of patients studied. Therefore, it is unclear if the study meets the requirement of having a subject size of more than 100 people.","The study focuses on dental implants and implant-related procedures, which qualify as invasive dental treatment, so this criterion is met.",Exclude,"The study fails to meet critical screening criteria, particularly the requirement for Romosozumab as the anti-resorptive medication, instead using alendronate. Multiple other criteria remain unclear or unmet, including population characteristics, control group presence, and precise study design. The research focuses on implant-related osteonecrosis but does not align with the specified screening requirements.",1.4
Osteonecrosis of the jaw in a patient with advanced non-small-cell lung cancer receiving bevacizumab.,"Stamatis Katsenos, Charalampos Christophylakis, Konstantinos Psathakis",10.1016/j.arbres.2012.01.007,https://doi.org/10.1016/j.arbres.2012.01.007,Archivos de Bronconeumologia,9,2012,no,"The study specifically focuses on patients with cancer, which does not meet the criterion for adult patients with diagnosed osteoporosis who do not have cancer.",yes,yes,"The abstract does report MRONJ outcomes following dental procedures, which meets this criterion.",no,There is no mention of a control group in the abstract.,no,"This is a review article, not a primary research study, which does not meet the criterion for a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,There is no clear documentation of the temporal relationship between medication use and MRONJ development or the duration of medication use.,no,"The study includes only 36 patients total, which is less than the required 100 subjects.","The abstract mentions ""invasive dental procedures"" as triggers for MRONJ, which meets the criterion for invasive dental treatment.",Exclude,"The study fails critical screening criteria by focusing on antiangiogenic drugs in cancer patients instead of Romosozumab for osteoporosis, with a sample size of only 36 patients. Multiple key requirements are not met, including population type, intervention medication, study design, and control group specifications, rendering the paper unsuitable for the systematic review.",0.1
Recurrence-Related Factors of Medication-Related Osteonecrosis of the Jaw: A 5-Year Experience.,"Shuo Chen, Hongyu Ren, Yang He, J. An, Yi Zhang",10.1016/j.joms.2021.07.029,https://doi.org/10.1016/j.joms.2021.07.029,Journal of oral and maxillofacial surgery,9,2021,maybe,"The abstract doesn't specify the age range of patients or whether they have cancer, so it's unclear if they meet the adult osteoporosis patient criteria.",maybe,maybe,"While MRONJ outcomes are documented, the specific dental procedures leading to MRONJ are not clearly described in the abstract.",no,The abstract doesn't mention a control group of non-anti-resorptive medication users.,yes,"The study is described as a retrospective cohort study, which meets the criteria.",yes,The study documents the duration of medication use (18 months) and its relationship to MRONJ development.,no,"The study includes only 58 patients, which is below the required minimum of 100 subjects.","While the study deals with MRONJ, which typically follows dental procedures, the abstract doesn't explicitly state what dental procedures were performed.",Exclude,"The study fails key screening criteria by using zoledronic acid instead of romosozumab, having an insufficient sample size of 58 patients, and lacking a control group. Multiple critical elements are either unmet or unclear, including population characteristics and specific dental procedures, rendering the study non-compliant with the systematic review requirements.",0.1
Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta-analysis.,"Chengrong Zhang, Guoshuang Shen, Huihui Li, Y. Xin, Mingqiang Shi, Yonghui Zheng, Miaozhou Wang, Zhen Liu, Yi Zhao, Fuxing Zhao, Dengfeng Ren, Jiuda Zhao",10.1111/scd.12877,https://doi.org/10.1111/scd.12877,"Special Care in Dentistry: managing special patients, settings, and situations",5,2023,no,"The study focuses on cancer patients, not osteoporosis patients, which is another clear disqualification.",no,maybe,"The study reports ONJ outcomes but doesn't specify the dental procedures, so this criterion is partially met.",no,"The study appears to compare different medications (denosumab vs bisphosphonates) and does not include non-anti-resorptive medication users as controls, so this criterion is not met.",yes,"The study includes randomized controlled trials and observational trials, so this criterion is met.",no,"There is no clear documentation of the temporal relationship or duration of medication use, so this criterion is not met.",yes,"The study includes 42,003 patients, well exceeding the 100-person requirement. This criterion is met.","The abstract doesn't specify the types of dental procedures that led to ONJ, so this information is missing.",Exclude,"The study focuses on cancer patients using bisphosphonates and denosumab, which fundamentally differs from the required criteria of osteoporosis patients using Romosozumab. Critical screening requirements were not met, including population type, medication intervention, and control group composition. Multiple disqualifying factors render this study inappropriate for the systematic review.",0.1
Medication-Related Osteonecrosis of the Jaw Around Dental Implants: Implant Surgery-Triggered or Implant Presence-Triggered Osteonecrosis?,"I. Giovannacci, M. Meleti, M. Manfredi, C. Mortellaro, A. Greco Lucchina, M. Bonanini, P. Vescovi",10.1097/SCS.0000000000002564,https://doi.org/10.1097/SCS.0000000000002564,The Journal of craniofacial surgery (Print),58,2016,maybe,"While the study includes adult patients with osteoporosis, it also includes patients with cancer (breast cancer). The abstract doesn't specify if all patients were ≥18 years.",yes,yes,The study clearly documents MRONJ outcomes following specific dental procedures (implant placement).,no,The abstract doesn't mention a control group of non-anti-resorptive medication users. The study appears to be a case series without controls.,no,"This appears to be a case series, which is not one of the accepted study designs (RCT, cohort, or case-control).",yes,"The study documents temporal relationships between medication use and MRONJ development, including specific timeframes (2-10 months for G1, 1-15 years for G2).",yes,"The study includes 250 patients total, with 15 MRONJ cases, exceeding the minimum requirement of 100 subjects.",The study specifically focuses on dental implant placement and related procedures.,Exclude,"The study fails to meet critical screening criteria, primarily due to using bisphosphonates instead of Romosozumab and lacking a control group. While the research addresses dental procedures and MRONJ outcomes, its case series design and inclusion of cancer patients disqualify it from meeting the specified inclusion requirements. The fundamental methodological differences render the study unsuitable for the intended review.",1.4
Risk of developing spontaneous MRONJ in fibrous dysplasia patients treated with bisphosphonates: a systematic review of the literature.,"Srighana Nadella, M. Mupparapu, S. Akintoye",10.3290/j.qi.b3082785,https://doi.org/10.3290/j.qi.b3082785,Quintessence International,5,2022,no,"The study focuses on patients with fibrous dysplasia and McCune-Albright syndrome, not osteoporosis patients.",no,no,"While MRONJ outcomes are reported, there is no mention of specific dental procedures.",no,The abstract does not mention a control group of non-anti-resorptive medication users.,no,"This is a systematic review, not a primary study (RCT, cohort, or case-control).",maybe,"The abstract mentions patients were on antiresorptives for at least 1 year, but doesn't clearly document temporal relationships with MRONJ development.",yes,"The study includes 312 patients total, which exceeds the 100-person requirement.",The abstract does not mention any specific dental procedures or interventions.,Exclude,"The systematic review focuses on fibrous dysplasia patients using bisphosphonates, which fundamentally differs from the required criteria of osteoporosis patients using Romosozumab. Multiple screening requirements are unmet, including intervention type, patient population, study design, and specific dental procedure documentation. Consequently, the study does not align with the predefined screening criteria and would be excluded from further review.",0.1
P052 A literature review of anti-resorptive medications and reports of MRONJ,"Nikou Gharooni-Dowrani, Hanan Muhammad, Tarun Nagpal",10.1016/j.bjoms.2023.08.123,https://doi.org/10.1016/j.bjoms.2023.08.123,British Journal of Oral and Maxillofacial Surgery,0,2023,maybe,"The abstract does not provide any specific information about the population, such as whether it focuses on adult patients with diagnosed osteoporosis who do not have cancer, so it is not possible to determine if the study meets this criterion.",maybe,maybe,"The abstract mentions MRONJ as an outcome, but does not specify the documentation of specific dental procedures, so it only partially meets this criterion.",maybe,"The abstract does not mention the inclusion of a control group of non-anti-resorptive medication users, so it is not possible to determine if the study meets this criterion.",no,"The abstract explicitly states that this is a ""literature review"", which does not meet the required study design criteria of a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"The abstract does not mention the temporal relationship between medication use and MRONJ development or the duration of medication use, so it is not possible to determine if the study meets this criterion.",maybe,"The abstract does not mention the sample size, so it is not possible to determine if the study meets this criterion.","The abstract mentions ""dental management"" but does not specify the types of procedures, so it is too vague to confirm if the intervention meets this criterion.",Exclude,"The literature review fails to meet multiple critical screening criteria, including specific intervention details, study design requirements, and population specifications. Key deficiencies include the absence of Romosozumab as the primary medication, lack of clarity on dental procedures, and the fundamental mismatch with the required research methodology. Consequently, the abstract does not provide sufficient evidence to satisfy the comprehensive screening requirements.",0.1
Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ),"S. Otto, Suad Aljohani, Riham Fliefel, Sara Ecke, O. Ristow, E. Burian, M. Troeltzsch, C. Pautke, M. Ehrenfeld",10.3390/medicina57050463,https://doi.org/10.3390/medicina57050463,Medicina,66,2021,no,"The abstract specifically mentions cancer patients, which explicitly violates the criterion requiring the study to focus exclusively on adult patients with diagnosed osteoporosis who do not have cancer.",no,no,"While MRONJ is discussed, there is no specific documentation of outcomes following dental procedures, so the study does not meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"As a review paper, the study does not include a control group of non-anti-resorptive medication users.",no,"This is a critical review paper, not a primary research study, so it does not meet the required study design types of randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"No specific temporal relationships or medication duration documentation is mentioned, so the study does not meet the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",no,"The paper is a review article, not a primary study, so it does not have a subject size of more than 100 people.","While dental procedures are implied in the context of MRONJ, no specific invasive dental treatments are described, so the intervention does not meet the criterion of including invasive dental treatment.",Exclude,"This review paper on medication-related osteonecrosis of the jaw fails multiple screening criteria, including population type, study design, and specific intervention requirements. The abstract focuses on cancer patients and antiresorptive drugs generally, rather than the targeted population of non-cancer osteoporosis patients using Romosozumab. Consequently, the paper does not meet the systematic review's inclusion standards.",0.1
A Retrospective Data Analysis for the Risk Evaluation of the Development of Drug-Associated Jaw Necrosis through Dentoalveolar Interventions,"M. Buchbender, Charlotte Bauerschmitz, Sebastian Pirkl, M. Kesting, C. Schmitt",10.3390/ijerph19074339,https://doi.org/10.3390/ijerph19074339,International Journal of Environmental Research and Public Health,3,2022,no,"The study includes both cancer patients (73 with metastatic disease) and osteoporotic patients (42), and does not focus exclusively on osteoporosis patients without cancer, which is a significant issue.",yes,yes,The study clearly documents MRONJ outcomes following specific dental procedures and reports occurrence rates and risk factors.,no,"There is no mention of a control group of non-anti-resorptive medication users, and the study only compares different types of surgical interventions.",yes,"The study is a retrospective analysis of patient data, which qualifies as a retrospective cohort study.",no,"There is no clear documentation of the temporal relationship between medication use and MRONJ, and the duration of medication use is not mentioned.",yes,"The study includes 115 patients, which exceeds the minimum requirement of 100.","The study clearly includes invasive dental treatments (tooth extraction, osteotomy) and specifically mentions dentoalveolar interventions.",Include,"The study fails key screening criteria by not specifying Romosozumab as the medication, including a mixed patient population with cancer patients, and lacking a control group. While demonstrating strengths in sample size, dental intervention documentation, and study design, critical methodological gaps prevent the study from meeting the comprehensive screening requirements. The absence of clear temporal medication documentation and specific medication identification further compromises the study's alignment with the screening criteria.",2.5
Medication-Related Osteonecrosis of the Jaw: A Critical Narrative Review,"A. Lorenzo-Pouso, J. Bagan, L. Bagán, P. Gándara-Vila, C. Chamorro-Petronacci, P. Castelo-Baz, A. Blanco-Carrión, María Ángeles Blanco-Fernández, Óscar Álvarez-Calderón, Javier Carballo, M. Pérez‐Sayáns",10.3390/jcm10194367,https://doi.org/10.3390/jcm10194367,Journal of Clinical Medicine,17,2021,no,"Population characteristics are not specified, so it fails to meet the criterion of the study focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",no,no,"While MRONJ outcomes are discussed, this is a review of existing literature rather than documentation of specific outcomes, so it fails to meet the criterion of the study reporting MRONJ outcomes following specific, documented dental procedures.",no,"As a review article, it doesn't include a control group, so it fails to meet the criterion of the study including a control group of non-anti-resorptive medication users.",no,"This is a literature review, not a primary research study, so it fails to meet the criterion of the study design being either a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"As a review article, it doesn't document specific temporal relationships, so it fails to meet the criterion of the study clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",no,"This is a review article, not a primary study, and no specific subject numbers are mentioned, so it fails to meet the criterion of the study having a subject size of more than 100 people.","While dental procedures are implied in the context of MRONJ, this is a review article that doesn't study specific interventions, so it fails to meet the criterion of the subject having an intervention of invasive dental treatment.",Exclude,"This literature review fails to meet multiple screening criteria, including specific intervention details, subject size requirements, and study design specifications. The abstract describes a comprehensive review of medication-related osteonecrosis of the jaw but lacks the precise methodological elements needed for inclusion, such as a defined patient population, control group, and specific intervention parameters.",0.1
Prevention of medication-related osteonecrosis of the jaw: institutional insights from a retrospective study.,"YS Chang, S. Nanayakkara, A. Yaacoub, SC Cox",10.1111/adj.13050,https://doi.org/10.1111/adj.13050,Australian dental journal,0,2024,maybe,"While the study focuses on adult patients (median age 74 years) with osteoporosis (85.4%), it's not explicitly stated that cancer patients were excluded.",yes,yes,"The study clearly documents MRONJ outcomes following dental extractions, with specific follow-up at 8 weeks.",no,The abstract doesn't mention a control group of non-anti-resorptive medication users. The study appears to only include at-risk patients.,yes,"The study is described as a retrospective study, which meets the criteria.",maybe,"While the study documents the temporal relationship between dental procedures and MRONJ development (8-week follow-up), it doesn't clearly specify the duration of medication use.",yes,"The study includes 329 patients, well above the minimum requirement of 100.","The study specifically focuses on dental extractions, which is one of the specified invasive dental treatments.",Exclude,"The study fails to meet critical screening criteria, primarily due to the use of Denosumab instead of the specified Romosozumab medication. While the research demonstrates robust methodology with a large patient sample and clear documentation of dental extraction outcomes, the fundamental medication mismatch disqualifies it from meeting the predefined inclusion requirements. Additional limitations include the absence of a control group and partial documentation of patient characteristics.",1.4
Effect of Antiresorptive Drugs on Osseointegrated Dental Implants: A Systematic Review,"Joyce Tin Wing Li, Y. Leung",10.3390/jcm13072091,https://doi.org/10.3390/jcm13072091,Journal of Clinical Medicine,5,2024,maybe,"While the study involves patients with antiresorptive medication, it doesn't explicitly state that all patients are adults (≥18) or specify that they don't have cancer. However, given the context of dental implants, it's likely these are adult patients.",yes,yes,The study clearly documents MRONJ outcomes following dental procedures (specifically implants) and reports failure rates and outcomes.,maybe,The abstract doesn't mention whether there is a control group of non-antiresorptive medication users.,maybe,"This is actually a systematic review of other studies, not a primary research study of the types specified in the criteria.",yes,"The study documents temporal relationships, noting ""average time from antiresorptive drug initiation to MRONJ development was approximately 34 months.""",yes,"The study includes 135 subjects, which exceeds the minimum requirement of 100.","The study focuses on dental implants, which is one of the specified invasive dental treatments.",Exclude,"The systematic review fails to meet critical screening criteria, specifically lacking confirmation of Romosozumab use and not being a primary research study. While the paper provides valuable insights into dental implant outcomes with antiresorptive medications, it does not align with the required methodological and intervention specifications. Uncertainties remain regarding population characteristics, control group presence, and precise study design.",1.4
Association Between Malignant Diseases and Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review and Meta-Analysis,"Sheng Yao, Xiaoyong Ding, Gang Rong, Jie Zhou, Bo Zhang",10.1097/SCS.0000000000009033,https://doi.org/10.1097/SCS.0000000000009033,The Journal of craniofacial surgery (Print),3,2022,no,"The paper focuses on patients with malignant diseases, which is explicitly excluded by the criteria. Therefore, it fails to meet the criterion of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",no,maybe,"The paper reports MRONJ outcomes, but does not specify the dental procedures leading to MRONJ. Therefore, it partially meets the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",yes,"As a meta-analysis, the paper includes comparative studies, and likely includes non-users as controls. Therefore, it meets the criterion of including a control group of non-anti-resorptive medication users.",yes,"The paper includes cohort and case-control studies, which meet the criterion of having a study design of either a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"The paper mentions ""cumulative dosages"", but does not clearly document the temporal relationship between medication use and MRONJ development, or the duration of medication use. Therefore, it partially meets the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development, and the duration of medication use.",maybe,"The paper is a meta-analysis of 9 studies (6 cohort + 3 case-control), but the individual study sizes are not specified. Therefore, it is uncertain whether the paper meets the criterion of having a subject size of more than 100 people.","The paper does not mention any specific dental procedures, and instead focuses on general MRONJ risk factors. Therefore, it fails to meet the criterion of having an intervention of invasive dental treatment, including tooth extraction, implant placement, periodontal surgery, other dental surgery, or removable prosthesis fabrication.",Exclude,"The study fails key screening criteria by focusing on cancer patients and broad antiresorptive medications rather than specifically examining Romosozumab in non-cancer osteoporosis patients. While the research includes appropriate study designs and control groups, it lacks specific documentation of dental procedures and does not meet the precise intervention requirements. Consequently, the paper does not align with the systematic review's targeted research parameters.",1.4
Management of Tooth Extraction in Patients Taking Antiresorptive Drugs: An Evidence Mapping Review and Meta-Analysis,"Chang Liu, Y. Xiong, T. Zhu, Wei Liu, W. Tang, W. Zeng",10.3390/jcm12010239,https://doi.org/10.3390/jcm12010239,Journal of Clinical Medicine,7,2022,maybe,"While the study involves patients with antiresorptive medication, it doesn't explicitly state that all subjects are adults (≥18) or that cancer patients are excluded. However, the context suggests these are likely adult patients.",yes,yes,"The study specifically documents MRONJ outcomes following dental procedures, particularly tooth extraction.",yes,"The study includes comparisons between different groups (drug holiday vs. drug continuation, different surgical techniques, antibacterial prophylaxis vs. control).",yes,The review includes randomized controlled trials and other study designs that meet the criteria.,yes,"The study discusses temporal relationships between medication use and MRONJ development, including follow-up periods.",maybe,"The abstract doesn't specify the total number of subjects across the included studies. This is a systematic review of multiple studies, but individual study sizes are not mentioned.","The study specifically focuses on tooth extraction and other dental procedures, which meets this criterion.",Exclude,"The systematic review fails to meet the critical screening criterion of focusing specifically on Romosozumab, instead discussing antiresorptive drugs in general. While the study addresses several other screening requirements such as dental interventions, control groups, and outcome documentation, the absence of Romosozumab as the primary intervention renders the paper ineligible for inclusion. The review's broad approach to antiresorptive medications prevents it from satisfying the targeted research parameters.",1.4
Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective Study,"C. Brunner, M. Arvandi, Christian Marth, Daniel Egle, Florentina Baumgart, Miriam Emmelheinz, Benjamin Walch, Johanna Lercher, C. Iannetti, Ewald Wöll, Agnes Pechlaner, August Zabernigg, B. Volgger, Maria Castellan, Oliver Tibor Andraschofsky, Alice Markl, M. Hubalek, Michael Schnallinger, S. Puntscher, Uwe Siebert, S. Schönherr, L. Forer, E. Bruckmoser, J. Laimer",10.1200/JCO.24.00171,https://doi.org/10.1200/JCO.24.00171,Journal of Clinical Oncology,4,2024,no,"The study focuses exclusively on breast cancer patients with bone metastases, which explicitly violates the criterion requiring patients without cancer.",maybe,maybe,"While MRONJ outcomes are reported, the specific dental procedures leading to these outcomes are not detailed in the abstract.",no,The study does not include a control group of non-anti-resorptive medication users. It only compares different types of anti-resorptive medications.,yes,"This is a retrospective multicenter study, which fits within the acceptable study designs.",yes,"The study clearly documents the temporal relationship between medication use and MRONJ development, including specific timeframes (4.6 years, 5.1 years, 8.4 years).",yes,"The study includes 639 patients, well above the 100-person minimum requirement.","The abstract doesn't explicitly mention dental procedures, and while MRONJ is discussed, the specific dental interventions leading to MRONJ are not detailed.",Exclude,"The study focuses on breast cancer patients receiving denosumab and bisphosphonates, which fundamentally conflicts with the screening criteria requiring non-cancer osteoporosis patients using Romosozumab. Critical disqualifying factors include the wrong medication, wrong patient population, and absence of a control group, rendering the study ineligible for the systematic review. Despite meeting some criteria like subject size and study design, the core requirements are not satisfied.",0.1
Genetic predisposition for medication-related osteonecrosis of the jaws: a systematic review.,"J. S. P. D. Silva, E. Pullano, N. Raje, M. Troulis, Meredith August",10.1016/j.ijom.2019.04.014,https://doi.org/10.1016/j.ijom.2019.04.014,International Journal of Oral & Maxillofacial Surgery,13,2019,no,"The study includes patients with multiple myeloma (54.8%), which violates the criterion of focusing exclusively on non-cancer patients.",maybe,maybe,"While MRONJ is the outcome, specific dental procedures are not detailed, so this information is unclear from the abstract.",yes,"The abstract mentions case-control analysis, which appears to meet the control group requirement.",no,"This is a systematic review, not a primary study of the required designs, so it fails to meet the criterion.",maybe,"The abstract doesn't mention temporal relationships or duration of medication use, so this information is unclear from the abstract.",yes,"The study includes 3301 patients across 15 studies, which clearly meets the >100 subject requirement.","While MRONJ is discussed, the abstract doesn't specifically detail the dental procedures involved, so this information is unclear from the abstract.",Exclude,"The systematic review fails key screening criteria by focusing on bisphosphonates instead of Romosozumab, including cancer patients, and using a review methodology rather than a primary research design. Multiple critical requirements were not met, including the specific medication, population type, and study design, rendering the paper ineligible for inclusion in the systematic review.",0.1
"A SINGLE REFERENCE CENTER, 2 YEARS RETROSPECTIVE STUDY ON THE RISK FACTORS ASSOCIATED WITH ANTI-RESORPTIVE MEDICATION-RELATED OSTEONECROSIS OF THE JAWS IN OSTEOPOROTIC AND ONCOLOGICAL PATIENTS","P. Pignatelli, G. Podda, D. Pergolini, F. Rocchetti, U. Romeo, G. Tenore, D. Gaglioti",10.32388/LPILZ7,https://doi.org/10.32388/LPILZ7,-,1,2021,maybe,"The study includes both osteoporotic and oncological patients, which does not fully meet the requirement of focusing exclusively on adult patients with diagnosed osteoporosis who do not have cancer.",yes,yes,"The study reports MRONJ outcomes following dental procedures, which meets the requirement for outcome documentation.",maybe,The abstract does not mention whether the study includes a control group of non-anti-resorptive medication users.,maybe,"While the study appears to be a retrospective review, the exact study design is not explicitly stated in the abstract.",maybe,"The study mentions analyzing ""drug treatment duration"" but does not clearly document the temporal relationship between medication use and MRONJ development.",maybe,"The abstract does not specify the total number of patients studied, so the subject size is unclear.","The study includes dental extraction and oral surgery procedures, which meet the requirement for invasive dental treatment.",Exclude,"The study fails to meet critical screening criteria, specifically the requirement for Romosozumab as the intervention medication. While the research includes dental procedures and MRONJ outcomes, it focuses on Bisphosphonates and Denosumab instead of the specified medication, and includes oncological patients which are explicitly excluded from the review. Multiple other screening criteria remain unclear or partially met, further supporting exclusion from the systematic review.",0.1
Lack of evidence in reducing risk of MRONJ after teeth extractions with systemic antibiotics.,"M. Cabras, A. Gambino, R. Broccoletti, S. Sciascia, P. Arduino",10.2334/josnusd.21-0016,https://doi.org/10.2334/josnusd.21-0016,Journal of Oral Science,17,2021,maybe,"The abstract does not specify age restrictions or whether the patients have cancer, so it is unclear if the study meets the requirement of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",yes,yes,"The abstract clearly documents MRONJ outcomes following dental procedures, indicating that the study meets the requirement of reporting MRONJ outcomes following specific, documented dental procedures.",no,"The abstract mentions ""patients unexposed to antibiotics"" in one study, but this is about antibiotic use, not anti-resorptive medication use. Therefore, the study does not meet the requirement of including a control group of non-anti-resorptive medication users.",yes,"The abstract includes retrospective/prospective studies and case-series, indicating that the study meets the requirement of having a study design of either a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The abstract does not provide clear documentation of the temporal relationship between medication use and MRONJ development or the duration of medication use, indicating that the study does not meet this requirement.",maybe,"The abstract mentions ""case-series with more than 10 patients"", but this is a systematic review of multiple studies, not a primary study. Therefore, it is unclear if the individual studies meet the requirement of having a subject size of more than 100 people.","The abstract clearly includes tooth extraction and mentions ""surgical flap"", indicating that the study meets the requirement of having an intervention of invasive dental treatment.",Exclude,"The systematic review fails to meet critical screening criteria, particularly the requirement for Romosozumab as the intervention medication. Multiple key elements are either unmet or uncertain, including population characteristics, control group composition, and temporal documentation of medication use. The study's focus on bisphosphonates and denosumab, rather than the specified medication, renders it ineligible for inclusion.",0.1
Pathogenesis of Medication-Related Osteonecrosis of the Jaw: Odontogenic Infection-Preceding Type and Osteonecrosis-Preceding Type,"Yuki Sakamoto, Shunsuke Sawada, Y. Kojima",10.7759/cureus.60223,https://doi.org/10.7759/cureus.60223,Cureus,1,2024,maybe,"While the study includes adult patients, it's not explicitly stated that all patients are ≥18 years. Additionally, the abstract mentions patients with malignancy, which violates the ""no cancer"" requirement.",maybe,yes,The study clearly documents MRONJ outcomes and includes detailed radiographic findings.,no,The abstract does not mention any control group of non-anti-resorptive medication users.,yes,"This is a retrospective review, which falls under the acceptable study designs.",maybe,"While the abstract mentions ""administration period"" of antiresorptive agents, it's not clear if the temporal relationship between medication use and MRONJ development is thoroughly documented.",yes,"The study includes 145 patients, which exceeds the minimum requirement of 100 subjects.","While the study discusses MRONJ and dental procedures, it's not clear if all cases were specifically related to invasive dental treatments. The study actually focuses on distinguishing between odontogenic and non-odontogenic MRONJ.",Exclude,"The study fails to meet critical screening criteria, particularly the requirement for Romosozumab as the intervention medication, instead focusing on denosumab. While the research includes a sufficient sample size and documents MRONJ outcomes, it lacks a control group and potentially includes cancer patients, which disqualifies it from meeting the specified screening requirements. The fundamental mismatch in medication type renders the study non-compliant with the core screening criteria.",1.4
Evaluation of medication-related osteonecrosis of the jaw using the Japanese Adverse Drug Event Report database,"A. Inada, K. Hosohata, S. Oyama, I. Niinomi, Y. Mori, Y. Yamaguchi, M. Uchida, K. Iwanaga",10.2147/TCRM.S176620,https://doi.org/10.2147/TCRM.S176620,Therapeutics and Clinical Risk Management,13,2018,maybe,"The study includes adult patients (mentions elderly patients), but doesn't explicitly state they all have diagnosed osteoporosis. It also doesn't specify whether cancer patients were excluded.",maybe,maybe,"While MRONJ outcomes are documented, the abstract doesn't specify the dental procedures that led to these outcomes.",no,This is a retrospective pharmacovigilance analysis using an adverse event database. There is no mention of a control group of non-users.,yes,This is a retrospective cohort study using the JADER database.,maybe,"The study documents temporal relationships for denosumab (onset after 1 year), but timing information for zoledronate is noted as unknown.",yes,"The study includes 3,875 cases of MRONJ, well above the 100-person threshold.","While the study discusses MRONJ, which typically follows dental procedures, the abstract doesn't explicitly specify the types of dental interventions involved.",Exclude,"The study fails to meet key screening criteria, primarily due to its focus on bisphosphonates and denosumab instead of romosozumab, and the absence of a control group. While the research includes a large sample size and represents a retrospective cohort study, critical methodological requirements for the systematic review are not satisfied, particularly regarding the specific medication intervention.",1.4
"Prevalence, initiating factor, and treatment outcome of medication-related osteonecrosis of the jaw-a 4-year prospective study.","F. Hallmer, G. Andersson, B. Götrick, G. Warfvinge, J. Anderud, T. Bjørnland",10.1016/j.oooo.2018.08.015,https://doi.org/10.1016/j.oooo.2018.08.015,"Oral surgery, oral medicine, oral pathology and oral radiology",70,2018,maybe,"While the study appears to focus on adult patients with MRONJ, it doesn't explicitly state the age range or whether patients have cancer. The population seems to be general patients with MRONJ.",yes,yes,"The study clearly documents MRONJ outcomes following specific dental procedures, including tooth extraction and periodontal disease.",no,The abstract doesn't mention a control group of non-anti-resorptive medication users.,yes,"The study is explicitly stated as a prospective cohort study, which meets the study design criteria.",maybe,"While the study documents the temporal relationship between dental procedures and MRONJ development, it doesn't clearly specify the duration of medication use.",no,"The study includes 55 patients, which exceeds the minimum requirement of 100. However, this is actually a problem as it's below the required threshold.","The study includes tooth extraction and periodontal disease as initiating factors for MRONJ, which meets the intervention criteria.",Exclude,"The study fails to meet critical screening criteria, primarily due to using bisphosphonates and denosumab instead of the required Romosozumab medication. Additionally, the sample size of 55 patients falls short of the 100-patient requirement, and the absence of a control group further disqualifies the study from meeting the specified screening criteria.",1.4
Medication-Related Osteonecrosis of the Jaw: A Systematic Review of Case Reports and Case Series,"Filipa Frutuoso, F. Freitas, M. Vilares, Helena Francisco, D. Marques, J. Caramês, André Moreira",10.3390/diseases12090205,https://doi.org/10.3390/diseases12090205,Diseases,0,2024,maybe,"The study includes an adult population with an average age of 66.27 years, which partially meets the criterion of focusing on adult patients (≥18 years) with diagnosed osteoporosis. However, there is no mention of the cancer status of the patients.",maybe,maybe,"MRONJ outcomes are documented, but the temporal relationship between dental procedures and MRONJ development is not clearly specified, so the study partially meets this criterion.",no,"There is no mention of a control group in the study, so it fails to meet this criterion.",no,"The study is a systematic review of case reports and case series, which does not meet the required study design criteria of a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"The duration of medication use is documented (60.88 months ± 50.92), but the temporal relationship between medication use and MRONJ development is not clearly specified, so the study partially meets this criterion.",yes,"The study includes 151 cases across 88 articles, which meets the requirement of having a subject size of more than 100 people.","While dental procedures are mentioned (surgical debridement), the abstract does not clearly specify if these were the cause or treatment of MRONJ, so the information is unclear or insufficient to determine if the study meets the criterion of having an intervention of invasive dental treatment.",Exclude,"The systematic review fails to meet critical screening criteria, particularly the specified intervention of Romosozumab and the required study design. Multiple key requirements were not satisfied, including the absence of a control group and unclear documentation of temporal relationships between medication use and MRONJ development. The study's focus on case reports and case series diverges significantly from the predefined methodological standards.",1.4
The Type of Antiresorptive Treatment Influences the Time to Onset and the Surgical Outcome of Medication-Related Osteonecrosis of the Jaw.,"C. Pautke, A. Wick, S. Otto, B. Hohlweg-Majert, J. Hoffmann, O. Ristow",10.1016/j.joms.2020.10.005,https://doi.org/10.1016/j.joms.2020.10.005,Journal of oral and maxillofacial surgery,11,2020,maybe,"The abstract doesn't explicitly state the age range or whether patients had cancer. While it mentions ""underlying disease,"" we can't confirm if these were exclusively adult osteoporosis patients without cancer.",maybe,yes,The study clearly documents MRONJ outcomes and includes specific success rates and time to onset measurements.,no,The study compares different antiresorptive medications (BP vs DNO vs BP/DNO) but doesn't include a control group of non-users.,yes,"The study is explicitly stated as a ""retrospective single-center cohort study,"" which meets the criteria.",yes,"The study explicitly documents temporal relationships, including time to onset of MRONJ and 12-month follow-up periods.",yes,"The study includes 132 patients, which exceeds the minimum requirement of 100 subjects.","While the abstract mentions ""trigger events"" and discusses MRONJ, it doesn't explicitly detail the types of dental procedures performed. However, given this is a MRONJ study, dental procedures were likely involved.",Exclude,"The study fails to meet key screening criteria, specifically the requirement for romosozumab as the intervention medication, instead focusing on bisphosphonates and denosumab. While the research demonstrates methodological rigor with a robust sample size and clear outcome documentation, the fundamental deviation from the specified medication type renders the study non-compliant with the primary screening requirements.",1.4
Medication-Related Osteonecrosis of Jaws (MRONJ) Prevention and Diagnosis: Italian Consensus Update 2020,"G. Campisi, R. Mauceri, F. Bertoldo, G. Bettini, M. Biasotto, G. Colella, U. Consolo, O. Di Fede, G. Favia, V. Fusco, M. Gabriele, A. Lo Casto, L. Lo Muzio, A. Marcianó, M. Mascitti, M. Meleti, M. Mignogna, G. Oteri, V. Panzarella, U. Romeo, A. Santarelli, P. Vescovi, C. Marchetti, A. Bedogni",10.3390/ijerph17165998,https://doi.org/10.3390/ijerph17165998,International Journal of Environmental Research and Public Health,115,2020,no,"The paper mentions both cancer and osteometabolic patients, and does not focus exclusively on non-cancer osteoporosis patients.",no,no,"While MRONJ is discussed, this paper does not report specific outcomes from dental procedures, as it is focused on general recommendations and guidelines.",no,"No control group is mentioned, as this is a consensus paper, not a comparative study.",no,"This is a consensus conference paper, not a randomized controlled trial, cohort study, or case-control study.",no,"No specific temporal relationships or medication durations are documented, as this is a consensus paper, not a primary research study.",no,"No specific subject size is mentioned, and this is a consensus conference paper, not a primary research study.","While dental procedures are discussed generally, this is a consensus paper about MRONJ prevention and diagnosis, and does not describe a specific intervention study.",Exclude,"This consensus conference paper fails to meet the systematic review's screening criteria, primarily because it is not a primary research study and does not focus on Romosozumab as the specific intervention. The document discusses general MRONJ prevention guidelines and lacks the required elements such as specific subject size, control group, and detailed outcome documentation for the targeted research parameters.",0.1
Disease Stage and Mode of Therapy Are Important Determinants of Treatment Outcomes for Medication-Related Osteonecrosis of the Jaw.,"S. Ruggiero, N. Kohn",10.1016/j.joms.2015.09.024,https://doi.org/10.1016/j.joms.2015.09.024,Journal of oral and maxillofacial surgery,78,2015,maybe,"The mean age of the subjects is 68.9 years, so the study includes an adult population. However, there is no mention of the subjects' cancer status or a specific diagnosis of osteoporosis.",no,no,"While MRONJ outcomes are documented, they are not in relation to specific dental procedures. The study focuses on treatment outcomes rather than dental procedure outcomes.",no,"The study does not mention a control group, and appears to only include MRONJ patients.",yes,"The study is clearly stated as a retrospective cohort study, which meets the criterion for study design.",no,"The study does not clearly document the temporal relationship between medication use and MRONJ development, nor does it mention the duration of medication use.",yes,"The study includes 337 subjects, which exceeds the minimum requirement of 100 people.","While the study discusses MRONJ treatment, it does not specifically focus on dental procedures as interventions. The study appears to be about treatment of existing MRONJ rather than dental procedures leading to MRONJ.",Exclude,"The study fails to meet critical screening criteria, particularly the requirement for Romosozumab as the specific medication and the focus on invasive dental treatments. While the research includes a substantial sample size and uses a retrospective cohort design, it lacks a control group and does not document the temporal relationship between medication use and MRONJ development. The abstract primarily discusses MRONJ treatment outcomes rather than meeting the systematic review's specific research parameters.",1.4
Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?,"S. Soutome, S. Hayashida, M. Funahara, Y. Sakamoto, Y. Kojima, S. Yanamoto, M. Umeda",10.1371/journal.pone.0201343,https://doi.org/10.1371/journal.pone.0201343,PLoS ONE,52,2018,no,"The study exclusively focuses on cancer patients, which is explicitly excluded in the screening criteria. The criteria specifically require patients WITHOUT cancer.",yes,yes,"The study clearly documents MRONJ outcomes following dental procedures, particularly tooth extraction.",no,The abstract does not mention a control group of non-anti-resorptive medication users. The study appears to only include patients receiving high-dose BP or Dmab.,yes,"This appears to be a retrospective cohort study, which is one of the acceptable study designs.",yes,"The study documents temporal relationships between medication use and MRONJ development, including duration of medication use and timing of dental procedures.",yes,"The study includes 135 patients, which exceeds the minimum requirement of 100 subjects.","The study specifically examines tooth extraction and other dental procedures, which meets the intervention criteria.",Exclude,"The study focuses on cancer patients receiving bisphosphonates and denosumab, which critically deviates from the required criteria of non-cancer patients using Romosozumab. Multiple key screening requirements were not met, including population type, medication intervention, and control group composition, rendering the study ineligible for inclusion in the systematic review.",0.1
Is Medication Related Osteonecrosis of the Jaw around implants a rare entity ? A case series with a focus on etiopathophysiology.,"Jean Massaad, M. Magremanne",10.1016/j.jormas.2021.12.002,https://doi.org/10.1016/j.jormas.2021.12.002,Journal of Stomatology Oral and Maxillofacial Surgery,5,2021,no,"The study includes both osteoporosis and cancer patients, and is not exclusively focused on adult osteoporosis patients without cancer, so it does not meet the population type criterion.",yes,yes,"The study clearly documents MRONJ outcomes following dental implant procedures, which meets the outcome documentation criterion.",no,"There is no mention of a control group in the study, so it does not meet the control group criterion.",yes,"The study is a retrospective analysis, which meets the study design criterion.",yes,"The study documents the temporal relationship between medication use and MRONJ development, as well as the duration of medication use, which meets the temporal documentation criterion.",maybe,"The study includes 168 MRONJ cases, but only 6 cases with implants, so while the total cases exceed 100, the relevant subgroup is too small to meet the subject size criterion.","The study clearly includes dental implant placement, which meets the requirement for an invasive dental treatment intervention.",Include,"The study fails key screening criteria by not specifying Romosozumab, including cancer patients, and lacking a control group. While demonstrating strong documentation of dental implant-related MRONJ outcomes, the research does not meet the fundamental requirements for population type and intervention specificity. The small sample size of relevant cases further compromises its alignment with the screening criteria.",2.5
An evidence-based review of risk-reductive strategies for osteonecrosis of the jaws among cancer patients.,"K. Athanassios, T. Tzellos, K. Toulis, A. Arora, D. Kouvelas, S. Triaridis",10.2174/1574884711308020005,https://doi.org/10.2174/1574884711308020005,Current Clinical Pharmacology,15,2013,no,"The abstract specifically focuses on ""cancer patients receiving bone antiresorptive therapy,"" which explicitly violates the criterion requiring non-cancer patients.",maybe,maybe,"While MRONJ (ONJ) outcomes are documented, this is a review of other studies rather than primary research documenting specific dental procedures and outcomes.",maybe,"While the abstract discusses comparative studies, it's not clear if there are control groups of non-anti-resorptive medication users.",yes,"The paper includes randomized controlled trials and cohort studies, which meet the criteria.",maybe,The abstract doesn't provide clear information about temporal relationships or duration of medication use.,maybe,"The abstract does not specify the total number of subjects across the included studies, so the subject size is unclear.","The abstract mentions dental extractions and dental prophylactic measures, but this is in the context of reviewing other studies rather than being the primary focus of a single study.",Exclude,"The systematic review fails key screening criteria by focusing on cancer patients and using medications other than Romosozumab, which immediately disqualifies it from meeting the specified research parameters. While the study includes appropriate study designs and discusses dental interventions, its fundamental deviation from the required population and intervention types renders it unsuitable for inclusion.",0.1
Evaluation of MRONJ Risk and Associated Factors in Patients Receiving Antiresorptive and/or Antiangiogenic Drug Therapy: A Retrospective Cohort Study,Ömer Ekici,10.5505/tjo.2022.3359,https://doi.org/10.5505/tjo.2022.3359,Turkish Journal of Oncology,0,2022,maybe,"No specific mention is made of age groups or osteoporosis diagnosis, and there is no mention of cancer exclusion, so it is unable to determine if the study meets this criterion.",yes,yes,"The abstract explicitly mentions MRONJ outcomes following dental procedures, which meets this criterion.",maybe,"No mention is made of control groups, so it is unable to determine if the study meets this criterion.",maybe,"The study design is not explicitly stated, so it is unable to determine if the study meets this criterion.",maybe,"No clear information is provided about the temporal relationships or duration of medication use, so it is unable to determine if the study meets this criterion.",maybe,"No information is provided about the sample size, so it is unable to determine if the study meets this criterion.","The abstract explicitly mentions ""tooth extraction and other dentoalveolar surgical procedures"", which clearly meets this criterion.",Include,"The abstract discusses medication-related osteonecrosis of the jaw (MRONJ) after dental procedures, but lacks specificity about Romosozumab use, which is a critical screening requirement. Multiple key methodological details are missing, including subject size, population characteristics, control group information, and study design, creating significant uncertainty about meeting the comprehensive screening criteria.",2.7
Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents,"F. Rodríguez-Lozano, R. Oñate-Sánchez",10.4317/medoral.20980,https://doi.org/10.4317/medoral.20980,Medicina Oral,22,2016,maybe,"The abstract does not provide any specific information about the age groups or cancer status of the study population, only mentioning ""patients treated with bisphosphonates"".",maybe,maybe,"While MRONJ outcomes are discussed, the specific dental procedures leading to MRONJ are not detailed in the abstract.",maybe,The abstract does not mention the inclusion of a control group of non-anti-resorptive medication users.,no,"The paper is a systematic review, not a primary research study, and therefore does not meet the specified study design criteria.",maybe,"The abstract does not mention the temporal relationship between medication use and MRONJ development, or the duration of medication use.",maybe,"The abstract does not specify the number of subjects in the study, and only mentions that it is a systematic review of 29 articles, without providing details on the individual study sizes.","The paper discusses MRONJ treatment but does not specify the dental procedures that led to MRONJ, so it is unclear if the study includes the required invasive dental treatment interventions.",Exclude,"The systematic review fails to meet multiple critical screening criteria, including specific focus on Romosozumab, lack of clarity on subject size, and absence of a primary research design. Key uncertainties exist around population characteristics, intervention specifics, and outcome documentation, rendering the study non-compliant with the established screening requirements.",1.4
Medication-related osteonecrosis of the jaw: a dentist's nightmare,"Arvind Muthukrishnan, Laliytha Bijai Kumar, G. Ramalingam",10.1136/bcr-2016-214626,https://doi.org/10.1136/bcr-2016-214626,BMJ Case Reports,48,2016,maybe,"The patient is an adult (50-year-old) and has osteoporosis, which partially meets the criterion of focusing on adult patients with diagnosed osteoporosis who do not have cancer.",no,maybe,"MRONJ is documented as an outcome, but the specific dental procedures are not documented, so the study partially meets this criterion.",no,"As a case report, the study does not include a control group of non-anti-resorptive medication users, so it fails this criterion.",no,"The study design is a case report, which is not one of the accepted study designs (randomized controlled trial, prospective/retrospective cohort study, or case-control study), so it fails this criterion.",no,"There is no clear documentation of the temporal relationship between medication use and MRONJ development, or the duration of medication use, so the study fails this criterion.",no,"The study is a case report of a single patient, which does not meet the requirement of having a subject size of more than 100 people.","While dental treatment is implied, the specific procedures are not documented, so it is unclear if the study meets the criterion of having an intervention of invasive dental treatment.",Exclude,"This case report fails multiple critical screening criteria, including the use of Romosozumab, insufficient sample size, and lack of a control group. The study does not meet the required methodological standards for inclusion, with significant limitations in documenting temporal relationships and specific dental interventions. Consequently, the paper does not qualify for systematic review based on the predefined screening criteria.",0.1
Incidence and risk factors associated to Medication-Related OsteoNecrosis of the Jaw (MRONJ) in patients with osteoporosis after tooth extractions. A 12-months observational cohort study.,"A. Cuozzo, V. Iorio-Siciliano, Emanuele Vaia, Leopoldo Mauriello, A. Blasi, L. Ramaglia",10.1016/j.jormas.2022.03.020,https://doi.org/10.1016/j.jormas.2022.03.020,Journal of Stomatology Oral and Maxillofacial Surgery,4,2022,yes,"The study focuses on adult patients (mean age 67.5 years) with osteoporosis, and there's no mention of cancer patients.",yes,yes,"The study clearly documents MRONJ outcomes following tooth extractions, with specific documentation of the procedures and outcomes.",no,The abstract doesn't mention a control group of non-anti-resorptive medication users.,yes,"While not explicitly stated, this appears to be a prospective cohort study with 12-month follow-up.",yes,"The study documents both the temporal relationship (12-month follow-up) and mentions duration of therapy, though specific durations aren't provided in the abstract.",no,"The study includes 45 patients, which is below the required minimum of 100 subjects.","The study focuses on tooth extractions, which is explicitly mentioned as one of the acceptable invasive dental treatments.",Exclude,"The study focuses on osteoporotic patients undergoing tooth extractions while on bisphosphonate therapy, but critically fails to meet key screening criteria including the required medication type, sample size, and control group composition. Despite documenting MRONJ outcomes and following a prospective cohort design, the fundamental mismatch with the specified intervention and methodological requirements renders the study non-compliant with the established screening criteria.",1.4
Critical Analysis of the Effect of Antiresorptive Drugs on Osteonecrosis Associated With Dental Implants: An Umbrella Review,"Mansi Dahiya, Pankaj Dhawan, Sapna Rani, Vidushi Saxena",10.7759/cureus.71506,https://doi.org/10.7759/cureus.71506,Cureus,0,2024,maybe,"While the study involves patients with ARD therapy, it doesn't explicitly state that all subjects are adults (≥18 years) or specify that they don't have cancer. The osteoporosis status is also not mentioned.",yes,yes,The study specifically documents MRONJ outcomes following dental implant procedures.,yes,"The abstract mentions comparison between ""ARD and non-ARD participants,"" indicating the presence of a control group.",no,"This is actually a systematic review of other studies, not a primary research study with one of the required designs (RCT, cohort, or case-control).",maybe,"While the abstract mentions patients with ""history of ARD before, during, or following implant placement,"" it doesn't clearly document the temporal relationship or duration of medication use.",maybe,"The abstract mentions ""524 failed implants"" but doesn't specify the total number of subjects. This information is insufficient to determine if the study meets the >100 subjects criterion.","The study specifically focuses on dental implant treatment, which meets this criterion.",Exclude,"The systematic review fails to meet critical screening criteria, particularly the requirement for a primary research study focusing on Romosozumab. While the study addresses dental implant treatment and includes a control group, it lacks specificity about population characteristics, medication type, and temporal documentation. The review's nature as a meta-analysis rather than a primary research study further disqualifies it from meeting the established screening requirements.",1.4
Medication-related osteonecrosis of the jaw associated with implant and regenerative treatments: Systematic review,"António Granate-Marques, Carlos Polis-Yanes, Maria Seminario-Amez, E. Jané‐Salas, J. López‐López",10.4317/medoral.22691,https://doi.org/10.4317/medoral.22691,Medicina Oral,30,2019,maybe,"The study mentions ""patients with benign bone diseases"" but does not specifically focus on osteoporosis patients, and no clear age criteria are mentioned, so it only partially meets the population type criterion.",yes,yes,"The study does document MRONJ outcomes (""osteonecrosis"") and links them to specific dental procedures, which meets the outcome documentation criterion.",maybe,"As a literature review, the study does not have its own control group, and the control group composition of the reviewed studies is not specified.",no,"This is a literature review, not a primary research study, and therefore does not meet the required study design criteria.",yes,"The study mentions the duration of treatment (>3 years) and discusses the temporal relationship between treatment and outcomes, which meets the temporal documentation criterion.",maybe,"The abstract does not specify the sample size of the included studies, and this is a review of other studies rather than a primary research study.","The study focuses on ""regenerative and/or implant treatments"" and specifically mentions ""sinus floor augmentation"" and ""dental implants"", which meets the criterion for invasive dental treatment.",Exclude,"The literature review fails to meet critical screening criteria, particularly the requirement for Romosozumab as the specific anti-resorptive medication and the need for a primary research study design. While the study addresses dental procedures and osteonecrosis, it lacks the precise population focus, control group, and intervention specifics mandated by the screening protocol. Consequently, the abstract does not qualify for inclusion in the systematic review.",1.4
Local radiographic risk factors for MRONJ in osteoporotic patients undergoing tooth extraction.,"C. Moreno-Rabié, Hugo Gaêta-Araujo, André Ferreira-Leite, W. Coucke, E. Gielen, T. Van den Wyngaert, R. Jacobs",10.1111/odi.14496,https://doi.org/10.1111/odi.14496,Oral Diseases,7,2023,maybe,"The study includes osteoporotic patients, but doesn't explicitly state they are all adults (≥18 years) or confirm absence of cancer patients. However, given the context and typical osteoporosis demographics, this is likely met.",yes,yes,"The study clearly documents MRONJ outcomes following tooth extractions, with specific documentation of 11 tooth extraction sites (3.1%) developing MRONJ.",yes,"The abstract explicitly mentions ""a matched control group was selected.""",yes,"The study is described as a ""retrospective, longitudinal, case-control study,"" which meets the criteria.",maybe,"While the study is retrospective and longitudinal, the abstract doesn't explicitly state how medication use duration was documented or the temporal relationship between medication use and MRONJ development.",yes,"The study includes 120 patients, which exceeds the minimum requirement of 100 subjects.","The study specifically focuses on tooth extraction, which is one of the specified invasive dental treatments.",Exclude,"The study involves osteoporotic patients undergoing tooth extraction with antiresorptive drug use, but critically fails to specify Romosozumab as the intervention. While meeting several screening criteria including subject size, control group, and study design, the lack of Romosozumab specificity disqualifies the paper from the intended review. Uncertainty remains regarding precise population characteristics and temporal medication documentation.",1.4
Analysis of Implant Associated Medication related osteonecrosis of the jaw: Retrospective clinical study,"Dongkyu Jang, Jin-Woo Kim",10.1111/clr.139_13644,https://doi.org/10.1111/clr.139_13644,-,1,2020,maybe,"While the study included adult patients (mean age 70.3 years) with osteoporosis, it was not explicitly stated that all patients were ≥18 years old or that none had cancer. However, given the mean age and context, this criterion was likely met.",yes,yes,The study clearly documented MRONJ outcomes following dental implant procedures and included detailed clinical and radiographic findings.,no,"The abstract did not mention a control group of non-anti-resorptive medication users, and the study appeared to only include patients who developed MRONJ.",yes,"While not explicitly stated, the study appears to be a retrospective cohort study based on the analysis of medical records.",yes,"The study documented temporal relationships, including mean times from implant installation to MRONJ occurrence (2.54 years) and from drug administration to MRONJ (3.92 years).",no,"The study only included 26 patients, which is well below the required 100+ subjects.","The study focused on dental implants and included surgical treatment, which meets the criterion for invasive dental treatment.",Exclude,"The study fails key screening criteria due to using bisphosphonates instead of Romosozumab and having a sample size of only 26 patients, which is significantly below the required 100 subjects. While the research provides valuable insights into medication-related osteonecrosis of the jaw, it does not meet the specified methodological requirements for inclusion in the systematic review.",0.1
Comparing the Surgical Response of Bisphosphonate-Related Versus Bisphosphonate-Related Osteonecrosis of the Jaws.,"B. Palla, E. Burian, A. Deek, C. Scott, John G. Anderson, N. Callahan, E. Carlson",10.1016/j.joms.2020.11.017,https://doi.org/10.1016/j.joms.2020.11.017,Journal of oral and maxillofacial surgery,5,2020,maybe,"The age range (19-77) meets the adult requirement, but the abstract doesn't specify if all patients had osteoporosis or if any had cancer.",no,maybe,"While MRONJ outcomes are documented, they focus on surgical treatment outcomes rather than outcomes following initial dental procedures.",no,No control group is mentioned in the abstract.,no,"The abstract describes this as a literature review with analysis of cases, which doesn't clearly fit into the required study design categories.",no,The abstract doesn't clearly document the temporal relationship between medication use and MRONJ development or the duration of medication use.,no,"The study only includes 20 patients, well below the required 100+ subjects.","While the study discusses surgical resection of MRONJ, it doesn't clearly specify whether these patients underwent initial invasive dental treatments that led to MRONJ.",Exclude,"The study fails key screening criteria by using denosumab instead of romosozumab, having a small sample size of 20 patients, and lacking a control group. Multiple other criteria remain unclear or partially met, including population type, intervention details, and temporal documentation of medication use and MRONJ development. The fundamental mismatch with the specified intervention and insufficient sample size render the study non-compliant with the established screening requirements.",1.4
A multicenter observational study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network in North-Western Italy,"V. Fusco, M. Cabras, F. Erovigni, Alessandro Dell’Acqua, P. Arduino, M. Pentenero, P. Appendino, L. Basano, F. Ferrera, A. Fasciolo, Majlinda Caka, M. Migliario, S. Franchi, A. Gambino",10.4317/medoral.24318,https://doi.org/10.4317/medoral.24318,Medicina Oral,21,2020,no,"The study focuses on cancer/myeloma patients, not osteoporosis patients, which fails this critical criterion.",maybe,maybe,"MRONJ outcomes are documented, but specific dental procedures are not detailed in the abstract, so it is unclear if this criterion is met.",no,"There is no mention of a control group in the study, so this criterion is not met.",yes,"The study has a mixed retrospective (2009-2015) and prospective (2015-2018) design, which meets this criterion.",yes,"Treatment duration is mentioned as being documented, and the temporal relationship is discussed, which meets this criterion.",yes,"The study includes 459 MRONJ cases, which meets the requirement of having a subject size of more than 100 people.","While MRONJ is discussed, the abstract does not explicitly state that all cases were related to dental procedures, so it is unclear if this criterion is met.",Exclude,"The study focuses on cancer and myeloma patients using zoledronic acid and denosumab, which fundamentally differs from the required osteoporosis patient population and romosozumab medication. Critical screening criteria were not met, including population type, medication intervention, and control group requirements. These significant deviations render the study ineligible for inclusion in the systematic review.",0.1
Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone.,T. Shibahara,10.1620/tjem.247.75,https://doi.org/10.1620/tjem.247.75,Tohoku journal of experimental medicine,58,2019,maybe,"While osteoporosis patients are mentioned, the abstract also discusses cancer patients, and does not specify age restrictions, so the reasoning is partially met or uncertain.",yes,no,"While MRONJ outcomes are discussed, this is a review of the condition rather than documentation of specific outcomes, so it fails this criterion.",maybe,"No mention of control groups is made in the abstract, so the reasoning is uncertain.",no,"This appears to be a review article (""This article overviews..."") rather than a primary research study, so it fails this criterion.",no,"No specific temporal relationships or medication durations are documented in the abstract, so it fails this criterion.",maybe,"No specific subject size is mentioned in the abstract, so the reasoning is uncertain.","The abstract mentions relevant dental treatments including ""tooth extraction, dental implants, and dentures"", which meets this criterion.",Exclude,"The abstract fails critical screening criteria, particularly the requirement for Romosozumab as the intervention, and does not represent a primary research study with documented outcomes. Multiple key elements are missing, including specific subject size, control group details, and precise temporal documentation of medication use and MRONJ development. The paper appears to be a general review of medication-related jaw necrosis rather than a focused research study meeting the systematic review requirements.",0.1
Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis,"Everts-Graber Judith, L. Daniel, Burkard John-Patrik, S. Benoît, Gahl Brigitta, Häuselmann HansJörg, Studer Ueli, Ziswiler Hans-Rudolf, R. Stephan, Lehmann Thomas",10.1002/jbmr.4472,https://doi.org/10.1002/jbmr.4472,Journal of Bone and Mineral Research,59,2021,yes,The study focuses on adult patients (median age 69 years) with osteoporosis. There's no mention of cancer patients.,maybe,maybe,"The study documents ONJ outcomes and uses the AAOMS case definition, but doesn't clearly specify the dental procedures leading to these outcomes.",maybe,"While the study compares different treatment groups (denosumab vs. bisphosphonates), it doesn't explicitly mention a control group of non-anti-resorptive medication users.",yes,This appears to be a retrospective cohort study using a real-world population database.,yes,"The study documents temporal relationships and duration of medication use, with clear patient-years calculations.",yes,"The study includes 9,956 registered patients, well above the 100-person minimum.","While the study examines ONJ cases, it doesn't explicitly state whether these were triggered by specific dental procedures. The abstract mentions ""dental procedures"" but doesn't specify which ones.",Exclude,"The study focuses on denosumab and bisphosphonates for osteoporosis treatment, which fundamentally differs from the specified Romosozumab intervention, rendering it ineligible for inclusion. While the research demonstrates robust methodology with a large patient cohort and clear outcome documentation, the primary intervention criterion is not met, necessitating exclusion from further review.",1.4
A Comprehensive Quality Meta-Review of Genetic and Pharmacogenomic Aspects of Medication-Related Osteonecrosis of The Jaw (MRONJ),"Roberto Sacco, S. Olate, M. Calasans-Maia, N. Sacco, A. Acocella, Carlos Fernando de Almeida Barros Mourão, V. Moraschini, O. Akintola, R. Guerra, J. Yates",10.3390/app122312289,https://doi.org/10.3390/app122312289,Applied Sciences,1,2022,no,"Population characteristics are not specified, so the study does not explicitly meet the criterion of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",no,no,"While MRONJ is the focus, specific dental procedures and outcomes are not detailed. Therefore, the study does not explicitly meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"As a meta-review, the study does not directly include control groups, so it does not meet the criterion of including a control group of non-anti-resorptive medication users.",no,"This is a meta-review of systematic reviews and meta-analyses, not a primary study with the required design types (randomized controlled trial, prospective/retrospective cohort study, or case-control study). Therefore, the study does not meet the criterion of having the specified study design.",no,"There is no mention of temporal relationships or medication duration, so the study does not meet the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",maybe,"This is a meta-review of systematic reviews, and no specific subject size is mentioned. Therefore, it is unclear whether the study meets the criterion of having a subject size of more than 100 people.","While MRONJ is discussed, specific dental interventions are not detailed. Therefore, the study does not explicitly meet the criterion of having an intervention of invasive dental treatment, including tooth extraction, implant placement, periodontal surgery, other dental surgery, or removable prosthesis fabrication.",Exclude,"This meta-review fails to meet multiple critical screening criteria, including specific medication type, patient population, intervention details, and study design requirements. The paper focuses on genetic and pharmacogenomics risk factors for MRONJ through a review of systematic reviews, which fundamentally differs from the desired primary research study. Consequently, the abstract does not align with the specified screening criteria for inclusion.",0.1
Microbial population changes in patients with medication-related osteonecrosis of the jaw treated with systemic antibiotics.,"L. De Bruyn, R. Coropciuc, W. Coucke, C. Politis",10.1016/j.oooo.2017.11.022,https://doi.org/10.1016/j.oooo.2017.11.022,"Oral surgery, oral medicine, oral pathology and oral radiology",20,2017,maybe,"The age range of 55-88 (mean 73) indicates an adult population, but the osteoporosis status is not explicitly mentioned, and the cancer status is not mentioned at all.",maybe,no,"The focus of the study is on bacterial analysis rather than MRONJ outcomes, and there is no specific documentation of the dental procedures that led to MRONJ.",maybe,"The study includes a control group of orally healthy patients, but this control group is not specifically non-anti-resorptive medication users.",yes,"The study appears to be a prospective cohort study, which includes a control group and specific measurements.",no,"There is no clear documentation of the temporal relationship between medication use and MRONJ, and the duration of medication use is not mentioned.",no,"The study includes 38 MRONJ patients and 29 controls, for a total sample size of 67, which is below the required 100 subjects.","While the study involves MRONJ patients, it doesn't specifically document the dental procedures that led to MRONJ. The focus is on bacterial analysis rather than dental interventions.",Exclude,"The study fails to meet critical screening criteria, particularly the requirement for Romosozumab intervention, with a sample size below 100 and an unclear focus on dental procedures. While the research involves adult patients and includes a control group, it lacks specific documentation of MRONJ outcomes, temporal medication relationships, and does not align with the core intervention requirements. The bacterial analysis approach diverges significantly from the intended research parameters.",1.4
A retrospective study on the incidence of medication-related osteonecrosis of the jaws (MRONJ) associated with different preventive dental care modalities,"C. Bacci, Alessia Cerrato, E. Bardhi, A. Frigo, Selma Ahcene Djaballah, S. Sivolella",10.1007/s00520-021-06587-x,https://doi.org/10.1007/s00520-021-06587-x,Supportive Care in Cancer,16,2021,no,"There is no explicit mention of the age range of the patients, and no clear indication if the patients have cancer or not. Therefore, it cannot be confirmed if the population meets the criteria.",maybe,maybe,"MRONJ outcomes are documented, but the specific dental procedures leading to MRONJ are not clearly documented.",no,"The study groups are based on different types of dental care, but there is no clear control group of non-anti-resorptive medication users.",yes,"The study is clearly stated as a retrospective study, which meets the criterion as a retrospective cohort study is acceptable.",no,"There is no clear documentation of the temporal relationship between medication use and MRONJ, and the duration of medication use is not mentioned.",no,"The study included 71 patients after exclusions, which is below the required minimum of 100 subjects.","The study focuses on preventive dental visits and treatments, but does not specifically document invasive dental procedures. While dental procedures are mentioned, they are not clearly specified.",Include,"The study fails to meet multiple critical screening criteria, including the specific requirement for Romosozumab intervention and a minimum sample size of 100 patients. Insufficient documentation of population characteristics, lack of a clear control group, and missing temporal relationship details further compromise the study's alignment with the systematic review requirements. While addressing medication-related osteonecrosis of the jaws, the research does not satisfy the predefined screening parameters.",2.5
Medication-Related Osteonecrosis of the Jaw: A Systematic Review and a Bioinformatic Analysis,"Galina Laputková, I. Talian, Vladimíra Schwartzová",10.3390/ijms242316745,https://doi.org/10.3390/ijms242316745,International Journal of Molecular Sciences,2,2023,maybe,"The abstract does not provide any specific mention of patient demographics or osteoporosis status, and does not mention cancer exclusion. Therefore, it is uncertain whether the study meets the criterion of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",no,no,"While MRONJ is the focus of the study, the abstract indicates that the study examines molecular mechanisms rather than documenting specific dental procedures and MRONJ outcomes. Therefore, the study does not meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"The abstract does not mention any control groups, and the study appears to be a systematic review of molecular studies rather than a primary research study. Therefore, the study does not meet the criterion of including a control group of non-anti-resorptive medication users.",no,"The abstract indicates that this is a systematic review of molecular studies, rather than a primary research study with the required design types (randomized controlled trial, prospective/retrospective cohort study, or case-control study). Therefore, the study does not meet the criterion of having the required study design.",no,"The abstract does not mention any temporal relationships or medication duration, and the focus is on molecular markers rather than clinical outcomes. Therefore, the study does not meet the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",maybe,"The abstract mentions analyzing 12 studies with various sample sizes, but does not provide a specific mention of the total subject count. Therefore, it is uncertain whether the study meets the criterion of having a subject size of more than 100 people.","The abstract does not mention any specific dental procedures or treatments, and the focus is on molecular mechanisms rather than clinical interventions. Therefore, the study does not meet the criterion of having an intervention of invasive dental treatment.",Exclude,"This systematic review of molecular mechanisms fails to meet multiple critical screening criteria, including specific intervention type, subject size, dental treatment focus, and study design requirements. The research primarily examines genetic and protein markers associated with medication-related osteonecrosis of the jaw, diverging significantly from the targeted clinical research parameters. Consequently, the study does not align with the predefined screening criteria for inclusion.",0.1
"Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals","L. Drudge-Coates, T. Van den Wyngaert, M. Schiødt, H. V. van Muilekom, G. Demonty, S. Otto",10.1007/s00520-020-05440-x,https://doi.org/10.1007/s00520-020-05440-x,Supportive Care in Cancer,31,2020,no,"The abstract mentions both cancer and osteoporosis patients, and does not focus exclusively on adult osteoporosis patients without cancer. Therefore, the population type does not meet the criterion of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",no,no,"While MRONJ outcomes are discussed, this is not a study documenting specific outcomes following dental procedures. Therefore, the study does not meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures (extractions, periodontal surgery, implants, or prosthetic treatments).",no,"There is no mention of control groups in the abstract, and this is a review paper rather than an interventional study. Therefore, the study does not meet the criterion of including a control group of non-anti-resorptive medication users.",no,"This is a literature review/guideline paper, not a primary research study. Therefore, the study design does not meet the criterion of being a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"No specific temporal relationships or medication durations are documented in the abstract. Therefore, the study does not meet the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",maybe,"The abstract does not mention any specific study size, so the subject size is unclear. However, this is a review paper rather than a primary study, so the subject size criterion is not applicable.","While dental procedures are implied in the context of MRONJ, this is a review paper about MRONJ management rather than a study of specific dental interventions. Therefore, the intervention does not meet the criterion of invasive dental treatment, including tooth extraction, implant placement, periodontal surgery, other dental surgery, or removable prosthesis fabrication.",Exclude,"This literature review fails to meet multiple screening criteria, including specific intervention type, subject size, population focus, and study design requirements. The paper provides general guidance on medication-related osteonecrosis of the jaw but does not constitute a primary research study with the necessary methodological characteristics for inclusion. Consequently, it does not align with the systematic review's targeted research parameters.",0.1
Revisiting best practice guidelines and patient care workflow for managing the risk of medication-related osteonecrosis of the jaw: comparative summary and case studies.,"Jen-Jih Chen, Chia-Yu Wu, Kristina Gallagher, Chin‐Wei Wang",10.3290/j.qi.b4213007,https://doi.org/10.3290/j.qi.b4213007,Quintessence International,1,2023,maybe,"The abstract doesn't specify age range or explicitly state patients don't have cancer, and while it discusses dental patients, it doesn't provide enough detail about the population characteristics.",yes,no,"While MRONJ is discussed, the paper focuses on guidelines rather than documenting specific outcomes, and the case studies mentioned are too few and appear to be illustrative rather than systematic documentation.",no,"There is no mention of a control group, and the paper appears to be a review of guidelines with case studies.",no,"This appears to be a review paper with case studies, and does not match the required study designs (RCT, cohort, or case-control).",no,"There is no clear documentation of temporal relationships or medication duration, and the paper focuses on guidelines rather than tracking specific patient outcomes.",no,"The abstract only mentions ""three case studies"", which is well below the required 100 subjects.","The abstract mentions ""advanced surgeries including alveoloplasty, tooth extraction, implant placement, and particulate bone grafting"", which clearly meets the criterion for invasive dental treatment.",Exclude,"The abstract fails to meet multiple critical screening criteria, including specific intervention type, subject size, study design, and control group requirements. While discussing antiresorptive medications and dental procedures, the paper is a guideline review with case studies that does not align with the systematic review's methodological standards. The lack of precise documentation and limited scope prevent the abstract from qualifying for inclusion.",0.1
Prognosis of Medication-Related Osteonecrosis of the Jaws in Metastatic Prostate Cancer Patients.,"Ling-Ying Wei, S. Kok, Yen-Ching Lee, Wei-Yih Chiu, J. Wang, Shih-Jung Cheng, Hao Chang, Jang-Jaer Lee",10.1111/odi.13737,https://doi.org/10.1111/odi.13737,Oral Diseases,11,2020,no,"The study focuses on prostate cancer patients, which explicitly fails the criterion as it includes cancer patients, and it is not focused on osteoporosis patients.",maybe,maybe,"MRONJ outcomes are documented, but the specific dental procedures are not detailed in the abstract.",no,"No control group is mentioned, and the study compares different antiresorptive agents but not against non-users.",yes,"The study design is a retrospective cohort study, which meets the acceptable study design criteria.",no,"The abstract does not clearly document the temporal relationship between medication use and MRONJ, and the duration of medication use is not explicitly stated.",yes,"The study includes 95 patients with 122 MRONJ lesions, which meets the minimum requirement of 100 subjects.","The abstract does not explicitly state the dental procedures that led to MRONJ, so the specific dental interventions are not detailed.",Exclude,"The study fails critical screening criteria by using zoledronic acid and denosumab instead of Romosozumab, and focusing on prostate cancer patients rather than osteoporosis patients. Multiple key requirements are not met, including the absence of a control group and lack of clear documentation of dental procedures and medication use duration. These significant deviations from the specified screening criteria render the study unsuitable for inclusion.",0.1
"ymposium : Imaging modalities for drug-related osteonecrosis of the aw ( 1 ) , role of imaging in drug-related osteonecrosis of the jaw : An pto-date review ( secondary publication )","akoto Tsuchimochia, Tohru Kurabayashib",-,-,-,18,2019,maybe,"The abstract mentions that the study included patients with osteoporosis, but also mentions patients with cancer (bone metastasis). Therefore, the study does not focus exclusively on adult patients with diagnosed osteoporosis who do not have cancer.",no,maybe,"The abstract mentions MRONJ/ARONJ as an outcome, but does not provide any specific documentation of the dental procedures that were performed. Therefore, the study partially meets this criterion.",maybe,"The abstract does not mention the inclusion of a control group of non-anti-resorptive medication users, so it is uncertain whether the study included such a control group.",maybe,"The abstract does not provide any information about the study design, so it is uncertain whether the study was a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The abstract does not clearly document the temporal relationship between medication use and MRONJ development, or the duration of medication use. Therefore, the study fails to meet this criterion.",maybe,"No information is provided about the sample size of the study, so it is uncertain whether the study had more than 100 participants.","The abstract does not mention any specific dental procedures, such as tooth extraction, implant placement, periodontal surgery, or removable prosthesis fabrication. Therefore, there is no evidence that the study included an intervention of invasive dental treatment.",Exclude,"The abstract lacks specific details about Romosozumab, dental interventions, and study methodology, failing to meet multiple critical screening criteria. While discussing MRONJ/ARONJ, the text appears to be a general review rather than a focused research study, with insufficient information to confirm alignment with the required parameters. Consequently, the abstract does not provide enough evidence to satisfy the comprehensive screening requirements.",1.4
Medication‐related osteonecrosis of the jaw – a current review,"F. Domah, Nirmal Shah, J. Domah, Raunaq Shah",10.1111/ORS.12329,https://doi.org/10.1111/ORS.12329,-,3,2018,no,"Population characteristics are not specified, so the study does not meet the criterion of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",no,no,"While MRONJ is discussed, this is not a study documenting specific outcomes, so the study does not meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"No control groups are mentioned, and this is a review article, not an interventional study, so the study does not meet the criterion of including a control group of non-anti-resorptive medication users.",no,"This is a literature review, not a primary research study, so the study does not meet the criterion of having a study design of a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"No temporal relationships or medication durations are documented, so the study does not meet the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",no,"This is a review article, not a primary study, and no specific subject numbers are mentioned, so the study does not meet the criterion of having a subject size of more than 100 people.","While dental procedures are implied in the context of MRONJ, this is a review of mechanisms and management, and no specific dental interventions are studied, so the study does not meet the criterion of having an intervention of invasive dental treatment.",Exclude,"This literature review fails to meet any of the specified screening criteria, as it is not a primary research study and lacks specific details about patient populations, interventions, or outcomes. The abstract discusses antiresorptive agents and medication-related osteonecrosis of the jaw in general terms, but does not provide the required clinical research parameters for inclusion.",0.1
CLEP_A_325080 1019..1026,"L. Stevens, L. Spangler, L. Yochum, Yan Ding, Florence T. Wang",-,-,-,0,2021,maybe,"The study focuses on postmenopausal women and women with postmenopausal osteoporosis, but there is no mention of cancer exclusion.",no,no,"While MRONJ is the outcome of interest, the study focuses on algorithm validation and does not provide specific documentation of dental procedures leading to MRONJ.",no,"There is no mention of a control group, and the study design appears to be focused on algorithm validation.",no,"This appears to be a validation study of claims-based algorithms, not a randomized controlled trial, cohort study, or case-control study as required.",no,There is no mention of temporal relationships or medication duration.,yes,"The study identified 1,273 potential cases, with 200 selected for chart review, which appears to be an adequate sample size. However, this is a validation study of MRONJ identification algorithms, not a study of the specified intervention.","The abstract does not specify any dental interventions, and the focus appears to be on MRONJ identification rather than dental procedures.",Exclude,"The study fails to meet multiple critical screening criteria, including specific anti-resorptive medication use, invasive dental treatment documentation, and required study design. While focusing on postmenopausal women with osteoporosis, the research is a methodological validation study of MRONJ identification algorithms rather than a clinical intervention study. Consequently, the abstract does not align with the systematic review's targeted research parameters.",1.4
Comparison of the Effectiveness of Conservative and Surgical Treatment of Medication-Related Osteonecrosis of the Jaw: a Systematic Review,"Rial Seluki, Moshe Seluki, I. Vaitkevičienė, E. Jagelavičienė",10.5037/jomr.2023.14401,https://doi.org/10.5037/jomr.2023.14401,eJournal of Oral Maxillofacial Research,3,2023,maybe,"The abstract does not mention the age groups or cancer status of the study population, so it is uncertain whether the studies focus exclusively on adult non-cancer patients.",maybe,maybe,"The abstract focuses on MRONJ outcomes, but does not specify the dental procedures leading to MRONJ, so it only partially meets this criterion.",maybe,"The abstract does not mention the inclusion of a control group of non-anti-resorptive medication users, so it is uncertain whether this criterion is met.",yes,"The abstract explicitly mentions including ""7 cohort studies and 2 randomized controlled trials"", which satisfies the study design criterion.",no,"The abstract does not mention the temporal relationships or duration of medication use, so it is unclear whether this criterion is met.",maybe,"The abstract includes 9 studies with a total of 4227 screened articles, but the individual study sizes are not specified, so it is uncertain whether the studies meet the requirement of having more than 100 subjects.","The abstract discusses treatment of MRONJ but does not specify the dental procedures that led to MRONJ, so it is uncertain whether the included studies focus on the required dental interventions.",Exclude,"The systematic review fails to meet critical screening criteria, particularly the specific requirement for Romosozumab intervention, and lacks clear documentation of dental procedures, patient population, and temporal medication relationships. Multiple screening criteria remain uncertain or unmet, significantly reducing the likelihood of study inclusion. The research appears more focused on treatment approaches for medication-related osteonecrosis of the jaw rather than addressing the specific screening requirements.",1.4
A nested case-control study of factors contributing to the development of medication-related osteonecrosis of the jaw in patients using bone resorption inhibitors in Mishima City.,"Keisuke Seki, Atsushi Kamimoto, Maki Wada, T. Iinuma",10.2334/josnusd.23-0096,https://doi.org/10.2334/josnusd.23-0096,Journal of Oral Science,2,2023,maybe,"Adult status is implied but not explicitly stated, and there is no mention of cancer status, so there is insufficient information to determine if this criterion is met.",maybe,maybe,"MRONJ outcomes are documented, but the specific dental procedures are not detailed.",yes,"The study includes 32 matched controls, so this criterion is met.",yes,"The case-control study design is explicitly stated, so this criterion is met.",no,"There is no clear documentation of the temporal relationship between medication use and MRONJ development, or the duration of medication use.",no,"The study includes 12 MRONJ cases and 32 controls, for a total of 44 subjects, which falls well below the required 100 subjects.","While dental treatment is mentioned, the abstract does not specify which procedures were performed, only mentioning ""prophylactic dental treatment"" generally.",Exclude,"The study fails critical screening criteria by using bisphosphonates instead of Romosozumab and having a sample size of only 44 participants, which is significantly below the required 100 subjects. Insufficient documentation of specific dental procedures, temporal medication use, and unclear population characteristics further disqualify the study from meeting the systematic review's screening requirements.",0.1
Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS),"Hardeep S. Ahdi, T. Wichelmann, Sasirekha Pandravada, E. Ehrenpreis",10.1186/s40360-023-00657-y,https://doi.org/10.1186/s40360-023-00657-y,BMC Pharmacology and Toxicology,16,2023,maybe,"The study includes adults (≥18 years) but does not specifically focus on osteoporosis patients, and instead includes various patient populations.",no,maybe,"The study reports MRONJ outcomes, but does not specify the dental procedures leading to MRONJ.",no,"There is no mention of a control group, as this is a database analysis of adverse event reports.",no,"This is a database analysis study, which does not match the required study designs of randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"There is no clear documentation of the temporal relationship between medication use and MRONJ, and the duration of medication use is not documented.",yes,"The study includes 8,908 cases meeting the inclusion criteria, which meets the requirement of having a subject size of more than 100 people.","The abstract does not specify the types of dental procedures, and while the study is about medication-related osteonecrosis of the jaw (MRONJ), it does not detail the specific dental interventions.",Exclude,"The study fails to meet critical screening criteria, particularly the requirement for Romosozumab as the specific intervention and the need for a randomized controlled trial or cohort study design. While the research includes a large sample size and focuses on medication-related osteonecrosis of the jaw, it lacks a control group, specific dental procedure documentation, and clear temporal relationship tracking. The broad medication analysis and database review approach do not align with the targeted systematic review requirements.",1.4
Evaluation of Various Therapeutic Approaches in Treating Medication-related Osteonecrosis of the Jaw: A Systematic Review,"Mário Jorge Augusto de Andrade, Marilia Oliveira Coelho Dutra Leal, C. Jodas, Renato Assis Machado, A. Bachesk, R. G. Teixeira",10.9734/jammr/2024/v36i45400,https://doi.org/10.9734/jammr/2024/v36i45400,Journal of Advances in Medicine and Medical Research,0,2024,maybe,The abstract does not specify the age range of patients or whether they have cancer. It only mentions patients with MRONJ.,maybe,maybe,"While MRONJ outcomes are documented, the specific dental procedures leading to these outcomes are not clearly detailed in the abstract.",no,The abstract does not mention any control group of non-anti-resorptive medication users.,no,"This is a systematic review of other studies, not a primary research study with one of the required designs (RCT, cohort, or case-control).",maybe,"The abstract provides some temporal information about medication use duration, but does not clearly document the temporal relationship between medication use and MRONJ development.",yes,"The study includes 2,079 patients, which is well above the 100-person threshold specified in the screening criteria.","While the study focuses on MRONJ, which is typically associated with dental procedures, the abstract does not explicitly state which dental procedures were involved in the cases studied.",Exclude,"The systematic review fails to meet multiple critical screening criteria, including the specific intervention of Romosozumab, study design requirements, and presence of a control group. Significant uncertainties exist regarding population characteristics, dental procedures, and temporal documentation of medication-related outcomes. Consequently, the study does not align with the predefined screening criteria and would be excluded from further review.",0.1
Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis.,"J. Bagan, A. Peydró, J. Calvo, M. Leopoldo, Y. Jiménez, L. Bagán",10.1111/odi.12447,https://doi.org/10.1111/odi.12447,Oral Diseases,37,2016,maybe,"While the patients have osteoporosis, the abstract doesn't explicitly state they are adults or confirm the absence of cancer.",yes,yes,"The study clearly documents MRONJ outcomes following dental procedures, particularly extractions.",no,No control group is mentioned in the abstract.,no,"This appears to be a case series, which is not one of the accepted study designs (RCT, cohort, or case-control).",yes,"The study documents temporal relationships, including mean doses of denosumab (3.4 ± 2.2) and prior bisphosphonate intake duration (46.78 ± 25.11 months).",no,"The study only includes 10 cases, well below the required minimum of 100 subjects.","The abstract mentions dental extraction as a common local factor (60% of cases), which meets this criterion.",Exclude,"The study fails key screening criteria due to using denosumab instead of romosozumab, having a sample size of only 10 patients, and lacking a control group. While documenting MRONJ outcomes and temporal relationships, the case series design and small sample size disqualify it from meeting the systematic review's requirements. Critical deviations from the specified inclusion criteria necessitate exclusion of this research.",0.1
Relevant factors for treatment outcome and time to healing in medication-related osteonecrosis of the jaws - A retrospective cohort study.,"Ana Silva Martins, J. A. Correia, F. Salvado, C. Caldas, Nuno R Santos, A. Capelo, Paulo Palmela",10.1016/j.jcms.2017.07.014,https://doi.org/10.1016/j.jcms.2017.07.014,Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,30,2017,maybe,"There is no explicit mention of age restrictions or cancer status, so it is uncertain whether this criterion is met.",maybe,maybe,"MRONJ outcomes are documented, but the specific dental procedures are not detailed, so this criterion is only partially met.",no,"There is no mention of a control group, so this criterion is not met.",yes,"The study is clearly stated as a ""retrospective longitudinal cohort study"", which meets this criterion.",yes,"There is clear documentation of the temporal relationship between medication discontinuation and healing, which meets this criterion.",no,"The study includes 77 patients, which is below the required 100 subjects.","While MRONJ is discussed, the abstract does not explicitly state which dental procedures were performed, so it is uncertain whether this criterion is met.",Exclude,"The study fails critical screening criteria, including using a different medication than specified and having an insufficient sample size of 77 patients. Multiple key requirements were not met, including the absence of a control group and lack of clarity on specific dental procedures and patient population characteristics. These deficiencies significantly reduce the study's alignment with the predefined screening criteria.",1.4
"A Review On Medication-Related Osteonecrosis Of The Jaw: Definition and Best Practice For Prevention, Diagnosis, and Treatment",L. Thangavelu,10.19070/2377-8075-21000400,https://doi.org/10.19070/2377-8075-21000400,-,0,2021,no,"The abstract mentions both osteoporosis and bone metastases patients, and does not specify age restrictions, so it cannot be confirmed if it meets the adult-only criterion.",no,no,"While MRONJ outcomes are discussed, this is not a primary study documenting specific procedures and outcomes, as the paper appears to be reviewing existing literature rather than reporting new data.",no,"There is no mention of control groups, and as a review article, it likely discusses various studies but does not conduct its own controlled research.",no,"This is explicitly a review article, not a primary research study, and therefore does not meet the required study design criteria.",no,"No specific temporal relationships or medication durations are mentioned, and as a review, it likely discusses these topics but does not provide primary data.",no,"The abstract does not mention any specific subject size, and since this is a review article rather than a primary study, it cannot be confirmed if it meets the >100 subjects criterion.","The abstract mentions dental procedures and prophylactic dental care, but this is a review of MRONJ in general, not a study of specific interventions.",Exclude,"This review article fails to meet multiple critical screening criteria, particularly the requirement for Romosozumab as the intervention medication. The paper lacks a primary research design, does not specify subject size, and does not include a control group or document specific dental procedure outcomes. Consequently, the abstract does not qualify for inclusion in the systematic review.",0.1
Patients Receiving Parenteral Bisphosphonates for Malignant Disease and Having Developed an Atypical Femoral Fracture Are at Risk of Concomitant Osteonecrosis of the Jaw: An Evidence-Based Review.,"L. Graves, S. Bukata, Nona Aghazadehsanai, Tina I. Chang, N. Garrett, A. Friedlander",10.1016/j.joms.2016.06.003,https://doi.org/10.1016/j.joms.2016.06.003,Journal of oral and maxillofacial surgery,15,2016,no,"The study focuses on patients with malignant disease, not osteoporosis, which is a critical failure of the population type criterion.",maybe,maybe,"While MRONJ is documented, the specific dental procedures leading to MRONJ are not detailed in the abstract, so the study only partially meets this criterion.",no,"There is no mention of a control group in the abstract, so the study fails this criterion.",no,"This is a systematic review of case series, not a primary study, so the study fails this criterion.",no,"There is no clear documentation of the temporal relationship or duration of medication use in the abstract, so the study fails this criterion.",maybe,"The abstract does not specify the total subject numbers, so it is unclear from the abstract whether the study meets the subject size criterion.","While MRONJ is discussed, the abstract does not specify the dental procedures that led to MRONJ, so it is unclear from the abstract whether the study meets the intervention criterion.",Exclude,"The study focuses on bisphosphonates in cancer patients, which fundamentally differs from the required criteria of Romosozumab in osteoporosis patients. Critical screening requirements were not met, including medication type, patient population, study design, and control group specifications. Multiple disqualifying factors render this paper unsuitable for the systematic review.",0.1
18 years of medication related osteonecrosis of the jaw (MRONJ) research: where are we now? – An umbrella review,"R. Sacco, M. Calasans-Maia, Julian Woolley, O. Akintola, Carlos Fernando de Almeida Barros Mourão, V. Moraschini, E. Kushnerev, A. Acocella, O. Obisesan, J. Yates",10.37766/inplasy2021.6.0061,https://doi.org/10.37766/inplasy2021.6.0061,Applied Sciences,4,2021,no,"The abstract mentions both benign and malignant conditions, and does not specify age restrictions or osteoporosis diagnosis, so it fails to meet the population type criterion.",maybe,maybe,"MRONJ outcomes are discussed broadly, but the specific dental procedures and their relationship to outcomes are not detailed, so it is unclear if this criterion is met.",maybe,"There is no mention of control groups in the abstract, so it is unclear if this criterion is met.",no,"This is an umbrella review of systematic reviews, which includes case series, retrospective cohort studies, and case reports, but is not a primary study of the required design types, so it fails this criterion.",maybe,"There is no specific mention of temporal relationships or medication duration, so it is unclear if this criterion is met.",yes,"The abstract mentions a total of 80,840 patients across 25 systematic reviews, which meets the requirement for a subject size of more than 100 people. However, this is an umbrella review, not a primary study.","While dental procedures are implied in the context of MRONJ, the specific interventions are not detailed in the abstract, so it is unclear if this criterion is met.",Exclude,"This umbrella review of systematic reviews fails to meet multiple critical screening criteria, including specific intervention requirements, population type, and study design specifications. The broad scope covering multiple medications and conditions, combined with the lack of precise documentation of dental procedures and patient characteristics, renders the study non-compliant with the established screening parameters.",1.4
"Osteonecrosis of the Jaw among Patients Receiving Antiresorptive Medication: A 4-year Retrospective Study at a Tertiary Cancer Center, Kerala, India","P. Sankar, SA Thilak, P. Nayak, Jp K Tripathy, B. Satheesan, A. Rajitha",10.4103/ccd.ccd_696_17,https://doi.org/10.4103/ccd.ccd_696_17,Contemporary Clinical Dentistry,2,2018,no,"The study was conducted at a ""tertiary cancer center"" and appears to focus on cancer patients, which explicitly violates the criterion requiring non-cancer patients.",yes,yes,"The study reports ONJ outcomes following dental procedures, though specific procedures aren't detailed in the abstract.",maybe,The abstract doesn't explicitly mention a control group of non-anti-resorptive medication users.,yes,"The study is described as a ""retrospective record review,"" which falls under the acceptable study designs.",maybe,"While the study mentions duration of medication use, the temporal relationship between medication use and ONJ development isn't clearly documented in the abstract.",yes,"The study includes 183 patients, which exceeds the minimum requirement of 100 subjects.",The abstract mentions dental interventions and specifically notes their statistical significance in relation to ONJ development.,Exclude,"The study fails key screening criteria by focusing on zoledronic acid instead of romosozumab and involving cancer patients rather than non-cancer osteoporosis patients. Despite meeting some methodological requirements like sample size and study design, the fundamental misalignment with specified intervention and population type necessitates exclusion from the systematic review.",0.1
Dental implants as risk factors for patients with medication-related osteonecrosis of the jaws (MRONJ).,"S. Pichardo, J. G. van der Hee, M. Fiocco, N. Appelman‐Dijkstra, J. V. van Merkesteyn",10.1016/j.bjoms.2020.03.022,https://doi.org/10.1016/j.bjoms.2020.03.022,British Journal of Oral and Maxillofacial Surgery,37,2020,maybe,"While the study involves adult patients with MRONJ, it doesn't explicitly state that all patients have diagnosed osteoporosis or exclude cancer patients.",yes,yes,The study clearly documents MRONJ outcomes following specific dental procedures (implant placement and peri-implantitis).,no,The abstract doesn't mention a control group of non-anti-resorptive medication users.,yes,"This appears to be a retrospective cohort study, which meets the criteria.",yes,"The study documents temporal relationships, noting median times between implant placement and MRONJ diagnosis (24 months and 6 months for different groups).",yes,"The study includes 180 patients with MRONJ, well above the 100-person minimum.","The study specifically focuses on dental implants, which is one of the specified invasive dental treatments.",Include,"The study involves 180 patients with medication-related osteonecrosis of the jaws, focusing on dental implant interventions, but critically fails to specify Romosozumab as the anti-resorptive medication. While meeting several screening criteria like subject size and study design, the abstract lacks clarity on osteoporosis diagnosis, cancer exclusion, and does not include a control group. The absence of specific Romosozumab documentation represents a fundamental disqualifying factor for the systematic review.",2.5
Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases,"H. Ikesue, Kohei Doi, M. Morimoto, M. Hirabatake, Nobuyuki Muroi, S. Yamamoto, T. Takenobu, T. Hashida",10.1007/s00280-021-04262-w,https://doi.org/10.1007/s00280-021-04262-w,Cancer Chemotherapy and Pharmacology,18,2021,no,"The study specifically focuses on patients with cancer and bone metastases, which is explicitly excluded in the screening criteria.",yes,yes,"The study clearly documents MRONJ outcomes following dental procedures, specifically mentioning tooth extraction.",maybe,"While the study compares different treatment groups (ZA, denosumab, and ZA-to-denosumab), it's not clear if there's a control group of non-anti-resorptive medication users.",yes,"This is a retrospective cohort study, which meets the acceptable study design criteria.",yes,"The study appears to document temporal relationships between medication use and MRONJ development, as evidenced by the analysis of risk factors and time to MRONJ development.",yes,"The study includes 795 patients, well above the minimum requirement of 100.","The study mentions tooth extraction as a risk factor and includes dental procedures, though specific details are limited in the abstract.",Exclude,"The study focuses on cancer patients using zoledronic acid and denosumab, which fundamentally conflicts with the screening criteria requiring non-cancer osteoporosis patients using romosozumab. Despite meeting several methodological criteria like sample size and study design, the core population and intervention specifications disqualify this research from inclusion in the systematic review.",0.1
Medication-Related Osteonecrosis of the Jaws in the Pediatric Population.,"T. Neal, T. Schlieve",10.1016/j.joms.2022.06.026,https://doi.org/10.1016/j.joms.2022.06.026,Journal of oral and maxillofacial surgery,11,2022,no,"The study focuses on pediatric patients (average age 8.18 years) and includes patients with cancer (6 patients), which does not meet the requirement of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",yes,yes,"The study documents MRONJ outcomes following dental procedures, which meets this criterion.",no,"The study does not mention a control group of non-anti-resorptive medication users, which fails to meet this criterion.",maybe,"The study design is a retrospective case series, which is not one of the acceptable study designs (randomized controlled trial, prospective/retrospective cohort study, or case-control study).",yes,"The study documents the temporal relationship between medication use and dental procedures, and includes follow-up time (average 4.89 years), which meets this criterion.",yes,"The study includes 122 subjects, which meets the requirement of having a subject size of more than 100 people.","The study includes dental extractions (74 teeth in 26 patients), which meets the requirement of having an intervention of invasive dental treatment.",Exclude,"The study fails key screening criteria by using pediatric patients instead of adults, lacking a control group, and not utilizing Romosozumab as the primary intervention. While the research documents dental procedures and MRONJ outcomes, critical methodological requirements are not met, rendering the study ineligible for systematic review inclusion. The pediatric population, absence of a control group, and use of alternative antiresorptive medications disqualify the study from meeting the predefined screening standards.",0.1
Medication related osteonecrosis of the jaw in osteoporotic vs oncologic patients-quantifying radiographic appearance and relationship to clinical findings.,"K. Walton, T. Grogan, E. Eshaghzadeh, D. Hadaya, D. Elashoff, T. Aghaloo, S. Tetradis",10.1259/dmfr.20180128,https://doi.org/10.1259/dmfr.20180128,Dento maxillo facial radiology,24,2019,maybe,"While the study includes adult osteoporosis patients, it also includes cancer patients, which violates the criterion requiring exclusive focus on non-cancer patients.",maybe,yes,"The study clearly documents MRONJ outcomes and their relationship to dental procedures, particularly tooth extraction.",no,No control group of non-anti-resorptive medication users is mentioned in the abstract.,yes,"The study is described as a retrospective assessment, which fits within the acceptable study designs.",maybe,"While the abstract mentions ""recent tooth extraction,"" it doesn't clearly document the temporal relationship between medication use and MRONJ development or the duration of medication use.",no,"The study includes only 70 patients, which is below the required minimum of 100 subjects.","The abstract mentions tooth extraction as a trigger for MRONJ, but doesn't clearly specify if all patients underwent dental procedures. It only mentions that ""most patients in medium and high CRI groups presented with MRONJ after recent tooth extraction.""",Exclude,"The study fails to meet critical screening criteria, including the specific requirement for Romosozumab medication and a minimum subject size of 100 patients. Multiple key requirements were not satisfied, such as the absence of a control group, inclusion of cancer patients, and incomplete documentation of temporal medication relationships. These fundamental shortcomings render the study non-compliant with the established screening criteria.",1.4
Medication‐Related Osteonecrosis of the Jaw Caused by Drugs With Antiangiogenic Effects—What Should the Clinician Be Aware of and What Course of Treatment Can Be Applied? A Systematic Review of Case Series and Case Reports,"Francisca Jennifer Duarte de Oliveira, Moan Jéfter Fernandes Costa, Carla Samily de Oliveira Costa, L. D. de Souza",10.1111/ors.12940,https://doi.org/10.1111/ors.12940,Oral Surgery,0,2024,no,"The abstract states that most of the patients had cancer, and only 20% had other diseases, indicating that the study does not focus exclusively on adult patients with diagnosed osteoporosis who do not have cancer.",yes,yes,"The abstract documents MRONJ outcomes following dental procedures, such as extractions, periodontal surgery, implants, or prosthetic treatments.",no,The abstract does not mention the inclusion of a control group of non-anti-resorptive medication users.,no,"The abstract indicates that this is a systematic review of case reports, which does not meet the required study design criteria of a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The abstract does not clearly document the temporal relationship between medication use and MRONJ development, or the duration of medication use.",maybe,"The review includes 32 articles, but the individual study sizes are not specified, so it is uncertain whether the subject size criterion of more than 100 people is met.","The abstract mentions that dental extraction was involved in more than half of the cases, indicating that the study includes invasive dental treatment as an intervention.",Exclude,"The systematic review fails to meet multiple critical screening criteria, including the specific medication intervention, population type, and study design requirements. Key disqualifying factors include a focus on antiangiogenic drugs rather than Romosozumab, a predominantly cancer patient population, and a case report methodology that does not align with the specified research parameters. Consequently, the study does not satisfy the essential screening criteria for inclusion in the systematic review.",0.1
"Medication-Related Osteonecrosis of The Jaw treatment Modalities, A review Article",Amirali Asadi,10.18502/jcr.v7i1.4005,https://doi.org/10.18502/jcr.v7i1.4005,Journal of craniomaxillofacial research,0,2020,maybe,"The abstract does not provide any specific information about the population type, such as whether the study focuses exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",maybe,maybe,"The abstract discusses MRONJ outcomes and treatments, and mentions specific procedures such as extractions and surgery, suggesting the study reports MRONJ outcomes following documented dental procedures.",no,The abstract does not mention the inclusion of a control group of non-anti-resorptive medication users.,no,"The abstract indicates that this is a review study of other studies, rather than a primary research study (RCT, cohort, or case-control).",no,"The abstract does not provide any clear documentation of the temporal relationship between medication use and MRONJ development, or the duration of medication use.",maybe,"The abstract does not mention the sample size of the study, so it is unclear if the study has a subject size of more than 100 people.","The abstract mentions ""minimally traumatic extraction technique"" and surgery, which suggests the study includes invasive dental treatments such as tooth extraction and other dental surgery.",Exclude,"The abstract fails to meet multiple critical screening criteria, including specific intervention with Romosozumab, lack of a control group, and absence of clear temporal documentation. As a review study rather than a primary research investigation, it does not align with the required methodological standards for inclusion. The paper's broad discussion of MRONJ treatments cannot compensate for its fundamental methodological shortcomings.",1.4
Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis,"P. Tennis, K. Rothman, Rhonda L. Bohn, H. Tan, A. Zavras, C. Laskarides, B. Calingaert, M. Anthony",10.1002/pds.3292,https://doi.org/10.1002/pds.3292,Pharmacoepidemiology and Drug Safety,77,2012,maybe,"The abstract doesn't specify the age range or whether patients have cancer, so it is not possible to confirm if the study focuses exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do NOT have cancer.",maybe,maybe,"The study does look at ONJ outcomes, but the abstract doesn't provide information about whether it documents specific dental procedures.",maybe,"The abstract mentions ""two cohorts"" but doesn't specify if one is a control group of non-users, so it is unclear if the study includes a control group of non-anti-resorptive medication users.",maybe,"While it appears to be a cohort study (mentions ""cohorts""), the abstract doesn't provide enough detail to confirm the specific study design.",maybe,"The abstract doesn't provide information about temporal relationships or medication duration, so it is unclear if the study clearly documents both the temporal relationship between medication use and MRONJ development AND the duration of medication use.",maybe,"The abstract mentions ""two cohorts"" but provides no specific numbers, so it is not possible to determine if the study has a subject size of more than 100 people.","While the study looks at ONJ, which is typically associated with dental procedures, the abstract doesn't explicitly mention any dental interventions, so it is unclear if the subject must have an intervention of invasive dental treatment.",Exclude,"The abstract focuses on bisphosphonate exposure and osteonecrosis of the jaw, which immediately disqualifies it from meeting the specific screening criteria for Romosozumab studies. Insufficient details are provided to assess most other screening requirements, with the primary disqualifying factor being the wrong medication class. The limited information prevents a comprehensive evaluation against the established screening criteria.",0.1
A real‐world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab,"P. Bracchi, E. Zecca, C. Brunelli, R. Miceli, Gabriele Tinè, M. Maniezzo, S. Lo Dico, M. Caputo, Morena Shkodra, A. Caraceni",10.1002/cam4.6429,https://doi.org/10.1002/cam4.6429,Cancer Medicine,2,2023,no,"The study focuses on cancer patients with bone metastases, which explicitly fails the criterion requiring non-cancer patients.",maybe,maybe,"MRONJ is mentioned as an outcome, but specific dental procedures are not mentioned, so it cannot be determined if this criterion is met.",maybe,"The abstract does not mention a control group, so it cannot be determined if this criterion is met.",maybe,"The study design is not specified in the abstract, so it cannot be determined if this criterion is met.",maybe,"The abstract does not provide clear information about the temporal relationships or duration of medication use, so it cannot be determined if this criterion is met.",maybe,"The abstract does not specify the sample size, so it cannot be determined if the study meets the requirement of having more than 100 subjects.","The abstract does not explicitly mention dental procedures, so it cannot be determined if this criterion is met.",Exclude,"The study focuses on Denosumab in cancer patients with bone metastases, which fundamentally conflicts with the screening criteria requiring Romosozumab and non-cancer patients. Critical mismatches in medication type and patient population render the study ineligible for inclusion, regardless of other potential screening requirements.",0.1
Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series.,"Suad Aljohani, R. Gaudin, J. Weiser, M. Tröltzsch, M. Ehrenfeld, G. Kaeppler, R. Smeets, S. Otto",10.1016/j.jcms.2018.05.046,https://doi.org/10.1016/j.jcms.2018.05.046,Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,53,2018,maybe,"While the study includes adult patients (mean age 70 ± 9 years), it appears to include both cancer and non-cancer patients, as it specifically mentions ""cancer patients"" in the results. The abstract doesn't clearly separate these populations.",yes,yes,"The study clearly documents MRONJ outcomes following specific dental procedures, particularly extractions.",no,No control group of non-anti-resorptive medication users is mentioned in the abstract.,yes,"The study is described as a retrospective review, which fits within the acceptable study designs.",yes,"The study documents temporal relationships, noting that ""Discontinuation of denosumab prior to treatment was recorded for 66.7% of the patients, with a mean period of 6 ± 3.4 months.""",no,"The study includes 63 cases, which is below the required minimum of 100 subjects.","The study includes dental procedures, specifically mentioning tooth extraction (55.6% of cases) and other surgical treatments.",Exclude,"The study fails key screening criteria due to using denosumab instead of romosozumab, having a sample size below 100, and lacking a control group. While the research includes relevant dental procedures and documents MRONJ outcomes, critical methodological requirements are not met, rendering the study ineligible for inclusion in the systematic review.",0.1
Medication-related osteonecrosis of the jaw after dental clearance: Prevalence in an oncology center,"Saad Hajeri, Yasir Alturkistany",10.1016/j.sdentj.2022.06.004,https://doi.org/10.1016/j.sdentj.2022.06.004,Saudi Dental Journal,2,2022,maybe,"While the study focuses on adult patients receiving antiresorptive therapy, it doesn't explicitly state whether all patients have diagnosed osteoporosis or exclude cancer patients.",yes,yes,The study clearly documents MRONJ outcomes following dental procedures and classifies them into different stages.,maybe,The abstract doesn't explicitly mention a control group of non-anti-resorptive medication users.,yes,"The study is described as a retrospective study, which meets the criteria.",yes,"The study documents temporal relationships between medication use and MRONJ development, including specific timeframes (<3 weeks, >3 weeks).",yes,"The study includes 622 patients, which is well above the 100-person minimum requirement.","The study includes dentoalveolar surgery and dental procedures, which fall under the required invasive dental treatments.",Include,"The study fails to meet critical screening criteria, specifically the requirement for Romosozumab as the intervention medication. While the research demonstrates robust methodology with a large sample size and clear documentation of dental procedures and MRONJ outcomes, the fundamental mismatch in medication type prevents qualification. Uncertainties regarding population characteristics and control group composition further complicate potential inclusion.",2.5
Denosumab-related osteonecrosis of the jaw: a systematic review,"P. Aulestia-Viera, A. Santos-Silva, G. Machado, A. Rocha",10.5935/2525-5711.20200026,https://doi.org/10.5935/2525-5711.20200026,JORDI - Journal of Oral Diagnosis,0,2000,maybe,"While the study includes adult patients (mean age 68.3 years), it appears to include both osteoporosis and cancer patients, which violates the criterion of focusing exclusively on non-cancer patients.",yes,yes,"The study clearly documents MRONJ outcomes following specific dental procedures, particularly extractions.",no,"As a systematic review of case reports, there is no mention of a control group of non-anti-resorptive medication users.",no,"This is a systematic review of case reports, which does not match the required study designs (RCT, cohort, or case-control).",maybe,"While the study documents the temporal relationship between medication use and MRONJ development (mentions onset and discontinuation), the duration of medication use is not clearly specified in the abstract.",yes,"The study includes 145 cases, which exceeds the minimum requirement of 100 subjects.",The study explicitly mentions dental extractions (60% of cases) and other dental procedures as triggering factors for MRONJ.,Exclude,"The systematic review focuses on Denosumab-related MRONJ, which fundamentally differs from the specified Romosozumab intervention, rendering it non-compliant with the primary screening criteria. Multiple methodological limitations exist, including a case report design, mixed patient population, and absence of a control group, which collectively disqualify the study from meeting the predefined inclusion requirements.",0.1
Surgical therapy for medication-related osteonecrosis of the jaw in osteoporotic patients treated with antiresorptive agents.,"L. Hauer, J. Jambura, D. Hrusak, M. Chalupova, P. Pošta, S. Rusnak, V. Vyskočil",10.5507/bp.2018.081,https://doi.org/10.5507/bp.2018.081,"Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia",16,2020,maybe,"The study focuses on adult osteoporotic patients without cancer, meeting this criterion. However, it's not explicitly stated that all patients are ≥18 years.",no,no,"While MRONJ outcomes are documented, the abstract doesn't specify the dental procedures that led to MRONJ development.",no,No control group is mentioned in the abstract.,yes,"This is a retrospective cohort study, which meets the criterion.",maybe,The study documents follow-up period (20.5 months) but doesn't clearly specify the temporal relationship between medication use and MRONJ development.,no,"The study only includes 26 patients, which is well below the required 100 subjects.","While the study discusses surgical treatment of MRONJ, it doesn't clearly specify whether these were triggered by dental procedures. The abstract focuses on treatment of existing MRONJ rather than dental procedures leading to MRONJ.",Exclude,"The study fails key screening criteria, particularly using bisphosphonates and denosumab instead of the required Romosozumab, and having a sample size of only 26 patients when 100 were needed. Multiple other criteria were not met, including lack of a control group and unclear documentation of dental procedures leading to MRONJ, rendering the study unsuitable for inclusion in the systematic review.",0.1
Osteoradionecrosis and medication-related osteonecrosis of the jaw: similarities and differences.,"K. Grisar, Matthias Schol, J. Schoenaers, T. Dormaar, R. Coropciuc, V. Poorten, C. Politis",10.1016/j.ijom.2016.06.016,https://doi.org/10.1016/j.ijom.2016.06.016,International Journal of Oral & Maxillofacial Surgery,33,2016,maybe,"The abstract does not provide any explicit information about the age or osteoporosis diagnosis of the patients, so it is unclear if the study focuses exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",yes,yes,"The study clearly documents MRONJ outcomes and mentions the relationship with dental extractions, meeting this criterion.",no,"The study compares MRONJ patients to ORN patients, but does not include a control group of non-anti-resorptive medication users, which is a requirement for this criterion.",yes,"The study appears to be a retrospective comparative study, which meets the requirement for a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The study does not provide any clear documentation of the temporal relationship between medication use and MRONJ development, nor does it mention the duration of medication use, which is a requirement for this criterion.",yes,"The study has a total sample size of 133 patients (74 MRONJ patients and 59 ORN patients), which meets the requirement of having more than 100 subjects.","The study mentions ""previous dental extractions"" as precipitating events, which indicates that the subjects underwent invasive dental treatment, meeting this criterion.",Exclude,"The study fails critical screening criteria, particularly the requirement for Romosozumab as the specific anti-resorptive medication, and lacks a control group of non-medication users. While meeting some criteria like subject size and dental intervention documentation, significant gaps exist in population characterization, temporal medication documentation, and specific intervention details. These deficiencies substantially reduce the study's alignment with the predefined screening requirements.",1.4
Conservative Management of Medication-Related Osteonecrosis of the Jaws (MRONJ): A Retrospective Cohort Study,"E. Varoni, N. Lombardi, G. Villa, A. Pispero, A. Sardella, G. Lodi",10.3390/antibiotics10020195,https://doi.org/10.3390/antibiotics10020195,Antibiotics,26,2021,maybe,"The abstract mentions patients with MRONJ from osteoporosis treatment, but doesn't explicitly state all patients are ≥18 years or exclude cancer patients. It does mention bone malignancies as a possible cause, suggesting some patients might have cancer.",maybe,yes,The study clearly documents MRONJ outcomes and their treatment.,no,No control group is mentioned in the abstract.,yes,"This is a retrospective cohort study, which meets the criteria.",maybe,"While the study documents follow-up periods, it doesn't clearly specify the temporal relationship between medication use and MRONJ development or the duration of medication use.",no,"The study only includes 35 patients, which is well below the required 100 subjects.","While the study deals with MRONJ, which typically follows dental procedures, the abstract doesn't explicitly state which dental procedures were performed. It only mentions ""surgical intervention to remove bone sequestrum.""",Exclude,"The study fails critical screening criteria, including using a different anti-resorptive medication than specified, having a sample size significantly below the required 100 patients, and lacking a control group. Multiple other criteria were either partially met or unclear, rendering the study non-compliant with the established screening requirements. The fundamental mismatch in medication type and insufficient sample size are particularly disqualifying factors.",1.4
“Spontaneous” medication‐related osteonecrosis of the jaw; two case reports and a systematic review,"A. Khominsky, Mawt Lim",10.1111/adj.12648,https://doi.org/10.1111/adj.12648,Australian dental journal,19,2018,maybe,"The study mentions patients with bone disease, but does not specify the age range or explicitly exclude cancer patients, so it is unclear if the population type criterion is met.",yes,yes,"The study documents MRONJ outcomes and includes dental procedures (extractions), which meets this criterion.",no,"There is no mention of a control group in the study, so it fails this criterion.",no,"The study appears to be a case series with a literature review, which does not match the required study designs of randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"The study mentions ""antiresorptive duration"" but does not clearly document the temporal relationship between medication use and MRONJ development, so it is unclear if this criterion is met.",no,"The study only describes two cases, which does not meet the requirement of having a subject size of more than 100 people.","The study mentions dental extractions, which meets the criterion of having an intervention of invasive dental treatment.",Exclude,"The study fails critical screening criteria due to its small sample size of only two cases, lack of a specific focus on Romosozumab, and absence of a control group. While the research addresses medication-related osteonecrosis of the jaw and includes dental procedures, it does not meet the required methodological standards for inclusion in the systematic review. The case series design and limited population characteristics further disqualify the study from meeting the established screening requirements.",0.1
Microarchitecture of medication-related osteonecrosis of the jaw (MRONJ); a retrospective micro-CT and morphometric analysis.,"Rouven Schoenhof, A. Munz, A. yuan, A. ElAyouti, H. Boesmueller, G. Blumenstock, S. Reinert, S. Hoefert",10.1016/j.jcms.2021.02.018,https://doi.org/10.1016/j.jcms.2021.02.018,Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,11,2021,maybe,"The study includes osteoporotic patients, but it's unclear if all subjects are adults (≥18 years) and whether any have cancer. The abstract doesn't provide this demographic information.",maybe,no,"While the study examines MRONJ, it focuses on bone microarchitecture analysis rather than documenting specific dental procedures and their outcomes.",yes,The study includes control groups (healthy jaw bone and osteoporotic jaw bone) of non-anti-resorptive medication users.,maybe,"The abstract mentions ""retrospective micro-CT and morphometric analysis"" but doesn't clearly specify if this is a retrospective cohort study or case-control study.",no,The abstract doesn't document the temporal relationship between medication use and MRONJ development or the duration of medication use.,yes,"The study includes 141 samples from 78 patients, which exceeds the minimum requirement of 100 subjects.","While the study examines jaw bone samples, it doesn't explicitly state whether these were obtained through specific dental procedures. The focus appears to be on analyzing bone microarchitecture rather than documenting dental interventions.",Exclude,"The study fails to meet critical screening criteria, primarily due to using bisphosphonates and denosumab instead of the specified Romosozumab medication. While the research includes a sufficient sample size and control groups, it lacks clear documentation of dental procedures, temporal medication relationships, and specific MRONJ outcomes. The focus on bone microarchitecture analysis diverges significantly from the required intervention and outcome parameters.",1.4
A Systematic Review of Oxygen Therapy for the Management of Medication-Related Osteonecrosis of the Jaw (MRONJ),"R. Sacco, R. Leeson, J. Nissan, S. Olate, Carlos Bettoni Cruz de Castro, A. Acocella, A. Lalli",10.3390/APP9051026,https://doi.org/10.3390/APP9051026,Applied Sciences,15,2019,no,"The abstract mentions patients with cancer and bone pathologies, and does not specify an exclusive focus on adult osteoporosis patients without cancer. This suggests the study population does not meet the criteria.",no,no,"While the study documents MRONJ outcomes, these are in relation to oxygen therapy treatments, not specific dental procedures. This suggests the study does not report MRONJ outcomes following documented dental procedures.",no,"The abstract does not mention a control group of non-anti-resorptive medication users, indicating the study does not include such a control group.",no,"The paper is described as a systematic review, rather than a primary study design such as a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The abstract does not provide clear documentation of the temporal relationship between medication use and MRONJ development, or the duration of medication use.",yes,"The study includes a total of 313 patients, which meets the criterion of having a subject size of more than 100 people.","The abstract does not discuss dental procedures as interventions, and instead focuses on oxygen therapies (OT and HBO) as treatments for MRONJ. This indicates the study does not examine invasive dental treatments as the intervention.",Exclude,"The systematic review fails to meet multiple critical screening criteria, including specific intervention type, population characteristics, and study design. Key disqualifying factors include the absence of Romosozumab as the primary medication, inclusion of cancer patients, and lack of a control group or focus on invasive dental treatments. The study's primary focus on oxygen therapies for MRONJ treatment fundamentally differs from the required research parameters.",0.1
Bacterial diversity in medication-related osteonecrosis of the jaw.,"F. Hallmer, T. Bjørnland, G. Andersson, J. Becktor, A. K. Kristoffersen, M. Enersen",10.1016/j.oooo.2016.11.011,https://doi.org/10.1016/j.oooo.2016.11.011,"Oral surgery, oral medicine, oral pathology and oral radiology",46,2017,maybe,"The study includes both osteoporosis patients (10) and cancer patients (8), and does not specify the age range of the participants. The population type is partially unclear.",maybe,maybe,"The study documents MRONJ outcomes, but does not specify which dental procedures led to MRONJ.",no,There is no mention of a control group in the study.,no,"The study appears to be a case series or observational study, and is not explicitly stated as a randomized controlled trial, cohort study, or case-control study.",no,"There is no clear documentation of the temporal relationship between medication use and MRONJ development, or the duration of medication use.",no,"The study includes only 18 patients, which is less than the required 100 subjects.","While the study discusses MRONJ, it does not explicitly state which dental procedures were performed, only mentioning ""periodontal infection"" in the conclusions. The intervention is unclear.",Exclude,"The study fails to meet multiple critical screening criteria, including the specific requirement of using Romosozumab, with a sample size of only 18 patients instead of the required 100. The research includes a mixed population of osteoporosis and cancer patients, lacks a control group, and does not clearly document the temporal relationship between medication use and MRONJ development.",1.4
Medication-Related Osteonecrosis of the Jaws.,"C. Migliorati, M. Brennan, D. Peterson",10.1093/jncimonographs/lgz009,https://doi.org/10.1093/jncimonographs/lgz009,Journal of the National Cancer Institute. Monographs,23,2019,no,"The abstract explicitly states that the study focused on ""cancer patients"", which violates the criterion requiring the study to focus on non-cancer patients.",maybe,maybe,"While the abstract discusses MRONJ, it does not indicate specific documentation of outcomes following dental procedures, so it is uncertain whether the study reported MRONJ outcomes following specific dental procedures.",maybe,"The abstract does not mention the inclusion of a control group, so it is uncertain whether the study included a control group of non-anti-resorptive medication users.",no,"The abstract indicates that this is a review article rather than a primary research study, which does not meet the required study design criteria.",maybe,"The abstract does not mention any temporal relationships or duration of medication use, so it is uncertain whether the study clearly documented the temporal relationship between medication use and MRONJ development.",maybe,"The abstract does not provide any information about the sample size of the study, so it is uncertain whether the study had more than 100 participants.","While the abstract discusses MRONJ, it does not specify which dental procedures were studied, so it is uncertain whether the study included invasive dental treatments.",Exclude,"The abstract describes a review of medication-related osteonecrosis of the jaw in cancer patients, which fundamentally conflicts with the screening criteria requiring non-cancer patients and specific intervention parameters. Multiple critical screening requirements are not met, including population type, intervention specifics, and study design, rendering the paper unsuitable for inclusion in the targeted research review.",0.1
Analysis of medication-related osteonecrosis of the jaw with bone SPECT/CT: relationship between patient characteristics and maximum standardized uptake value.,"Ruri Ogawa, I. Ogura",10.1259/dmfr.20200516,https://doi.org/10.1259/dmfr.20200516,Dento maxillo facial radiology,16,2021,no,"The study includes both osteoporosis patients and cancer patients, and is not exclusively focused on adult osteoporosis patients without cancer.",no,maybe,"The study focuses on MRONJ outcomes, but does not specify the dental procedures that were performed.",no,There is no mention of a control group of non-anti-resorptive medication users.,yes,"The study is described as a prospective study, which meets the criterion for study design.",no,"There is no clear documentation of the temporal relationship between medication use and MRONJ development, or the duration of medication use.",no,"The study includes 48 patients, which is less than the required 100 subjects.","There is no mention of any invasive dental treatments, such as tooth extraction, implant placement, periodontal surgery, or removable prosthesis fabrication.",Exclude,"The study fails critical screening criteria, particularly using different medications than specified and including a mixed patient population with cancer. The small sample size of 48 patients, lack of dental intervention details, and absence of a control group further disqualify the research from meeting the systematic review requirements. Multiple fundamental screening criteria were not satisfied, rendering the study non-compliant with the predefined selection parameters.",0.1
Real-world study of antiresorptive-related osteonecrosis of jaw based on the US food and drug administration adverse event reporting system database,"Jing Peng, Hui Wang, Zhen Liu, Zhengguo Xu, Mei Wang, Qi-Miao Chen, Mingxin Wu, Xiaowei Ren, Qiu-hua Liang, Fu-Peng Liu, Boroath Ban",10.3389/fphar.2022.1017391,https://doi.org/10.3389/fphar.2022.1017391,Frontiers in Pharmacology,23,2022,no,"The study includes both osteoporosis patients and cancer patients, and doesn't specify age restrictions, so it doesn't fully meet the criterion of focusing exclusively on adult osteoporosis patients without cancer.",maybe,no,"While the study documents ONJ outcomes, it doesn't specifically detail the dental procedures that led to these outcomes.",no,The study doesn't mention a control group of non-anti-resorptive medication users.,maybe,"This appears to be a retrospective analysis of adverse event reports, which could be considered a retrospective cohort study.",yes,"The study does document temporal relationships between medication use and ONJ development, providing specific onset times for different medications.",yes,"The study analyzes 18,421 reports from FAERS, which far exceeds the 100-person minimum requirement.","The abstract doesn't explicitly mention specific dental procedures, and while it discusses ONJ, it doesn't detail the dental interventions that led to these cases.",Include,"The study partially meets screening criteria with a large sample size and temporal documentation of medication-related jaw necrosis, but fails to exclusively focus on romosozumab, lacks a control group, and includes cancer patients. While providing insights into antiresorptive drug risks, the research does not fully align with the specified screening requirements for a targeted osteoporosis intervention study.",2.7
Medication Related Osteonecrosis of the Jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons,"K. M. Kim, Y. Rhee, Yong-Dae Kwon, T. Kwon, J. K. Lee, D. Kim",10.11005/jbm.2015.22.4.151,https://doi.org/10.11005/jbm.2015.22.4.151,Journal of Bone Metabolism,78,2015,maybe,"The abstract mentions that the study focuses on both osteoporosis patients and cancer patients, which does not meet the criterion of focusing exclusively on adult patients with diagnosed osteoporosis who do not have cancer.",no,no,"While the abstract discusses MRONJ, it does not provide details on the specific dental procedures that were performed or the outcomes that were reported.",no,The abstract does not mention the inclusion of a control group of non-anti-resorptive medication users.,no,"The abstract indicates that this is a guideline/review paper rather than a primary research study, which does not meet the criterion of being a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The abstract does not mention any information about the temporal relationship between medication use and MRONJ development, or the duration of medication use.",no,The abstract does not provide any information about the subject size of the study.,"While the abstract discusses ONJ/MRONJ, it does not describe any specific invasive dental treatments that were performed on the subjects.",Exclude,"The abstract fails to meet critical screening criteria, specifically lacking focus on Romosozumab and not representing a primary research study with clear intervention details. Multiple key requirements are unmet, including specific dental treatment documentation, control group presence, and precise population characteristics. The paper appears to be a guideline review rather than a research study suitable for systematic review inclusion.",0.1
Workshop of European Task Force on Medication Related Osteonecrosis of the Jaw.Current challenges.,"M. Schiødt, S. Otto, S. Fedele, A. Bedogni, O. Nicolatou‐Galitis, R. Guggenberger, B. B. Herlofson, O. Ristow, T. Kofod",10.1111/odi.13160,https://doi.org/10.1111/odi.13160,Oral Diseases,107,2019,no,"No specific patient population is described, and the paper appears to be about MRONJ in general rather than focusing on a specific patient group. Therefore, the population type criterion is not met.",no,no,"While MRONJ is the topic, this paper does not report specific outcomes from dental procedures. It appears to be a general discussion of MRONJ rather than a documentation of outcomes. Therefore, the outcome documentation criterion is not met.",no,"No control group is mentioned, and this is not an interventional study. Therefore, the control group criterion is not met.",no,"This is a workshop report/consensus paper, which does not fit any of the required study designs (RCT, cohort, or case-control). Therefore, the study design criterion is not met.",no,"No temporal relationships or medication durations are documented, and this is a consensus paper rather than a primary research study. Therefore, the temporal documentation criterion is not met.",no,"No specific subject size is mentioned, and this appears to be a workshop report rather than a primary research study. Therefore, the subject size criterion is not met.","While dental procedures are implied in the context of MRONJ, no specific interventions are studied. This is a consensus/review paper rather than an intervention study. Therefore, the intervention criterion is not met.",Exclude,"This workshop report fails to meet any of the specified screening criteria, lacking specific details about patient population, intervention, study design, and outcome documentation. The abstract represents a consensus paper discussing medication-related osteonecrosis of the jaws in general terms, rather than presenting a research study with the required methodological elements. Consequently, the document does not qualify for inclusion based on the predefined systematic review criteria.",0.1
Medication-Related Osteonecrosis of the Jaw—A Continuing Issue,"Krzysztof Wróbel, Maciej Sikora, M. Chęciński, Maria Jas, D. Chlubek",10.3390/app11177781,https://doi.org/10.3390/app11177781,Applied Sciences,8,2021,maybe,"No specific mention of age groups, no explicit mention of osteoporosis patients, and no mention of cancer exclusion, so it is uncertain if this criterion is met.",maybe,maybe,"The paper discusses MRONJ outcomes generally, but does not provide specific documentation of outcomes following specific procedures, so it partially meets this criterion.",no,"No mention of control groups, so it fails this criterion.",no,"The paper appears to be a review article rather than primary research, and does not fit any of the required study designs, so it fails this criterion.",no,"No mention of temporal relationships or duration of medication use, so it fails this criterion.",maybe,"No mention of sample size, so it cannot be determined if the study meets the requirement of having more than 100 subjects.","The abstract mentions ""dental procedures"" and ""oral cavity area"" and discusses dental prostheses, so it partially meets this criterion, but lacks specific details.",Exclude,"The abstract fails to meet multiple critical screening criteria, including specific intervention details, study design requirements, and population characteristics. While discussing medication-related osteonecrosis of the jaw, the text appears to be a review article lacking the precise methodological elements needed for inclusion. Key deficiencies include absence of a control group, unclear subject demographics, and insufficient documentation of temporal medication relationships.",1.4
"Editorial: Medication-related osteonecrosis of the jaw (MRONJ): Bisphosphonates, antiresorptives, and antiangiogenic agents. What next?",M. Mupparapu,10.3290/j.qi.a35303,https://doi.org/10.3290/j.qi.a35303,Quintessence International,8,2016,no,"The abstract discusses both cancer and osteoporosis patients, and is not focused exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",no,no,"While the abstract discusses MRONJ in general, it does not report any specific MRONJ outcomes following documented dental procedures like extractions, periodontal surgery, implants, or prosthetic treatments.",no,The abstract does not mention the inclusion of a control group of non-anti-resorptive medication users.,no,"The abstract appears to be a review or commentary paper, rather than a primary research study with a specific study design like a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The abstract does not clearly document the temporal relationship between medication use and MRONJ development, or the duration of medication use.",no,The abstract does not provide any information about the subject size of the study. It appears to be a review or overview paper rather than a primary research study.,"While the abstract mentions ""dentoalveolar surgery"" in a general context, it does not describe a specific study of invasive dental treatments like tooth extraction, implant placement, periodontal surgery, or removable prosthesis fabrication.",Exclude,"The abstract fails to meet any of the specified screening criteria, primarily because it is a general review of medication-related osteonecrosis of the jaw rather than a focused research study. It lacks specific details about Romosozumab, patient population, intervention type, study design, and outcome documentation required by the systematic review protocol. The text provides a broad overview of anti-resorptive medications and their potential risks but does not constitute a research study meeting the predefined inclusion criteria.",0.1
Comprehensive Study of the Risk Factors for Medication-Related Osteonecrosis of the Jaw Based on the Japanese Adverse Drug Event Report Database,"Shinya Toriumi, Akinobu Kobayashi, Y. Uesawa",10.3390/ph13120467,https://doi.org/10.3390/ph13120467,Pharmaceuticals,18,2020,no,"The study mentions ""elderly"" and ""female"" patients, but does not specify that the population has a diagnosed osteoporosis. Additionally, the study includes cancer patients, which is not allowed by the criterion.",no,no,"While the study examines MRONJ, it does not document specific dental procedures such as extractions, periodontal surgery, implants, or prosthetic treatments.",no,There is no mention of a control group of non-anti-resorptive medication users in the study.,no,"The study appears to be a database analysis study, which does not clearly fit into the specified study design categories of randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The study does not clearly document the temporal relationship between medication use and MRONJ development, nor the duration of medication use.",maybe,"The study uses a ""large voluntary reporting database"" but the specific number of subjects is not mentioned, so it is uncertain whether the study meets the criterion of having more than 100 subjects.",There is no specific mention of dental procedures or interventions in the study.,Exclude,"The study fails to meet multiple critical screening criteria, including the specific medication (Romosozumab), dental intervention focus, and population type. Key deficiencies include analyzing a broad range of medications, including cancer-related drugs, and lacking specific documentation of dental procedures and temporal medication relationships. The research does not align with the required parameters for the targeted study design.",0.1
Italian position paper (SIPMO-SICMF) on medication-related osteonecrosis of the jaw (MRONJ).,"A. Bedogni, R. Mauceri, V. Fusco, F. Bertoldo, G. Bettini, O. Di Fede, Antonio Lo Casto, Claudio Marchetti, V. Panzarella, G. Saia, P. Vescovi, G. Campisi",10.1111/odi.14887,https://doi.org/10.1111/odi.14887,Oral Diseases,21,2024,no,"The paper does not specify a particular patient population, and it appears to be a general review of MRONJ rather than focusing on adult patients with osteoporosis.",no,no,"While MRONJ outcomes are discussed, this is not a study documenting specific outcomes, but rather providing recommendations about MRONJ.",no,"No control group is mentioned, as this is not a comparative study but rather a position paper/consensus statement.",no,"This is a position paper/consensus statement, not a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"No specific temporal relationships or medication durations are documented, as this is a general review paper rather than a primary research study.",no,"This is not a primary research study with subjects, but rather a position paper/review, so it does not have a subject size of more than 100 people.","While the paper discusses dental procedures, it is not studying specific interventions, but rather providing recommendations about dental procedures.",Exclude,"This position paper fails to meet all screening criteria, as it is a consensus statement rather than a primary research study with specific interventions, patient populations, or comparative design. The document provides general recommendations about MRONJ but lacks the required elements of subject size, intervention specifics, control groups, and detailed outcome documentation needed for systematic review inclusion.",0.1
Risk Factors Influencing Medication-Related Osteonecrosis of the Jaws (MRONJ) Following Dental Extraction Among Osteoporotic Patients in Taiwan.,"Ling-Ying Wei, Yi-Wen Cheng, Wei-Yih Chiu, Sang-Heng Kok, Hao-Hong Chang, Shih-Jung Cheng, Jang-Jaer Lee",10.1002/hed.28011,https://doi.org/10.1002/hed.28011,Head and Neck,0,2024,maybe,"The study mentions osteoporotic patients, but doesn't explicitly state they are all adults (≥18 years) or confirm the absence of cancer patients. However, given the context and typical osteoporosis patient demographics, this is likely met.",yes,yes,"The study clearly documents MRONJ outcomes following dental extractions, with specific risk factors and outcomes reported.",maybe,The abstract doesn't explicitly mention a control group of non-anti-resorptive medication users. This is a significant uncertainty.,yes,"The study is described as a retrospective cohort study, which meets the criteria.",yes,"The study documents temporal relationships between medication use and MRONJ development, including specific duration of medication use (≥24 months) and timing of treatment interruption.",yes,"The study includes 937 patients with 1067 dental extractions, well exceeding the 100-person minimum.","The study specifically focuses on dental extractions, which is one of the specified invasive dental treatments.",Exclude,"The study fails to meet the primary screening criterion of using Romosozumab, instead focusing on alternative anti-resorptive medications like alendronate, denosumab, and zoledronate. While the research demonstrates robust methodology with a large patient sample and comprehensive analysis of dental extraction risks, the fundamental deviation from the specified intervention disqualifies it from inclusion. The absence of Romosozumab renders the study non-compliant with the core screening requirements.",0.1
The impact of surgical intervention and antibiotics on MRONJ stage II and III - Retrospective study.,"M. Zirk, M. Kreppel, Johannes Buller, Julij Pristup, F. Peters, T. Dreiseidler, M. Zinser, J. Zöller",10.1016/j.jcms.2017.05.027,https://doi.org/10.1016/j.jcms.2017.05.027,Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,33,2017,maybe,"The abstract mentions osteoporosis patients but doesn't explicitly state they are all adults (≥18). It also mentions metastatic bone disease patients, suggesting a mixed population, and there is no clear exclusion of cancer patients.",maybe,no,"While MRONJ outcomes are documented, they focus on treatment outcomes rather than initial dental procedures. The study appears to be about treatment of existing MRONJ rather than incidence following dental procedures.",no,There is no mention of a control group of non-anti-resorptive medication users.,yes,The study is clearly stated as a retrospective study.,no,"There is no clear documentation of the temporal relationship between medication use and MRONJ development, and the duration of medication use is not mentioned.",yes,"The study includes 143 patients, which exceeds the minimum requirement of 100.","The study focuses on surgical interventions for MRONJ treatment, but doesn't clearly specify the initial dental procedures that led to MRONJ. While surgical interventions are mentioned, they appear to be treatments for MRONJ rather than the initial dental procedures.",Exclude,"The study fails to meet critical screening criteria, particularly the requirement for Romosozumab as the intervention, and lacks a clear control group. While the research involves a sufficient sample size and uses a retrospective design, it focuses on MRONJ treatment rather than the specified research parameters, rendering it unsuitable for the intended screening process.",1.4
Case series: Osteonecrosis of the jaw related to denosumab preceded by bisphosphonates in cancer and osteoporotic patients,"D. Falinda, N. Malden",10.1016/j.adoms.2022.100258,https://doi.org/10.1016/j.adoms.2022.100258,Advances in Oral and Maxillofacial Surgery,1,2022,maybe,"The study includes both cancer and osteoporotic patients, but doesn't specify the proportion of each. The abstract doesn't explicitly state that all patients are ≥18 years.",yes,yes,The study clearly documents MRONJ outcomes following dental procedures (extractions) and uses standardized staging (AAOMS).,no,No control group is mentioned in the abstract.,yes,"This is described as a retrospective case series, which falls under the acceptable study designs.",yes,"The study documents temporal relationships between medication use and MRONJ development, including specific timeframes (8 weeks, 12 weeks, 20 weeks).",no,"The study only includes 7 patients, well below the required minimum of 100 subjects.","The study includes dental extraction as an intervention, which meets this criterion.",Exclude,"The study fails key screening criteria due to using denosumab and bisphosphonates instead of romosozumab, having a sample size of only 7 patients, and lacking a control group. While the research documents dental extraction-related MRONJ outcomes, the fundamental mismatch with required intervention and population characteristics disqualifies it from systematic review inclusion.",0.1
Can dental panoramic radiographic findings serve as indicators for the development of medication-related osteonecrosis of the jaw?,"C. Klingelhöffer, Manja Klingelhöffer, S. Müller, T. Ettl, U. Wahlmann",10.1259/dmfr.20160065,https://doi.org/10.1259/dmfr.20160065,Dento maxillo facial radiology,34,2016,maybe,"The study includes adult patients with AT, but also includes patients with cancer (mentioned in results). The abstract doesn't specify if non-cancer patients were included.",maybe,maybe,"While MRONJ outcomes are documented, the specific dental procedures leading to MRONJ are not clearly described in the abstract.",yes,The study includes a clear control group of 60 patients without AT.,yes,The abstract explicitly states this is a case-control study.,no,The abstract does not mention the temporal relationship between medication use and MRONJ development or the duration of medication use.,no,"The study includes 120 total patients (60 AT patients + 60 controls), but this is below the required minimum of 100 patients per group.","While the study discusses dental procedures and MRONJ, it doesn't explicitly state which dental procedures were performed. The focus seems to be on radiographic findings rather than specific dental interventions.",Exclude,"The study fails to meet critical screening criteria, particularly the requirement for Romosozumab as the specific antiresorptive medication, and lacks sufficient sample size and clear documentation of dental interventions. Multiple methodological limitations, including a mixed patient population and absence of temporal documentation, significantly reduce the study's alignment with the predefined screening requirements.",1.4
Oral Complications in Cancer Patients–Medication-Related Osteonecrosis of the Jaw (MRONJ),C. Migliorati,10.3389/froh.2022.866871,https://doi.org/10.3389/froh.2022.866871,Frontiers in Oral Health,8,2022,no,"The abstract explicitly states that this is a review focused on cancer patients, which directly contradicts the requirement for the study to focus exclusively on adult patients with diagnosed osteoporosis who do not have cancer.",no,no,"While MRONJ outcomes are discussed, this is in a general review context, and no specific documented dental procedures and outcomes are presented, so it does not meet the requirement of reporting MRONJ outcomes following specific, documented dental procedures.",no,"No control group is mentioned, and this is a review article, not an interventional study, so it does not meet the requirement of including a control group of non-anti-resorptive medication users.",no,"This is a mini-review article, not a primary research study, and does not meet the required study design types of randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"No specific temporal relationships or medication durations are documented, and this is a general review rather than a study with specific documentation, so it does not meet the requirement of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",no,"No specific subject size is mentioned, and this is a review article rather than a primary study, so it does not meet the requirement of having a subject size of more than 100 people.","While dental procedures are mentioned, this is a review article discussing MRONJ in general, and no specific intervention study is described, so it does not meet the requirement of having an intervention of invasive dental treatment.",Exclude,"This mini-review article fails to meet multiple critical screening criteria, including the specific intervention of Romosozumab, subject size requirements, and population type. The paper focuses on cancer patients and is a review rather than a primary research study, which fundamentally disqualifies it from meeting the systematic review's inclusion criteria.",0.1
Medication Related Osteonecrosis of the Jaw: 2021 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons,"Jin-Woo Kim, M. Kwak, J. Han, Sung-Tak Lee, H. Y. Kim, Se Hwa Kim, Junho Jung, J. K. Lee, Young-Kyun Lee, Yong-Dae Kwon, D. Kim",10.11005/jbm.2021.28.4.279,https://doi.org/10.11005/jbm.2021.28.4.279,Journal of Bone Metabolism,21,2021,no,"The abstract mentions osteoporosis patients but also discusses other conditions (bone metastases, multiple myeloma, Paget's disease), and it is not exclusively focused on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer. Therefore, the study does not meet the requirement of focusing on the specified population type.",no,no,"While MRONJ is discussed, the abstract does not report specific MRONJ outcomes following documented dental procedures. Therefore, the study does not meet the requirement of documenting MRONJ outcomes.",no,"The abstract does not mention the inclusion of a control group of non-anti-resorptive medication users. Therefore, the study does not meet the requirement of having a control group.",no,"The abstract indicates that this is a guideline/review paper, not a primary research study with a randomized controlled trial, prospective/retrospective cohort study, or case-control study design. Therefore, the study does not meet the requirement of having the specified study design.",no,"The abstract does not clearly document the temporal relationship between medication use and MRONJ development, nor the duration of medication use. Therefore, the study does not meet the requirement of documenting the temporal relationship and duration of medication use.",no,"The abstract does not mention the subject size of the study, and it appears to be a guideline/review paper rather than a primary research study. Therefore, the study does not meet the requirement of having a subject size of more than 100 people.","While dental procedures are implied in the context of MRONJ, the abstract does not describe specific invasive dental treatments such as tooth extraction, implant placement, periodontal surgery, or removable prosthesis fabrication. Therefore, the study does not meet the requirement of having an intervention of invasive dental treatment.",Exclude,"This guideline paper fails to meet multiple screening criteria, including specific intervention requirements, subject size, and study design specifications. The document discusses medication-related osteonecrosis of the jaw in general terms but lacks the precise research parameters needed for inclusion, such as a focus on Romosozumab, a defined patient population, and documented clinical outcomes.",0.1
Impact of Bisphosphonate-related Osteonecrosis of the Jaw on Osteoporotic Patients after Dental Extraction: A Population-Based Cohort Study,"Yi Fang Huang, Chung-Ta Chang, C. Muo, Chun-Hao Tsai, Yu-Fu Shen, Ching-Zong Wu",10.1371/journal.pone.0120756,https://doi.org/10.1371/journal.pone.0120756,PLoS ONE,47,2015,maybe,"The study includes adult osteoporosis patients, but also includes patients with cancer (mentioned in results). The abstract doesn't specify if cancer patients were excluded from the analysis.",yes,yes,The study reports ONJ outcomes following dental procedures (specifically extractions).,yes,"The study includes a comparison cohort of 38,669 age and gender-matched individuals without osteoporosis.",yes,"This is a cohort study using national health insurance data, which meets the acceptable study design criteria.",maybe,"While the study follows patients from the date of dental extraction, it's unclear if the duration of medication use is documented.",yes,"The study includes 19,399 osteoporosis patients and 38,669 comparison subjects, well exceeding the 100-person minimum.","The study specifically focuses on dental extraction, which is one of the specified invasive dental treatments.",Exclude,"The study focuses on bisphosphonates rather than Romosozumab, which fundamentally disqualifies it from meeting the primary intervention criterion. While the research demonstrates robust methodology with a large sample size and appropriate study design, the critical mismatch in medication type prevents it from satisfying the core screening requirements. Additional concerns include the potential inclusion of cancer patients and incomplete documentation of medication use duration.",1.4
A comparative study of the clinical characteristics of patients with medication-related osteonecrosis of the jaw and osteoporosis or malignancy.,"Zhiqiang Feng, An Jingang, Yang He, Yi Zhang",10.1016/j.oooo.2022.04.049,https://doi.org/10.1016/j.oooo.2022.04.049,"Oral surgery, oral medicine, oral pathology and oral radiology",2,2022,maybe,"The study includes adult patients with osteoporosis, but also includes a large malignancy group. The osteoporosis group is only 12 patients, which is too small for meaningful analysis.",maybe,maybe,"While MRONJ outcomes are documented, the specific dental procedures leading to MRONJ are not detailed in the abstract.",no,"The study compares osteoporosis vs malignancy groups, not anti-resorptive medication users vs non-users.",maybe,"The study appears to be a retrospective analysis of hospitalized patients, but the exact study design isn't explicitly stated.",yes,The study documents incubation periods and medication exposure (cumulative dose of bisphosphonates).,yes,"The study includes 91 patients (12 in osteoporosis group, 79 in malignancy group), exceeding the minimum requirement of 100 people.","While the study focuses on MRONJ, which typically follows dental procedures, the abstract doesn't explicitly state which dental procedures were performed.",Exclude,"The study fails to meet critical screening criteria, primarily due to the use of bisphosphonates instead of Romosozumab and the absence of a control group comparing anti-resorptive medication users. While the study includes a sufficient sample size and documents temporal relationships, the fundamental mismatch with the specified intervention and population type disqualifies it from inclusion in the systematic review.",1.4
Clinical and radiologic treatment outcomes of implant presence tirggered-MRONJ: Systematic review of literature.,"M. Nisi, Stefano Gennai, Filippo Graziani, Antonio Barone, R. Izzetti",10.1111/odi.15066,https://doi.org/10.1111/odi.15066,Oral Diseases,1,2024,maybe,"While the study includes adult patients with osteoporosis (70%), it also includes patients with oncologic disease (30%), which violates the criterion of focusing exclusively on non-cancer patients.",yes,yes,The study clearly documents MRONJ outcomes following specific dental procedures (implant placement and peri-implantitis).,no,The abstract does not mention any control group of non-anti-resorptive medication users.,maybe,"This is a systematic review rather than a primary study of the specified designs (RCT, cohort, or case-control), so the study design is unclear.",yes,"The study documents the temporal relationship, noting that MRONJ developed on average 46.5 ± 33.2 months following implant placement.",yes,"The study includes 111 patients, which exceeds the minimum requirement of 100 subjects.","The study focuses on dental implants and peri-implantitis, which qualifies as invasive dental treatment.",Exclude,"The systematic review fails to meet several critical screening criteria, including the specific use of Romosozumab, exclusive focus on non-cancer patients, and inclusion of a control group. While the study addresses dental implant-related MRONJ with a sufficient sample size, fundamental deviations from the required parameters render it unsuitable for inclusion. The mixed patient population and lack of a control group represent significant methodological limitations.",1.4
Romosozumab-associated medication-related osteonecrosis of the jaw,"B. Palla, John Anderson, M. Miloro, S. Moles, N. Callahan",10.1016/j.omsc.2023.100318,https://doi.org/10.1016/j.omsc.2023.100318,Oral and Maxillofacial Surgery Cases,4,2023,maybe,The abstract doesn't specify the patient's age or whether they have osteoporosis or cancer.,maybe,maybe,"While MRONJ is documented, the specific dental procedure isn't detailed in the abstract.",no,"As a case report, there is no control group.",no,"This is a case report, which doesn't meet the required study designs (RCT, cohort, or case-control).",maybe,The abstract doesn't provide clear information about the temporal relationship or duration of medication use.,no,"This is a case report of a single patient, which fails to meet the minimum requirement of 100 subjects.","The abstract doesn't specify the dental procedure that led to MRONJ, though it implies some dental intervention occurred.",Exclude,"A single-patient case report fails to meet multiple critical screening criteria, including required subject size, study design, and control group specifications. Despite addressing romosozumab and medication-related osteonecrosis of the jaw, the study lacks the methodological rigor and comprehensive documentation needed for inclusion in the review.",0.1
Medication-related osteonecrosis of the jaw: a preliminary retrospective study of 130 patients with multiple myeloma,"W. Choi, Jae-Il Lee, H. Yoon, C. Min, Sang-Hwa Lee",10.1186/s40902-016-0099-4,https://doi.org/10.1186/s40902-016-0099-4,Maxillofacial plastic and reconstructive surgery,34,2017,no,"The study population consists of multiple myeloma patients, not patients with diagnosed osteoporosis. Additionally, these patients have cancer, which is explicitly excluded in the criteria.",yes,yes,"The study clearly documents MRONJ outcomes following dental procedures, particularly extractions.",no,The abstract does not mention a control group of non-anti-resorptive medication users. The study appears to only include patients who received bisphosphonates.,yes,"The study is described as a retrospective review, which fits within the acceptable study designs.",yes,"The study documents the temporal relationship, noting the median BP administration time was 19 months and discusses the relationship between medication use and MRONJ development.",yes,"The study includes 130 patients, which exceeds the minimum requirement of 100 subjects.","The study mentions dental procedures including extractions, and discusses dental evaluations and treatments.",Exclude,"The study focuses on multiple myeloma patients using bisphosphonates, which fundamentally differs from the required osteoporosis patient population and Romosozumab intervention. Critical screening criteria were not met, including medication type, patient population, and control group requirements. These significant deviations render the study ineligible for inclusion in the systematic review.",0.1
Medication-Related Osteonecrosis of the Jaw Subsequent to Periimplantitis: A Case Report and Literature Review.,"Keisuke Seki, S. Namaki, Atsushi Kamimoto, Y. Hagiwara",10.1563/aaid-joi-D-19-00385,https://doi.org/10.1563/aaid-joi-D-19-00385,Journal of Oral Implantology,12,2020,yes,The subject is an adult (73-year-old) with osteoporosis and no mention of cancer.,yes,yes,The study clearly documents MRONJ development following dental procedures (implant placement and maintenance).,no,"As a case report, there is no control group mentioned.",no,"This is a case report, which is not one of the accepted study designs (RCT, cohort, or case-control study).",yes,The abstract clearly documents the temporal relationship between medication use and MRONJ development (4 years after commencing BP) and the duration of medication use.,no,"This is a single case report of one patient, far below the required minimum of 100 subjects.","The study involves dental implants and subsequent implant removal, which qualifies as invasive dental treatment.",Exclude,"This single-patient case report fails multiple critical screening criteria, including the use of alendronate instead of Romosozumab, insufficient subject size, and an inappropriate study design. Despite documenting MRONJ development and temporal medication relationships, the fundamental misalignment with core inclusion requirements necessitates exclusion from the systematic review.",0.1
Surgical Therapy for Bisphosphonate-Related Osteonecrosis of the Jaw: Six-Year Experience of a Single Institution.,"R. Lopes, G. Rabelo, A. Rocha, P. Carvalho, F. Alves",10.1016/j.joms.2015.01.008,https://doi.org/10.1016/j.joms.2015.01.008,Journal of oral and maxillofacial surgery,61,2015,no,"The study includes adult patients (39-83 years) but also includes patients with hypercalcemia of malignancy and bone metastases, so it does not exclusively focus on osteoporosis patients without cancer.",no,no,"While MRONJ outcomes are documented, they are not following dental procedures. The study looks at surgical treatment outcomes for existing MRONJ.",no,"There is no mention of a control group, as the study only looks at surgical outcomes in MRONJ patients.",yes,The retrospective study design is acceptable.,no,"There is no clear documentation of the temporal relationship between medication use and MRONJ, and the duration of medication use is not clearly documented.",no,"The study includes 33 patients with 46 MRONJ sites, which falls well below the required 100+ subjects.","The study focuses on surgical treatment OF MRONJ, not dental procedures leading TO MRONJ, which is a fundamental mismatch with the criterion.",Exclude,"The study fundamentally fails key screening criteria by focusing on bisphosphonates instead of Romosozumab, having a small sample size of 33 patients, and examining surgical treatment of MRONJ rather than dental procedures leading to MRONJ. Multiple critical requirements are not met, including population type, control group, and temporal documentation, rendering the paper unsuitable for the systematic review.",0.1
Osseous changes in patients with medication-related osteonecrosis of the jaws.,"Z. Gönen, Canay Yillmaz Asan, G. Zararsiz, E. Kılıç, A. Alkan",10.1259/dmfr.20170172,https://doi.org/10.1259/dmfr.20170172,Dento maxillo facial radiology,15,2018,maybe,"The study does not explicitly mention the age or osteoporosis diagnosis of the patients, nor does it mention their cancer status.",no,no,"While the study examines MRONJ, there is no documentation of specific dental procedures, as the focus is on imaging findings rather than procedure-related outcomes.",yes,"The study does include a control group, which meets this criterion.",yes,"The study has a retrospective study design, which meets this criterion.",no,"The study does not mention the temporal relationship between medication use and MRONJ development, nor does it document the duration of medication use.",no,"The study includes only 25 patients, which is less than the required subject size of more than 100 people.","There is no mention of dental procedures or treatments in the study, as it focuses on imaging findings rather than interventions.",Exclude,"The study fails critical screening criteria, particularly the requirement for Romosozumab as the specific medication and a subject size exceeding 100 participants. Multiple key elements are missing, including documentation of dental procedures, temporal medication use, and specific patient population characteristics. The research primarily focuses on imaging findings of medication-related osteonecrosis, rendering it unsuitable for the intended screening parameters.",0.1
"Incidence and trend of antiresorptive agent-related osteonecrosis of the jaw from 2016 to 2020 in Kure, Japan","Takahiro Kunihara, H. Tohmori, Manabu Tsukamoto, M. Kobayashi, Toshiya Okumura, H. Teramoto, T. Hamasaki, Takuma Yamasaki, Tsuyoshi Nakagawa, N. Okimoto, S. Fujiwara",10.1007/s00198-023-06732-8,https://doi.org/10.1007/s00198-023-06732-8,Osteoporosis International,11,2023,maybe,"The study includes both osteoporosis patients and cancer patients. While it does separate the analysis between these groups, it's not exclusively focused on non-cancer patients with osteoporosis.",no,no,"While MRONJ outcomes are documented, the abstract doesn't specify whether these were following specific documented dental procedures.",yes,"The study includes a control group of ""people without antiresorptive agents"" for comparison.",yes,This appears to be a prospective cohort study with a registry system and clear temporal documentation.,maybe,"The study documents temporal trends over 5 years, but doesn't clearly specify the duration of medication use for individual patients.",maybe,"The study includes 98 eligible ONJ patients, which is below the required 100 subjects, but very close to the threshold.","While the study focuses on ONJ/MRONJ, which typically occurs after dental procedures, the abstract doesn't explicitly state that all cases followed specific dental interventions.",Include,"The study fails to meet key screening criteria, particularly the specific requirement for Romosozumab as the intervention, and includes both cancer and osteoporosis patients. While the research demonstrates a robust methodology with a control group and prospective design, the fundamental mismatch in intervention type and population characteristics prevents its inclusion in the systematic review.",2.7
Medication-related osteonecrosis of the jaw. Introduction of a new modified experimental model.,"Cláudia Curra, C. Cardoso, O. Ferreira, M. Curi, M. Matsumoto, B. Cavenago, P. Santos, J. Santiago",10.1590/S0102-865020160050000003,https://doi.org/10.1590/S0102-865020160050000003,Acta Cirurgica Brasileira,15,2016,no,"The study uses rats, not adult human patients with osteoporosis, so it fails this criterion.",maybe,maybe,"The study does document MRONJ outcomes following extraction, but this is in an animal model.",yes,"The study does include a control group (15 rats without medication), which meets this criterion, but it is in an animal model.",no,"This is an experimental animal study, which does not meet the required study design criteria (RCT, cohort, or case-control in humans).",maybe,"The study documents the temporal relationship between medication and MRONJ, but this is in an animal model.",no,"The study uses 45 rats, not human subjects, and the sample size is below the required 100 subjects, so it fails this criterion.","The study includes tooth extraction, which meets this criterion, but it is in rats, not humans.",Exclude,"This experimental rat study fundamentally fails multiple screening criteria, primarily by using zoledronic acid instead of Romosozumab and conducting research on an animal model rather than human subjects. The small sample size, non-human study design, and lack of alignment with specified population and intervention requirements render the study non-compliant with the established screening criteria.",0.1
Clinicostatistical analyses of medication‐related osteonecrosis of the jaws (MRONJ): Evaluation of the treatment method and prognosis,"Ryuta Osaka, H. Kato, Y. Hamada, Y. Fujimoto, Nobuhito Mizusawa, D. Watanabe, A. Kaneko",10.1002/osi2.1098,https://doi.org/10.1002/osi2.1098,Oral Science International,4,2020,maybe,"The abstract doesn't specify the age range of patients or whether they have cancer. It only mentions ""patients with MRONJ.""",maybe,maybe,"While MRONJ outcomes are documented, the specific dental procedures leading to MRONJ are not clearly described in the abstract.",no,No control group is mentioned in the abstract.,yes,"The study is described as a retrospective study, which meets the criteria.",maybe,"The abstract mentions ""low-dose administration"" but doesn't clearly document the temporal relationship or duration of medication use.",no,"The study includes 88 patients, which is below the required 100 subjects.","While the study focuses on MRONJ, which typically follows dental procedures, the abstract doesn't explicitly state which dental procedures were performed.",Exclude,"The study fails key screening criteria by using bisphosphonates and denosumab instead of romosozumab, and having a sample size of 88 patients below the required 100. Multiple other criteria remain unclear or unmet, including lack of a control group, incomplete documentation of dental procedures, and uncertain patient population characteristics. These significant deviations from the screening requirements suggest the study does not meet the specified research parameters.",1.4
Platelet concentrates as an adjunctive therapy for medication-related osteonecrosis of the Jaw: A systematic review and meta-analysis,"M. Fabbro, S. Taschieri, F. Goker",10.4103/GFSC.GFSC_19_18,https://doi.org/10.4103/GFSC.GFSC_19_18,-,6,2018,maybe,"The study does not specify the age range or osteoporosis diagnosis of the population, and does not explicitly exclude cancer patients, so there is insufficient information to determine if this criterion is met.",yes,yes,"The study documents MRONJ outcomes following dental procedures, specifically mentioning tooth extraction, which meets the outcome documentation criterion.",no,"The study mentions a ""control"" group in the context of APC treatment, but does not specifically mention a control group of non-anti-resorptive users, so it fails to meet this criterion.",yes,"The study includes both prospective and retrospective studies, which meets the study design criterion.",maybe,"The study mentions follow-up periods of 3-94 months, but does not clearly document the temporal relationship between medication use and MRONJ development, so it only partially meets this criterion.",yes,"The study includes 946 patients across 18 studies, which meets the subject size criterion.","The study mentions tooth extraction and ""oral surgery procedures"", which meets the intervention criterion.",Include,"The systematic review fails to meet critical screening criteria, particularly the specific requirement for Romosozumab intervention and a clear control group of non-anti-resorptive medication users. While the study includes a large patient sample and documents dental procedures and MRONJ outcomes, key population and intervention details are insufficiently defined to satisfy the comprehensive screening requirements.",2.5
Key insights into antiresorptive drug use and osteonecrosis in osteoporotic patients undergoing tooth extractions: A clinical and CBCT assessment,"C. Moreno-Rabié, R. C. Fontenele, N. Oliveira-Santos, F. Nogueira-Reis, T. Van den Wyngaert, R. Jacobs",10.1007/s00198-024-07108-2,https://doi.org/10.1007/s00198-024-07108-2,Osteoporosis International,1,2024,maybe,"The study focuses on osteoporotic patients, but doesn't explicitly state they are all adults (≥18 years). However, given the context of osteoporosis treatment, it's highly likely these are adult patients. The abstract doesn't mention cancer patients.",yes,yes,"The study clearly documents MRONJ outcomes following tooth extractions, with specific documentation of cases (4 patients, 5 sites) and outcomes.",yes,The study includes a control group of 98 patients who did not receive ARD treatment.,yes,"The abstract explicitly states this is a ""retrospective cohort study,"" which meets the criteria.",maybe,"While the study documents the temporal relationship between medication use and MRONJ development (post-extraction), it doesn't explicitly state the duration of medication use.",yes,"The study includes 176 patients (78 in treatment group, 98 in control group), exceeding the minimum requirement of 100 subjects.","The study specifically focuses on tooth extraction, which is one of the specified invasive dental treatments.",Exclude,"The study involves osteoporotic patients undergoing tooth extraction with antiresorptive drug treatment, but critically fails to use Romosozumab as the specified intervention. While meeting most screening criteria including subject size, control group, and outcome documentation, the fundamental mismatch in medication type renders the study non-compliant with the core intervention requirement. The research provides valuable insights into medication-related osteonecrosis of the jaw, but does not align with the specific screening parameters.",1.4
Risk factors of medication-related osteonecrosis of the jaw: a retrospective study in a Turkish subpopulation,"O. Şahin, O. Odabaşı, Toghrul Aliyev, B. Tatar",10.5125/jkaoms.2019.45.2.108,https://doi.org/10.5125/jkaoms.2019.45.2.108,Journal of the Korean Association of Oral and Maxillofacial Surgeons,12,2019,no,"The study includes both cancer and osteoporosis patients, and is not exclusively focused on non-cancer patients with osteoporosis.",maybe,maybe,"MRONJ outcomes are documented, but the specific dental procedures are not clearly documented in the abstract.",no,There is no mention of a control group of non-anti-resorptive medication users.,yes,"The study appears to be a retrospective cohort study (medical records review), which meets this criterion.",maybe,"The duration of drug treatment is mentioned as being collected, and the temporal relationship is somewhat documented.",no,"The study includes 52 patients, which fails to meet the minimum requirement of 100 subjects.","While MRONJ is discussed, the abstract does not explicitly state which dental procedures were performed, so this information is unclear.",Exclude,"The study fails critical screening criteria by using bisphosphonates instead of Romosozumab, having a small sample size of 52 patients, and including a mixed population with cancer patients. Multiple key requirements are not met, including the lack of a control group and unclear documentation of specific dental procedures, rendering the study unsuitable for the systematic review.",0.1
Risk of Medication-Related Osteonecrosis of the Jaw after Dental Extractions in Patients Receiving Bone Resorption Inhibitors – A Retrospective Study of 240 Patients,"R. Coropciuc, R. Coopman, M. Garip, E. Gielen, C. Politis, T. Van den Wyngaert, B. Beuselinck",10.2139/ssrn.4248587,https://doi.org/10.2139/ssrn.4248587,Social Science Research Network,0,2022,maybe,"While the study includes adult osteoporosis patients, it also includes a significant cohort with bone metastases (cancer patients). The abstract doesn't specify if all osteoporosis patients are ≥18 years.",yes,yes,"The study clearly documents MRONJ outcomes following dental extractions, with specific percentages reported (10.3% in osteoporosis cohort).",maybe,The abstract doesn't mention a control group of non-anti-resorptive medication users.,yes,"The study is described as retrospective, which meets the criteria for acceptable study designs.",yes,"The study documents temporal relationships, noting median drug exposure of 43 months and discussing drug holiday effects.",yes,"The study includes 240 patients (126 osteoporosis + 114 bone metastases), which is well above the 100-person threshold.","The study specifically focuses on dental extractions, which is one of the specified invasive dental treatments.",Include,"The study involves dental extractions in patients with bone resorption inhibitors, but critically fails to specify Romosozumab as the intervention medication. While meeting several screening criteria like sample size and study design, the lack of medication specificity and inclusion of cancer patients create significant barriers to systematic review inclusion. The absence of a clear control group and incomplete population characterization further complicate the study's alignment with screening requirements.",2.7
Medication-related osteonecrosis of the jaw: An update,H. Bansal,10.4103/njms.NJMS_236_20,https://doi.org/10.4103/njms.NJMS_236_20,National Journal of Maxillofacial Surgery,14,2022,maybe,"The abstract mentions osteoporosis patients but also discusses multiple myeloma, and no specific age criteria are mentioned, so it cannot be confirmed if cancer patients are excluded.",maybe,no,"While MRONJ is discussed, there's no indication of specific documented dental procedures and outcomes, and the paper appears to be a general review rather than documenting specific cases.",no,"There is no mention of control groups, and the paper appears to be a review paper rather than a comparative study.",no,"This appears to be a review/update paper rather than an original research study, and it does not match any of the required study designs.",no,"While duration of treatment is mentioned as a risk factor, there's no indication of specific temporal documentation, and the paper appears to be reviewing general knowledge rather than documenting specific cases.",no,"The abstract does not mention any specific study size, and the paper appears to be a review/update paper rather than an original research study.","The abstract mentions tooth extraction as a risk factor, but this is discussed generally rather than as part of a specific study.",Exclude,"The abstract describes a review paper on antiresorptive medications and medication-related osteonecrosis of the jaw, which fundamentally fails to meet the systematic review's core screening criteria. Specifically, the paper does not involve Romosozumab, lacks a specific study design, and does not document specific dental procedures or patient outcomes. The review's general nature and broad scope disqualify it from meeting the required research parameters.",0.1
THU442 A Case Of Early Medication Related Osteonecrosis Of The Jaw In Patient Receiving Intravenous Zoledronate For Treatment Of Osteoporosis,-,10.1210/jendso/bvad114.403,https://doi.org/10.1210/jendso/bvad114.403,Journal of the Endocrine Society,1,2023,yes,"The patient is an adult (63-year-old) with osteoporosis, and no cancer is mentioned.",no,no,"While MRONJ is documented, it's not following a specific dental procedure.",no,This is a case report with no control group.,no,"This is a case report, which is not one of the accepted study designs.",maybe,"The abstract mentions ""several years of oral bisphosphonate treatment and three annual administrations of zoledronic acid"", but this is not specifically for Romosozumab.",no,"This is a single case report of one patient, which does not meet the minimum requirement of 100 subjects.",The abstract mentions dental evaluation but does not describe any invasive dental procedures. The patient had gum pain but no specific dental intervention is mentioned.,Exclude,"This case report fails multiple critical screening criteria, including using the wrong medication (bisphosphonates instead of Romosozumab), having a sample size of one instead of over 100, and lacking a control group or invasive dental intervention. The study design as a single case report does not meet the required methodological standards for inclusion in the systematic review.",0.1
Medication-related osteonecrosis: Literature review,"Idrovo Campoverde María Coralía, Bacuilima Ñauta Erika Susana, Pesántez Alvarado Juan Martín, Lafebre Carrasco Milton Fabricio",10.30574/wjarr.2023.18.2.0832,https://doi.org/10.30574/wjarr.2023.18.2.0832,World Journal of Advanced Research and Reviews,0,2023,no,"Population characteristics are not specified, and there is no mention of osteoporosis or cancer status, so the population type does not meet the criterion of focusing exclusively on adult patients with diagnosed osteoporosis who do not have cancer.",maybe,maybe,"While MRONJ is the focus, specific dental procedures and outcomes are not detailed, so the study partially meets the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"As a literature review, it does not include its own control group, so it fails to meet the criterion of including a control group of non-anti-resorptive medication users.",no,"This is a literature review, not a primary research study, so it fails to meet the criterion of having a study design of a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"The abstract mentions ""prolonged use"" but does not specify temporal relationships or duration, so the study partially meets the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",no,"This is a literature review, not a primary study, so the subject size is not specified and does not meet the criterion of having a subject size of more than 100 people.","While dental procedures are implied in the context of MRONJ, specific interventions are not detailed, so the intervention partially meets this criterion.",Exclude,"This literature review fails to meet multiple critical screening criteria, including specific intervention with Romosozumab, defined subject size, and precise population characteristics. While addressing medication-related osteonecrosis of the jaw broadly, the study lacks the detailed methodological requirements for inclusion, such as a control group, specific dental interventions, and clear temporal documentation of medication use and outcomes.",1.4
Systemic comorbidities are associated with medication-related osteonecrosis of the jaws: Case-control study.,"K. McGowan, C. Acton, S. Ivanovski, N. Johnson, R. Ware",10.1111/odi.13046,https://doi.org/10.1111/odi.13046,Oral Diseases,11,2019,maybe,"The study appears to focus on adult patients, but it's unclear if all patients had diagnosed osteoporosis. The abstract mentions ""primary disease"" but doesn't specify if this was osteoporosis.",no,no,"While MRONJ is the primary outcome, the abstract doesn't specify which dental procedures were documented or how outcomes were tracked.",yes,The study includes a control group of 204 subjects matched to cases.,yes,"The study is explicitly described as a case-control study, which meets the criteria.",maybe,"The study mentions ""duration of antiresorptive therapy"" in matching criteria, but doesn't clearly document the temporal relationship between medication use and MRONJ development.",yes,"The study includes 68 cases and 204 controls (272 total subjects), exceeding the minimum requirement of 100 subjects.","While the study is about MRONJ, which typically follows dental procedures, the abstract doesn't explicitly state which dental procedures were involved or whether they were invasive.",Include,"The study fails to meet critical screening criteria, specifically the requirement for Romosozumab as the intervention medication. While the research demonstrates methodological rigor with a case-control design and adequate sample size, the lack of specificity regarding the antiresorptive medication disqualifies it from inclusion. Uncertainties around dental procedure documentation and population characteristics further complicate its potential eligibility.",2.5
"Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial.","Ie-Wen Sim, G. Borromeo, C. Tsao, R. Hardiman, M. Hofman, Christian Papatziamos Hjelle, M. Siddique, G. Cook, J. Seymour, P. Ebeling",10.1200/JCO.19.02192,https://doi.org/10.1200/JCO.19.02192,Journal of Clinical Oncology,75,2020,maybe,"While the study involves adult patients with MRONJ, it doesn't explicitly state whether they have osteoporosis or cancer status. The population characteristics are not fully detailed in the abstract.",no,maybe,"While the study documents MRONJ outcomes, it doesn't clearly specify the initial dental procedures that led to MRONJ development.",yes,"The study is a randomized controlled trial with a placebo group, meeting this criterion.",yes,"The study is explicitly described as a ""double-blind, randomized, controlled trial,"" meeting this criterion.",maybe,The abstract doesn't provide clear information about the temporal relationship between medication use and MRONJ development or the duration of medication use.,no,"The study only includes 34 participants, which is well below the required minimum of 100 subjects.","While the study involves MRONJ patients, it doesn't explicitly state whether these cases were triggered by specific dental procedures. The abstract doesn't provide enough information about the initial dental interventions.",Exclude,"The study fails key screening criteria by using Teriparatide instead of Romosozumab and having a sample size of only 34 participants, which is significantly below the required 100 subjects. Multiple other criteria remain unclear or partially met, rendering the study unsuitable for inclusion in the systematic review.",0.1
Osteonecrosis of the jaws in patients under osteoporosis treatment: a nine-year experience report,"D. C. Penoni, J. Canellas, Marcos Antonio Nunes Costa Silami, Flávia Sader, Gonçalo Sobreira Pimentel, A. T. T. Leão",10.20945/2359-3997000000612,https://doi.org/10.20945/2359-3997000000612,Archives of Endocrinology and Metabolism,2,2023,maybe,"While the study focuses on osteoporotic patients, it doesn't explicitly state they are adults (≥18 years) or confirm absence of cancer patients.",yes,yes,"The study clearly documents MRONJ outcomes following specific dental procedures, with specific percentages reported for different procedures.",no,No mention of a control group of non-anti-resorptive medication users.,yes,This appears to be a retrospective cohort study based on digital records over a 9-year period.,maybe,"While the study spans 9 years, it doesn't clearly document the temporal relationship between medication use and MRONJ development or the duration of medication use.",yes,"The study includes 6,742 procedures, well above the 100-person minimum requirement.","The study explicitly includes tooth extractions, dental implant placement, periodontal procedures, and removable prostheses.",Exclude,"The study fails to meet critical screening criteria, particularly the requirement for Romosozumab as the specific anti-resorptive medication. While demonstrating a large sample size and comprehensive dental intervention documentation, the lack of specificity about medication type and absence of a control group significantly compromise its potential for inclusion. Uncertainty around population characteristics and temporal documentation further reduces its alignment with the screening requirements.",1.4
Medication Related Osteonecrosis of the Jaws,"Semih Özbayrak, Ö. Okumuş",-,-,-,0,2020,no,"The paper mentions osteoporosis patients but also includes cancer patients, and is not exclusively focused on adult non-cancer patients. This suggests that the study does not focus exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",maybe,maybe,"While MRONJ is the focus, specific dental procedures and outcomes are not detailed. This suggests that the study does not clearly report MRONJ outcomes following specific, documented dental procedures.",no,"There is no mention of control groups, and as a review article, the paper does not describe specific study groups. This indicates that the study does not include a control group of non-anti-resorptive medication users.",no,"The paper is described as a review article, not a primary research study, and does not match any of the required study designs (randomized controlled trial, prospective/retrospective cohort study, or case-control study).",no,"The paper only mentions that ""long-term use"" may increase the risk of MRONJ, and does not provide specific temporal relationships or duration documentation. This indicates that the study does not clearly document both the temporal relationship between medication use and MRONJ development and the duration of medication use.",no,"No specific subject size is mentioned, and the paper is described as a review article rather than a primary study. This suggests that the study does not have a subject size of more than 100 people.","While MRONJ is discussed, specific dental procedures are not detailed, and the paper only mentions ""bone destruction in the jaws"" generally. This indicates that the study does not clearly focus on invasive dental treatment, including tooth extraction, implant placement, periodontal surgery, other dental surgery, or removable prosthesis fabrication.",Exclude,"This review article fails to meet multiple critical screening criteria, including specific intervention requirements, study design, and population specifications. The abstract discusses medication-related osteonecrosis of the jaw broadly but lacks the precise focus on Romosozumab, osteoporosis patients, and detailed dental intervention outcomes needed for inclusion. Consequently, the paper does not align with the established screening requirements.",0.1
Radiographic predictors for MRONJ in oncologic patients undergoing tooth extraction,"C. Moreno-Rabié, Laurence Lapauw, H. Gaêta-Araujo, André Ferreira-Leite, W. Coucke, T. Van den Wyngaert, R. Jacobs",10.1038/s41598-022-15254-y,https://doi.org/10.1038/s41598-022-15254-y,Scientific Reports,14,2022,no,"The abstract specifically states these are ""oncologic patients,"" which violates the criterion requiring patients without cancer.",yes,yes,The study clearly documents MRONJ outcomes following tooth extractions and includes specific documentation of the procedures.,maybe,"The abstract mentions a ""case-control and subgroup analysis"" but doesn't clearly indicate if there's a control group of non-ARD users.",yes,"The study is described as a ""retrospective longitudinal cohort study,"" which meets the criteria.",maybe,"The abstract mentions ""longer ARD treatment"" was associated with MRONJ development, but doesn't clearly document the duration of medication use or temporal relationship.",no,"The study includes 77 patients, which is below the required minimum of 100 subjects.","The study focuses on tooth extraction, which is explicitly mentioned as one of the required invasive dental treatments.",Exclude,"The study fails key screening criteria by using general antiresorptive drugs instead of Romosozumab, including oncologic patients instead of non-cancer patients, and having a sample size below 100 subjects. Despite meeting some criteria like study design and outcome documentation, the fundamental deviations from the required parameters necessitate exclusion from the systematic review.",0.1
Assessment of a Claims-Based ICD-9 and ICD-10 Medication-Related Osteonecrosis of the Jaw Algorithm in the United States,"Lauren A S Stevens, L. Spangler, L. Yochum, Yan Ding, Florence T. Wang",10.2147/CLEP.S325080,https://doi.org/10.2147/CLEP.S325080,Clinical Epidemiology,0,2021,maybe,"The study focuses on postmenopausal women and women with postmenopausal osteoporosis, which partially meets the criterion of focusing on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",no,no,"While MRONJ is the outcome of interest, the study does not document specific dental procedures, and instead focuses on algorithm validation rather than procedure outcomes.",no,"The study does not mention a control group, and the study design appears to be a chart review validation study rather than a study with a control group.",no,"The study is a validation study of claims-based algorithms, which is not a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The study does not mention any temporal relationships or medication duration, and instead focuses on algorithm validation rather than temporal aspects.",no,"The study identified 1,273 potential cases and reviewed 104 charts, but the actual study size is below 100 confirmed cases, which does not meet the criterion of having a subject size of more than 100 people.","The study does not mention any specific dental procedures or treatments, and instead focuses on MRONJ identification algorithms rather than dental interventions.",Exclude,"The study fails to meet multiple critical screening criteria, including specific intervention type, subject size, dental treatment documentation, and study design requirements. While focusing on postmenopausal women with osteoporosis, the research does not align with the systematic review's precise methodological and intervention specifications. The paper appears to be a methodological validation study rather than a clinical investigation meeting the predefined screening parameters.",1.4
Medication related osteonecrosis of the jaw (MRONJ),"A. Bedogni, G. Campisi, V. Fusco",10.32388/594095,https://doi.org/10.32388/594095,Definitions,6,2018,no,"The abstract mentions osteoporosis patients but also discusses other conditions like Paget's disease, multiple myeloma, and metastatic conditions. It is not exclusively focused on adult osteoporosis patients without cancer.",no,no,"While MRONJ is discussed, the abstract does not provide specific documentation of outcomes following dental procedures.",maybe,"The abstract does not mention any control groups, so it cannot be determined if this criterion is met.",no,"The abstract indicates that this is a review article rather than a primary research study, and it does not match any of the required study designs (randomized controlled trial, prospective/retrospective cohort study, or case-control study).",no,"The abstract does not mention any specific temporal relationships between medication use and MRONJ development, or the duration of medication use.",maybe,"The abstract does not mention the study size or number of participants, so it cannot be determined if the criterion of more than 100 people is met.","While the abstract discusses dental procedures in general, it does not describe specific invasive dental treatments like tooth extraction, implant placement, periodontal surgery, or removable prosthesis fabrication. The paper appears to be a review/overview rather than an intervention study.",Exclude,"The abstract fails to meet multiple critical screening criteria, including the specific medication requirement, study design, and population type. It appears to be a general review of medication-related osteonecrosis rather than a focused research study on Romosozumab and dental interventions in osteoporosis patients. Consequently, the paper does not align with the systematic review's precise inclusion requirements.",0.1
Reporting Criteria for Clinical Trials on Medication-Related Osteonecrosis of the Jaw (MRONJ): A Review and Recommendations,"Camille Gaudet, Stéphane Odet, C. Meyer, B. Chatelain, E. Weber, A. Parmentier, S. Derruau, S. Laurence, C. Mauprivez, Esteban Brenet, H. Kerdjoudj, M. Fénelon, J. Fricain, N. Zwetyenga, D. Hoarau, R. Curien, É. Gérard, A. Louvrier, F. Gindraux",10.3390/cells11244097,https://doi.org/10.3390/cells11244097,Cells,5,2022,no,"Population characteristics are not specified, so the study does not meet the criterion of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",maybe,no,"While MRONJ outcomes are discussed, this paper is about developing protocols and does not report actual outcomes from specific procedures, so the study does not meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"There is no mention of control groups, and this is a review/protocol paper, not an intervention study, so the study does not meet the criterion of including a control group of non-anti-resorptive medication users.",no,"This is a literature review and protocol development paper, not an RCT, cohort, or case-control study, so the study does not meet the criterion of having a study design of a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The paper actually highlights the lack of temporal documentation in existing literature and does not provide temporal documentation itself, so the study does not meet the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",no,"This is a literature review/protocol development paper, and no specific subject size is mentioned, so the study does not meet the criterion of having a subject size of more than 100 people.","While dental procedures are implied in the context of MRONJ, specific interventions are not detailed, so the study only partially meets the criterion of having an intervention of invasive dental treatment.",Exclude,"This literature review and protocol development paper fails to meet multiple critical screening criteria, including specific intervention details, subject size, population characteristics, and study design requirements. The abstract discusses medication-related osteonecrosis of the jaw but lacks the precise methodological elements needed for systematic review inclusion, such as a defined patient population, control group, and specific intervention outcomes.",0.1
Osteonecrosis of the jaw and dental extractions: a single-center experience.,"Shaiba Sandhu, Moaiad H Salous, V. Sankar, D. Margalit, A. Villa",10.1016/j.oooo.2020.07.001,https://doi.org/10.1016/j.oooo.2020.07.001,"Oral surgery, oral medicine, oral pathology and oral radiology",7,2020,maybe,"While the study includes adult patients, it doesn't explicitly state they have diagnosed osteoporosis. Additionally, some patients received radiotherapy, which may indicate cancer treatment.",yes,yes,The study clearly documents MRONJ outcomes following dental extractions.,maybe,"While there are two groups (RT-HN and antiresorptive users), neither serves as a true control group of non-anti-resorptive medication users.",yes,"This is a retrospective study, which is one of the accepted study designs.",maybe,"While the study period (2003-2019) is documented, the abstract doesn't clearly specify the temporal relationship between medication use and MRONJ development or the duration of medication use.",yes,"The study includes 90 patients total, with 40 patients in the antiresorptive group, meeting the >100 requirement when considering the total cohort.","The study specifically focuses on dental extractions, which is one of the specified invasive dental treatments.",Exclude,"The study fails to meet critical screening criteria, specifically the requirement for Romosozumab as the anti-resorptive medication. While the research includes dental extractions and documents MRONJ outcomes, the lack of specificity about the medication type and unclear patient population characteristics prevent it from qualifying for inclusion. Multiple screening criteria remain partially or completely unmet, rendering the study unsuitable for the intended review.",1.4
CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.,"A. Baba, T. Goto, H. Ojiri, M. Takagiwa, Chiho Hiraga, M. Okamura, S. Hasegawa, Yumi Okuyama, Nobuhiro Ogino, H. Yamauchi, Y. Kobashi, S. Yamazoe, Yohei Munetomo, T. Mogami, T. Nomura",10.1259/dmfr.20170323,https://doi.org/10.1259/dmfr.20170323,Dento maxillo facial radiology,52,2018,maybe,"The abstract doesn't specify the age range of patients or whether they have cancer. It only mentions ""Japanese patients.""",maybe,maybe,"While the study documents MRONJ outcomes, it focuses on radiological characteristics rather than specific dental procedures leading to MRONJ.",no,No control group is mentioned in the abstract.,maybe,"The study appears to be a retrospective analysis of CT scans, but the exact study design classification isn't explicitly stated.",maybe,"The study mentions ""long-term administration and short-term administration"" but doesn't clearly document the temporal relationship between medication use and MRONJ development.",no,"The study includes 74 patients, which exceeds the minimum requirement of 100. However, this is actually a failure as it's below the threshold.","While the study is about ARONJ/MRONJ which typically follows dental procedures, the abstract doesn't explicitly state which dental procedures were performed.",Exclude,"The study focuses on bisphosphonates and denosumab, not romosozumab, which immediately disqualifies it from meeting the primary intervention criterion. With a sample size of 74 patients, the study falls short of the required 100 participants, and lacks a control group. Multiple screening criteria remain unmet, rendering the paper unsuitable for inclusion in the systematic review.",0.1
LOW RISK OF SPONTANEOUS MEDICATION-RELATED OSTEONECROSIS OF THE JAW IN FIBROUS DYSPLASIA PATIENTS AFTER ANTIRESORPTIVE THERAPIES: A SYSTEMATIC REVIEW,"Srighana Nadella, M. Mupparapu, S. Akintoye",10.1016/j.oooo.2021.08.043,https://doi.org/10.1016/j.oooo.2021.08.043,"Oral surgery, oral medicine, oral pathology and oral radiology",0,2022,no,"The study focuses on patients with fibrous dysplasia (FD) and McCune-Albright syndrome (MAS), not on adult patients with diagnosed osteoporosis. Therefore, it fails to meet the criterion of the population type.",no,no,"While the paper discusses MRONJ, it focuses on the spontaneous occurrence of MRONJ, not on MRONJ outcomes following specific, documented dental procedures. Therefore, it fails to meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"The paper does not mention any control groups, so it fails to meet the criterion of including a control group of non-anti-resorptive medication users.",no,"The paper is a systematic review, not a primary research study, so it fails to meet the criterion of having a study design of a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"The paper mentions ""at least 2 years of therapy,"" but does not specifically document the temporal relationship between medication use and MRONJ development. Therefore, it partially meets the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",no,"The abstract mentions only 3 eligible articles were found, but does not provide the specific subject size. Therefore, it is unclear whether the study meets the criterion of having a subject size of more than 100 people.","The paper does not mention any dental procedures or interventions, and instead focuses on the spontaneous occurrence of MRONJ. Therefore, it fails to meet the criterion of the subject having an intervention of invasive dental treatment.",Exclude,"The systematic review focuses on fibrous dysplasia and McCune-Albright syndrome patients, not osteoporosis patients, and does not involve Romosozumab or dental interventions. Multiple screening criteria are unmet, including population type, intervention specifics, study design, and outcome documentation. The paper fundamentally differs from the required research parameters, rendering it unsuitable for the intended review.",0.1
Medication-Related Osteonecrosis of the Jaw: A Reflection of Current Preventative and Therapeutic Guidelines: A Review,"Hassan H. Dib, W. Khalil, Houssam Jassar, Mohamad Houmnani",10.24018/ejdent.2022.3.2.57,https://doi.org/10.24018/ejdent.2022.3.2.57,European Journal of Dental and Oral Health,1,2022,no,"The abstract does not mention the specific population type, such as adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer. Therefore, the study does not meet the criterion of focusing exclusively on this population type.",no,no,"While MRONJ is discussed, the abstract does not provide specific documentation of MRONJ outcomes following dental procedures such as extractions, periodontal surgery, implants, or prosthetic treatments. Therefore, the study does not meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"The abstract does not mention the inclusion of a control group of non-anti-resorptive medication users. Therefore, the study does not meet the criterion of including a control group.",no,"The abstract explicitly states that this is a review paper, not a primary research study. Therefore, the study does not meet the criterion of having a study design of a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The abstract does not mention the temporal relationship between medication use and MRONJ development or the duration of medication use. Therefore, the study does not meet the criterion of clearly documenting both the temporal relationship and the duration of medication use.",no,"The abstract does not mention the specific subject size of the study, and it is a review paper rather than a primary study. Therefore, the study does not meet the criterion of having a subject size of more than 100 people.","While dental procedures are implied in the context of MRONJ, the abstract does not provide details on specific invasive dental treatments such as tooth extraction, implant placement, periodontal surgery, or removable prosthesis fabrication. Therefore, the study does not meet the criterion of having an intervention of invasive dental treatment.",Exclude,"This review paper fails to meet any of the specified screening criteria, including lack of focus on Romosozumab, absence of a defined subject population, and no documentation of specific dental interventions or outcomes. As a literature review rather than a primary research study, it does not provide the required clinical data or methodological elements needed for inclusion in the systematic review.",0.1
Nonsurgical Management of Medication-Related Osteonecrosis of the Jaws Using Local Wound Care.,"D. Hadaya, A. Soundia, E. Freymiller, T. Grogan, D. Elashoff, S. Tetradis, T. Aghaloo",10.1016/j.joms.2018.05.025,https://doi.org/10.1016/j.joms.2018.05.025,Journal of oral and maxillofacial surgery,36,2018,maybe,"The study includes adult patients with MRONJ, but doesn't explicitly state they all have diagnosed osteoporosis or exclude cancer patients. The abstract mentions ""primary condition"" as a variable but doesn't specify what conditions were included.",maybe,maybe,"While the study documents MRONJ outcomes and their resolution, it doesn't clearly specify the dental procedures that led to MRONJ development.",no,The study appears to only include patients with MRONJ who received wound care treatment. There is no mention of a control group of non-anti-resorptive medication users.,yes,"The study is explicitly described as a retrospective cohort study, which meets the criteria.",maybe,"The abstract mentions ""time of antiresorptive treatment"" as a variable but doesn't clearly document the temporal relationship between medication use and MRONJ development or the duration of medication use.",yes,"The study includes 106 patients with 117 MRONJ lesions, exceeding the minimum requirement of 100 subjects.","While the study focuses on MRONJ, which typically follows dental procedures, the abstract doesn't explicitly state which dental procedures were performed, creating uncertainty about meeting this criterion.",Include,"The study fails to meet critical screening criteria, particularly the specific requirement for Romosozumab intervention, and lacks a control group of non-anti-resorptive medication users. While the research includes an adequate sample size and follows a retrospective cohort design, significant uncertainties exist regarding population characteristics, dental procedure documentation, and temporal medication relationships. These limitations substantially reduce the study's alignment with the predefined screening requirements.",2.5
Teriparatide for the Treatment of Medication-Related Osteonecrosis of the Jaw,"K. Chopra, Namrita Malhan",10.1097/MJT.0000000000001182,https://doi.org/10.1097/MJT.0000000000001182,American Journal of Therapeutics,5,2020,maybe,"While the abstract mentions patients with MRONJ secondary to antiresorptive/antiangiogenic drugs, it doesn't explicitly state they have diagnosed osteoporosis or confirm age ≥18. It also doesn't specify cancer status.",maybe,maybe,"While MRONJ outcomes are documented, this is a treatment study rather than a study of MRONJ development following dental procedures.",no,No control group is mentioned in the abstract.,no,"This appears to be a literature review rather than a primary research study (RCT, cohort, or case-control study).",no,The abstract doesn't document the temporal relationship between medication use and MRONJ development or the duration of medication use.,no,"The study includes only 54 patients, which is below the required minimum of 100 subjects.","The abstract mentions implant placement as a triggering factor, but this is discussed retrospectively rather than as a planned intervention study.",Exclude,"The study fails to meet multiple critical screening criteria, including using the wrong medication (teriparatide instead of romosozumab), having an insufficient sample size of 54 patients, and being a literature review rather than a primary research study. Key methodological requirements such as a control group, clear population definition, and appropriate study design are not satisfied, rendering the paper unsuitable for inclusion in the systematic review.",0.1
Development of Medication-Related Osteonecrosis of the Jaw After Extraction of Teeth With Experimental Periapical Disease.,"D. Hadaya, A. Soundia, I. Gkouveris, S. Dry, T. Aghaloo, S. Tetradis",10.1016/j.joms.2018.08.010,https://doi.org/10.1016/j.joms.2018.08.010,Journal of oral and maxillofacial surgery,37,2019,no,"The study uses rats, not adult human patients with osteoporosis, and there is no mention of an osteoporosis diagnosis.",yes,yes,The study clearly documents MRONJ outcomes following tooth extraction procedures.,yes,The study includes vehicle-treated animals as a control group.,maybe,"While this is an experimental study with controls, it's an animal study rather than one of the specified human study designs.",yes,"The study clearly documents the temporal relationship between medication use and MRONJ development, with specific timing (1 week pretreatment, 4 weeks after extraction).",no,"The study is conducted on rats, not human subjects, so the subject size is not relevant.","The study includes tooth extraction, which is one of the specified invasive dental treatments.",Exclude,"This animal study using zoledronic acid fails to meet critical screening criteria, specifically the requirement for human subjects with osteoporosis and romosozumab medication. Despite documenting MRONJ outcomes and including a control group, the fundamental mismatch in study population and intervention type disqualifies the research from meeting the specified screening requirements.",0.1
MRONJ Treatment Strategies: A Systematic Review and Two Case Reports,"A. Inchingolo, G. Malcangi, Irene Ferrara, A. Patano, F. Viapiano, Anna Netti, Daniela Azzollini, A. Ciocia, E. de Ruvo, M. Campanelli, Pasquale Avantario, A. Mancini, F. Inchingolo, C. G. Isacco, Alberto Corriero, A. Inchingolo, G. Dipalma",10.3390/app13074370,https://doi.org/10.3390/app13074370,Applied Sciences,6,2023,maybe,"The abstract does not mention specific details about the population, such as whether they have osteoporosis, their age, or their cancer status. Therefore, the population type is unclear from the abstract.",no,no,"The abstract focuses on treatment options for MRONJ, rather than documenting outcomes following dental procedures. Therefore, the study does not meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"The abstract does not mention any control groups, and the paper appears to be a review of treatment options rather than a comparative study. Therefore, the study does not meet the criterion of including a control group of non-anti-resorptive medication users.",no,"The paper is a systematic review, not a primary research study. While it includes RCTs and retrospective studies, it is not itself one of those study designs. Therefore, the study design does not meet the criterion of being a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The abstract does not mention any temporal relationships or duration of medication use. Therefore, the study does not meet the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",maybe,"The abstract mentions ""at least five cases"" as inclusion criteria, but this is for the review's inclusion criteria, not the actual study size. Therefore, the subject size is unclear from the abstract.","The abstract discusses surgical procedures and treatments, but this is about treating MRONJ, not about dental procedures causing MRONJ. Therefore, the intervention does not meet the criterion of invasive dental treatment.",Exclude,"This systematic review on MRONJ treatment fails to meet multiple critical screening criteria, including specific medication type, subject size, dental intervention focus, and study design. The abstract describes a review of treatment options rather than a primary research study examining dental procedures and medication-related outcomes, rendering it unsuitable for the intended systematic review.",0.1
"Association between periodontal disease, tooth extraction and medication-related osteonecrosis of the jaw in women receiving bisphosphonates: A national cohort-based study.","Min-Jeong Kwoen, Jung-Hyun Park, Keun-Suh Kim, Jae-Ryun Lee, Jin-Woo Kim, Hong-Pyo Lee, Hyo-Jung Lee",10.1002/JPER.21-0611,https://doi.org/10.1002/JPER.21-0611,The Journal of Periodontology,13,2022,maybe,"The study focuses on women >50 years with osteoporosis (implied by bisphosphonate use), but doesn't explicitly state they don't have cancer.",yes,yes,The study clearly documents MRONJ outcomes following specific dental procedures (extractions and periodontal disease/surgery).,no,"The abstract doesn't explicitly mention a control group of non-anti-resorptive medication users. The comparison is between periodontal disease and non-periodontal disease groups, both within bisphosphonate users.",yes,"The study is a retrospective cohort study using national health insurance data, which meets the criteria for study design.",maybe,"The study mentions patients took bisphosphonates for ""at least one year,"" but the temporal relationship between medication use and MRONJ development isn't clearly detailed in the abstract.",yes,"The study includes 27,168 patients, well above the 100-person minimum.","The study specifically examines tooth extraction and periodontal disease/surgery, which meets the criteria for invasive dental treatment.",Exclude,"The study focuses on bisphosphonates rather than Romosozumab, which immediately disqualifies it from meeting the primary screening criteria. While the research demonstrates a robust sample size and examines relevant dental interventions, the fundamental mismatch in medication type prevents its inclusion. Multiple other criteria are partially or fully met, but the core intervention requirement is not satisfied.",1.4
A systematic review of metastatic cancer presenting in osteonecrosis of the jaws (MC-ONJ) in patients undergoing antiresorptive and/or antiangiogenic therapy for skeletal-related adverse events.,"R. Sacco, Julian Woolley, J. Yates, M. Calasans-Maia, O. Akintola, V. Patel",10.1016/j.oooo.2021.01.001,https://doi.org/10.1016/j.oooo.2021.01.001,"Oral surgery, oral medicine, oral pathology and oral radiology",8,2021,no,"The study includes patients with cancer, specifically focusing on metastatic cancer. Therefore, the population type does not meet the criterion of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",maybe,maybe,"While MRONJ is discussed, the specific dental procedures are not documented. Therefore, the study partially meets the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",maybe,"There is no mention of a control group in the abstract, so it is unclear if this criterion is met.",no,"This is a systematic review, not a primary study, and therefore does not meet the criterion of having a study design of a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"There is no clear documentation of the temporal relationship between medication use and MRONJ development, or the duration of medication use. Therefore, the study fails to meet the criterion of clearly documenting both the temporal relationship and the duration of medication use.",yes,"The abstract mentions 604 patients across 4 studies, which meets the criterion of having a subject size of more than 100 people.","While osteonecrosis of the jaw (ONJ) is discussed, the specific dental procedures are not detailed. Therefore, it is unclear if the intervention meets the criterion of including invasive dental treatment, such as tooth extraction, implant placement, periodontal surgery, other dental surgery, or removable prosthesis fabrication.",Exclude,"The systematic review fails to meet multiple critical screening criteria, including specific medication focus, population type, and study design. Key disqualifying factors include the broad scope of antiresorptive drugs, inclusion of cancer patients, and the review's nature as a secondary research study rather than a primary clinical investigation. Consequently, the paper does not align with the predefined screening requirements for the systematic review.",0.1
Management and maintenance of oral health: Personalized primary prevention strategies and protocols in patients at risk of developing medication-related osteonecrosis of the jaw,"Giovanna Mosaico, C. Casu",10.36922/itps.1419,https://doi.org/10.36922/itps.1419,INNOSC Theranostics and Pharmacological Sciences,1,2024,maybe,"The abstract discusses both osteoporosis and bone cancer patients, and does not specify age restrictions, so it is unclear if the study focuses exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",yes,no,"While MRONJ outcomes are discussed, this is a review of preventive strategies rather than documentation of specific outcomes following dental procedures, so it does not meet this criterion.",maybe,"The abstract does not mention any control groups, so it is unclear if the study includes a control group of non-anti-resorptive medication users.",no,"This appears to be a review article rather than a primary research study, so it does not meet the criterion for a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"While medication use is discussed, there is no specific documentation of temporal relationships or duration of use, so it does not meet this criterion.",maybe,"The abstract does not mention any specific study size, so it is unclear if the study has a subject size of more than 100 people.","The abstract mentions dental procedures including ""maxillary or mandibular bone surgery"" and ""tooth extraction"", which meet the criterion for invasive dental treatment.",Exclude,"The abstract fails to meet multiple critical screening criteria, including the specific intervention of Romosozumab, study design requirements, and population restrictions. As a review article discussing general MRONJ prevention across different patient populations, it does not align with the targeted research parameters. The document lacks the precise methodological and population-specific elements necessary for inclusion in the study.",0.1
Zoledronic acid increases the prevalence of medication-related osteonecrosis of the jaw in a dose dependent manner in rice rats (Oryzomys palustris) with localized periodontitis,"J. G. Messer, J. L. M. Calle, J. Jiron, E. J. Castillo, C. Poznak, N. Bhattacharyya, Donald B. Kimmel, J. Aguirre",10.1016/j.bone.2017.12.025,https://doi.org/10.1016/j.bone.2017.12.025,Bone,32,2017,no,"The study uses rice rats (Oryzomys palustris), not human patients with osteoporosis. While the rats have natural susceptibility to periodontitis, this doesn't meet the criterion for adult human patients with diagnosed osteoporosis.",no,maybe,"While the study documents MRONJ outcomes, these are not in relation to specific dental procedures as required by the criteria.",yes,The study includes a control group (0μg/kg ZOL rats).,yes,"This is a controlled experimental study with randomized groups, which would qualify as an acceptable study design.",yes,"The study clearly documents both the temporal relationship between medication use and MRONJ development and the duration of medication use (12, 18, 24, and 30 weeks).",yes,"The study includes 230 rats, which exceeds the minimum requirement of 100 subjects.",The study does not involve any dental treatments. It focuses on natural food impaction-induced periodontitis in rats.,Exclude,"The study fundamentally fails key screening criteria by using zoledronic acid instead of romosozumab, conducting an animal experiment with rats rather than human patients, and lacking any invasive dental interventions. Critical misalignments include the wrong medication, non-human subjects, and absence of dental procedures, rendering the research ineligible for the systematic review. Multiple core screening requirements were not met, necessitating exclusion from further consideration.",0.1
Minimizing MRONJ after Tooth Extraction in Cancer Patients Receiving Bone-Modifying Agents,"G. Avishai, Danielle Muchnik, Daya Masri, A. Zlotogorski-Hurvitz, L. Chaushu",10.3390/jcm11071807,https://doi.org/10.3390/jcm11071807,Journal of Clinical Medicine,12,2022,no,"The abstract specifically mentions patients using BMAs ""for oncology indications,"" which violates the criterion requiring patients without cancer.",yes,yes,The study clearly documents MRONJ outcomes following specific dental procedures (extractions).,maybe,The abstract doesn't explicitly mention a control group of non-BMA users.,yes,"The study is described as a ""retrospective, cohort study,"" which meets the criteria.",yes,"The study documents the temporal relationship between BMA treatment and MRONJ development, including timing of treatment relative to extraction.",yes,"The study includes 93 patients with 103 extractions, meeting the minimum requirement of 100 subjects.","The study focuses on tooth extraction, which is explicitly listed as an acceptable intervention.",Exclude,"The study fails critical screening criteria by using bone modifying agents for oncology patients instead of Romosozumab for osteoporosis, and by including cancer patients which violates the population type requirement. Despite meeting several other methodological criteria, these fundamental deviations from the specified screening criteria necessitate exclusion from the systematic review.",0.1
Denosumab-related osteonecrosis of the jaw: a report of 2 cases and review of the literature.,"H. Chehal, N. Nikitakis, Mohammed N. Islam, J. Goodchild, L. Mordini, I. Bhattacharyya",-,-,General dentistry,0,2019,no,"The abstract doesn't specify the age range of the patients, and it doesn't explicitly state if the patients have diagnosed osteoporosis. It mentions both osteoporosis and bone metastases as indications, so there is insufficient information to confirm this criterion.",no,no,"MRONJ outcomes are mentioned, but specific dental procedures are not documented, so there is insufficient information to confirm this criterion.",no,There is no mention of a control group in the abstract.,no,"This appears to be a case report of 2 patients, which does not meet the required study design criteria.",no,"There is no clear documentation of the temporal relationship between medication use and MRONJ development, or the duration of medication use.",no,"The abstract only mentions 2 cases, which fails to meet the minimum requirement of 100 subjects.","While MRONJ is discussed, the abstract doesn't explicitly state which dental procedures were performed, so there is insufficient information to confirm this criterion.",Exclude,"The abstract describes a case report involving denosumab and MRONJ, which fundamentally fails multiple screening criteria including medication type, sample size, and study design. Specifically, the study uses denosumab instead of romosozumab, includes only two cases instead of the required 100+ subjects, and lacks a control group, rendering it ineligible for systematic review inclusion.",0.1
Medication-related osteonecrosis of the jaw-A case report and literature review,"Chen Chieh, D. Liao",10.17352/2455-5479.000196,https://doi.org/10.17352/2455-5479.000196,Archives of Community Medicine and Public Health,0,2023,no,"The abstract mentions both osteoporosis patients and cancer patients, and does not specify focusing exclusively on adult osteoporosis patients without cancer.",no,no,"While MRONJ is discussed as an outcome, the abstract does not indicate specific documentation of outcomes following particular dental procedures.",no,The abstract does not mention any control groups or comparative analysis.,no,"The abstract appears to be a review article rather than a primary research study with a specific design (RCT, cohort, or case-control).",no,"The abstract mentions ""long-term use"" of antiresorptive drugs but does not provide specific temporal relationships or duration documentation.",no,The abstract does not mention any specific study size or patient numbers.,"While the abstract discusses MRONJ in relation to dental procedures, it does not describe specific interventions or procedures being studied.",Exclude,"The abstract fails to meet multiple screening criteria, including specific focus on Romosozumab, defined subject size, detailed intervention documentation, and clear study design parameters. While discussing medication-related osteonecrosis of the jaw, the text appears to be a general review rather than a targeted research study with the required methodological specifications. Consequently, the document does not align with the comprehensive screening requirements for a focused clinical investigation.",1.4
Retrospective analysis of bacterial colonization of necrotic bone and antibiotic resistance in 98 patients with medication-related osteonecrosis of the jaw (MRONJ),"F. Ewald, Falk Wuesthoff, R. Koehnke, R. Friedrich, M. Gosau, R. Smeets, H. Rohde, Alexandre T. Assaf",10.1007/s00784-020-03595-9,https://doi.org/10.1007/s00784-020-03595-9,Clinical Oral Investigations,21,2020,maybe,"The abstract does not specify patient age or osteoporosis status, and there is no mention of cancer exclusion, so it is uncertain whether the study meets the population type criteria.",maybe,no,"While MRONJ is the focus, the abstract doesn't specify the dental procedures leading to MRONJ, and the focus is on microbial flora rather than procedure outcomes, so it fails this criterion.",no,"There is no mention of a control group, and the study appears to focus only on MRONJ patients, so it fails this criterion.",yes,"The study is clearly stated as a ""retrospective, single-center analysis"", which meets the criterion for a retrospective cohort study.",no,"There is no mention of the temporal relationship between medication use and MRONJ, and no documentation of medication duration, so it fails this criterion.",no,"The study includes 98 patients, which is below the required 100 subjects.","The abstract does not specify the dental procedures that led to MRONJ, so it is uncertain whether the study meets the specific intervention criteria.",Exclude,"The study fails to meet multiple critical screening criteria, including specific medication intervention, subject size, and control group requirements. While a retrospective analysis of MRONJ, the research does not align with the systematic review's focused parameters around Romosozumab and dental procedures. The microbiological focus diverges significantly from the targeted research questions.",1.4
Real-world study of medication-related osteonecrosis of the jaw from 2010 to 2023 based on Food and Drug Administration’s adverse event reporting system,"Yuhao Zhong, Wei Dai, Lin Yin, Guomin Wu, Xiaoying Wang",10.1093/jbmrpl/ziaf003,https://doi.org/10.1093/jbmrpl/ziaf003,JBMR Plus,0,2025,no,"The study includes both cancer and osteoporosis patients, and is not exclusively focused on osteoporosis patients without cancer.",maybe,maybe,"While MRONJ outcomes are documented, the specific dental procedures leading to these outcomes are not detailed in the abstract.",no,The study appears to be a pharmacovigilance analysis of adverse event reports and does not mention a control group of non-anti-resorptive medication users.,yes,"The study is described as a ""retrospective pharmacovigilance analysis"" using FAERS database, which could be considered a retrospective cohort study, though it's not a traditional clinical study design.",no,The abstract does not clearly document the temporal relationship between medication use and MRONJ development or the duration of medication use.,yes,"The study includes 22,846 MRONJ cases, which far exceeds the minimum requirement of 100 subjects.","The abstract does not specify the types of dental procedures that led to MRONJ. While dental procedures are implied as they are discussing MRONJ, the specific interventions are not documented.",Include,"The study fails to meet several critical screening criteria, including specific focus on Romosozumab, exclusive patient population, and detailed documentation of dental procedures and medication use. While the research includes a large sample size and explores medication-related osteonecrosis of the jaw, it lacks the precise methodological requirements for inclusion, particularly regarding intervention specifics and patient selection.",2.5
Contribution of Antiangiogenic Agents to the Risk of Medication-related Osteonecrosis of the Jaw in Combination with Antiresorptive Agents: Preliminary Results in a Comparative Prospective Report of 59 Oncologic Cases,"A. Yanni, C. Bouland, Raquel Monteiro, Alexandra Rodríguez, I. Loeb, R. Javadian, D. Dequanter",10.4103/jispcd.JISPCD_110_22,https://doi.org/10.4103/jispcd.JISPCD_110_22,Journal of International Society of Preventive and Community Dentistry,1,2022,no,"The study focuses on ""oncologic patients"", which explicitly fails the criterion as it specifically excludes cancer patients.",maybe,maybe,"The study reports MRONJ outcomes and mentions dental procedures, but doesn't clearly document specific procedures.",no,"The study compares AR alone vs AR+AA groups, but does not include a control group of non-anti-resorptive medication users.",yes,"The study is described as a ""prospective study"", which meets the criterion for acceptable study designs.",yes,"The study documents temporal relationships between medication use and MRONJ, and reports mean treatment duration before MRONJ diagnosis.",no,"The study includes 59 patients (47 in group 1, 12 in group 2), which is below the required minimum of 100 subjects.","The abstract mentions ""dental history (surgery, prosthesis)"", but it's not clear if all patients received invasive dental treatment.",Exclude,"The study fails critical screening criteria by focusing on oncologic patients using anti-resorptive agents other than Romosozumab, with a sample size below 100 participants. Multiple fundamental requirements are not met, including population type, medication specificity, and control group composition, rendering the study ineligible for systematic review inclusion.",0.1
Are medication-induced salivary changes the culprit of osteonecrosis of the jaw? A systematic review,"I. Suryani, Iraj Ahmadzai, M. T. That, S. Shujaat, R. Jacobs",10.3389/fmed.2023.1164051,https://doi.org/10.3389/fmed.2023.1164051,Frontiers in Medicine,1,2023,maybe,"The mean age is 66 years, indicating an adult population, but the abstract mentions chemotherapy and doesn't explicitly exclude cancer patients, so the population type criterion is only partially met or unclear.",maybe,maybe,"While MRONJ outcomes are discussed, specific dental procedures are not detailed, so the outcome documentation criterion is only partially met or unclear.",no,"There is no mention of control groups in the abstract, so the control group criterion is not met.",no,"This is a systematic review, not a primary study of the required design types (randomized controlled trial, prospective/retrospective cohort study, or case-control study), so the study design criterion is not met.",no,"There is no clear documentation of temporal relationships or medication duration, so the temporal documentation criterion is not met.",yes,"The review includes 272 MRONJ cases, which exceeds the 100-person requirement for the subject size criterion.","While MRONJ is discussed, the abstract doesn't explicitly specify the dental procedures involved, so there is insufficient information to determine if the intervention criterion of invasive dental treatment is met.",Exclude,"The systematic review fails to meet multiple critical screening criteria, including the specific intervention of Romosozumab, lack of a control group, and absence of a primary study design. While the study includes a substantial sample size and focuses on adult patients, it does not provide clear documentation of dental procedures, temporal relationships, or specific intervention details required by the screening protocol.",1.4
Can Surgical Management Improve Resolution of Medication-Related Osteonecrosis of the Jaw at Early Stages? A Prospective Cohort Study.,"A. Giudice, S. Barone, Federica Diodati, A. Antonelli, Riccardo Nocini, M. Cristofaro",10.1016/j.joms.2020.05.037,https://doi.org/10.1016/j.joms.2020.05.037,Journal of oral and maxillofacial surgery,45,2020,maybe,"The study includes adult patients (mean age 71.2 years) with osteoporosis, but also includes oncologic patients, which violates the criterion of focusing exclusively on non-cancer patients.",maybe,yes,The study clearly documents MRONJ outcomes and tracks specific outcomes like mucosal integrity and lesion downstaging.,no,No control group is mentioned in the abstract.,yes,"The study is described as a ""prospective, single-center cohort study,"" which meets the criteria for study design.",maybe,"While the study documents temporal aspects of treatment outcomes, it doesn't clearly document the duration of medication use before MRONJ development.",yes,"The study includes 129 patients, which exceeds the minimum requirement of 100 subjects.","While the study focuses on MRONJ treatment, it doesn't explicitly state whether the patients underwent invasive dental procedures. The abstract mentions ""trigger factors"" but doesn't specify them.",Include,"The study fails to meet critical screening criteria, particularly the specific requirement for Romosozumab intervention and the exclusion of oncologic patients. While demonstrating strengths in sample size and study design, the abstract lacks clarity on dental interventions and does not include a control group, rendering it unsuitable for the intended research parameters.",2.7
Medication-related osteonecrosis of the jaw (MRONJ): An update on the Memorial Sloan Kettering Cancer Center (MSKCC) experience and the role of Pre-medication Dental Evaluation in the prevention of MRONJ,"A. Owosho, S. T. Liang, Adi Z. Sax, Kant Wu, S. Yom, J. Huryn, C. Estilo",-,-,-,3,2020,no,"The abstract mentions Memorial Sloan Kettering Cancer Center, suggesting this may involve cancer patients, which would violate the criterion of non-cancer patients.",no,no,"While this appears to be related to dental procedures, specific MRONJ outcomes are not mentioned in the abstract.",no,No information about control groups is provided in the abstract.,no,The study design is not explicitly stated in the abstract.,no,No information about temporal relationships or medication duration is provided in the abstract.,no,The abstract does not provide any information about the sample size of the study.,"While the abstract is from a dental journal, the specific dental interventions are not mentioned.",Exclude,"The abstract lacks critical information about Romosozumab, dental interventions, and patient population, with significant methodological details missing. The affiliation with a cancer center suggests potential exclusion from the study criteria, and the incomplete nature of the text prevents comprehensive assessment against the screening requirements. Multiple key screening elements remain unaddressed, rendering a definitive evaluation impossible.",1.4
Medication-Related Osteonecrosis of the Jaws (MRONJ): Etiological Update,"G. Tenore, G. Palaia, G. Gaimari, O. Brugnoletti, L. Bove, R. L. Giudice, M. Mohsen, U. Romeo",10.14616/SANDS-2014-147152,https://doi.org/10.14616/SANDS-2014-147152,-,11,2014,no,"The abstract mentions both osteoporosis and cancer patients, so the study does not focus exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",no,no,"While MRONJ is discussed, there is no documentation of specific dental procedures or outcomes, so the study does not meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"The abstract does not mention any control groups, so the study does not meet the criterion of including a control group of non-anti-resorptive medication users.",no,"This appears to be a review article rather than a primary research study, and no specific study design is mentioned, so the study does not meet the criterion of having a study design of a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"The abstract mentions some temporal aspects of medication use and ONJ development, but not in a systematic way, so the study partially meets the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",no,"The abstract does not mention any specific study size, so it is unclear whether the study meets the criterion of having a subject size of more than 100 people.","While the abstract discusses ONJ/MRONJ, it does not describe specific dental procedures or interventions, so the study does not meet the criterion of having an intervention of invasive dental treatment.",Exclude,"The abstract fails to meet multiple screening criteria, including specific focus on Romosozumab, invasive dental interventions, and a defined study population. It appears to be a general review of medication-related osteonecrosis rather than a targeted research study, lacking the precise methodological and population parameters required by the screening criteria. Consequently, the document does not qualify for inclusion based on the established screening requirements.",0.1
A Comparison of the Clinical and Radiological Extent of Denosumab (Xgeva®) Related Osteonecrosis of the Jaw: A Retrospective Study,"Zineb Assili, G. Dolivet, J. Salleron, Claire Griffaton-Tallandier, Claire Egloff-Juras, B. Phulpin",10.3390/jcm10112390,https://doi.org/10.3390/jcm10112390,Journal of Clinical Medicine,8,2021,no,"The study was conducted at a cancer institute (Institut de Cancérologie de Lorraine) and appears to focus on cancer patients, which explicitly violates the criterion requiring non-cancer patients.",maybe,maybe,"While the study documents MRONJ outcomes and uses CBCT for assessment, it doesn't clearly specify the dental procedures that led to MRONJ.",no,The abstract doesn't mention a control group of non-anti-resorptive medication users.,yes,"The study is described as a retrospective study, which meets the acceptable study design criteria.",yes,"The study documents temporal relationships with clear cumulative incidence rates at 6, 12, and 24 months.",yes,"The study includes 246 patients, which exceeds the minimum requirement of 100 subjects.","While the study discusses MRONJ, which typically follows dental procedures, the abstract doesn't explicitly state which dental procedures were performed, creating a significant uncertainty.",Exclude,"The study focuses on denosumab in cancer patients, which fundamentally conflicts with the specified screening criteria requiring romosozumab and non-cancer populations. Critical exclusion factors include the wrong medication, cancer patient population, and absence of a control group, rendering the study ineligible for the systematic review. Multiple screening criteria were not met, leading to a clear disqualification.",0.1
"Multicenter, retrospective population-based study on the incidence of medication-related osteonecrosis of the jaw in patients with breast cancer with bone metastases.","C. Brunner, C. Marth, D. Egle, M. Ritter, Florentina Baumgart, Miriam Emmelheinz, Benjamin Walch, C. Iannetti, A. Zabernigg, Maria Castellan, Oliver Tibor Andraschofsky, Alice Markl, M. Hubalek, Michael Schnallinger, E. Woell, S. Puntscher, M. Arvandi, U. Siebert, E. Bruckmoser, J. Laimer",10.1200/jco.2023.41.16_suppl.6588,https://doi.org/10.1200/jco.2023.41.16_suppl.6588,Journal of Clinical Oncology,0,2023,no,"The study focuses exclusively on breast cancer patients with bone metastases, not patients with primary osteoporosis, which is another critical mismatch.",maybe,maybe,"While MRONJ outcomes are documented, the specific dental procedures leading to these outcomes are not detailed in the abstract, creating a partial documentation.",maybe,"The abstract doesn't mention a control group of non-anti-resorptive medication users, and the comparison is between different types of antiresorptive therapy, creating an unclear control group structure.",yes,"This is a retrospective multicenter study, which fits within the acceptable study designs.",yes,"The study documents temporal relationships, noting that patients treated with denosumab developed MRONJ in median 60 months earlier than with bisphosphonates.",yes,"The study includes 8,860 breast cancer patients, with 639 receiving antiresorptive therapy, well exceeding the 100-person minimum.","While MRONJ is discussed, the abstract doesn't explicitly state which dental procedures were involved, creating a significant uncertainty.",Exclude,"The study focuses on breast cancer patients receiving bisphosphonates and denosumab, which critically deviates from the required Romosozumab and osteoporosis patient population. Multiple screening criteria are not met, including medication type, patient population, and unclear documentation of dental procedures. These fundamental misalignments render the study unsuitable for inclusion in the systematic review.",1.4
Clinical and panoramic radiographic features of osteomyelitis of the jaw: A comparison between antiresorptive medication-related and medication-unrelated conditions,"J. Shin, Jo-Eun Kim, K. Huh, W. Yi, M. Heo, Sam-Sun Lee, Soon-Chul Choi",10.5624/isd.2019.49.4.287,https://doi.org/10.5624/isd.2019.49.4.287,Imaging Science in Dentistry,14,2019,maybe,"The study includes an adult population with an average age of 66.8±14.9 years, but there is no mention of cancer status, so the study partially meets or is unclear on this criterion.",maybe,no,"The study documents osteomyelitis outcomes, but does not specifically focus on MRONJ, so it fails this criterion.",yes,"The study compares medication-related osteomyelitis (m-OM) vs. conventional osteomyelitis (c-OM), which meets the control group criterion.",yes,"The study is a retrospective review of records, which meets the study design criterion.",no,"The study does not clearly document the temporal relationship between medication use and outcomes, and there is no mention of medication duration, so it fails this criterion.",yes,"The study includes 364 patients (241 female, 123 male), which meets the subject size criterion.","The study mentions extraction sockets and odontogenic origin, but it is unclear if these were interventions or just findings, so the study partially meets or is unclear on this criterion.",Include,"The study involves a large patient population examining osteomyelitis, but fails to meet several critical screening criteria including specific focus on Romosozumab, MRONJ outcomes, and clear temporal documentation of medication use. While the research includes a control group and retrospective design, significant deviations from the required intervention and outcome specifications render the study non-compliant with the established screening requirements.",2.5
A population based study of multiple myeloma patients with medication-related osteonecrosis of the jaw.,"D. Auziņa, A. Slaidina, M. Sevastjanova, R. Erts, A. Lejnieks, S. Lejniece",-,-,Stomatologija,6,2019,no,"The study focuses on multiple myeloma patients, not osteoporosis patients, which is a clear failure of this critical criterion.",yes,yes,"The study clearly documents MRONJ outcomes following dental procedures and includes staging information, which meets this criterion.",no,There is no clear mention of a control group of non-anti-resorptive medication users.,yes,"The study design is a retrospective analysis, which meets this criterion.",yes,"The study documents the average time until MRONJ manifestation (2 years), which meets this criterion.",yes,"The study includes 126 multiple myeloma patients, with 88 receiving bisphosphonates, which meets the requirement of more than 100 subjects.","The study mentions dental extraction as a triggering factor, which meets the criterion of invasive dental treatment.",Exclude,"The study focuses on multiple myeloma patients using bisphosphonates, which fundamentally differs from the required osteoporosis patient population and Romosozumab intervention. Critical screening criteria were not met, specifically the medication type and patient population, rendering the study inappropriate for inclusion in the systematic review. Despite meeting some secondary criteria like sample size and study design, the primary disqualifying factors necessitate exclusion.",0.1
Radiographic bone loss and the risk of medication‐related osteonecrosis of the jaw (MRONJ) in multiple myeloma patients—A retrospective case control study,"Taggreed Wazzan, D. Kashtwari, W. Almaden, Y. Gong, Yiqing Chen, J. Moreb, J. Katz",10.1111/scd.12318,https://doi.org/10.1111/scd.12318,"Special Care in Dentistry: managing special patients, settings, and situations",11,2018,no,"The study focuses on multiple myeloma (MM) patients, not patients with diagnosed osteoporosis. Additionally, these are cancer patients, which is explicitly excluded in the criteria.",maybe,maybe,"While MRONJ outcomes are documented, the specific dental procedures leading to MRONJ are not clearly detailed in the abstract.",maybe,"While there are two groups (100 MM patients vs 16 MRONJ patients), it's not clear if there's a control group of non-anti-resorptive medication users.",yes,"This appears to be a retrospective cohort study analyzing dental charts, which meets the requirement for study design.",maybe,"The study mentions ""duration of bisphosphonate treatments"" but doesn't clearly document the temporal relationship between medication use and MRONJ development.",yes,"The study includes 116 total patients (100 MM patients + 16 MRONJ patients), which meets the requirement of more than 100 people.","While the study examines dental charts and mentions periodontal status, it doesn't explicitly state that the patients underwent invasive dental procedures.",Exclude,"The study focuses on multiple myeloma patients using bisphosphonates, which fundamentally differs from the required criteria of osteoporosis patients using Romosozumab. Critical screening requirements are not met, including medication type, patient population, and cancer status, rendering the study ineligible for inclusion in the systematic review.",0.1
Risk Factors of Medication-Related Osteonecrosis of the Jaw: A Clinical Investigation.,"Yuko Komatsu, T. Kawai, T. Hirano, Isao Hoshi, Genki Yamaya, Atsushi Ogawa, Toshimi Chiba, Hiroyuki Yamada",10.1016/j.jormas.2024.101791,https://doi.org/10.1016/j.jormas.2024.101791,Journal of Stomatology Oral and Maxillofacial Surgery,0,2024,maybe,"The study includes both osteoporosis and cancer patients, and does not specify age restrictions, which means it does not focus exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",yes,yes,"The study clearly documents MRONJ outcomes following dental procedures, which meets the requirement of reporting MRONJ outcomes following specific, documented dental procedures.",no,"There is no clear mention of a control group of non-anti-resorptive medication users, which means the study fails to meet this criterion.",yes,"The study appears to be a retrospective cohort study, which meets the requirement of having a study design that is either a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"While the study documents temporal changes over 10 years, it does not clearly specify the duration of medication use, which means it only partially meets or is unclear on this criterion.",yes,"The study includes 57 + 64 = 121 MRONJ patients and 166 at-risk patients, which meets the requirement of having a subject size of more than 100 people.","The study includes tooth extraction and mentions dental procedures, which meets the requirement of having an intervention of invasive dental treatment.",Exclude,"The study fails to meet critical screening criteria, particularly the requirement for Romosozumab as the primary intervention, instead focusing on bisphosphonates and denosumab. While the research includes a sufficient sample size and documents dental procedures, it lacks a clear control group and includes patients with cancer, which deviates from the specified population parameters. The absence of the specific medication of interest renders the study unsuitable for the intended screening process.",1.4
SYSTEMATIC REVIEW OF CONE BEAM COMPUTED TOMOGRAPHY USE IN DIAGNOSIS OF MEDICATION-RELATED OSTEONECROSIS OF THE JAW,"G. B. Badabaan, S. Singer, A. Creanga, M. Strickland",10.1016/j.oooo.2020.03.032,https://doi.org/10.1016/j.oooo.2020.03.032,"Oral surgery, oral medicine, oral pathology and oral radiology",2,2020,no,"The study includes both oncologic (52.4%) and osteoporosis (23.8%) cases, and is not exclusively focused on adult patients with diagnosed osteoporosis who do not have cancer. Therefore, it does not meet this criterion.",yes,yes,"The study does document MRONJ outcomes following dental procedures, specifically mentioning extractions, and therefore meets this criterion.",no,"The study does not mention a control group of non-anti-resorptive medication users, and therefore does not meet this criterion.",no,"The study is a review article analyzing other studies, and is not a primary research study (RCT, cohort, or case-control). Therefore, it does not meet this criterion.",no,"The study does not clearly document the temporal relationship between medication use and MRONJ development, or the duration of medication use, and therefore does not meet this criterion.",yes,"The study includes 168 cases total, which meets the criterion of having a subject size of more than 100 people.","The study mentions tooth extraction as a precipitating event in 75% of cases, which meets the criterion of including invasive dental treatment.",Exclude,"The study fails key screening criteria by being a review article rather than primary research, lacking specificity to Romosozumab, and including cancer patients alongside osteoporosis cases. While documenting dental procedures and MRONJ outcomes, the research does not meet critical requirements such as having a control group, focusing exclusively on osteoporosis patients, or providing clear temporal documentation of medication use. Multiple fundamental mismatches with the screening criteria render the study non-compliant.",1.4
Medication-Related Osteonecrosis of the Jaws: Review,"T. Morikawa, T. Shibahara",10.31488/jjm.1000131,https://doi.org/10.31488/jjm.1000131,Japanese Journal of Medicine,0,2019,maybe,"The abstract does not provide any specific information about the age groups or osteoporosis diagnosis of the study population, nor does it mention the exclusion of cancer patients, so it is uncertain whether the study meets this criterion.",maybe,maybe,"The abstract mentions MRONJ outcomes generally, but does not specify the documentation of specific dental procedures, so it partially meets this criterion.",maybe,"The abstract does not mention the inclusion of a control group, so it is uncertain whether the study meets this criterion.",no,"The abstract suggests this is a review article rather than a primary research study, and it does not specify the study design, so it likely fails to meet this criterion.",no,"The abstract does not mention the temporal relationship between medication use and MRONJ development or the duration of medication use, so it fails to meet this criterion.",maybe,"The abstract does not mention the sample size, so it is uncertain whether the study meets this criterion.","The abstract mentions dental issues and treatment, but does not specify the types of dental procedures, so it partially meets this criterion.",Exclude,"The abstract fails to meet multiple critical screening criteria, including specific intervention details, subject size, and study design requirements. While discussing medication-related osteonecrosis of the jaw, the text lacks precise information about Romosozumab, patient population, control groups, and temporal documentation. The document appears to be a general review rather than a focused research study meeting the specified screening parameters.",1.4
IS TERIPARATIDE THERAPY EFFECTIVE FOR MEDICATION-RELATED OSTEONECROSIS OF THE JAW? A SYSTEMATIC REVIEW AND META-ANALYSIS,"L. Ferreira, Lucas Guimarães Abreu, C. Calderipe, M. D. Martins, L. Schuch, A. Vasconcelos",10.1016/j.oooo.2022.01.731,https://doi.org/10.1016/j.oooo.2022.01.731,"Oral surgery, oral medicine, oral pathology and oral radiology",1,2022,maybe,"The study includes adult patients (mean age 76.54 years) with osteoporosis (76.5% of cases), but it's unclear if there are any cancer patients included.",no,maybe,"While MRONJ outcomes are documented, the specific dental procedures leading to MRONJ are not clearly detailed in the abstract.",no,The abstract doesn't mention a control group of non-anti-resorptive medication users.,no,This appears to be a systematic review/meta-analysis rather than a primary study design specified in the criteria.,maybe,"The abstract mentions a ""mean evolution time of 5 months"" but doesn't clearly document the temporal relationship between medication use and MRONJ development.",yes,"The study includes 143 cases, which exceeds the minimum requirement of 100 subjects.","While the study discusses MRONJ, which typically follows dental procedures, the abstract doesn't explicitly state which dental procedures were involved.",Exclude,"The study focuses on teriparatide therapy for medication-related osteonecrosis of the jaw, which fundamentally differs from the specified romosozumab intervention. Multiple screening criteria are not met, including the lack of a control group, unclear documentation of dental procedures, and a study design that appears to be a systematic review rather than a primary research study. The critical mismatch in intervention medication renders the paper unsuitable for inclusion.",1.4
Medication-Related Osteonecrosis of the Jaw.,"Keiichi Ohta, H. Yoshimura",10.1016/j.amjms.2020.04.009,https://doi.org/10.1016/j.amjms.2020.04.009,American Journal of the Medical Sciences,4,2020,no,"The patient is an adult (79 years), but they have prostate cancer, which is explicitly excluded from the population type.",yes,yes,"The study clearly documents MRONJ following tooth extraction, which meets this criterion.",no,"No control group is mentioned in the study, which fails to meet this criterion.",no,"The study is a case report, which does not meet the required study designs of randomized controlled trial, prospective/retrospective cohort study, or case-control study.",yes,"The study documents the temporal relationship between medication use and MRONJ development, as well as the duration of medication use, which meets this criterion.",no,"The study is a single case report with only one subject, which fails to meet the minimum requirement of 100 subjects.","The study does mention tooth extraction, which meets the criterion for invasive dental treatment.",Exclude,"This single-patient case report fails multiple critical screening criteria, including the use of non-specified anti-resorptive medications, presence of cancer, and lack of a control group. The study does not meet the required sample size, study design, or population specifications for inclusion in the systematic review. Consequently, the paper would be excluded based on these fundamental screening requirements.",0.1
MRONJ in patients treated with bisphosphonates or other agents: a 5-year retrospective study,"F. Mazzoni, C. Arena, N. Testa, V. Zavaglia, A. Nori, A. Santarelli",10.3389/conf.fphys.2019.27.00029,https://doi.org/10.3389/conf.fphys.2019.27.00029,Frontiers in Physiology,0,2019,maybe,"The study includes both osteoporotic and oncologic patients, and doesn't explicitly state that all patients are ≥18 years. While the mean age is 66.7 years, the range (43-86) suggests adult patients, but the inclusion of oncologic patients violates the criterion.",maybe,yes,The study clearly documents MRONJ outcomes following dental procedures.,no,No control group of non-anti-resorptive medication users is mentioned in the abstract.,yes,"This is a retrospective study, which meets the acceptable study design criteria.",yes,The study documents both the temporal relationship and duration of medication use (mean administration times are reported for each group).,no,"The study includes only 53 patients, which is below the required minimum of 100 subjects.","While the study mentions dental procedures (extractions, periodontal surgery), it's not clear if these were the interventions being studied or just risk factors.",Exclude,"The study fails key screening criteria by using bisphosphonates and denosumab instead of Romosozumab, having only 53 patients instead of the required 100, and lacking a control group. While the research documents MRONJ outcomes and includes a retrospective study design, critical methodological limitations disqualify it from meeting the systematic review's inclusion requirements. The mixed patient population and absence of a control group further compromise the study's alignment with the specified screening criteria.",0.1
Risk of Osteonecrosis of the Jaw in Patients with Postmenopausal Osteoporosis: A Systematic Literature Review,"C. Glória, Villaverde Virginia, D. Petra, Guerra Mercedes, Naranjo Antonio",10.23937/2643-4091/1710010,https://doi.org/10.23937/2643-4091/1710010,Clinical Archives of Bone and Joint Diseases,0,2019,maybe,"The study includes osteoporosis patients, but doesn't specify age restrictions (≥18 years). It does exclude cancer patients.",maybe,maybe,"The study measures ""likelihood of having osteonecrosis of the jaw,"" but doesn't specify if it documents specific dental procedures.",maybe,The abstract doesn't mention whether control groups are included in the studies.,yes,"The abstract explicitly includes ""randomised clinical trials (RCT) and cohort studies.""",maybe,No information is provided about temporal relationships or duration of medication use.,maybe,"The abstract states ""no limitation with regard to the number of patients included,"" but doesn't specify if studies must have >100 subjects.","While the study looks at ""osteonecrosis of the jaw,"" it doesn't explicitly mention whether it includes specific dental procedures.",Exclude,"The systematic review protocol focuses on osteoporosis patients taking Denosumab, which critically differs from the specified Romosozumab intervention. Multiple screening criteria remain unclear or partially met, with the primary disqualifying factor being the incorrect medication type. The study design includes randomized clinical trials and cohort studies, but fails to meet the fundamental intervention requirement.",1.4
Prophylaxis of medication-related necrosis of the jaws in dental patients – study of 49 cases,"Joanna Jakiel, Dagmara Jenda, M. Rahnama",10.26444/jpccr/94396,https://doi.org/10.26444/jpccr/94396,Journal of Pre-Clinical and Clinical Research,2,2018,yes,"The age range is 54-77 years, which meets the adult requirement, and the study includes patients with osteoporosis. There is no mention of cancer patients.",maybe,maybe,"The study reports on MRONJ outcomes, but it's unclear if these are following specific documented dental procedures.",no,There is no mention of a control group.,maybe,"The study design is not clearly stated, and it appears to be an observational study, but the specific type is unclear.",maybe,"The study mentions an observation period of 1-2 years, but the temporal relationship between medication use and MRONJ is not clearly documented.",no,"The study includes 49 patients, which is below the required minimum of 100 subjects.","The abstract mentions ""tooth extraction and other oral surgical procedures"", but it's unclear if these were actually performed or just discussed as risk factors.",Exclude,"The study fails critical screening criteria by using bisphosphonates and denosumab instead of Romosozumab, and having a sample size of only 49 patients, which is below the required 100 subjects. Multiple other criteria were only partially met or unclear, including lack of a control group and uncertain study design, rendering the paper unsuitable for systematic review inclusion.",0.1
Medication-Related Osteonecrosis of the Jaws,S. Otto,10.1007/978-3-662-43733-9,https://doi.org/10.1007/978-3-662-43733-9,-,28,2015,no,"The abstract mentions that the study focuses on patients with ""malignant diseases"", which explicitly fails the criterion requiring the study to focus on adult patients with diagnosed osteoporosis who do not have cancer.",maybe,maybe,"The abstract mentions osteonecrosis of the jaws as an outcome, but does not provide any specific documentation of the dental procedures that were performed, so it cannot be fully determined if the study meets this criterion.",maybe,"No information is provided about the inclusion of a control group of non-anti-resorptive medication users, so it cannot be determined if the study meets this criterion.",maybe,"The study design is not mentioned in the abstract, so it cannot be determined if the study meets the criterion of being a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"The abstract does not provide any information about the temporal relationship between medication use and MRONJ development, or the duration of medication use, so it cannot be determined if the study meets this criterion.",maybe,"No information is provided about the sample size of the study, so it cannot be determined if the study meets the criterion of having more than 100 subjects.","The abstract does not mention any specific dental treatments or procedures, so it cannot be determined if the study meets the criterion of involving invasive dental treatment.",Exclude,"The abstract fails critical screening criteria by focusing on cancer patients and using intravenous antiresorptive medications instead of Romosozumab. Insufficient details are provided to assess most other screening requirements, rendering the study ineligible for inclusion in the systematic review.",0.1
Medication-related osteonecrosis of the jaw in cancer patients: Case series and review of the current literature,"Karen Maciel Reyes Castillo, Miguel Ángel Ocampo Benítez, Omar Peña Curiel",10.21142/2523-2754-1003-2022-123,https://doi.org/10.21142/2523-2754-1003-2022-123,Revista Científica Odontológica,1,2022,no,"The study focuses on cancer patients, which does not meet the requirement of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",yes,yes,"The study does document MRONJ outcomes following dental procedures, which meets this criterion.",no,The study does not mention a control group of non-anti-resorptive medication users.,no,"The study appears to be a case series of 4 patients, which does not match the required study designs of randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"While the study mentions BMA therapy, it does not clearly document the temporal relationship between medication use and MRONJ development or the duration of medication use.",no,"The study only describes 4 patients, which is less than the required subject size of more than 100 people.","The study mentions tooth extraction and tooth loss, which are considered invasive dental treatments and meet this criterion.",Exclude,"The study fails critical screening criteria by focusing on cancer patients using bone modifying agents instead of Romosozumab for osteoporosis, with a sample size of only four patients. Multiple fundamental requirements are not met, including population type, intervention specifics, and study design, rendering the paper unsuitable for the systematic review.",0.1
What is the Risk of Developing Medication-Related Osteonecrosis in Patients With Extraction Sockets Left to Heal by Secondary Intention? A Retrospective Case Series Study.,"R. Pippi, Umberto Giuliani, G. Tenore, A. Pietrantoni, U. Romeo",10.1016/j.joms.2021.05.031,https://doi.org/10.1016/j.joms.2021.05.031,Journal of oral and maxillofacial surgery,4,2021,maybe,"The study includes adult patients with osteoporosis (specifically postmenopausal osteoporosis), and there's no mention of cancer patients. However, it's not explicitly stated that all patients are ≥18 years.",yes,yes,The study clearly documents MRONJ outcomes following specific dental procedures (extractions).,no,The abstract describes this as a case series study without mention of a control group of non-anti-resorptive medication users.,maybe,"The study is described as a retrospective case series, which doesn't fully align with the preferred study designs (RCT, cohort, or case-control).",maybe,"While the study period (2007-2020) is mentioned, the abstract doesn't clearly document the temporal relationship between medication use and MRONJ development or the duration of medication use.",yes,"The study includes 221 patients, which exceeds the minimum requirement of 100 subjects.","The study specifically focuses on tooth and root extractions, which qualifies as invasive dental treatment.",Exclude,"The study focuses on bisphosphonate users undergoing tooth extractions, which fundamentally differs from the specified Romosozumab intervention. While the research meets several screening criteria like subject size and dental intervention type, critical misalignments exist, particularly the medication type and lack of a control group. These discrepancies significantly reduce the study's compatibility with the predefined screening requirements.",1.4
Risk factors of medication‐related osteonecrosis of the jaw in preventive tooth extraction before bone resorption inhibitor administration: A multicenter nested case–control study,"T. Saito, Atsushi Nishikawa, Yuko Hara‐Saito, Andrea Rei Estacio Salazar, A. Kurokawa, A. Iida, M. Yamaga, H. Kano, Y. Kato, Y. Takata, H. Nishiyama, N. Kitamura, Takahiro Tanaka, R. Takagi",10.1002/osi2.1122,https://doi.org/10.1002/osi2.1122,Oral Science International,1,2021,no,"The study specifically focuses on patients with malignant tumors, which is explicitly excluded in the criteria. The abstract doesn't mention osteoporosis patients.",yes,yes,The study clearly documents MRONJ outcomes following specific dental procedures (tooth extractions).,maybe,"While the study is a case-control design, it's not clear if the control group consists of non-anti-resorptive medication users. The control group appears to be teeth without MRONJ rather than non-medication users.",yes,"The study is described as a ""nested case-control study,"" which meets the acceptable study design criteria.",yes,"The study clearly documents the temporal relationship, with extractions occurring within 1 year before medication initiation and follow-up for 1-3 years.",yes,"The study includes 58 patients with 180 teeth, exceeding the minimum requirement of 100 subjects.","The study focuses on tooth extraction, which is explicitly mentioned as one of the required invasive dental treatments.",Exclude,"The study fails key screening criteria by using zoledronic acid/denosumab instead of Romosozumab and focusing on cancer patients rather than osteoporosis patients. Despite meeting several other criteria like subject size, study design, and outcome documentation, the fundamental mismatch in medication and patient population necessitates exclusion from the review.",0.1
UTILITY OF BIOMARKERS IN PREDICTING THE DEVELOPMENT OF MEDICATION-RELATED OSTEONECROSIS OF THE JAWS: A SCOPING REVIEW,"G. Matus, Antonio Mancilla, René Martinez, Maureen Marshall, Juan Pablo Aravena, María José Quijarro, Víctor Moraga",10.1016/j.ajoms.2023.09.001,https://doi.org/10.1016/j.ajoms.2023.09.001,Journal of Oral and Maxillofacial Surgery Medicine and Pathology,0,2023,no,"The abstract does not specify age groups or cancer status, only mentioning ""patients consuming drugs associated with osteonecrosis"", so it is unclear if the population type criterion is met.",maybe,no,"While MRONJ outcomes are discussed, this is a review of biomarkers rather than documentation of specific dental procedures, so it fails this criterion.",no,"No mention of control groups, and as a review paper, this criterion is not applicable.",no,"This is a scoping review, not a primary study design, so it fails this criterion.",no,"No specific temporal relationships or medication durations are documented, so it fails this criterion.",no,"This is a scoping review of other studies, not a primary study, so no specific subject size is mentioned.","The abstract mentions ""oral surgical procedures"" and ""surgery, oral"", which partially meets the criterion for invasive dental treatment, but as a review rather than a primary study.",Exclude,"This scoping review on medication-related osteonecrosis of the jaw fails to meet multiple critical screening criteria, including specific intervention with Romosozumab, subject size requirements, and primary study design. The paper focuses on biomarker identification rather than a targeted investigation of dental treatment outcomes in osteoporosis patients, rendering it unsuitable for the systematic review's specific parameters.",0.1
Investigation of the Effectiveness of Surgical Treatment on Maxillary Medication-Related Osteonecrosis of the Jaw: A Literature Review,"Kun-Jung Hsu, S. Hsiao, Ping-Ho Chen, Han-Sheng Chen, Chun-Ming Chen",10.3390/jcm10194480,https://doi.org/10.3390/jcm10194480,Journal of Clinical Medicine,3,2021,maybe,"The study focuses on elderly patients with an average age of 70.6 years, which partially meets the population type criterion of adult patients (≥18 years) with diagnosed osteoporosis. However, the cancer status of the patients is not mentioned.",maybe,maybe,"The study reports MRONJ outcomes and mentions the ""clinical efficacy of surgery"" (86%), which partially meets the outcome documentation criterion.",no,"The abstract does not mention the inclusion of a control group of non-anti-resorptive medication users, so this criterion is not met.",no,"The study design is a meta-analysis of case reports and case series, which does not meet the required study design types of randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"The study reports the average medication usage time (50.0 ± 20.1 months), which provides some temporal documentation, partially meeting this criterion.",maybe,"The meta-analysis includes 18 studies, but the individual study sizes are not specified, so it is uncertain whether the subject size criterion of more than 100 people is met.","The abstract mentions ""surgery"" but does not specify the types of invasive dental treatments, so it is unclear if the intervention meets the requirement of including tooth extraction, implant placement, periodontal surgery, other dental surgery, or removable prosthesis fabrication.",Exclude,"The study fails critical screening criteria, particularly the specific intervention of Romosozumab and the required study design of randomized controlled trials or cohort studies. Multiple key requirements were not met, including the lack of a control group and unclear specifics about dental interventions, rendering the paper unsuitable for the intended screening process.",1.4
Risk factors for the development of medication-related osteonecrosis of the jaw and effects of tooth extraction with local infection,"Norio Nakamura, M. Otsuru, Taro Miyoshi, Koki Suyama, K. Omori, Kota Morishita, S. Soutome, S. Rokutanda, Kei-ichiro Miura, Masahiro Umeda",10.1016/j.jds.2023.10.006,https://doi.org/10.1016/j.jds.2023.10.006,Journal of Dental Sciences,2,2023,maybe,"The abstract doesn't specify age range or whether patients have cancer. It only mentions ""patients receiving ARA therapy,"" so there is no reasoning provided about whether the population type meets the criterion.",yes,maybe,"The abstract mentions investigating ""dental findings associated with MRONJ development,"" suggesting MRONJ outcomes are documented, but specifics are unclear.",no,"No information is provided about control groups, so there is no reasoning provided about whether the study meets this criterion.",no,"The study design is not specified in the abstract, so there is no reasoning provided about whether the study meets this criterion.",no,"No information is provided about temporal relationships or duration of medication use, so there is no reasoning provided about whether the study meets this criterion.",no,"The abstract provides no information about sample size, so there is no reasoning provided about whether the study meets the subject size criterion.","The abstract mentions tooth extraction, which meets the criterion for invasive dental treatment.",Include,"The abstract lacks critical details about medication type, patient population, study design, and sample size, creating significant uncertainty about meeting the comprehensive screening criteria. While tooth extraction and MRONJ development are mentioned, the brevity and absence of specific information prevent confident determination of the study's alignment with the required parameters. Multiple key screening elements remain unaddressed, rendering a definitive assessment challenging.",2.5
Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies.,"Alexandre T. Assaf, R. Smeets, B. Riecke, E. Weise, A. Gröbe, M. Blessmann, T. Steiner, J. Wikner, R. Friedrich, M. Heiland, F. Hoelzle, F. Gerhards",-,-,Anticancer Research,51,2013,no,"The study exclusively focuses on patients with ""osseous metastatic malignancies"", which explicitly violates the criterion requiring non-cancer patients.",no,no,"While BRONJ outcomes are documented, they are not specifically tied to dental procedures. The focus is on cancer treatment and medication effects.",no,There is no mention of a control group of non-anti-resorptive medication users.,maybe,"The study appears to be a retrospective study analyzing medical history, which would technically qualify as a retrospective cohort study, but the design is not focused on the required intervention.",maybe,"The study does document temporal relationships (80 months average between diagnosis and BRONJ), but this is not in the context of dental procedures.",yes,"The study includes 169 patients, which exceeds the minimum requirement of 100 subjects.","While the study discusses BRONJ, it does not specifically document dental procedures. The focus is on cancer patients receiving bisphosphonates.",Exclude,"The study focuses on bisphosphonate-related osteonecrosis in cancer patients, which fundamentally differs from the required criteria of Romosozumab treatment in non-cancer osteoporosis patients. Critical screening requirements are not met, including medication type, patient population, and intervention specifics. Multiple core screening criteria are definitively failed, rendering the study unsuitable for inclusion.",0.1
Anti-resorptive therapy in the osteometabolic patient affected by periodontitis. A joint position paper of the Italian Society of Orthopaedics and Traumatology (SIOT) and the Italian Society of Periodontology and Implantology (SIdP),"L. Landi, P. T. Leali, L. Barbato, A. Carrassi, N. Discepoli, P. Muti, G. Oteri, M. Rigoni, E. Romanini, C. Ruggiero, U. Tarantino, E. Varoni, N. Sforza, M. Brandi",10.1186/s10195-023-00713-7,https://doi.org/10.1186/s10195-023-00713-7,Journal of Orthopaedics and Traumatology,3,2023,maybe,"The abstract focuses on osteoporotic patients, but does not explicitly state they are all adults (≥18 years) or exclude cancer patients, so the population type only partially meets the criterion.",yes,maybe,"While MRONJ outcomes are discussed, this is not a primary research study documenting specific outcomes from dental procedures, so the outcome documentation criterion is only partially met.",no,"As this appears to be a consensus report rather than a primary research study, there is no mention of a control group, so the control group criterion is unclear.",no,"This is a consensus report/guideline paper, not a randomized controlled trial, cohort study, or case-control study, so the study design criterion is not met.",no,"While the abstract mentions ""long-term use"" of AR therapy, it doesn't document specific temporal relationships or durations of medication use, so the temporal documentation criterion is unclear.",no,"The abstract does not mention any specific study size, as this appears to be a consensus report rather than a primary research study.","The abstract discusses various dental interventions including tooth extraction, surgical dental procedures, and dental implants, indicating that the intervention meets the criterion of invasive dental treatment.",Exclude,"This consensus report fails to meet multiple screening criteria, including specific intervention type, study design, and subject size requirements. While addressing anti-resorptive therapy and dental interventions, the document lacks the methodological rigor of a primary research study and does not provide the detailed documentation needed for systematic review inclusion. The paper appears more suited as a background reference rather than a primary research source.",1.4
Denosumab‐related osteonecrosis of the jaw following non‐surgical periodontal therapy: A case report,"M. Diniz-Freitas, J. Fernández-Feijoo, P. Diz Dios, X. Pousa, J. Limeres",10.1111/jcpe.12882,https://doi.org/10.1111/jcpe.12882,Journal of Clinical Periodontology,28,2018,yes,"The subject is an adult (77 years) with diagnosed osteoporosis and no mention of cancer, which meets the population type criteria.",yes,yes,The study clearly documents MRONJ outcomes following specific dental procedures.,no,"As a case report, there is no control group.",no,"This is a case report, which is not one of the accepted study designs (RCT, cohort, or case-control).",maybe,"The abstract indicates the temporal relationship between denosumab treatment and MRONJ development, though the exact duration of medication use is not explicitly stated.",no,"This is a single case report (n=1), far below the required minimum of 100 subjects.","The study involves periodontal therapy and subsequent surgical interventions including exodontia and sequestrectomy, which meets the requirement for invasive dental treatment.",Exclude,"This case report fails key screening criteria by using denosumab instead of romosozumab, having a single subject instead of the required 100+ participants, and lacking a control group. Despite documenting MRONJ outcomes and involving an appropriate adult patient population, the study design and medication type disqualify it from meeting the systematic review's inclusion requirements.",0.1
Removal of Pre-Existing Periodontal Inflammatory Condition before Tooth Extraction Ameliorates Medication-Related Osteonecrosis of the Jaw-Like Lesion in Mice.,"Terresa Kim, Sol Kim, Minju Song, Cindy Lee, H. Yagita, D. Williams, E. C. Sung, C. Hong, K. Shin, Mo K. Kang, N. Park, R. Kim",10.1016/j.ajpath.2018.06.019,https://doi.org/10.1016/j.ajpath.2018.06.019,American Journal of Pathology,49,2018,no,"The study uses mice, not adult human patients with osteoporosis.",yes,yes,The study clearly documents MRONJ outcomes following tooth extraction procedures.,maybe,"While the study has different treatment groups, it's not clear if there's a control group of non-anti-resorptive medication users.",no,"This is an experimental animal study, not a randomized controlled trial, cohort study, or case-control study in humans.",maybe,"While the study documents the temporal relationship between medication use and MRONJ development, it's in an animal model context.",no,"This is a mouse model study, not a human study with 100+ subjects.","The study includes tooth extraction, which is one of the specified invasive dental treatments.",Exclude,"This mouse model study fails key screening criteria by using zoledronic acid and denosumab instead of romosozumab, and by not involving human subjects with osteoporosis. The experimental design, while scientifically rigorous, does not meet the required methodological standards for inclusion, including population type, intervention medication, and study design.",0.1
Anti-resorptive therapy and MRONJ. A survey of the Italian Society of Periodontology and Implantology.,"L. Landi, G. Oteri, L. Barbato, N. Discepoli, A. Carrassi, M. Rigoni, F. Cairo, R. Cavalcanti, A. Crea, R. Gianserra, N. M. Sforza",10.1111/odi.14907,https://doi.org/10.1111/odi.14907,Oral Diseases,1,2024,maybe,"The abstract mentions patients with ""osteometabolic disorders"" but does not specify osteoporosis, and no clear age criteria are mentioned, so the study only partially meets or is unclear on the criterion of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",yes,no,"While MRONJ is mentioned, this is not a study documenting specific outcomes, but rather a survey of dentists' experiences, so the study fails to meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"No control group is mentioned, and this is a survey study, not an interventional study, so the study fails to meet the criterion of including a control group of non-anti-resorptive medication users.",no,"This is a survey study of dentists, which does not match any of the required study designs (RCT, cohort, or case-control), so the study fails to meet the criterion of having a study design of a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"No temporal relationships or medication duration are documented, so the study fails to meet the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",no,"This is a survey of 451 dentists, not a study of patients, so the study does not meet the criterion of having a subject size of more than 100 people.","The study discusses dental procedures including tooth extractions and implant surgery, which meets the criterion of having an intervention of invasive dental treatment. However, this is only reported by dentists, not as primary data.",Exclude,"This survey of dentists fails to meet most screening criteria, including specific intervention type, subject size, study design, and outcome documentation. While touching on anti-resorptive agents and dental procedures, the study lacks the required clinical research elements such as patient data, control groups, and detailed outcome tracking. The research primarily captures professional perspectives rather than providing a structured clinical investigation of MRONJ.",0.1
"Complementarity of Photo-Biomodulation, Surgical Treatment, and Antibiotherapy for Medication-Related Osteonecrosis of the Jaws (MRONJ)","D. Nica, Mircea Riviș, C. Roi, C. Todea, Virgil-Florin Duma, C. Sinescu",10.3390/medicina57020145,https://doi.org/10.3390/medicina57020145,Medicina,16,2021,maybe,"The abstract doesn't specify the age range of patients or whether they have cancer. It only mentions patients ""previously exposed to antiresorptive or anti-angiogenic therapy.""",maybe,maybe,"While MRONJ outcomes are documented, they appear to be focused on treatment outcomes rather than outcomes following specific dental procedures.",no,No control group is mentioned in the abstract. The study appears to focus only on patients who have been exposed to antiresorptive therapy.,maybe,"While this appears to be a clinical study, the exact design (RCT, cohort, case-control) is not explicitly stated in the abstract.",no,The abstract doesn't clearly document the temporal relationship between medication use and MRONJ development or the duration of medication use.,yes,"The study includes 241 patients, well above the minimum requirement of 100.","While the study involves surgical treatment of MRONJ, it's not clear if these were specifically for dental procedures like extractions or implants. The abstract focuses on treatment of existing MRONJ rather than dental procedures that might cause MRONJ.",Exclude,"The study fails to meet critical screening criteria, particularly the specific requirement for Romosozumab as the intervention medication. Multiple key elements are either unclear or unmet, including lack of a control group, undefined population characteristics, and absence of clear temporal documentation of medication use and MRONJ development. The research appears to focus on treatment of existing MRONJ rather than the specific parameters outlined in the screening criteria.",1.4
Medication-related osteonecrosis of the jaw – a scoping review,"N. Gogtay, Dhruve Soni, Sukant Pandit",10.1097/fad.0000000000000061,https://doi.org/10.1097/fad.0000000000000061,Adverse Drug Reaction Bulletin,0,2022,maybe,"The abstract doesn't specify age groups or cancer status, and it appears to be a general review covering multiple patient populations.",no,no,"While MRONJ is discussed, the abstract doesn't describe specific documentation of outcomes following dental procedures. It's a general overview rather than a study of specific outcomes.",no,"There is no mention of control groups, and this appears to be a review rather than a comparative study.",no,"This appears to be a review article rather than a primary research study, and it does not match any of the required study designs.",no,"No specific temporal relationships or medication durations are documented, and the paper appears to be a general review rather than a study tracking specific cases.",no,"The abstract does not mention any specific study size, and it appears to be a review article rather than a primary research study.","While dental procedures are implied in the context of MRONJ, the abstract doesn't describe specific interventions. It's a general review of MRONJ rather than a study of specific dental procedures.",Exclude,"The abstract fails to meet the specified screening criteria, lacking specific details about Romosozumab, subject size, invasive dental treatments, and study design. It appears to be a general review of medication-related osteonecrosis of the jaw rather than a focused research study addressing the required parameters. Consequently, the document does not qualify for inclusion based on the established screening requirements.",0.1
Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan,"Fang-Chun Liu, K. Luk, Yung-Chih Chen",10.1007/s00198-023-06818-3,https://doi.org/10.1007/s00198-023-06818-3,Osteoporosis International,10,2023,maybe,"The study includes adult patients (≥40 years) with diagnosed osteoporosis, but doesn't explicitly exclude cancer patients. However, the focus appears to be on osteoporotic patients without mention of cancer.",no,maybe,"While ONJ outcomes are documented, the specific dental procedures leading to these outcomes are not clearly detailed in the abstract.",no,The study compares two active treatment groups (denosumab vs. bisphosphonates) but doesn't include a control group of non-anti-resorptive medication users.,yes,"This is a retrospective cohort study, which meets the acceptable study design criteria.",yes,"The study clearly documents temporal relationships, showing outcomes over time (first year, second year, third year onwards) and duration of medication use.",yes,"The study includes 8,962 eligible patients, well above the 100-person minimum requirement.","While the study examines ONJ outcomes, it doesn't explicitly state which dental procedures were involved, which is a significant limitation.",Exclude,"The study fails to meet critical screening criteria, primarily due to examining denosumab and bisphosphonates instead of the specified romosozumab intervention. While the research demonstrates a robust methodology with a large sample size and appropriate study design, the fundamental mismatch in medication type disqualifies it from inclusion. Additional limitations include the absence of a non-medication control group and unclear documentation of specific dental procedures.",1.4
Preventing medication-related osteonecrosis of the jaw,"L. Zebic, V. Patel",10.1136/bmj.l1733,https://doi.org/10.1136/bmj.l1733,British medical journal,14,2019,no,"The paper mentions both cancer and osteoporosis patients and does not focus exclusively on osteoporosis patients, so it does not meet the criterion of focusing on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",no,no,"While MRONJ is discussed, this is not a study documenting specific outcomes, so it does not meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"There is no mention of control groups, and the paper appears to be a review article rather than an interventional study, so it does not meet the criterion of including a control group of non-anti-resorptive medication users.",no,"This is a review article drawing from various sources including RCTs and case reports, and not a primary research study of the required design types, so it does not meet the criterion of having a study design of a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"No specific temporal relationships or medication durations are documented, so it does not meet the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",no,"No specific subject size is mentioned, and the paper appears to be a review article rather than a primary study, so it does not meet the criterion of having a subject size of more than 100 people.","While dental procedures are implied in the context of MRONJ, no specific interventions are studied, and the paper appears to be a review of management and prevention rather than a study of invasive dental treatment.",Exclude,"The abstract fails to meet all screening criteria, primarily because it is a review article rather than a primary research study focused on Romosozumab and osteoporosis patients. No specific intervention, subject size, control group, or outcome documentation is provided, rendering the document unsuitable for the systematic review's requirements. The text provides general guidance on medication-related osteonecrosis of the jaw but lacks the precise research parameters needed for inclusion.",0.1
Denosumab-Induced Medication-Related Osteonecrosis of the Jaw (DRONJ): A 5-Year Retrospective Cohort Study,"Jaeyoung Kim, Seoyeon Jung, Jin Hoo Park, Hyung.Jun. Kim, Wonse Park",10.21203/rs.3.rs-1186902/v1,https://doi.org/10.21203/rs.3.rs-1186902/v1,-,0,2022,maybe,"The abstract mentions ""osteoporotic patients"" but doesn't explicitly state they are all adults (≥18 years) or confirm absence of cancer patients.",yes,yes,The study clearly documents MRONJ outcomes following specific dental procedures (tooth extraction).,no,The abstract doesn't mention a control group of non-anti-resorptive medication users.,maybe,"While this appears to be an observational study, the exact design (whether prospective/retrospective cohort or case-control) is not explicitly stated.",yes,"The study documents temporal relationships between medication use and MRONJ development, including cases before and after treatment.",maybe,"The study includes 98 patients, which is very close to the minimum requirement of 100, but slightly below the threshold.","The study explicitly focuses on invasive dental treatment, specifically tooth extraction.",Exclude,"The study focuses on Denosumab for osteoporotic patients, which fundamentally differs from the specified Romosozumab intervention, representing a critical screening criterion mismatch. While the research addresses dental treatment and MRONJ outcomes with a near-threshold sample size, the medication deviation and unclear control group details prevent full compliance with the established screening requirements.",1.4
Implications in dental treatment during the use of antiresorptive drugs - a literature review,"Aleksandra Dziewulska, Weronika Kiełt, Julia Kozłowska, Gabriela Broniec, Barbara Wajdowicz, Aleksandra Kudła, Rozalia Czapiewska, Aleksandra Wróbel, Laura Pacek, Klaudia Kowalska",10.12775/jehs.2024.69.55356,https://doi.org/10.12775/jehs.2024.69.55356,"Journal of Education, Health and Sport",0,2024,maybe,"The abstract mentions osteoporosis patients, but also mentions ""metastatic bone disease"" which may include cancer patients. Therefore, it is uncertain if the study focuses exclusively on adult patients with diagnosed osteoporosis who do not have cancer.",yes,maybe,"The abstract mentions MRONJ as an outcome and discusses dental procedures, which indicates that the study partially meets the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",maybe,"The abstract does not mention any control groups, so it is not possible to determine if the study meets the criterion of including a control group of non-anti-resorptive medication users.",no,"The abstract indicates that the study is a literature review/synthesis, and not a primary research study (RCT, cohort, or case-control). Therefore, the study does not meet the criterion of having a study design of a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"The abstract does not provide any specific information about the temporal relationship between medication use and MRONJ development, or the duration of medication use. Therefore, it is not possible to determine if the study meets the criterion of clearly documenting both the temporal relationship and the duration of medication use.",maybe,"The abstract does not provide any information about the sample size of the study, so it is not possible to determine if the study meets the criterion of having a subject size of more than 100 people.","The abstract mentions ""invasive dental procedures"" and various dental treatments, which indicates that the study meets the criterion of having an intervention of invasive dental treatment.",Exclude,"The abstract fails critical screening criteria by not using Romosozumab and not being a primary research study, with significant uncertainties around population type, control group, and temporal documentation. Multiple key requirements are unmet, rendering the study ineligible for inclusion based on the predefined screening criteria. The literature review's topical relevance cannot compensate for its fundamental methodological shortcomings.",0.1
Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline Summary.,"C. Shapiro, N. Yarom, D. Peterson, Kari Bohlke, D. Saunders",10.1200/JOP.19.00384,https://doi.org/10.1200/JOP.19.00384,Journal of Oncology Practice,3,2019,no,"The abstract focuses on cancer patients with skeletal metastases or multiple myeloma, which explicitly contradicts the criterion requiring the study to focus on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",maybe,maybe,"While the abstract discusses MRONJ, it does not provide any specific documentation of MRONJ outcomes following the dental procedures mentioned in the criterion.",maybe,"The abstract does not mention the inclusion of a control group of non-anti-resorptive medication users, so it is uncertain whether this criterion is met.",no,"The abstract appears to be a review or overview rather than a primary research study, and does not mention any specific study design, such as a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"The abstract does not mention any specific temporal relationships between medication use and MRONJ development, or the duration of medication use, so it is uncertain whether this criterion is met.",maybe,"The abstract does not provide any information about the subject size of the study, so it is uncertain whether the study meets the criterion of having a subject size of more than 100 people.","While the abstract discusses dental procedures in the context of medication-related osteonecrosis of the jaw (MRONJ), it does not describe any specific invasive dental treatments, such as tooth extraction, implant placement, periodontal surgery, or removable prosthesis fabrication.",Exclude,"The abstract fails critical screening criteria by focusing on cancer patients and bone-modifying agents other than Romosozumab, which immediately disqualifies it from the systematic review. Multiple key requirements are not met, including population type, medication intervention, and study design, rendering the paper unsuitable for inclusion. The fundamental mismatch with the specified screening criteria means the abstract cannot be considered for further review.",0.1
Characteristic Multimodal Imaging of Medication-Related Osteonecrosis of the Jaw: Comparison Between Oral and Parenteral Routes of Medication Administration,"I. Ogura, Yoshihiko Sasaki, A. Kameta, Mikiko Sue, Takaaki Oda",10.12659/PJR.902513,https://doi.org/10.12659/PJR.902513,Polish Journal of Radiology,18,2017,maybe,"The abstract does not provide explicit information about the age or osteoporosis diagnosis of the study population, nor does it mention the cancer status of the participants.",no,no,"While MRONJ is documented, there is no mention of specific dental procedures or treatments. The focus is on imaging features rather than procedure outcomes.",no,The study only looks at MRONJ patients and does not include a control group of non-anti-resorptive medication users.,yes,"The study design is mentioned as a retrospective study, which meets the criterion for a retrospective cohort study.",no,"The abstract does not provide clear documentation of the temporal relationship between medication use and MRONJ development, nor does it mention the duration of medication use.",no,"The study only includes 16 patients, which is less than the required 100 subjects.",There is no mention of any dental procedures or treatments in the study. The focus is on imaging features of MRONJ rather than invasive dental interventions.,Exclude,"The study fails to meet multiple critical screening criteria, including the specific intervention of Romosozumab, required sample size, and documentation of dental procedures. With only 16 patients and a focus on imaging features rather than treatment outcomes, the research does not align with the predefined screening requirements. Key deficiencies include lack of a control group, unclear population characteristics, and absence of specific dental intervention documentation.",0.1
Medication-Related Osteonecrosis of the Jaw: 14 Years’ Retrospective Study on Pathogenetic Trigger Events,"Raffaele Marino, A. Squillacioti, G. Lo Giudice, S. Cicchiello, C. Scozzaro, S. Mummolo, F. De Ponte, E. Nastro Siniscalchi",10.1097/SCS.0000000000008719,https://doi.org/10.1097/SCS.0000000000008719,The Journal of craniofacial surgery (Print),1,2022,maybe,"The study includes patients with osteoporosis, but there is no explicit mention of age restrictions or cancer status, so it is unclear if the population type fully meets the criteria.",yes,yes,"The study clearly documents MRONJ outcomes and mentions specific dental procedures (extractions, oral surgery), meeting this criterion.",no,"There is no mention of a control group in the study, so it fails to meet this criterion.",yes,"The study is a retrospective analysis of cases, which meets the requirement for a retrospective cohort study.",maybe,"The study period is 14 years (2008-2021), and it mentions the onset of disease and trigger events, but the temporal documentation is not fully clear.",no,"The study includes 52 analyzed cases, which is less than the required subject size of more than 100 people.","The study mentions tooth extraction and oral surgery as trigger events, indicating that it includes the required intervention of invasive dental treatment.",Exclude,"The study fails key screening criteria by not using Romosozumab, having a small sample size of 52 patients, and lacking a control group. While the research explores medication-related osteonecrosis of the jaw and includes dental procedures, it does not meet the fundamental requirements for inclusion in the systematic review. Critical methodological limitations prevent the study from satisfying the predefined screening criteria.",1.4
Medication-Related Osteonecrosis of the Jaw: Update and Future Possibilities,"J. Borke, J. Elo, H. Sun, Shirley Y. Kang",10.1080/19424396.2018.12222022,https://doi.org/10.1080/19424396.2018.12222022,Journal - California Dental Association,0,2018,no,"The abstract mentions both osteoporosis and cancer patients, and is not focused exclusively on adult osteoporosis patients without cancer, so it fails this criterion.",no,no,"While MRONJ is discussed, the abstract does not indicate documentation of specific dental procedures, so it fails this criterion.",maybe,"The abstract does not mention control groups, so it is uncertain whether this criterion is met.",no,"This appears to be a review article, not a primary research study, and does not match the required study designs, so it fails this criterion.",no,"The abstract does not mention temporal relationships or medication duration, so it fails this criterion.",maybe,"The abstract does not mention the study size, so it is uncertain whether this criterion is met.","While MRONJ is discussed, the abstract does not specify studying particular dental procedures, and it appears to be a review rather than an intervention study, so it fails this criterion.",Exclude,"The abstract fails to meet multiple critical screening criteria, including specific intervention with Romosozumab, required study design, and exclusive focus on adult osteoporosis patients without cancer. As a review article discussing MRONJ mechanisms broadly, it does not align with the systematic review's targeted research parameters. Consequently, the manuscript would be excluded from further consideration.",0.1
Removal of a sequestrum by a patient with medication-related osteonecrosis of the jaw.,"M. Davies, A. Power, A. Kanatas",10.1016/j.bjoms.2017.06.019,https://doi.org/10.1016/j.bjoms.2017.06.019,British Journal of Oral and Maxillofacial Surgery,2,2017,no,"The abstract mentions both cancer and osteoporosis patients, and does not focus exclusively on adult osteoporosis patients without cancer, which fails to meet the criterion.",maybe,no,"While MRONJ outcomes are discussed, they are not specifically documented in relation to dental procedures, and the information is too general.",no,"No mention of control groups, so this information is missing.",no,"This appears to be a review/position paper rather than a primary research study, and does not meet the required study design criteria.",no,"While duration of drug treatment is mentioned as a risk factor, there is no specific documentation of temporal relationships, and this information is missing.",no,"The abstract does not mention any specific study size, so this information is missing.","The abstract mentions ""dentoalveolar surgery"" as a risk factor, which partially meets the criterion, but lacks specific details.",Exclude,"The abstract fails to meet multiple critical screening criteria, including specific focus on Romosozumab, exclusive patient population, and required study design. Key deficiencies include lack of precise documentation of dental interventions, absence of a control group, and insufficient details about temporal medication use and MRONJ outcomes. The paper appears to be a general review rather than a targeted research study meeting the systematic review requirements.",0.1
Determinants Of Outcome In Cancer Patients With Medication-Related Osteonecrosis Of The Jaw: A 19-Year Retrospective Study,"Jenna Marcinczyk, Annu Singh, Charlie White, Elyn Reidel, S. Yom, J. Huryn, C. Estilo",10.1016/j.oooo.2023.07.039,https://doi.org/10.1016/j.oooo.2023.07.039,"Oral surgery, oral medicine, oral pathology and oral radiology",0,2023,no,"The study specifically focuses on cancer patients, which is explicitly excluded in the screening criteria. The abstract mentions ""cancer patients"" multiple times and discusses specific cancer diagnoses like multiple myeloma.",maybe,maybe,"While MRONJ outcomes are documented, the specific dental procedures leading to MRONJ are not clearly detailed in the abstract.",no,No control group of non-anti-resorptive medication users is mentioned. The study only looks at patients who received antiresorptive therapy.,yes,"This is a retrospective cohort study, which meets the acceptable study design criteria.",yes,The study documents temporal relationships with a median follow-up time of 94.9 months and clear documentation of medication use and MRONJ development.,yes,"The study includes 300 patients, well above the minimum requirement of 100.","While the study discusses MRONJ, it doesn't explicitly state which dental procedures were performed. The focus appears to be on outcomes rather than interventions.",Exclude,"The study focuses on cancer patients using antiresorptive medications other than Romosozumab, which immediately disqualifies it from the screening criteria. Critical exclusion factors include the wrong patient population, absence of a control group, and use of different medications than specified. Despite having a large sample size and appropriate study design, these fundamental mismatches render the study ineligible for inclusion.",0.1
"Position Papers on MRONJ(Medication related osteonecrosis of the jaw), What has changed?",Tae-Geon Kwon,10.22974/jkda.2023.61.7.001,https://doi.org/10.22974/jkda.2023.61.7.001,The Journal of The Korean Dental Association,0,2023,no,"The abstract does not focus on a specific patient population. It discusses antiresorptive medications broadly, including their use in cancer patients (multiple myeloma, bone metastases).",no,no,"While MRONJ outcomes are discussed, this is not a study documenting specific outcomes following dental procedures.",no,No control group is mentioned as this is not an original research study.,no,"This appears to be a review/commentary paper discussing position paper updates, not a primary research study with any of the specified designs.",no,The paper does not document temporal relationships or medication duration as it is not an original research study.,no,"The abstract does not mention any specific study population size, as this is a review/position paper rather than an original research study.","While the abstract discusses dental procedures in the context of MRONJ, it does not study specific dental interventions. It only mentions them as part of the position paper recommendations.",Exclude,"This abstract represents a review of position paper updates on medication-related osteonecrosis of the jaw, not an original research study. It fails to meet critical screening criteria including specific patient population, intervention details, study design, and outcome documentation. The text provides a commentary on clinical guidelines rather than presenting a research investigation with the required methodological elements.",0.1
WHAT ARE THE MAIN CLINICAL FEATURES OF ONCOLOGICAL PATIENTS WITH MRONJ? A SYSTEMATIC REVIEW AND META-ANALYSIS,"C. Calderipe, L. Ferreira, L. Schuch, M. Martins, F. Silveira, L. Abreu, A. Vasconcelos",10.1016/j.oooo.2023.03.083,https://doi.org/10.1016/j.oooo.2023.03.083,"Oral surgery, oral medicine, oral pathology and oral radiology",0,2023,no,"The study focuses exclusively on cancer patients, which does not meet the requirement of focusing on adult patients with diagnosed osteoporosis who do not have cancer.",maybe,maybe,"The study reports MRONJ outcomes, but does not clearly document the specific dental procedures that were performed.",no,The study does not mention a control group of non-anti-resorptive medication users.,maybe,"The study appears to be a retrospective analysis of published cases, which could qualify as a retrospective cohort study, but this is not clearly stated.",maybe,"The study mentions the duration of ARD use, but does not clearly document the temporal relationship between medication use and MRONJ development.",yes,"The study includes 1,598 cases, which is well above the 100-person requirement for subject size.","The study mentions ""traumatic events"" as the etiology of MRONJ, but does not clearly document the specific dental procedures that were performed.",Exclude,"The study fails critical screening criteria by focusing on cancer patients using bisphosphonates and denosumab, rather than non-cancer patients taking Romosozumab. While the research includes a large sample size and reports MRONJ outcomes, it does not meet the specified intervention, population type, and control group requirements. Consequently, the paper would be excluded from the systematic review based on these fundamental screening criteria.",0.1
Osteonecrosis of the jaws: a 14‐year retrospective survey of hospital admissions,"K. McGowan, Saso Ivanovski, Caroline Acton",10.1111/adj.12603,https://doi.org/10.1111/adj.12603,Australian dental journal,11,2018,no,"The study includes both cancer and non-cancer patients, and only 52.5% of the MRONJ cases were for osteoporosis, so the population is not exclusively adult patients with diagnosed osteoporosis who do not have cancer.",no,no,"While the study documents MRONJ outcomes, it does not provide specific details about the dental procedures that were performed.",no,The abstract does not mention the inclusion of a control group of non-anti-resorptive medication users.,yes,"The study appears to be a retrospective review of medical records, which meets the criterion of being a retrospective cohort study.",no,"The abstract does not clearly document the temporal relationship between medication use and MRONJ development, nor the duration of medication use.",no,"The study includes 238 patients total, with approximately 61 MRONJ cases, which is less than the required 100 subjects.","The abstract does not mention any specific invasive dental treatments, such as tooth extraction, implant placement, periodontal surgery, or removable prosthesis fabrication.",Exclude,"The study fails to meet most screening criteria, including specific medication type, subject size, dental intervention details, and population exclusivity. While the research provides insights into medication-related osteonecrosis of the jaw, it lacks the precise methodological requirements for inclusion, particularly around Romosozumab use and comprehensive dental procedure documentation. The retrospective design is the only criterion definitively satisfied.",1.4
[Osteonecrosis of the jaw associated with bisphosphonate therapy in primary osteoporosis. Review of the literature].,A. Outeiriño-Fernández,-,-,Anales del Sistema Sanitario de Navarra,2,2013,yes,"The study focuses on adults with primary osteoporosis and does not mention cancer patients, which appears to meet the population type criterion.",yes,yes,"The study reports MRONJ outcomes following dental procedures, specifically mentioning extractions, which meets the outcome documentation criterion.",no,"There is no mention of a control group, and the study appears to be case report series only, which does not meet the control group criterion.",no,"This is a systematic review of case reports, which does not meet the required study design criteria of RCT, cohort, or case-control.",yes,"The study reports the mean duration of treatment before MRONJ (48.25 months), which documents the temporal relationship and duration of medication use, meeting this criterion.",no,"The study includes only 43 cases, which fails to meet the minimum requirement of 100 subjects.","The abstract mentions ""dentoalveolar surgery"" and specifically mentions extractions, which meets the requirement for invasive dental treatment.",Exclude,"The study fails critical screening criteria by using bisphosphonates instead of Romosozumab, having only 43 cases instead of the required 100 subjects, and lacking a control group. While the research addresses dental procedures and osteoporosis in adults, its systematic review design and limited sample size disqualify it from meeting the comprehensive screening requirements.",0.1
Three-dimensional clinical assessment for MRONJ risk in oncologic patients following tooth extractions,"Catalina Moreno Rabie, Rocharles Cavalcante Fontenele, Nicolly Oliveira Santos, Fernanda Nogueira Reis, T. Van den Wyngaert, R. Jacobs",10.1259/dmfr.20230238,https://doi.org/10.1259/dmfr.20230238,Dento maxillo facial radiology,2,2023,no,"The abstract specifically mentions ""oncologic patients"" which violates the criterion requiring patients without cancer.",yes,yes,"The study clearly documents MRONJ outcomes following tooth extractions, with specific documentation of 33 sites (38%) developing MRONJ.",yes,"The study includes a control group of non-ARD users (50 patients, 106 tooth extractions).",yes,"The study is described as a ""retrospective, longitudinal, case-control study"" which meets the criteria for study design.",maybe,"While the study mentions ""drug holidays"" and timing of MRONJ development, it's not entirely clear if the duration of medication use is comprehensively documented.",no,"The study includes 97 patients total (47 in study group, 50 in control), which is below the required 100 subjects.","The study focuses on tooth extractions, which is explicitly mentioned as one of the required invasive dental treatments.",Exclude,"The study fails key screening criteria by focusing on oncologic patients using bisphosphonates and denosumab, not Romosozumab, and having a sample size below 100 participants. Despite meeting some methodological requirements like having a control group and documenting dental intervention outcomes, the fundamental deviations from specified inclusion criteria render the study unsuitable for the systematic review.",0.1
Associated systemic diseases and etiologies of medication-related osteonecrosis of the jaw: a retrospective study of 265 surgical cases,"Hoon-Je Chang, Minjoo Kim, K. Ahn",10.1186/s40902-023-00377-7,https://doi.org/10.1186/s40902-023-00377-7,Maxillofacial plastic and reconstructive surgery,5,2023,no,"The study includes both osteoporosis patients and cancer patients, and does not exclusively focus on non-cancer osteoporosis patients, which fails to meet this criterion.",yes,yes,"The study clearly documents MRONJ outcomes following specific dental procedures, which meets this criterion.",no,"There is no mention of a control group in the study, which fails to meet this criterion.",maybe,"The study is a retrospective review of cases, which appears to be more of a case series than a proper cohort study, and therefore only partially meets this criterion.",no,"There is no clear documentation of the temporal relationship between medication use and MRONJ, and no mention of the duration of medication use, which fails to meet this criterion.",yes,"The study includes 265 MRONJ operations, which meets the criterion of having a subject size of more than 100 people.","The study includes various dental procedures such as extractions, implants, and prosthesis, which meets the criterion of having an intervention of invasive dental treatment.",Exclude,"The study fails key screening criteria by not specifying Romosozumab use, including cancer patients, and lacking a control group. While the research documents dental procedures and MRONJ outcomes, it does not meet the required population and intervention specifications. Multiple critical screening requirements were not satisfied, rendering the study unsuitable for inclusion.",1.4
Mechanisms Underlying Medication-Related Osteonecrosis of the Jaw.,"Kyeongho Lee, Kihun Kim, June Yeon Kim, Jin-Woo Kim, Young-Hoon Kang, Yun Hak Kim, Sung-Jin Kim",10.1111/odi.15198,https://doi.org/10.1111/odi.15198,Oral Diseases,0,2024,no,"The paper discusses MRONJ patients in general, and no specific population characteristics are mentioned, so the paper does not meet this criterion.",no,no,"While MRONJ is discussed, the paper does not report specific outcomes from dental procedures, so the paper does not meet this criterion.",no,"As a narrative review, there is no control group, so the paper does not meet this criterion.",no,"This is a narrative review, not a RCT, cohort study, or case-control study, so the paper does not meet this criterion.",no,"The paper does not document temporal relationships or medication duration, so the paper does not meet this criterion.",no,"This is a narrative review paper, not an original research study, and no specific subject size is mentioned, so the paper does not meet this criterion.","While the paper discusses MRONJ, it does not study specific dental interventions, as this is a review of pathogenesis mechanisms, so the paper does not meet this criterion.",Exclude,"This narrative review paper fails to meet any of the specified screening criteria, as it is a theoretical exploration of MRONJ pathogenesis rather than an original research study. The abstract lacks specific details about patient population, intervention, control groups, study design, and outcome documentation required by the screening protocol. Consequently, the paper does not qualify for inclusion based on the predefined criteria.",0.1
"Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma","Petra Rugani, C. Walter, B. Kirnbauer, S. Acham, Yvonne Begus-Nahrman, N. Jakse",10.3390/dj4040032,https://doi.org/10.3390/dj4040032,Dental journal,31,2016,no,"The study focuses exclusively on cancer patients (breast cancer, prostate cancer, multiple myeloma), which explicitly contradicts the requirement for non-cancer patients.",no,no,"While MRONJ outcomes are documented, there is no mention of specific dental procedures, so the study does not meet the requirement of reporting MRONJ outcomes following specific, documented dental procedures.",no,"There is no mention of a control group in the abstract, so the study does not meet the requirement of including a control group of non-anti-resorptive medication users.",no,"The study appears to be a systematic review/meta-analysis of 69 articles, rather than a primary research study of the required design types (randomized controlled trial, prospective/retrospective cohort study, or case-control study).",no,"There is no clear documentation of the temporal relationship between medication use and MRONJ development, or the duration of medication use, so the study does not meet the requirement of clearly documenting these aspects.",yes,"The study includes 29,437 patients, which is well above the 100-person threshold specified in the criterion.","There is no mention of dental procedures or interventions in the abstract, so the study does not meet the requirement of having an intervention of invasive dental treatment.",Exclude,"The study focuses on cancer patients receiving parenteral antiresorptive therapy, which fundamentally differs from the required criteria of oral Romosozumab treatment in non-cancer osteoporosis patients. Multiple critical screening requirements are unmet, including population type, intervention specifics, study design, and outcome documentation. The research does not align with the systematic review's targeted parameters.",0.1
Oral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw,-,-,-,-,6,2017,no,"The abstract does not provide any specific mention of adult patients or osteoporosis diagnosis, and it does not mention cancer exclusion. Therefore, it cannot be confirmed if the study focuses exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",maybe,no,"While MRONJ is mentioned, the abstract describes a guidance document about managing risk, not a study that reports specific outcomes from dental procedures. Therefore, it does not report MRONJ outcomes following specific, documented dental procedures.",no,"The abstract does not mention any control groups, and it is a guidance document rather than a comparative study. Therefore, it fails to include a control group of non-anti-resorptive medication users.",no,"The abstract indicates that this is a guidance document, not a clinical study. Therefore, it does not fit any of the required study designs (randomized controlled trial, prospective/retrospective cohort study, or case-control study).",no,"The abstract does not provide any documentation of the temporal relationship between medication use and MRONJ development, or the duration of medication use.",no,"The abstract does not mention the subject size, and it appears to be a guidance document rather than a clinical study. Therefore, it is unclear if the study has a subject size of more than 100 people.","The abstract mentions ""routine dental treatment"" but does not specify invasive procedures, so it is too vague to confirm if the subject has an intervention of invasive dental treatment.",Exclude,"This guidance document fails multiple critical screening criteria, including the specific intervention of Romosozumab, lack of a clinical study design, and absence of a control group. The text provides general recommendations for managing medication-related osteonecrosis of the jaw but does not meet the systematic review's rigorous methodological requirements for inclusion.",0.1
Antiresorptive drug-related changes of the mandibular bone densitiy in medication-related osteonecrosis of the jaw patients.,"N. Heim, W. Götz, F. Kramer, A. Faron",10.1259/dmfr.20190132,https://doi.org/10.1259/dmfr.20190132,Dento maxillo facial radiology,18,2019,maybe,The abstract doesn't specify the age range of patients or whether they have cancer. It only mentions patients with MRONJ.,maybe,maybe,"While MRONJ outcomes are documented, the specific dental procedures leading to MRONJ are not detailed in the abstract.",yes,The study includes a reference group of 40 patients.,maybe,The study design is not explicitly stated in the abstract.,maybe,"The study mentions ""duration of treatment"" but doesn't clearly document the temporal relationship between medication use and MRONJ development.",yes,"The study includes 101 patients, which exceeds the minimum requirement of 100.","While the study discusses MRONJ, which typically occurs after dental procedures, the abstract doesn't explicitly state which dental procedures were performed.",Exclude,"The study focuses on bisphosphonates and denosumab, not romosozumab, which immediately disqualifies it from meeting the primary intervention criterion. While the research includes a sufficient sample size and a control group, the fundamental mismatch in medication type renders the study non-compliant with the specified screening requirements. Critical details about patient demographics, specific dental procedures, and study design remain unclear from the abstract.",0.1
Surgical Treatment of Medication-Related Osteonecrosis of the Jaw: A Retrospective Study,"N. Choi, Jung Han Lee, Jin Young Park, Dae-Seok Hwang",10.3390/ijerph17238801,https://doi.org/10.3390/ijerph17238801,International Journal of Environmental Research and Public Health,7,2020,no,"The abstract doesn't specify the age range or osteoporosis diagnosis of the subjects, and there is no mention of cancer status, so there is insufficient information to determine if the study focuses exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",maybe,maybe,"While MRONJ outcomes are documented, the specific dental procedures leading to MRONJ are not detailed, so there is insufficient information to determine if the study reports MRONJ outcomes following specific, documented dental procedures.",no,"There is no mention of a control group, and the study appears to focus only on MRONJ cases, so it does not include a control group of non-anti-resorptive medication users.",yes,"The study appears to be a retrospective analysis of treatment outcomes, which meets the criteria for an acceptable study design (randomized controlled trial, prospective/retrospective cohort study, or case-control study).",maybe,"Some temporal information is provided regarding zoledronate dose, but the specific duration of medication use is not clearly documented, so there is insufficient information to determine if the study clearly documents both the temporal relationship between medication use and MRONJ development and the duration of medication use.",yes,"The study includes 116 cases (109 success + 7 failure), which meets the requirement of a subject size of more than 100 people.","The abstract focuses on surgical treatment of MRONJ, but it doesn't specify the dental procedures that led to MRONJ, so there is insufficient information to determine if the intervention includes invasive dental treatment.",Exclude,"The study fails to meet critical screening criteria, primarily due to using zoledronate instead of the specified romosozumab medication. While the research includes an adequate sample size and appears to be a retrospective analysis, it lacks essential details about population characteristics, dental procedures, and a control group. The fundamental mismatch in medication type renders the study non-compliant with the established screening requirements.",1.4
Surgical Management of Medication-Related Osteonecrosis of the Jaw Patients Related to Dental Implants.,"M. Nisi, R. Izzetti, S. Gennai, P. Bellini, F. Graziani, M. Gabriele",10.1097/SCS.0000000000006283,https://doi.org/10.1097/SCS.0000000000006283,The Journal of craniofacial surgery (Print),9,2020,no,"The study includes both osteoporotic and oncologic patients, and is not exclusively focused on adult osteoporosis patients without cancer, so it does not meet the population type criterion.",yes,yes,"The study clearly documents MRONJ outcomes following dental procedures (implants), including staging and treatment outcomes, so it meets the outcome documentation criterion.",no,"There is no mention of a control group in the study, so it does not meet the control group criterion.",maybe,"The study is a retrospective case series, which is not one of the acceptable study designs (randomized controlled trial, prospective/retrospective cohort study, or case-control study), so it only partially meets this criterion.",maybe,"While the study documents treatment outcomes at 12 months, it does not clearly document the temporal relationship between medication use and MRONJ development, so it only partially meets this criterion.",no,"The study includes only 15 patients, which is less than the required 100 subjects.","The study focuses on dental implants and their complications, which meets the criterion of having an intervention of invasive dental treatment.",Exclude,"The study fails key screening criteria including medication type, sample size, population specificity, and control group requirements. While documenting dental implant-related MRONJ outcomes, the research does not meet the predefined methodological standards for inclusion. Multiple critical screening elements were not satisfied, rendering the study non-compliant with the established protocol.",1.4
Incidence and risk factors of bisphosphonate‐associated osteonecrosis of the jaws,"Matthew R. Stumpe, R. Chandra, F. Yunus, S. Samant",10.1002/hed.20941,https://doi.org/10.1002/hed.20941,Head and Neck,37,2007,no,"The abstract mentions ""benign and malignant bone diseases"", which suggests the inclusion of cancer patients, which violates the criterion. Additionally, the abstract does not specify the age range of the population.",maybe,maybe,"While osteonecrosis of the jaws is mentioned, the abstract does not provide details on the specific dental procedures and outcomes, so there is insufficient information to confirm this criterion.",maybe,"The abstract does not mention any control groups, so it is not possible to determine if this criterion is met.",maybe,"The study design is not specified in the abstract, so it is not possible to determine if this criterion is met.",maybe,"The abstract does not provide any information about the temporal relationships between medication use and MRONJ development, or the duration of medication use, so it is not possible to determine if this criterion is met.",maybe,"The abstract does not mention the sample size, so it is not possible to determine if this criterion is met.","While the abstract mentions osteonecrosis of the jaws, it does not specifically detail the dental procedures, so there is insufficient information to confirm this criterion.",Exclude,"The abstract focuses on intravenous bisphosphonates for bone diseases, which immediately disqualifies it from meeting the specified screening criteria for Romosozumab and osteoporosis treatment. Multiple critical screening requirements are not met, including medication type, population characteristics, and specific intervention details. The lack of alignment with the predefined screening criteria renders this abstract unsuitable for further review.",0.1
Medication--related osteonecrosis of the jaws. The first reported cases in the Baltic States and a literature review.,"L. Zaleckas, Mindaugas Stacevičius, Dovilė Proškutė, Jurgita Povilaitytė",-,-,Stomatologija,2,2015,no,"The study includes patients with cancer (mentions ""prostate cancer""), which does not meet the requirement for a cancer-free population.",no,maybe,"The study documents MRONJ outcomes, but does not specify the dental procedures leading to MRONJ, which only partially meets the outcome documentation requirement.",no,There is no mention of a control group in the study.,yes,"The study design is a retrospective review of patient charts, which meets the acceptable study design criteria.",no,"There is no clear documentation of the temporal relationship between medication use and MRONJ development, or the duration of medication use, which fails to meet the temporal documentation requirement.",no,"The study only includes 9 cases, which is less than the required 100 subjects.","There is no specific mention of dental procedures, only ""inflammatory conditions of the jaws"", which does not meet the requirement for invasive dental treatment.",Exclude,"The study fails to meet multiple critical screening criteria, including the specific medication intervention, subject size, and population type requirements. Key deficiencies include the absence of Romosozumab, a sample size of only 9 patients, and the inclusion of cancer patients, which disqualify the study from the systematic review's parameters. The research, while relevant to medication-related osteonecrosis, does not align with the predefined screening criteria.",0.1
[Risk assessment of medication-related osteonecrosis of the jaw in general dental practice].,"Anna Zurányi, Enikő Vasziné Szabó, Z. Tóth",10.1556/650.2019.31204,https://doi.org/10.1556/650.2019.31204,Orvosi Hetilap,10,2019,maybe,"The paper mentions patients with antiresorptive therapy, which partially meets the criterion of focusing on adult patients with diagnosed osteoporosis, but it also includes oncological patients, which does not meet the criterion.",maybe,no,"The paper discusses MRONJ outcomes generally but does not report specific outcomes from documented procedures, so the outcome documentation criterion is not met.",no,"There is no mention of a control group, and this is a review paper rather than an interventional study, so the control group criterion is not met.",no,"This is a literature review of risk factors, not a randomized controlled trial, prospective/retrospective cohort study, or case-control study, so the study design criterion is not met.",no,"The paper does not document specific temporal relationships or duration of medication use, so the temporal documentation criterion is not met.",no,"No specific subject size is mentioned, and this is a review of risk factors rather than a primary study, so the subject size criterion is not met.","The paper mentions ""dentoalveolar surgery"" and other dental procedures, which partially meets the criterion of having an intervention of invasive dental treatment, but this is as part of a review rather than a primary study.",Exclude,"This literature review on medication-related osteonecrosis of the jaw fails to meet multiple critical screening criteria, including specific intervention type, subject size, and study design. The paper lacks a focused intervention with Romosozumab, does not include a control group, and does not provide specific outcome documentation or temporal relationship analysis. Consequently, the study does not align with the required screening parameters for inclusion.",1.4
Cross-Sectional Study of four Serological Bone Turnover Markers for the Risk Assessment of Medication-Related Osteonecrosis of the Jaw,"André Peisker, G. Raschke, Mina D Fahmy, A. Guentsch, Korosh Roshanghias, K. König, S. Schultze–Mosgau",10.1097/SCS.0000000000004224,https://doi.org/10.1097/SCS.0000000000004224,The Journal of craniofacial surgery (Print),14,2017,maybe,"The abstract doesn't specify the age range of participants or whether they have cancer. It only mentions patients on ""antiresorptive therapies.""",maybe,no,The study focuses on biomarkers rather than documenting specific dental procedures and their outcomes.,yes,The study includes a control group of patients on antiresorptive therapies without MRONJ.,no,"This is a cross-sectional study, which is not explicitly listed in the accepted study designs (RCT, cohort, or case-control).",no,The abstract doesn't document the temporal relationship between medication use and MRONJ development or the duration of medication use.,no,"The study only includes 40 total subjects (20 MRONJ patients and 20 controls), which is well below the required 100+ subjects.","While the study mentions ""invasive oral surgery,"" it appears to be studying biomarkers for risk assessment rather than documenting outcomes of specific dental procedures.",Exclude,"The study fails to meet multiple critical screening criteria, including the use of Romosozumab, insufficient sample size, and lack of focus on specific dental procedure outcomes. Key deficiencies include studying different medications, having only 40 subjects, and examining biomarkers instead of documenting dental intervention results. These fundamental misalignments with the screening requirements render the study unsuitable for inclusion in the systematic review.",0.1
Medication-related Osteonecrosis of the Jaw Induced by Regenerative Therapy in Implant Dentistry: A Scoping Review.,"Farah A. Al-Omari, S. Kuroshima, T. Sawase",10.1016/j.jdent.2023.104682,https://doi.org/10.1016/j.jdent.2023.104682,E -journal of dentistry,2,2023,maybe,"The population characteristics are not explicitly stated, so it cannot be confirmed if the subjects are exclusively adults with osteoporosis.",yes,yes,"The abstract documents MRONJ outcomes following dental procedures, which meets this criterion.",no,"There is no mention of control groups, and as a scoping review, this criterion is not directly applicable.",no,"This is a scoping review, not a primary research study, so it does not meet the criterion of being a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"There is limited information about the temporal relationships and medication duration, so this criterion is only partially met or uncertain.",no,"This is a scoping review of 18 articles, not a primary study, so the subject size cannot be determined from the abstract.","The abstract discusses dental implant treatment and regenerative therapy, which meets the criterion of invasive dental treatment.",Exclude,"The scoping review fails to meet multiple critical screening criteria, including specific intervention with Romosozumab, subject size verification, and required study design. While addressing dental implant treatment and MRONJ outcomes, the paper lacks the precise population characteristics, control group, and temporal documentation necessary for inclusion. Consequently, the study does not align with the systematic review's stringent screening requirements.",1.4
"Medication-Related Osteonecrosis of the Jaw, a Hidden Enemy. An Integrative Review",Odel Chediak-Barbur,10.11144/javeriana.uo40.mroj,https://doi.org/10.11144/javeriana.uo40.mroj,Universitas Odontologica,0,2021,no,"The study includes both osteoporosis and cancer patients, and is not exclusively focused on adult osteoporosis patients without cancer, so it fails this criterion.",maybe,maybe,"The abstract discusses ONJ outcomes following dental procedures, which partially meets this criterion, but as a review rather than primary documentation.",maybe,"The abstract does not mention any control groups, so it is uncertain whether this criterion is met.",no,"This is an integrative review of literature, not a primary research study, so it fails this criterion.",no,"The abstract does not provide any specific documentation of the temporal relationship between medication use and MRONJ development, or the duration of medication use, so it fails this criterion.",maybe,"The abstract does not specify the number of subjects, so the subject size is uncertain.","The abstract mentions extractions as a risk factor (52-61%), which partially meets the criterion for invasive dental treatment, but it is not the primary focus of the study.",Exclude,"The study fails critical screening criteria by focusing on bisphosphonates and denosumab instead of Romosozumab, and by being a literature review rather than a primary research study. Additionally, the research includes cancer patients and lacks specific documentation of temporal medication use, further disqualifying it from meeting the established screening requirements.",0.1
"Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator‐mandated cohort postauthorization safety study in Denmark, Norway, and Sweden","V. Ehrenstein, U. Heide-Jørgensen, M. Schiødt, O. Akre, B. B. Herlofson, S. Hansen, Cecilia Larsson Wexell, S. Nørholt, S. Tretli, A. Kjellman, A. Glennane, K. Lowe, H. Sørensen",10.1002/cncr.33802,https://doi.org/10.1002/cncr.33802,Cancer,15,2021,no,"The study focuses on ""cancer patients with bone metastases"", which explicitly violates the criterion requiring the study to focus exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",no,maybe,"The abstract mentions ONJ outcomes, but does not provide specific documentation of dental procedures, so the study partially meets the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",maybe,"The abstract does not mention any control groups, so it is uncertain whether the study meets the criterion of including a control group of non-anti-resorptive medication users.",yes,"The abstract indicates that the study appears to be an observational study in ""routine clinical practice"", which likely meets the criterion of being a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"The abstract does not clearly mention the temporal relationship between medication use and MRONJ development or the duration of medication use, so it is uncertain whether the study meets the criterion of clearly documenting both the temporal relationship and duration of medication use.",maybe,"The abstract does not mention the specific subject size, so it is uncertain whether the study meets the criterion of having a subject size of more than 100 people.","The abstract does not mention any invasive dental treatments, so the study does not meet the criterion of having an intervention of invasive dental treatment.",Exclude,"The study focuses on cancer patients with bone metastases, which immediately disqualifies it from meeting the screening criteria for non-cancer osteoporosis patients. Additionally, the abstract lacks specificity about dental interventions, medication type, and control groups, further preventing alignment with the required screening parameters. Multiple critical screening criteria are unambiguously not met, rendering the study unsuitable for inclusion.",0.1
Medication-related osteonecrosis of the jaw and the role of the doctor of dental surgery: a literature review,"Juliana Lima de Oliveira Amorim Cabral, Susana Braga Santoro Santiago, Nicole Serqueira da Silva, Livia Cristina Buriche Ferreira da Silva, C. Silva-Boghossian, I. Tuñas",10.33448/rsd-v12i4.41284,https://doi.org/10.33448/rsd-v12i4.41284,"Research, Society and Development",0,2023,no,"The abstract does not mention adult patients or a diagnosis of osteoporosis, and does not exclude patients with cancer. Therefore, there is insufficient information to determine if the study meets the criterion of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",maybe,maybe,"While the abstract discusses MRONJ in a general context, it does not provide specific documentation of MRONJ outcomes following specific dental procedures. This indicates that the study only partially meets the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"The abstract does not mention a control group of non-anti-resorptive medication users. As this is a literature review rather than a primary study, it does not meet the criterion of including a control group.",no,"This is a literature review/systematic review, not a primary study of any of the specified designs (randomized controlled trial, prospective/retrospective cohort study, or case-control study). Therefore, the study does not meet the criterion of having a study design of one of these types.",maybe,"The abstract mentions the duration of treatment generally, but does not provide specific temporal documentation of the relationship between medication use and MRONJ development. This suggests that the study only partially meets the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",no,"This is a literature review, not a primary study, and no specific subject size is mentioned. Therefore, the study does not meet the criterion of having a subject size of more than 100 people.","The abstract mentions ""oral surgery procedures"" generally, but does not specify particular procedures such as tooth extraction, implant placement, periodontal surgery, or removable prosthesis fabrication. This indicates that the study only partially meets the criterion of having an intervention of invasive dental treatment.",Exclude,"This literature review fails to meet multiple critical screening criteria, including specific intervention type, subject size, and study design. The abstract discusses medication-related osteonecrosis of the jaw in general terms but lacks the precise details required for inclusion, such as focusing on Romosozumab, having a defined subject population, and documenting specific dental procedures and outcomes. Consequently, the paper does not align with the systematic review's rigorous screening requirements.",0.1
Incidence of osteonecrosis of the jaw by the use of osteoclast inhibitors in patients with bone metastases: a retrospective cohort study.,"Jorge Chaurand-Lara, Laura Pacheco-Ruiz, José L. Trejo-Campos, Jose Alfredo Facio-Umaña, Josué Mora-Pérez",10.24875/CIRU.18000661,https://doi.org/10.24875/CIRU.18000661,Cirugía y Cirujanos,5,2019,no,"The study focuses on patients with metastatic bone disease due to solid tumors, which explicitly fails the criterion as it includes cancer patients. Additionally, it's not focused on osteoporosis patients.",no,maybe,"While MRONJ (osteonecrosis) is documented, the specific dental procedures leading to it are not detailed, so this criterion is partially met.",no,"No control group of non-anti-resorptive medication users is mentioned, so this criterion is not met.",yes,"The study is a retrospective cohort study, which meets this criterion.",yes,"The study documents the duration of medication use (25 months for zoledronic acid, 16 months for denosumab), which meets this criterion.",yes,"The study includes 802 patients, which exceeds the minimum requirement of 100 subjects.","The abstract does not specify the dental procedures that led to osteonecrosis, so this information is missing and cannot be confirmed.",Exclude,"The study focuses on bisphosphonates and denosumab in cancer patients, which fundamentally differs from the required criteria of Romosozumab in osteoporosis patients. Critical screening requirements were not met, including the specific medication, patient population, and lack of a control group. Multiple core screening criteria were definitively failed, rendering the study ineligible for inclusion.",0.1
Medication-related osteonecrosis of the jaw (MRONJ) treated with piezosurgery – case report and review of literature,"A. Perini, G. Oliveira, F. Seguin",10.21726/RSBO.V15I2.679,https://doi.org/10.21726/RSBO.V15I2.679,RSBO,1,2018,yes,"The patient is 66 years old, which meets the adult requirement. The patient also has osteoporosis, as implied by the bisphosphonate treatment, and there is no mention of cancer, which meets the population type criterion.",yes,yes,"The study clearly documents MRONJ following dental extraction, which meets the outcome documentation criterion.",no,"No control group is mentioned, which fails to meet the criterion.",no,"The study is a case report, which does not meet the required study designs of randomized controlled trial, prospective/retrospective cohort study, or case-control study.",yes,"The study documents the temporal relationship between medication use and MRONJ development, as well as the duration of medication use (>4 years), which meets the temporal documentation criterion.",no,"The study is a single case report with only 1 subject, which fails to meet the minimum requirement of 100 subjects.","The study mentions dental extraction, which meets the criterion for invasive dental treatment.",Exclude,"This single case report fails multiple critical screening criteria, including using the wrong medication (alendronate instead of Romosozumab), having an insufficient sample size (n=1), and lacking a control group. Despite meeting some criteria like documenting dental intervention and patient characteristics, the fundamental methodological limitations disqualify the study from systematic review inclusion.",0.1
Influence of induced infection in medication-related osteonecrosis of the jaw development after tooth extraction: A study in rats.,"Adrien Bolette, G. Lecloux, E. Rompen, A. Albert, G. Kerckhofs, F. Lambert",10.1016/j.jcms.2018.08.011,https://doi.org/10.1016/j.jcms.2018.08.011,Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,22,2019,no,"The study uses rats, not adult human patients with osteoporosis, and therefore does not meet this criterion.",maybe,maybe,"The study does document MRONJ outcomes following dental procedures, but this is in an animal model, not human patients.",no,"There is no mention of a control group in the abstract, so it cannot be confirmed if this criterion is met.",no,"The study appears to be an experimental animal study, which does not meet the required study design criteria.",maybe,"The study does document the temporal relationship between medication use and MRONJ development, but this is in an animal model, not human patients.",no,"The study uses 26 rats, which falls well below the required 100+ subject size.","The study does include dental extraction, which meets this criterion. However, this is in rats, not humans.",Exclude,"This animal study using zoledronate fails to meet multiple critical screening criteria, including the requirement for human subjects, romosozumab medication, and a minimum sample size of 100 participants. The research focuses on rats with dental extractions, which fundamentally differs from the specified systematic review parameters, rendering it ineligible for inclusion.",0.1
Can medication-related osteonecrosis of the jaw be attributed to specific microorganisms through oral microbiota analyses? A preliminary study,"Heon-Young Kim, Young-Soo Jung, Wonse Park, Yoon Jeong Choi, Jun-Young Kim",10.1186/s12903-024-03945-z,https://doi.org/10.1186/s12903-024-03945-z,BMC Oral Health,2,2024,maybe,"The mean age is 82.67 years, so the patients are adults (≥18). However, there is no mention of cancer status, so the criterion is only partially met.",no,maybe,"While MRONJ is documented, the abstract doesn't specify which dental procedures led to MRONJ, only partially meeting this criterion.",no,"There is no mention of a control group, and the study appears to only include MRONJ patients, failing to meet this criterion.",yes,"The study is described as a ""single-center prospective cohort study"", which meets this criterion.",no,"There is no clear documentation of the temporal relationship between medication use and MRONJ, and the duration of medication use is not mentioned, failing to meet this criterion.",no,"The study only included 12 patients, which clearly fails to meet the minimum requirement of 100 subjects. This is a critical failure point.","While the study involves MRONJ patients, it doesn't explicitly state which dental procedures were performed. The focus appears to be on microbiota analysis rather than dental interventions.",Exclude,"The study fails to meet critical screening criteria, including a sample size of only 12 patients instead of the required 100, and lacks specification of the anti-resorptive medication Romosozumab. Multiple key requirements are not satisfied, such as absence of a control group, incomplete documentation of dental procedures, and unclear temporal relationships between medication use and MRONJ development.",1.4
A comparison of the cone beam computed tomography findings in medication-related osteonecrosis of the jaws related to denosumab versus bisphosphonates: an observational pilot study.,"S. Pichardo, Frans W. Ten Broek, M. Fiocco, N. Appelman‐Dijkstra, J. V. van Merkesteyn",10.1016/j.oooo.2019.09.010,https://doi.org/10.1016/j.oooo.2019.09.010,"Oral surgery, oral medicine, oral pathology and oral radiology",15,2019,no,"The abstract doesn't specify the age range of patients or whether they have cancer. While these are likely adult patients with osteoporosis (given the medications used), this isn't explicitly stated.",no,maybe,"The study documents MRONJ outcomes and uses CBCT for assessment, but doesn't specify the dental procedures that led to MRONJ.",no,The study compares two treatment groups (denosumab vs. bisphosphonates) but doesn't include a control group of non-anti-resorptive medication users.,maybe,"This appears to be a retrospective cohort study comparing two groups, which would qualify under the acceptable study designs.",maybe,"While the study mentions ""duration of drug therapy,"" it doesn't clearly document the temporal relationship between medication use and MRONJ development.",no,"The study only includes 34 patients (17 in each group), which is well below the required minimum of 100 subjects.","While the study discusses MRONJ, which typically follows dental procedures, the abstract doesn't explicitly state which dental procedures were performed on these patients.",Exclude,"The study fails key screening criteria by using denosumab and bisphosphonates instead of romosozumab, and having a sample size of only 34 patients, which is significantly below the required 100 subjects. Multiple other criteria remain unclear or partially met, including population type, dental intervention specifics, and temporal documentation of medication use and MRONJ development.",1.4
Osteonecrosis of the jaw in patients with inflammatory bowel disease treated with tumour necrosis factor alpha inhibitors.,"K. Brijs, I. Miclotte, S. Vermeire, V. Darche, Constantinus Politis",10.1016/j.ijom.2019.08.007,https://doi.org/10.1016/j.ijom.2019.08.007,International Journal of Oral & Maxillofacial Surgery,24,2020,no,"The study focuses on IBD patients, not osteoporosis patients, and there is no mention of an osteoporosis diagnosis.",no,maybe,"MRONJ outcomes are documented, but the initial dental procedures leading to MRONJ are not specified.",no,There is no mention of a control group of non-TNF-α inhibitor users.,yes,"The study is described as a cohort study, which meets the study design criterion.",maybe,"While the study period (1994-2018) is mentioned, specific temporal relationships between medication use and MRONJ development are not clearly documented.",yes,"The study includes 2,701 patients, which is well above the 100 minimum subject size specified in the screening criteria.","While dental procedures are mentioned (sequestrectomy), they are treatments for MRONJ rather than the initial dental interventions specified in the screening criteria. The abstract does not specify the initial dental procedures that led to MRONJ.",Exclude,"The study fundamentally fails key screening criteria by focusing on TNF-α inhibitors in IBD patients instead of Romosozumab for osteoporosis treatment. Critical misalignments include the wrong medication, patient population, and lack of specified dental interventions, rendering the study non-compliant with the systematic review requirements. Multiple core screening criteria were not met, necessitating exclusion from further review.",0.1
"Medication Related Osteonecrosis of the Jaw: An Update on Pathophysiology, Risk Factors, and Treatment","L. Rasmusson, J. Abtahi",10.37247/PAMED2ED.2.2020.25,https://doi.org/10.37247/PAMED2ED.2.2020.25,Prime Archives in Medicine,0,2020,no,"The abstract does not specify the age range or explicitly state that the population is cancer-free, so it cannot be confirmed if the study focuses exclusively on adult patients with diagnosed osteoporosis who do not have cancer.",yes,maybe,"The abstract discusses MRONJ outcomes following dental procedures, including specific procedures like extractions and implants, which partially meets this criterion.",no,The abstract does not mention any control groups.,no,"The abstract indicates that this is a narrative review, not a randomized controlled trial, prospective/retrospective cohort study, or case-control study, which fails this criterion.",no,"The abstract mentions ""long-term"" treatment but does not clearly document the temporal relationship between medication use and MRONJ development or the duration of medication use.",no,"The abstract is a narrative review of 91 articles and does not report a specific subject size, so it cannot be confirmed if the study has more than 100 subjects.","The abstract mentions tooth extractions and implant placement, which meets the criterion for invasive dental treatment.",Exclude,"The abstract fails critical screening criteria by discussing bisphosphonates instead of Romosozumab and presenting a narrative review rather than a primary research study. Multiple key requirements are not met, including lack of clear subject characteristics, absence of a control group, and inappropriate study design. These deficiencies render the paper unsuitable for inclusion in the systematic review.",0.1
A pragmatic window of opportunity to minimise the risk of MRONJ development in individuals with osteoporosis on Denosumab therapy: a hypothesis,"G. Campisi, R. Mauceri, F. Bertoldo, V. Fusco, A. Bedogni",10.1186/s13005-021-00280-4,https://doi.org/10.1186/s13005-021-00280-4,Head & Face Medicine,13,2021,maybe,"The abstract mentions osteoporosis patients, but does not explicitly state they are all adults (≥18 years). It does exclude cancer patients, focusing on ""metabolic bone fragility.""",yes,maybe,"While MRONJ outcomes are discussed, this appears to be a theoretical paper proposing protocols rather than reporting actual outcomes from specific procedures.",no,The abstract does not mention any control group.,no,The abstract appears to be a hypothesis paper or review rather than presenting original research with a specific study design.,maybe,The abstract discusses timing considerations (1-month deferral) but does not document actual temporal relationships from a study.,no,"The abstract does not mention the number of subjects in any study, so the subject size is unclear.","The abstract discusses tooth extraction and oral surgery as interventions, which meets the criterion for invasive dental treatment.",Exclude,"The abstract focuses on Denosumab rather than the specified Romosozumab, which immediately disqualifies it from meeting the primary intervention criterion. While the paper discusses dental interventions and osteoporosis patients, it appears to be a theoretical hypothesis paper lacking the required research design elements such as clear subject numbers, control groups, and documented outcomes. The fundamental mismatch with the intervention medication renders the abstract unsuitable for inclusion in the systematic review.",0.1
Genome‐wide Association Study Identified Chromosome 8 Locus Associated with Medication‐Related Osteonecrosis of the Jaw,"Guang Yang, Sonal Singh, C. McDonough, J. Lamba, Issam S. Hamadeh, L. Holliday, Danxin Wang, J. Katz, P. Lakatos, B. Balla, J. Kósa, G. Pelliccioni, D. Price, S. V. Van Driest, W. Figg, T. Langaee, J. Moreb, Y. Gong",10.1002/cpt.2397,https://doi.org/10.1002/cpt.2397,Clinical pharmacology and therapy,11,2021,maybe,"The study includes both cancer patients and osteoporosis patients. While it does include adult osteoporosis patients, it's not exclusively focused on them, and includes cancer patients which is explicitly excluded in the criteria.",maybe,maybe,"While MRONJ is the outcome, the abstract doesn't specify which dental procedures were documented.",yes,"The study includes controls (4,564 controls vs 444 cases).",yes,This appears to be a case-control study (GWAS meta-analysis with cases and controls).,maybe,The abstract doesn't mention documentation of temporal relationships or duration of medication use.,yes,"The study includes 5,008 individuals (444 cases and 4,564 controls), well above the 100-person minimum.","While the study examines MRONJ, which typically follows dental procedures, the abstract doesn't explicitly mention the types of dental interventions studied.",Exclude,"The study focuses on bisphosphonates rather than Romosozumab, which immediately disqualifies it from meeting the primary screening criteria. Additionally, the research includes cancer patients and lacks clear documentation of specific dental procedures and temporal medication use, further compromising its alignment with the required parameters. Despite having a large sample size and appropriate study design, these fundamental misalignments render the study unsuitable for inclusion.",1.4
Why do some extraction sites develop medication-related osteonecrosis of the jaw and others do not? A within-patient study assessing radiographic predictors.,"H. Gaêta-Araujo, André Ferreira Leite, K. de Faria Vasconcelos, R. Coropciuc, C. Politis, R. Jacobs, C. Oliveira-Santos",-,-,International journal of oral implantology,9,2021,no,"The abstract specifically states these are ""oncological patients,"" which directly contradicts the requirement for non-cancer patients.",yes,yes,The study clearly documents MRONJ outcomes following dental extractions and includes specific radiographic features.,yes,"The study includes a control group of ""age-, sex- and extracted tooth-matched healthy patients.""",yes,"This is a retrospective study, which is one of the acceptable study designs.",maybe,"While the study examines extraction sites and MRONJ development, the abstract doesn't clearly specify the temporal relationship between medication use and MRONJ development or the duration of medication use.",no,"The study includes 41 patients in the treatment group and 57 controls, totaling 98 subjects, which is below the required 100 subjects.","The study focuses on dental extraction sites, which meets the criterion for invasive dental treatment.",Exclude,"The study fails key screening criteria due to using oncological patients instead of non-cancer patients, employing a different antiresorptive medication than specified, and having a sample size below the required threshold. Multiple critical exclusion factors, including the wrong patient population and medication type, render this study ineligible for the systematic review.",0.1
Radiological manifestations and clinical findings of patients with oncologic and osteoporotic medication-related osteonecrosis of the jaw,"Jeong Won Shin, Jo-Eun Kim, K. Huh, W. Yi, M. Heo, Sam-Sun Lee, Soon-Chul Choi",10.1038/s41598-024-59500-x,https://doi.org/10.1038/s41598-024-59500-x,Scientific Reports,1,2024,maybe,"The study includes adult patients with osteoporosis, but also includes a significant oncologic group (39 patients). The abstract does not specify if the osteoporotic patients are exclusively ≥18 years.",maybe,yes,The study clearly documents MRONJ outcomes and includes detailed clinical and radiological features.,no,"The study compares osteoporotic vs. oncologic patients, but does not mention a control group of non-anti-resorptive medication users.",maybe,"The study design is not explicitly stated in the abstract. It appears to be a retrospective analysis of clinical data, but this is not certain.",yes,The study documents duration of medication use (58.1 vs. 28.0 months) and temporal relationships between medication use and MRONJ development.,yes,"The study includes 159 patients (120 osteoporotic + 39 oncologic), which is well above the 100-person minimum.","While the study focuses on MRONJ, which typically follows dental procedures, the abstract does not explicitly state which dental procedures were performed, creating uncertainty.",Exclude,"The study fails to meet critical screening criteria, particularly the specific requirement for Romosozumab as the intervention medication. While the research includes a substantial patient sample and documents MRONJ outcomes, it lacks a control group and includes oncologic patients, which deviates from the targeted population. The absence of a clear focus on Romosozumab and the inclusion of non-osteoporotic patients render the study non-compliant with the established screening requirements.",1.4
Patients' osteometabolic control improves the management of medication-related osteonecrosis of the jaw.,"G. Colapinto, R. Volpi, G. Forino, V. Tricarico, M. De Benedittis, R. Cortelazzi, T. Testori, M. Del Fabbro",10.1016/j.oooo.2017.10.015,https://doi.org/10.1016/j.oooo.2017.10.015,"Oral surgery, oral medicine, oral pathology and oral radiology",9,2018,no,"The study includes both osteoporosis patients (53) and cancer patients (42), while the criteria specifically require patients with diagnosed osteoporosis who do NOT have cancer.",maybe,yes,"The study clearly documents ONJ outcomes following surgical treatment, including specific complications like fistulae, abscesses, and dehiscences.",yes,The study includes a control group of 94 patients who were also on anti-resorptive therapy.,yes,"This is a prospective study with a control group, meeting the acceptable study design criteria.",yes,"The study documents temporal relationships, including a 3-month drug holiday before and after intervention, and follow-up periods (28.2 ± 7.8 months for test group, 28.1 ± 4.9 months for control group).",no,"The study includes 95 test patients and 94 control patients, totaling 189 patients. While this exceeds the minimum requirement of 100, this is irrelevant given the failure on criterion 1.","While the study involves surgical treatment for ONJ, it's not clear if this includes the specific dental procedures mentioned in the criteria. The abstract is vague about the exact nature of the interventions.",Exclude,"The study fails critical screening criteria by not specifying Romosozumab and including cancer patients, which deviates from the required population type. While demonstrating some methodological strengths like a control group and clear outcome documentation, the fundamental misalignment with key inclusion requirements renders the study unsuitable for the systematic review.",1.4
OSTEONECROSIS OF THE JAW (ONJ) IN CANCER AND MYELOMA PATIENTS. A 16-YEAR EXPERIENCE OF “RETE ONCOLOGICA PIEMONTE–VALLE D’AOSTA” CANCER NETWORK,"M. Cabras, A. Gambino, F. Erovigni, Francesco Della Ferrera, R. Freilone, M. Pentenero, A. Fasciolo, M. Di Maio, G. Ramieri, M. Migliario, P. Appendino, V. Fusco",10.32388/YIVAW8,https://doi.org/10.32388/YIVAW8,Qeios,2,2021,no,"The study focuses on cancer/myeloma patients, not osteoporosis patients, which is the required population for this criterion.",no,maybe,"The study reports MRONJ outcomes but doesn't specify the dental procedures that led to them, so it only partially meets this criterion.",no,There is no mention of a control group of non-anti-resorptive medication users.,yes,"The study is described as a ""regional-wide, multicenter retrospective survey"", which meets the requirement for a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",yes,"The study documents the temporal relationship between medication use and MRONJ development (12-36 months of treatment, range 1-227 months), which meets this criterion.",yes,"The study includes 691 patients, which is well above the 100-person requirement.","While the study discusses MRONJ, it doesn't specifically detail the dental procedures that led to MRONJ, so it's unclear if this criterion is met.",Exclude,"The study focuses on cancer and myeloma patients using zoledronate and denosumab, which fundamentally differs from the required osteoporosis patient population and Romosozumab medication. Critical screening criteria were not met, including patient population type, medication intervention, and lack of a control group. These significant deviations render the study ineligible for inclusion in the systematic review.",0.1
Predictive risk factors of medication-related osteonecrosis of the jaw,"A. Rodriguez-Archilla, Irene Rodriguez-Soriano",-,-,-,1,2019,no,"The abstract discusses both cancer and osteoporosis patients, which means the study is not exclusively focused on non-cancer osteoporosis patients, as required by the population type criterion.",yes,maybe,"The abstract mentions MRONJ outcomes, but does not provide details on the documentation of specific dental procedures, so the level of outcome documentation is unclear.",maybe,"The abstract does not mention the inclusion of a control group of non-anti-resorptive medication users, so it is unclear whether this criterion is met.",maybe,"The abstract does not specify the study design, so it is unclear whether the study design criterion of a randomized controlled trial, prospective/retrospective cohort study, or case-control study is met.",maybe,"The abstract mentions ""duration of treatment"" as a factor, but does not specify the documentation methods for the temporal relationship between medication use and MRONJ development, so the level of temporal documentation is unclear.",maybe,"The abstract does not provide any information about the study size, so it is unclear whether the subject size criterion of more than 100 people is met.","The abstract mentions ""invasive dental procedures (tooth extraction, implant placement, periodontal treatment, removable denture wearers)"", which indicates that the intervention criterion of invasive dental treatment is met.",Exclude,"The abstract fails to meet critical screening criteria, specifically lacking specification of Romosozumab as the intervention and including both cancer and osteoporosis patients. Multiple screening elements remain uncertain due to limited information, with significant gaps in documentation of medication use, study design, and control group composition. The broad discussion of antiresorptive medications and MRONJ prevents clear alignment with the predefined screening requirements.",1.4
Awareness of Medication-Related Osteonecrosis of the Jaws Amongst Patients on Antiresorptive and Antiangiogenic Medications,"Ahmad Assari, Yosef Alanazi, Elaf Mubarak Algharbi, A. Abuhabsha, B. Alshammry, Ali Alzahrani, A. Alduhaim, R. Abuhaimed",10.7759/cureus.52896,https://doi.org/10.7759/cureus.52896,Cureus,1,2024,maybe,"The study includes both osteoporosis and cancer patients, and the age range includes patients under 18, so it only partially meets or fails this criterion.",no,no,"The study focuses on patient awareness rather than clinical outcomes, so there is no documentation of MRONJ outcomes following dental procedures.",no,"There is no mention of a control group in the abstract, so it fails this criterion.",no,"This is a cross-sectional survey study, which does not match the required study designs of randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"There is no documentation of the temporal relationship between medication use and MRONJ development, or the duration of medication use.",yes,"The study includes 110 patients, which meets the requirement of more than 100 subjects.","The abstract does not mention any dental procedures or interventions, so it fails this criterion.",Exclude,"The study fails to meet multiple critical screening criteria, including the specific medication requirement, study design, and intervention type. While the sample size exceeds 100 participants, the research focuses on patient awareness of medication-related jaw osteonecrosis rather than documenting clinical outcomes of dental procedures in Romosozumab users. Consequently, the abstract does not align with the systematic review's targeted research parameters.",0.1
New paradigms for dental prevention of medication related osteonecrosis of jaws (MRONJ),G. Campisi,10.32388/652365,https://doi.org/10.32388/652365,Qeios,1,2018,no,"The abstract mentions both cancer and non-cancer patients, indicating that the study is not exclusively focused on adult patients with diagnosed osteoporosis who do not have cancer.",maybe,no,"While the abstract discusses MRONJ, it is not an outcomes study, and there is no specific documentation of MRONJ outcomes following dental procedures.",maybe,"The abstract does not mention anything about a control group of non-anti-resorptive medication users, so it is not possible to determine if this criterion is met.",no,"The paper appears to be a review/guideline paper rather than an original research study, so it does not meet the requirement of being a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The abstract mentions timing conceptually, but it is not an outcomes study, and there is no actual documentation of the temporal relationship between medication use and MRONJ development or the duration of medication use.",maybe,"The abstract does not provide any information about the study size, so it is not possible to determine if the study meets the requirement of having more than 100 subjects.","The abstract mentions dental treatments and procedures, which suggests that the study may include invasive dental interventions. However, the paper appears to be a review/paradigm paper rather than an original study, so it is not clear if it fully meets this criterion.",Exclude,"This review paper fails multiple critical screening criteria, including not focusing on Romosozumab, not being an original research study, and including cancer patients. The document appears to be a guideline summary rather than a research study, lacking specific outcome documentation and temporal relationship analysis. Consequently, the paper does not meet the required screening parameters for inclusion.",0.1
Retrospective evaluation of pathologic fractures in medication related osteonecrosis of the jaw.,"Goknur Topaloglu Yasan, S. Adiloğlu, O. Koseoglu",10.1016/j.jcms.2021.03.007,https://doi.org/10.1016/j.jcms.2021.03.007,Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,4,2021,no,"The study includes patients with cancer (specifically mentioning metastatic prostate and renal cell cancer), which is explicitly excluded in the criteria.",maybe,maybe,"While MRONJ outcomes are documented, the specific dental procedures leading to these outcomes are not clearly detailed in the abstract.",no,No mention of a control group of non-anti-resorptive medication users.,yes,"This is described as a case series study, which while not explicitly listed in the criteria, could be considered a type of cohort study.",maybe,"The abstract mentions median antiresorptive usage of 24 months, but the temporal relationship between medication use and MRONJ development is not clearly documented.",yes,"The study includes 116 patients, which exceeds the minimum requirement of 100 subjects.","The abstract mentions ""dento-alveolar surgical procedures"" but doesn't specify the types of procedures, so the details of the dental interventions are not clearly documented.",Exclude,"The study fails key screening criteria by using Zoledronic acid instead of Romosozumab and including cancer patients, which are explicit exclusion factors. While the study meets some criteria like subject size and study design, critical mismatches with the specified intervention and population type render it unsuitable for inclusion. Incomplete documentation of dental procedures and temporal relationships further compromise its alignment with the screening requirements.",1.4
"Prevalence of Medication-Related Osteonecrosis of the Jaw in Osteoporotic Patients Treated with Antiresorptive Drugs at Pranangklao Tertiary Care Hospital in Nonthaburi Province, Thailand",-,10.35755/jmedassocthai.2023.04.13832,https://doi.org/10.35755/jmedassocthai.2023.04.13832,Journal of the Medical Association of Thailand = Chotmaihet thangphaet,0,2023,yes,"The study focuses on osteoporotic patients, and while age isn't explicitly stated, the context suggests adult patients. No mention of cancer patients.",maybe,maybe,"While MRONJ outcomes are documented following tooth extraction, the documentation of other dental procedures is unclear.",no,The abstract doesn't mention a control group of non-anti-resorptive medication users.,yes,"This is a retrospective cohort study, which meets the criteria.",maybe,"The study documents mean and median drug exposure time (1.52 years and 0.85 years), but the temporal relationship between medication use and MRONJ development isn't clearly specified.",yes,"The study includes 1,188 patients, well above the minimum requirement of 100.","The study mentions tooth extraction in 49 patients, but doesn't clearly specify other dental procedures, so this criterion is only partially met.",Include,"The study primarily uses bisphosphonates instead of the specified Romosozumab, which fundamentally disqualifies it from meeting the intervention criteria. While the research includes a large sample size of osteoporotic patients and follows a retrospective cohort design, critical screening requirements like medication type and control group presence are not satisfied. The partial documentation of dental procedures and temporal relationships further limits the study's alignment with the specified screening criteria.",2.5
"Histologic analysis of medication-related osteonecrosis of the jaw compared with antiresorptive-exposed bone and other infectious, inflammatory, and necrotic jaw diseases.","A. yuan, A. Munz, S. Reinert, S. Hoefert",10.1016/j.oooo.2019.08.018,https://doi.org/10.1016/j.oooo.2019.08.018,"Oral surgery, oral medicine, oral pathology and oral radiology",12,2020,maybe,The abstract doesn't specify whether all patients were adults (≥18 years) or if they had diagnosed osteoporosis. It also doesn't mention cancer status.,maybe,no,"While the study examines MRONJ, it doesn't report outcomes following specific dental procedures. Instead, it focuses on histological features of MRONJ.",maybe,"The study includes ""healthy individuals"" as a comparison group, but this isn't specifically a control group of non-anti-resorptive medication users.",no,"This appears to be a histological analysis study, not a randomized controlled trial, cohort study, or case-control study as required.",no,The abstract doesn't document the temporal relationship between medication use and MRONJ development or the duration of medication use.,yes,"The study includes 105 patients, which exceeds the minimum requirement of 100 subjects.","While the study examines jaw diseases and bone samples, it doesn't explicitly state whether these were from patients who underwent specific dental procedures. The focus appears to be on histological analysis rather than dental interventions.",Exclude,"The study focuses on histological analysis of medication-related osteonecrosis of the jaw using bisphosphonates and denosumab, which fundamentally differs from the specified screening criteria involving romosozumab. Critical misalignments include the wrong medication type, study design, and lack of documentation on dental procedures and temporal relationships. Multiple screening criteria were not met, rendering the study non-compliant with the specified requirements.",1.4
Awareness among patient at risk of developing Medication Related Osteonecrosis of the Jaw (MRONJ) – A primary prevention strategy,"Abdulrhman Al Abdullateef, Muhanad Alhareky",10.1016/j.jsps.2020.05.004,https://doi.org/10.1016/j.jsps.2020.05.004,Saudi Pharmaceutical Journal,8,2020,no,"The study includes both cancer and osteoporotic patients, and is not exclusively focused on adult osteoporosis patients without cancer.",no,no,"No MRONJ outcomes are documented, as the study only assesses awareness of MRONJ.",no,No control group is mentioned in the study.,no,"The study is a prospective survey study, which does not match the required study designs of randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,No temporal relationships or medication duration are documented in the study.,no,"The study includes 68 patients, which is less than the required 100 subjects.","While dental treatment is mentioned, this is a survey about awareness rather than a study of actual dental interventions.",Exclude,"The study fails to meet multiple critical screening criteria, including the specific medication intervention, subject size, and study design requirements. It is a survey about MRONJ awareness rather than a clinical study of Romosozumab's effects, and does not include the necessary elements such as a control group, documented outcomes, or temporal medication analysis. The research fundamentally differs from the specified screening parameters.",0.1
Risk profile for antiangiogenic agent-related osteonecrosis of the jaws,"R. Caminha, G. Chicrala, Luiz Alberto Valente Soares Júnior, P. S. Santos",10.31744/einstein_journal/2019RW4628,https://doi.org/10.31744/einstein_journal/2019RW4628,Einstein,10,2019,no,"The abstract mentions patients with tumors, which explicitly fails the ""no cancer"" requirement for the population type.",maybe,maybe,"While osteonecrosis is discussed, specific dental procedures and outcomes are not clearly documented in the abstract.",no,There is no mention of a control group in the abstract.,no,"This is a case report review, which does not meet the required study design criteria.",no,There is no clear documentation of temporal relationships or medication duration in the abstract.,no,"The abstract mentions 19 case reports, which is well below the required 100 subjects.","While dental procedures are mentioned, they are discussed in general terms, and the abstract does not specify which procedures were performed.",Exclude,"The study focuses on antiangiogenic agents in cancer patients, which fundamentally differs from the required criteria of Romosozumab for osteoporosis treatment. With only 19 case reports and a population of cancer patients, the research fails to meet multiple critical screening requirements, including subject size, population type, and intervention specifics. Consequently, the abstract does not align with the systematic review's predefined screening criteria.",0.1
Analysis of Status and Costs of Medication-Related Osteonecrosis of the Jaw in Korea using the National Health Insurance Service Database,"Yong-Wook Kwon, Minjung Park",10.17480/psk.2020.64.4.312,https://doi.org/10.17480/psk.2020.64.4.312,-,0,2020,maybe,The abstract doesn't specify the age range of patients or whether they have cancer. It only mentions patients with MRONJ.,maybe,maybe,"While MRONJ outcomes are documented, the specific dental procedures leading to MRONJ are not clearly detailed in the abstract.",no,The abstract doesn't mention any control group of non-anti-resorptive medication users.,yes,This appears to be a retrospective cohort study using National Health Insurance Service sample cohort data.,maybe,"The abstract mentions ""less than three years from the last dose of drugs"" but doesn't provide detailed temporal relationships or duration of medication use.",yes,"The study includes 183 MRONJ patients, which exceeds the minimum requirement of 100 subjects.","While the study discusses MRONJ, which typically occurs after dental procedures, the abstract doesn't explicitly specify the types of dental interventions involved.",Exclude,"The study fails to meet critical screening criteria, particularly the requirement for Romosozumab as the intervention medication, instead focusing on other bone-modifying agents. While the research includes a sufficient sample size and appears to be a retrospective cohort study, it lacks a control group and clear documentation of specific dental procedures and patient characteristics. The absence of Romosozumab and incomplete documentation of key screening elements significantly reduce the study's alignment with the specified criteria.",1.4
Incidence of and risk for osteonecrosis of the jaw in Korean osteoporosis patients treated with bisphosphonates: A nationwide cohort-study.,"Se Hwa Kim, Young-Kyun Lee, Tae-Young Kim, Y. Ha, S. Jang, H. Y. Kim",10.1016/j.bone.2020.115650,https://doi.org/10.1016/j.bone.2020.115650,Bone,18,2020,yes,The study focuses on adult osteoporosis patients with no mention of cancer patients.,maybe,maybe,"While ONJ outcomes are documented, the specific dental procedures leading to ONJ are not clearly detailed in the abstract, though tooth extraction is mentioned as a risk factor.",yes,The study includes a well-matched control group of non-BP users.,yes,This appears to be a retrospective cohort study using national health insurance data.,yes,The study documents a 4-year follow-up period and temporal relationship between BP use and ONJ development.,yes,"The study includes 164,926 BP users and 164,926 controls, well exceeding the 100-person minimum.","The study mentions tooth extraction and periodontal disease as risk factors, but doesn't specifically focus on these as interventions. It's more of an observational study of risk factors.",Exclude,"The study focuses on bisphosphonates in osteoporosis patients, which fundamentally differs from the specified Romosozumab intervention, representing a critical screening criterion mismatch. While the research demonstrates robust methodology with a large sample size and appropriate population, the primary medication type disqualifies it from meeting the core screening requirements. The dental intervention aspects are secondary and do not align with the specific intervention criteria.",1.4
Dental pathologies in tumor patients with bone metastases or multiple myeloma scheduled for antiresorptive therapy.,"J. Laimer, Martin Hechenberger, D. Müller, Benjamin Walch, A. Kolk, D. Schnabl, M. Schomaker, E. Bruckmoser",10.2217/fon-2020-1240,https://doi.org/10.2217/fon-2020-1240,Future Oncology,1,2021,no,"The study specifically focuses on patients with ""solid tumors with osseous metastases or multiple myeloma"", which explicitly violates the criterion requiring patients without cancer.",no,no,"The study does not report MRONJ outcomes following specific dental procedures, but only screens for pre-existing conditions, so it does not meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"There is no mention of a control group in the study, so it does not meet the criterion of including a control group of non-anti-resorptive medication users.",yes,"The study is described as a prospective study, which meets the criterion of having a study design of a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The study does not document the temporal relationship between medication use and MRONJ development or the duration of medication use, so it does not meet the criterion of clearly documenting both the temporal relationship and duration of medication use.",yes,"The study includes 119 subjects, which meets the criterion of having a subject size of more than 100 people.","The study focuses on screening for dental pathologies before treatment and does not document actual dental procedures performed, so it does not meet the criterion of having an intervention of invasive dental treatment.",Exclude,"The study fails multiple critical screening criteria, including using the wrong medication, focusing on cancer patients instead of osteoporosis patients, and lacking documentation of actual dental interventions or MRONJ outcomes. While the study meets some criteria like subject size and prospective design, it fundamentally differs from the systematic review's requirements by examining pre-treatment screening rather than post-procedure outcomes.",0.1
Jaw osteonecrosis in patients treated with denosumab 120 mg with regular dental monitoring: 4-year retrospective study,"Sophie Beaudouin, Lucie-Marie Scailteux, C. Lefeuvre, Romain Gamby, Sophie Cairon-Lejeune",10.1051/mbcb/2021035,https://doi.org/10.1051/mbcb/2021035,Journal of Oral Medicine and Oral Surgery,3,2021,maybe,The study includes adults (≥18 years) but doesn't explicitly state that all patients have diagnosed osteoporosis. The abstract doesn't mention cancer status.,maybe,yes,"The study clearly documents MRONJ outcomes, including staging (stage 0 and 1).",no,No control group of non-anti-resorptive medication users is mentioned in the abstract.,yes,"This is a retrospective study, which is one of the acceptable study designs.",yes,The study documents temporal relationships through regular 4-month follow-ups and tracks medication use duration.,yes,"The study includes 251 patients, well above the minimum requirement of 100.","While the study mentions ""regular dental monitoring,"" it doesn't explicitly state whether invasive dental procedures were performed. The focus seems to be on monitoring rather than specific dental interventions.",Exclude,"The study focuses on denosumab rather than the specified romosozumab, representing a critical deviation from the screening criteria. While the research demonstrates methodological strengths like appropriate sample size and outcome documentation, the fundamental medication mismatch and absence of a control group disqualify it from meeting the established screening requirements.",1.4
Medication-Related Osteonecrosis of the Jaw in Women with Breast Cancer: A Narrative Review,"Alina Čebatariūnienė, Niyosha Rasekhi",10.18103/mra.v12i12.6194,https://doi.org/10.18103/mra.v12i12.6194,Medical Research Archives,0,2024,no,"The study focuses on breast cancer patients, not osteoporosis patients, which indicates it does not meet the criterion of focusing exclusively on adult patients with diagnosed osteoporosis who do not have cancer.",no,no,"While MRONJ outcomes are discussed, they are not documented in relation to specific dental procedures, indicating the study does not meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"There is no mention of control groups in the abstract, so it is unclear whether the study meets the criterion of including a control group of non-anti-resorptive medication users.",no,"The paper appears to be a review article, not a primary research study, which suggests it does not meet the criterion of having a study design of a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"No specific temporal relationships or medication durations are documented, suggesting the study does not meet the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",maybe,"The abstract does not mention any specific subject size, so it is uncertain whether the study meets the criterion of having a subject size of more than 100 people.","While dental procedures are mentioned, they are discussed in general terms, and the paper appears to be a review of MRONJ management rather than a study of specific dental interventions. This suggests the study does not meet the criterion of having an intervention of invasive dental treatment.",Exclude,"The abstract describes a review article about MRONJ in breast cancer patients, which fundamentally differs from the required study parameters involving Romosozumab and osteoporosis patients. Critical screening criteria are not met, including medication type, patient population, study design, and specific intervention requirements. The paper fails to align with the systematic review's core screening elements, rendering it unsuitable for inclusion.",0.1
Medication‐related osteonecrosis of the jaw: Analysing the range of implicated drugs from the Australian database of adverse event notifications,"L. Teoh, G. Moses, A. Nguyen, M. McCullough",10.1111/bcp.14681,https://doi.org/10.1111/bcp.14681,British Journal of Clinical Pharmacology,17,2020,maybe,"The abstract does not mention any specific age groups or cancer status, so the population type cannot be determined.",maybe,maybe,"While MRONJ is the outcome, the abstract does not specify the documentation of specific dental procedures, so the outcome documentation is unclear.",maybe,"The abstract does not mention any control groups, so the presence of a control group is uncertain.",no,"The study appears to be a case report analysis from a database, which does not match the required study designs of randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"The abstract does not mention any temporal relationships or duration of medication use, so the temporal documentation is uncertain.",maybe,"The abstract does not specify the number of cases analyzed, so the subject size cannot be determined from the information provided.","While MRONJ is discussed, the abstract does not specify which dental procedures were involved, so the intervention details are unclear.",Exclude,"The study fails critical screening criteria by not focusing on Romosozumab and using a case report analysis instead of the required study designs. Multiple screening elements remain uncertain, including subject size, population type, and specific intervention details. The fundamental mismatch with the specified medication and study design renders the abstract unsuitable for inclusion.",0.1
5PSQ-026 Medication-related osteonecrosis of the jaws andCDK4/6 inhibitors,"L. Domínguez Senín, D. Morales Pancorbo, MY Rodríguez Garcés, M. Rodriguez Jorge, M. Santos-Rubio, J. Bayo Calero",10.1136/ejhpharm-2023-eahp.250,https://doi.org/10.1136/ejhpharm-2023-eahp.250,Section 5: Patient safety and quality assurance,0,2023,no,"The study focuses on cancer patients (breast, prostate, lung cancer), which explicitly fails the criterion requiring non-cancer patients.",no,maybe,"MRONJ outcomes are documented, but no specific dental procedures are mentioned, so this criterion is only partially met.",no,"The study does compare groups (denosumab with/without CDK4/6 inhibitors), but this is not the type of control group specified in the criteria (non-anti-resorptive users).",yes,"The study is described as a ""retrospective observational study"", which meets the criterion as it falls under retrospective cohort study.",yes,"The study documents temporal relationships and duration of medication use, including the median treatment duration for denosumab (19 months) and the time to MRONJ development (23 months), so this criterion is met.",yes,"The study includes 363 patients, which exceeds the minimum requirement of 100, so this criterion is met.","The abstract does not mention any specific dental procedures or interventions, which is a significant missing element.",Exclude,"The study focuses on denosumab in cancer patients, which fundamentally conflicts with the screening criteria requiring romosozumab in non-cancer osteoporosis patients. Critical disqualifying factors include the wrong medication, inappropriate patient population, and absence of specific dental intervention details. These core deviations render the study ineligible for inclusion in the systematic review.",0.1
Oral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw Dental Clinical Guidance,Michele West,-,-,-,3,2017,maybe,"The abstract does not mention adult patients or a diagnosis of osteoporosis, and it does not mention the exclusion of cancer patients, so it cannot be determined if the study focuses exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",maybe,no,"While MRONJ is mentioned, this is a guidance document about managing risk, not a study documenting MRONJ outcomes following specific, documented dental procedures (extractions, periodontal surgery, implants, or prosthetic treatments).",maybe,"The abstract does not mention a control group of non-anti-resorptive medication users, so it cannot be determined if the study includes such a control group.",no,"The abstract indicates that this is a clinical guidance document, not a research study, so it does not meet the study design criterion of being a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The abstract does not document the temporal relationship between medication use and MRONJ development or the duration of medication use, so it cannot be determined if the study clearly documents these aspects.",maybe,"The abstract does not mention the study size or number of participants, so it cannot be determined if the subject size is more than 100 people.","The abstract mentions ""routine dental treatment"" but does not specify invasive procedures, so it is too vague to confirm if the intervention includes invasive dental treatment, such as tooth extraction, implant placement, periodontal surgery, other dental surgery, or removable prosthesis fabrication.",Exclude,"This clinical guidance document fails multiple screening criteria, primarily because it is not a research study and does not focus on Romosozumab as the intervention. The abstract lacks specific details about patient population, study design, and outcome documentation, rendering it unsuitable for inclusion in the systematic review.",0.1
Retrospective analysis of medication-related osteonecrosis of the jaw at a maxillofacial prosthetics clinic,"Islam E. Ali, Cheewin Towithelertkul, Y. Sumita, Noriyuki Wakabayashi",10.26629/ijmp.2024.04,https://doi.org/10.26629/ijmp.2024.04,International Journal of Maxillofacial Prosthetics,0,2024,no,"The study includes cancer patients (breast and prostate cancer mentioned), which means it fails to meet the criterion of focusing exclusively on adult patients with diagnosed osteoporosis who do not have cancer.",maybe,maybe,"MRONJ outcomes are documented, but the specific dental procedures leading to MRONJ are not clearly documented, so the study only partially meets this criterion.",no,"There is no mention of a control group, so the study fails to meet this criterion.",yes,"The study is described as a ""retrospective analysis"", which means it meets the criterion of having a study design that is either a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"There is no clear documentation of the temporal relationship between medication use and MRONJ, and no mention of the duration of medication use, so the study fails to meet this criterion.",maybe,"The abstract does not specify the total number of patients, so it is uncertain whether the study meets the criterion of having a subject size of more than 100 people.","While prosthetic treatment is mentioned, it is not clear if this was the cause or treatment of MRONJ, so it is uncertain whether the study meets the criterion of having an intervention of invasive dental treatment.",Exclude,"The study fails to meet multiple critical screening criteria, including specific focus on Romosozumab, exclusion of cancer patients, and clear documentation of dental procedures and medication temporal relationships. While the research provides insights into MRONJ, it does not align with the precise requirements for the targeted intervention and population. The broad approach and inclusion of cancer patients significantly deviate from the specified screening parameters.",1.4
Awareness About Medication-Related Osteonecrosis of the Jaw Among Dental Professionals: A Multicentre Study,"Vathsala Patil, S. Acharya, R. Vineetha, Krithi Nikhil",10.3290/j.ohpd.a43361,https://doi.org/10.3290/j.ohpd.a43361,Oral Health & Preventive Dentistry,20,2020,no,"The study population consists of dentists, not patients, and there is no mention of osteoporosis patients. Therefore, the study does not meet the criterion of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",no,no,"While MRONJ is discussed, it's not documenting outcomes in patients. The focus is on dentist knowledge about MRONJ. Therefore, the study does not meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"No control group is mentioned, and this is not a clinical study. Therefore, the study does not meet the criterion of including a control group of non-anti-resorptive medication users.",no,"This is a survey study of dentist knowledge, which does not match any of the required study designs (randomized controlled trial, prospective/retrospective cohort study, or case-control study). Therefore, the study does not meet the criterion of having a study design that is either a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"There is no documentation of temporal relationships or medication duration, as this is not a clinical study. Therefore, the study does not meet the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",no,"The study involves 234 dentists as respondents, not a study of patients. Therefore, the study does not meet the criterion of having a subject size of more than 100 people.","While the paper discusses dental procedures, it's from the perspective of dentist knowledge, not a study of patients undergoing these procedures. Therefore, the study does not meet the criterion of having an intervention of invasive dental treatment.",Exclude,"This survey study of dentist knowledge about medication-related osteonecrosis of the jaw fails to meet any of the specified screening criteria, as it does not involve patients, Romosozumab, invasive dental treatments, or clinical outcomes. The research focuses on dental professionals' awareness rather than patient-centered clinical investigation, rendering it ineligible for the systematic review.",0.1
Risk of Jaw Osteonecrosis After Intravenous Bisphosphonates in Cancer Patients and Patients Without Cancer,"J. Goodwin, Jie Zhou, Y. Kuo, J. Baillargeon",10.1016/j.mayocp.2016.09.015,https://doi.org/10.1016/j.mayocp.2016.09.015,Mayo Clinic proceedings,12,2017,maybe,"The study includes adult patients with osteoporosis (non-cancer group), but also includes cancer patients. The non-cancer group appears to be the focus of interest.",maybe,maybe,"While jaw osteonecrosis is documented, the abstract doesn't specify whether this was following specific dental procedures.",yes,The study includes a comparison group of non-IV bisphosphonate users (oral bisphosphonate for 30 days or less).,yes,"This is a retrospective cohort study, which meets the criteria.",maybe,The study documents the temporal relationship (follow-up period from 2008-2013) but doesn't clearly specify the duration of medication use.,yes,"The study includes large sample sizes (9,482 cancer patients and 16,046 non-cancer patients), well above the 100-person requirement.","While the study looks at jaw osteonecrosis, it doesn't explicitly state whether this was following specific dental procedures. The abstract mentions ""surgical procedures"" but doesn't specify dental procedures.",Exclude,"The study primarily focuses on IV bisphosphonates rather than the specified Romosozumab, which represents a fundamental deviation from the screening criteria. While the research includes a large sample size and appropriate study design, the core intervention does not match the required medication type. Consequently, the paper fails to meet the primary screening requirement despite having some methodological strengths.",1.4
The importance of treating dental caries in the prevention of medication related osteonecrosis of the Jaw,"Mehmet Salık, E. Bakır",10.51271/jdse-0021,https://doi.org/10.51271/jdse-0021,Journal of Dental Sciences and Education,0,2023,maybe,"The abstract mentions patients with ""bone metabolism diseases"" but also includes cancer patients, and does not specify age restrictions, so it only partially meets this criterion.",yes,no,"While MRONJ is discussed, the paper appears to focus on prevention strategies rather than documenting specific outcomes, so it does not clearly meet this criterion.",no,"There is no mention of control groups, so it cannot be determined if this criterion is met.",no,"This is explicitly stated to be a review paper, not a primary research study, so it does not meet the required study design criteria.",no,"There is no mention of temporal relationships or duration of medication use, so this criterion is not met.",no,"The abstract does not mention any specific subject size, and this is a review paper rather than a primary study, so it cannot be determined if this criterion is met.","The abstract mentions tooth extraction and oral surgery, so this criterion appears to be met.",Exclude,"The abstract describes a review paper on medication-related osteonecrosis of the jaw, focusing on prevention strategies, which fundamentally differs from the required primary research study design. Critical screening criteria are not met, including the specific medication type, study population, and outcome documentation requirements. Multiple core screening elements are unambiguously absent, rendering the paper unsuitable for inclusion.",0.1
RE: American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update: Quantitative Risk Assessment and Controversial Issues.,"V. Fusco, R. Mauceri, G. Campisi, A. Bedogni",10.1016/j.joms.2022.07.143,https://doi.org/10.1016/j.joms.2022.07.143,Journal of oral and maxillofacial surgery,10,2022,no,"The abstract specifically mentions patients with ""bone metastases from solid cancer or by multiple myeloma"", which explicitly violates the criterion requiring non-cancer patients.",no,no,"While MRONJ is the focus, this paper doesn't report specific outcomes from dental procedures.",no,No control group is mentioned as this is a position paper.,no,"This is a position paper/clinical guideline document, not a primary research study.",no,No temporal relationships or medication durations are documented.,no,"No specific subject size is mentioned in the abstract, and the paper is described as a position paper rather than a primary research study.","While dental procedures are implied in the context of MRONJ, this is a position paper rather than a study of specific invasive dental treatments.",Exclude,"This position paper fails to meet multiple screening criteria, including specific intervention type, subject size, population characteristics, and study design requirements. The document focuses on cancer patients and MRONJ management, which directly contradicts the specified inclusion criteria for a study on Romosozumab and non-cancer osteoporosis patients. Consequently, the paper does not qualify for further review based on the established screening parameters.",0.1
"279P Incidence, risk factors and management of medication-related osteonecrosis of the jaw in breast cancer patients treated with zoledronic acid or denosumab over a 5-year period in a UK tertiary institution","O. Akala, S. Bhagani, O. Ayodele, B. Varadhan, K. Sampson, K.N. Kancherla, J. Wood, S. Ahmed",10.1016/j.esmoop.2024.103337,https://doi.org/10.1016/j.esmoop.2024.103337,ESMO Open,2,2024,no,"The study focuses on breast cancer patients, not patients with diagnosed osteoporosis, which is another critical mismatch.",yes,yes,"The study reports MRONJ outcomes following dental procedures, though specific procedures aren't detailed in the abstract.",maybe,The abstract doesn't mention a control group of non-anti-resorptive medication users.,yes,"This is a retrospective cohort study, which meets the criteria.",yes,"The study documents temporal relationships, including mean duration of BMA treatment (2.2 years) and timing of MRONJ development.",yes,"The study includes 455 patients, well above the minimum requirement of 100.","The study mentions dental interventions, though specific procedures aren't detailed in the abstract. 10 of 17 MRONJ cases had dental interventions.",Exclude,"The study fails key screening criteria by focusing on breast cancer patients using Zoledronic acid and Denosumab, rather than osteoporosis patients taking Romosozumab. While the research demonstrates a robust methodology with a large sample size and clear documentation of medication-related osteonecrosis of the jaw, the fundamental population and intervention characteristics disqualify it from meeting the specified inclusion requirements.",0.1
Clinical and Radiographic Features of Peri-Implant Medication-Related Osteonecrosis of the Jaw: A Retrospective Study.,"Hyeon-Gyu Jo, Wonse Park, In-Ho Cha, Young-Soo Jung, Da Yun Lee, Jun-Young Kim",10.1111/cid.13412,https://doi.org/10.1111/cid.13412,Clinical Implant Dentistry and Related Research,0,2024,maybe,"While the study mentions patients taking ARDs, it doesn't explicitly state they have diagnosed osteoporosis or confirm they don't have cancer. The abstract mentions ""concomitant disease"" but doesn't specify.",yes,yes,The study clearly documents MRONJ outcomes following specific dental procedures (implant placement).,no,No control group of non-anti-resorptive medication users is mentioned in the abstract.,yes,"The study is described as a retrospective examination of cases, which qualifies as a retrospective cohort study.",maybe,"The abstract mentions ""time of ARD therapy"" was collected, but doesn't clearly document the temporal relationship between medication use and MRONJ development.",no,"The study only includes 75 patients, which is below the required minimum of 100 subjects.","The study focuses on dental implant placement and related procedures, which qualifies as invasive dental treatment.",Exclude,"The study fails key screening criteria, specifically using general anti-resorptive drugs instead of the required Romosozumab and having a sample size below the minimum 100 subjects. Critical methodological limitations include the absence of a control group and unclear population characteristics, which prevent the study from meeting the systematic review's rigorous requirements.",1.4
Surgical Therapy in Patients With Medication-Related Osteonecrosis of the Jaw Is Associated With Disease Resolution and Improved Quality of Life: A Prospective Cohort Study.,"M. El-Rabbany, N. Blanas, S. Sutherland, D. Lam, P. Shah, A. Azarpazhooh",10.1016/j.joms.2022.01.012,https://doi.org/10.1016/j.joms.2022.01.012,Journal of oral and maxillofacial surgery,5,2022,maybe,"The abstract doesn't specify the age range or whether patients had cancer. It only mentions ""consecutive MRONJ patients.""",maybe,yes,The study clearly documents MRONJ outcomes and their resolution following treatment.,no,"The study compares operative vs. nonoperative treatment groups, not anti-resorptive medication users vs. non-users.",yes,"The abstract explicitly states this is a ""prospective cohort study.""",no,The abstract doesn't mention the temporal relationship between medication use and MRONJ development or the duration of medication use.,no,"The study only included 60 patients, which is below the required 100 subjects.","While the study focuses on MRONJ treatment, it doesn't explicitly state whether the patients had invasive dental procedures. However, given that MRONJ typically occurs after dental procedures, this criterion is likely met but not confirmed in the abstract.",Exclude,"The study fails to meet multiple critical screening criteria, including specific medication type, required sample size, and control group composition. Significant gaps exist in documenting patient population characteristics, temporal medication relationships, and precise intervention details. These deficiencies substantially reduce the study's alignment with the predefined screening requirements.",1.4
Antimicrobial peptide gene expression in medication-related osteonecrosis of the jaw.,"Yasmin Thiel, C. Ghayor, D. Lindhorst, H. Essig, F. Weber, M. Rücker, P. Schumann",10.1016/j.prp.2020.153245,https://doi.org/10.1016/j.prp.2020.153245,"Pathology, Research and Practice",7,2020,maybe,"The study includes patients with MRONJ, but it's unclear if all patients are adults ≥18 years. The abstract doesn't specify age ranges or explicitly exclude cancer patients.",no,no,"While MRONJ is discussed, the study focuses on AMP expression rather than documenting specific dental procedures and their outcomes.",yes,The study includes a control group of healthy subjects with no history of bone metabolism-influencing drugs.,maybe,"The study design isn't explicitly stated, but appears to be a case-control study based on the comparison groups.",no,The abstract doesn't document the temporal relationship between medication use and MRONJ development or the duration of medication use.,no,"The study only includes 18 total subjects, well below the required 100+ subjects.","While the study discusses MRONJ, it doesn't explicitly state which dental procedures were performed. The focus appears to be on analyzing AMP expression rather than documenting dental procedures.",Exclude,"The study fails to meet multiple critical screening criteria, including using the wrong medication (bisphosphonates/denosumab instead of romosozumab) and having an insufficient sample size of only 18 subjects. Additionally, the research focuses on molecular mechanisms of MRONJ rather than documenting specific dental procedures and their clinical outcomes, rendering it unsuitable for the systematic review.",0.1
Medication-related osteonecrosis and osteoradionecrosis of the jaws: Update and current management.,"J. Kün-Darbois, F. Fauvel",10.1016/j.morpho.2020.11.008,https://doi.org/10.1016/j.morpho.2020.11.008,Morphologie : bulletin de l'Association des anatomistes,23,2020,no,"The paper does not mention adult patients or osteoporosis, and discusses MRONJ in general terms. Therefore, the paper fails to meet the criterion of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",maybe,no,"While the paper discusses MRONJ outcomes, this is not in the context of a specific study, and there is no specific documentation of outcomes following procedures. Therefore, the paper fails to meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"The paper does not mention any control groups, and appears to be a review paper comparing MRONJ and ORNJ. Therefore, the paper fails to meet the criterion of including a control group of non-anti-resorptive medication users.",no,"The paper appears to be a review paper, not an original research study, and does not match any of the required study designs (randomized controlled trial, prospective/retrospective cohort study, or case-control study). Therefore, the paper fails to meet the criterion of having an appropriate study design.",no,"The paper does not discuss any specific temporal relationships or medication duration. Therefore, the paper fails to meet the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",no,"No specific subject size is mentioned in the abstract, and the paper appears to be a review/comparison paper rather than an original study. Therefore, the paper fails to meet the criterion of having a subject size of more than 100 people.","The paper mentions tooth extraction as a triggering factor and discusses dental procedures in general, but not in the context of a specific study. Therefore, the paper partially meets this criterion, but not in the required context.",Exclude,"This review article comparing MRONJ and ORNJ fails to meet multiple critical screening criteria, including specific intervention type, subject size, population characteristics, and study design requirements. The paper lacks the necessary details for inclusion, such as a control group, specific outcome documentation, and temporal relationship analysis. Consequently, it does not qualify for the systematic review based on the predefined screening criteria.",0.1
The progress of medication-related osteonecrosis of the jaw with conservative initial treatment: A 12-year retrospective study of 129 patients,"N. Kaibuchi, K. Hoshi, A. Yamazaki, Noriko Miyamoto-Sangu, Y. Akagi, T. Okamoto",10.1016/j.bonr.2021.101072,https://doi.org/10.1016/j.bonr.2021.101072,Bone Reports,16,2021,maybe,"While the study includes adult patients with osteoporosis, it also includes patients with cancer. The abstract does not specify the age range, and the study is not exclusively focused on osteoporosis patients.",maybe,yes,The study clearly documents MRONJ outcomes and mentions specific dental procedures (teeth extraction).,no,There is no mention of a control group of non-anti-resorptive medication users. The study compares different groups of MRONJ patients.,yes,"This is a retrospective study, which meets the criteria for acceptable study designs.",maybe,"While the study period is mentioned (2008-2018), the abstract does not clearly document the temporal relationship between medication use and MRONJ development or the duration of medication use.",yes,"The study includes 129 patients, which exceeds the minimum requirement of 100 subjects.","The abstract mentions ""teeth extraction"" as a trigger for MRONJ, but does not clearly specify other dental procedures. The study is not focused on studying the dental interventions themselves.",Exclude,"The study fails to meet critical screening criteria, particularly the requirement for Romosozumab as the intervention medication. While the research includes a sufficient sample size and documents MRONJ outcomes, it uses different bone-modifying agents and includes cancer patients, which disqualifies it from the specified research parameters. The absence of a control group and unclear temporal documentation further compromise its alignment with the screening requirements.",1.4
The Case of Lower Jaw Resection due to Medication-Induced Osteonecrosis Mronj,"Tsolov, G. Yordanov, T. Dushkova",10.20431/2456-0030.0501004,https://doi.org/10.20431/2456-0030.0501004,-,0,2020,no,"The abstract focuses on cancer patients, and does not specify an adult-only population.",maybe,no,"The abstract discusses MRONJ outcomes generally, but does not provide specific documentation of outcomes following dental procedures.",maybe,"The abstract mentions a placebo group for comparison, but this is in reference to other studies, not a specific study design.",no,"The abstract appears to be from a review article rather than a primary research study, and no specific study design is mentioned.",no,"The abstract mentions ""average of 14 doses"" for Denosumab, but does not provide specific temporal documentation of medication use and MRONJ development.",maybe,"The abstract discusses general statistics (1% risk, 100 cases in 10,000 patients), but does not provide a specific subject size for the study.","The abstract mentions dental extraction and ""dental remediation"", but this is in a general context, not as part of a specific study.",Exclude,"The abstract fails multiple critical screening criteria, including the absence of Romosozumab as the intervention, focus on cancer patients instead of a general osteoporosis population, and lack of a specific research study design. Key deficiencies include no documentation of specific dental procedures, temporal relationships, or control group comparisons, rendering the text unsuitable for the systematic review.",0.1
Associations between Systemic Markers of Bone Turnover or Bone Mineral Density and Anti-Resorptive Agent-Related Osteonecrosis of the Jaw in Patients Treated with Anti-Resorptive Agents,"Kazuhito Tohashi, M. Nakabayashi, Isamu Kodani, K. Kidani, K. Ryoke",-,-,Yonago acta medica,8,2016,maybe,"The abstract does not specify the age range of the patients, does not explicitly state if they have diagnosed osteoporosis, and does not mention their cancer status, so there is insufficient information to determine if the population type meets the criterion.",yes,yes,"The study documents ARONJ outcomes and mentions tooth extraction, which meets the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",maybe,"The study has a control group of 24 patients who did not develop ARONJ, but it is unclear if these are non-anti-resorptive users, so there is insufficient information to determine if the control group criterion is met.",yes,"The study appears to be a case-control study, which meets the criterion of having a randomized controlled trial, prospective/retrospective cohort study, or case-control study design.",no,"The study does not clearly document the temporal relationship between medication use and ARONJ development, and the duration of medication use is not specified, so it fails to meet the temporal documentation criterion.",no,"The study includes 56 patients, which is less than the required 100 subjects, so it fails to meet the subject size criterion.","The study mentions tooth extraction, which meets the criterion of having an intervention of invasive dental treatment.",Exclude,"The study fails key screening criteria, including using a different anti-resorptive medication than specified and having a sample size below the required 100 participants. While the research explores anti-resorptive agent-related osteonecrosis of the jaw and includes a control group, critical methodological requirements are not met, rendering the study non-compliant with the predefined screening standards.",1.4
Pathophysiology of Medication‐Related Osteonecrosis of the Jaw—A Minireview,"S. Tetradis, M. Allen, S. Ruggiero",10.1002/jbm4.10785,https://doi.org/10.1002/jbm4.10785,JBMR Plus,16,2023,no,"The abstract mentions osteoporosis patients but also includes other conditions, and it is not exclusively focused on adult osteoporosis patients, so it does not meet the criterion of the study focusing on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",no,no,"While MRONJ is the focus, the abstract does not describe specific documented dental procedures, so it does not meet the criterion of the study reporting MRONJ outcomes following specific, documented dental procedures.",no,"The abstract does not mention any control groups, and this is a review article, not an interventional study, so it does not meet the criterion of the study including a control group of non-anti-resorptive medication users.",no,"The abstract explicitly states that this is a ""minireview"" article, not a primary research study of any of the specified designs, so it does not meet the criterion of the study design being a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The abstract does not mention any temporal relationships or medication duration, so it does not meet the criterion of the study clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",no,"The abstract does not mention the study size, and it appears to be a review article rather than a primary study, so it does not meet the criterion of having a subject size of more than 100 people.","While MRONJ is discussed, the abstract does not describe specific dental interventions, so it does not meet the criterion of the subjects having an intervention of invasive dental treatment.",Exclude,"This minireview article fails to meet any of the specified screening criteria for a primary research study on medication-related osteonecrosis of the jaw. The abstract describes a review of pathogenesis and progression, lacking specific details about patient populations, interventions, control groups, or study design required by the screening protocol. Consequently, the paper would be excluded from further systematic review consideration.",0.1
Clinical and Histopathological Aspects of MRONJ in Cancer Patients,"GEORGE-ADRIAN Ciobanu, L. Mogoantă, A. Camen, Mihaela Ionescu, D. Vlad, I. Staicu, C. Munteanu, M. Gheorghiță, R. Mercuț, Elena-Claudia Sin, S. Popescu",10.3390/jcm12103383,https://doi.org/10.3390/jcm12103383,Journal of Clinical Medicine,7,2023,no,"The study specifically focuses on cancer patients, which is explicitly excluded in the screening criteria. The criteria require patients with diagnosed osteoporosis who do NOT have cancer.",yes,yes,"The study clearly documents MRONJ outcomes following specific dental procedures, including extractions and surgical treatments.",no,The abstract does not mention any control group of non-anti-resorptive medication users.,yes,"The study is described as a retrospective study, which fits within the acceptable study designs.",maybe,"While the study documents the relationship between medication use and MRONJ development, the duration of medication use is not clearly specified in the abstract.",no,"The study includes only 51 patients, which is below the required minimum of 100 subjects.","The study includes surgical treatment and mentions tooth extraction, which qualifies as invasive dental treatment.",Exclude,"The study fails key screening criteria by focusing on cancer patients using bisphosphonates instead of Romosozumab for osteoporosis, with a sample size below 100 participants. Critical exclusion factors include the wrong medication type, patient population, and absence of a control group, rendering the study ineligible for the systematic review.",0.1
Evaluation of Preventive Treatment Protocols for Patients under Antiresorptive Therapy Undergoing Tooth Extraction at a Swiss University Clinic,"Ellen Pick, N. Leuenberger, Irina Kuster, Nicole Selina Stutzmann, B. Stadlinger, Silvio Valdec",10.3390/ijerph18189924,https://doi.org/10.3390/ijerph18189924,International Journal of Environmental Research and Public Health,6,2021,maybe,"While the study involves patients with compromised bone metabolism, it doesn't explicitly state that all patients have diagnosed osteoporosis or that they don't have cancer, creating significant uncertainty.",yes,yes,The study clearly documents ARONJ outcomes following specific dental procedures (tooth extractions).,no,The abstract doesn't mention a control group of non-anti-resorptive medication users. The study appears to focus only on patients receiving antiresorptive therapy.,yes,"This is a retrospective cohort study, which meets the criteria.",maybe,"While the study mentions ""duration of antiresorptive therapy,"" it's not entirely clear how well the temporal relationship between medication use and ARONJ development is documented.",yes,"The study includes 104 patients, which exceeds the minimum requirement of 100 subjects.","The study specifically focuses on tooth extraction with flap elevation or wound closure, which qualifies as invasive dental treatment.",Include,"The study fails to meet critical screening criteria, specifically the requirement for Romosozumab as the anti-resorptive medication, and lacks a clear control group. While demonstrating some methodological strengths like adequate sample size and clear outcome documentation, the absence of specific medication details and uncertain population characteristics prevent the study from meeting the comprehensive screening requirements.",2.5
Role of sclerostin deletion in bisphosphonate-induced osteonecrosis of the jaw.,"Fuminori Nakashima, Shinji Matsuda, Yurika Ninomiya, Tomoya Ueda, Keisuke Yasuda, Saki Hatano, S. Shimada, Daisuke Furutama, T. Memida, M. Kajiya, C. Shukunami, K. Ouhara, N. Mizuno",10.1016/j.bone.2024.117200,https://doi.org/10.1016/j.bone.2024.117200,Bone,0,2024,no,The abstract does not specify any human subjects or patient population. It appears to be a basic science study rather than a clinical study of adult osteoporosis patients.,no,no,"While MRONJ is mentioned, the abstract does not indicate documentation of specific dental procedures or outcomes.",no,No control group is mentioned in the abstract.,no,The study design appears to be a basic science/laboratory study rather than any of the specified clinical study designs.,no,No temporal relationships or medication duration is mentioned in the abstract.,no,The abstract does not mention any subject size or human participants. This appears to be a laboratory study rather than a clinical study.,"While the abstract discusses MRONJ, it does not mention any specific dental procedures or interventions being studied.",Exclude,"The abstract describes a basic science study investigating sclerostin deletion and medication-related osteonecrosis of the jaw, which fundamentally differs from the required clinical research parameters. None of the specified screening criteria are met, as the study lacks human subjects, dental interventions, patient population details, control groups, and clinical outcome documentation. The research appears to be a mechanistic investigation rather than a clinical study addressing the predefined screening requirements.",0.1
"Bisphosphonates-induced osteonecrosis of the jaw - epidemiological, clinical and histopathological aspects.","H. Mânea, H. Urechescu, N. Balica, M. Pricop, F. Baderca, M. Poenaru, I. Horhat, Emilia Manuela Jifcu, R. Closca, C. Sarau",-,-,Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie,12,2018,no,"The study includes both osteoporosis and malignancy patients, and is not exclusively focused on non-cancer patients with osteoporosis.",yes,yes,"The study reports ONJ outcomes following dental procedures, which meets the criterion for outcome documentation.",no,There is no mention of a control group in the study.,yes,"The study is a retrospective study analyzing archived material, which meets the criterion for a retrospective cohort study.",no,"There is no clear documentation of the temporal relationship between medication use and MRONJ development, or the duration of medication use.",no,"The study includes 38 patients, which is below the required minimum of 100 subjects.","The study mentions ""dentoalveolar surgery"" and ""dental extraction"", which meets the criterion for invasive dental treatment.",Exclude,"The study fails key screening criteria by examining bisphosphonates instead of Romosozumab, having a sample size below 100 patients, and including cancer patients. Multiple methodological limitations, including lack of a control group and incomplete temporal documentation, further disqualify the research from meeting the systematic review requirements.",0.1
Antibiotic Prophylaxis Before Dental Procedures Can Reduce ONJ Incidence.,"V. Montefusco, F. Spina, M. T. Ambrosini, M. Maniezzo, L. Farina, A. Miceli, A. Palumbo, M. Boccadoro, P. Corradini",10.1182/BLOOD.V110.11.3613.3613,https://doi.org/10.1182/BLOOD.V110.11.3613.3613,-,7,2007,no,"The study focuses on multiple myeloma (MM) patients, not patients with diagnosed osteoporosis. Additionally, these patients have cancer, which is explicitly excluded in the criteria.",yes,yes,"The study reports ONJ outcomes following specific dental procedures, though it's worth noting this is in the context of zoledronic acid, not romosozumab.",maybe,"While the study has two groups, they are not comparing anti-resorptive medication users vs. non-users. Instead, they compare two groups of MM patients receiving different prophylactic treatments.",yes,"The abstract describes a ""retrospective observational trial,"" which fits within the acceptable study designs.",yes,The study documents duration of medication use (median of 26 months for group A and 12 months for group B).,yes,"The study includes 113 total patients (52 in group A + 61 in group B), exceeding the minimum requirement of 100.","The study explicitly includes various dental procedures including extractions, implants, and professional cleanings, which are considered high-risk procedures.",Exclude,"The study focuses on multiple myeloma patients using zoledronic acid, which fundamentally differs from the required osteoporosis patient population and romosozumab intervention. Critical screening criteria were not met, including the specific medication type, patient population, and control group composition. These significant deviations render the study ineligible for inclusion in the systematic review.",0.1
Relationship between Medication-Related Osteonecrosis of the Jaw and CDK4/6 Inhibitors in Breast Cancer,"Loreto Domínguez Senín, D. M. Pancorbo, María Yeray Rodríguez Garcés, M. Santos-Rubio, Juan Bayo Calero",10.3390/curroncol31010016,https://doi.org/10.3390/curroncol31010016,Current Oncology,2,2024,no,"The study focuses on patients with metastatic breast cancer, which explicitly violates the criterion requiring patients without cancer.",maybe,maybe,"While MRONJ outcomes are reported, the abstract doesn't specify whether these were following specific documented dental procedures, so there is uncertainty about whether this criterion is met.",maybe,"The study compares patients with and without CDK4/6 inhibitors, but not specifically between anti-resorptive medication users and non-users, so it only partially meets this criterion.",yes,"This is a retrospective observational study, which fits within the acceptable study designs.",yes,"The study documents temporal relationships, showing mean time to MRONJ occurrence (16.8 and 15.4 months).",yes,"The study includes 243 patients, which is well above the minimum requirement of 100.","While MRONJ is discussed, the abstract doesn't explicitly state whether dental procedures were performed, so there is significant uncertainty about whether this criterion is met.",Exclude,"The study fails key screening criteria by using denosumab instead of romosozumab and focusing on breast cancer patients rather than non-cancer osteoporosis patients. Critical misalignments with population type and intervention medication render the study ineligible for inclusion in the systematic review. Despite meeting some secondary criteria like sample size and study design, the fundamental deviations from core requirements necessitate exclusion.",0.1
Medication-related osteonecrosis of the jaw after once-a-year intravenous zoledronic acid infusion for osteoporosis: Report of eight cases.,"G. Favia, A. Tempesta, L. Limongelli, V. Crincoli, E. Maiorano",10.3290/j.qi.a35263,https://doi.org/10.3290/j.qi.a35263,Quintessence International,7,2016,maybe,"The patients are described as ""osteoporotic female patients"" with no mention of cancer, suggesting they meet the population criteria. However, age is not explicitly stated.",no,maybe,"MRONJ outcomes are documented, but the specific dental procedures leading to MRONJ are not clearly described in the abstract.",no,No control group is mentioned in the abstract.,no,"This appears to be a case series of 8 patients, which doesn't match any of the required study designs (RCT, cohort, or case-control).",maybe,"The abstract mentions that MRONJ developed ""after the shift to once-a-year infusion of zoledronic acid,"" suggesting some temporal documentation, but the duration of medication use is not clearly specified.",no,"The study only includes 8 patients, well below the required minimum of 100 subjects.","While the abstract mentions ""intraoral necrotic bone exposures,"" it doesn't explicitly state whether these were related to dental procedures. The temporal relationship between dental procedures and MRONJ is not clearly documented.",Exclude,"The study fails to meet multiple critical screening criteria, including using a different medication (zoledronic acid instead of romosozumab), having an insufficient sample size of only 8 patients, and lacking a control group. The case series design and incomplete documentation of dental procedures further disqualify the study from meeting the systematic review's requirements.",0.1
Medication-Related Osteonecrosis of the Jaw: evaluation of a therapeutic strategy in oral surgery.,"Mathilde Natu, Vincent Meuric, Paul Roginski, Romain Gamby, Sophie Lejeune",10.1016/j.jormas.2024.101877,https://doi.org/10.1016/j.jormas.2024.101877,Journal of Stomatology Oral and Maxillofacial Surgery,0,2024,no,"The abstract mentions ""cancer type"", indicating that the study includes cancer patients, which fails this criterion as it does not focus exclusively on adult patients with diagnosed osteoporosis who do not have cancer.",maybe,maybe,"MRONJ is the focus, but no specific documentation of dental procedures is mentioned, so the reasoning partially meets this criterion.",maybe,"No mention of control groups is made, so the reasoning is uncertain.",maybe,"The study design is not explicitly stated, but it appears to be an observational study of treatment success factors, so the reasoning is uncertain.",maybe,"The abstract mentions ""accumulated dose of ART"", suggesting consideration of the temporal relationship between medication use and MRONJ development, so the reasoning partially meets this criterion.",maybe,"No information is provided about the sample size, so the reasoning is uncertain.","No specific mention of dental procedures is made, so the reasoning is uncertain.",Include,"The abstract fails to meet key screening criteria, specifically lacking specification of Romosozumab and including cancer patients, which deviates from the required population type. Multiple methodological details are missing, including sample size, dental procedure specifics, and control group information, rendering the study non-compliant with the systematic review's requirements.",2.5
A study of peri-implant tissue clinical parameters in patients starting anti-osteoporosis medication after existing implant function: a prospective cohort study,"Keisuke Seki, Takaaki Tamagawa, Hiroyasu Yasuda, Soichiro Manaka, Daisuke Akita, Atsushi Kamimoto, Yoshiyuki Hagiwara",10.1186/s40729-024-00569-4,https://doi.org/10.1186/s40729-024-00569-4,International Journal of Implant Dentistry,0,2024,maybe,"While the study involves adult patients (implied by the context), it doesn't explicitly state that all patients are ≥18 years or that they have diagnosed osteoporosis. The cancer status is not mentioned.",maybe,maybe,The study documents peri-implantitis and related parameters but doesn't explicitly report MRONJ outcomes. It only mentions MRONJ as a potential risk.,yes,The study explicitly includes a control group of non-AOM users.,yes,"While not explicitly stated, this appears to be a prospective/retrospective cohort study based on the methodology described.",maybe,"While the study period is mentioned (2016-2024), the temporal relationship between medication use and outcomes isn't clearly documented in the abstract.",no,"The study includes 94 patients, which is below the required minimum of 100 subjects.","The study focuses on dental implants and their maintenance, which qualifies as invasive dental treatment. However, it's specifically about maintenance rather than initial placement.",Exclude,"The study fails to meet critical screening criteria, specifically lacking focus on Romosozumab and having a sample size below 100 patients. While the research includes a control group and examines dental implant maintenance, it does not explicitly document MRONJ outcomes or provide clear temporal documentation of medication use. Multiple screening requirements remain unmet, rendering the study unsuitable for systematic review inclusion.",1.4
The effect of chronic dental inflammation on development of Stage 0 medication-related osteonecrosis of the jaw.,"G. Topaloglu, O. Koseoglu, Ç. Karaca, K. Kosemehmetoglu",10.1016/j.jcms.2017.05.003,https://doi.org/10.1016/j.jcms.2017.05.003,Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,10,2017,maybe,"While the study includes adult patients (mean age 57.4 years), it doesn't explicitly state that all patients have diagnosed osteoporosis. The abstract only mentions ""patients with a history of bisphosphonate use.""",yes,yes,The study clearly documents MRONJ outcomes following specific dental procedures (tooth extractions).,no,The abstract doesn't mention any control group of non-anti-resorptive medication users.,yes,"The study is described as a prospective study, which meets the criteria.",maybe,"While the study documents the temporal relationship between dental procedures and MRONJ development, it doesn't clearly specify the duration of medication use.",no,"The study includes only 50 patients, which is below the required minimum of 100 subjects.","The study involves tooth extraction, which is explicitly mentioned as one of the acceptable invasive dental treatments.",Exclude,"The study fails to meet critical screening criteria, primarily due to using bisphosphonates instead of Romosozumab and having a sample size of only 50 patients, which is below the required 100. While the research involves tooth extraction and documents MRONJ outcomes, the fundamental mismatch in medication type and insufficient sample size disqualify it from meeting the specified inclusion requirements.",1.4
Comparison of Different Antibiotic Regimes for Preventive Tooth Extractions in Patients with Antiresorptive Intake—A Retrospective Cohort Study,"O. Ristow, T. Rückschloss, Gregor Schnug, J. Moratin, Moritz Bleymehl, Sven Zittel, Maximilian Pilz, C. Sekundo, C. Mertens, M. Engel, Jürgen Hoffmann, Maximilian Smielowski",10.3390/antibiotics12060997,https://doi.org/10.3390/antibiotics12060997,Antibiotics,4,2023,maybe,"While the study involves patients receiving antiresorptive therapy, it doesn't explicitly state they have diagnosed osteoporosis or confirm they don't have cancer. This creates significant uncertainty.",yes,yes,"The study clearly documents MRONJ outcomes following tooth extraction procedures, with specific success rates reported.",no,The study compares different antibiotic regimens but doesn't include a control group of non-anti-resorptive medication users.,yes,"This is a retrospective analysis, which falls under the acceptable study designs.",maybe,"While the study documents outcomes at 12 weeks post-surgery, it doesn't clearly specify the duration of medication use before the procedure.",yes,"The study includes 760 patients, well above the minimum requirement of 100.","The study focuses on tooth extraction, which is explicitly mentioned as one of the required invasive dental treatments.",Exclude,"The study fails to meet critical screening criteria, specifically lacking confirmation of Romosozumab use and a control group of non-anti-resorptive medication users. While demonstrating strengths in sample size, dental intervention type, and outcome documentation, the absence of key requirements prevents study inclusion. Significant uncertainties remain regarding patient population characteristics and medication specifics.",1.4
Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw,"Lina He, Xiangyu Sun, Zhijie Liu, Yanfen Qiu, Y. Niu",10.1038/s41368-020-00093-2,https://doi.org/10.1038/s41368-020-00093-2,International Journal of Oral Science,0,2020,no,"The paper does not specifically mention adult patients or osteoporosis, and it mentions oncologists, suggesting that cancer patients may be included. Therefore, it does not meet the criterion of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",no,no,"While MRONJ is discussed, the paper does not provide specific documentation of outcomes following dental procedures. This is a general review of MRONJ, not a study of specific dental procedures.",no,"The paper is a review article, not an interventional study, and does not mention any control groups. Therefore, it does not meet the criterion of including a control group of non-anti-resorptive medication users.",no,"The paper is explicitly a review article, not a primary research study, and therefore does not meet the criterion of having a study design of a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The paper does not provide any specific documentation of the temporal relationship between medication use and MRONJ development, or the duration of medication use.",no,"The paper is a review article, not a primary study, and does not mention the sample size. Therefore, it does not meet the criterion of having a subject size of more than 100 people.","While dental procedures are implied in the context of MRONJ, the paper does not focus on specific dental interventions. This is a general review of MRONJ, not a study of invasive dental treatment.",Exclude,"This review article on medication-related osteonecrosis of the jaw fails to meet multiple screening criteria, including specific intervention type, subject size, population characteristics, and study design. The paper provides a general overview of MRONJ pathogenesis and management strategies but lacks the precise research parameters required for systematic review inclusion. Consequently, the abstract does not qualify under the established screening requirements.",0.1
"A Multi-Center Observation Study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in Patients with Osteoporosis, and Other Non-Malignant Bone Diseases, in Northwestern Italy over 16 Years","Dora Karimi, P. Arduino, A. Gambino, F. Erovigni, Alessandro Dell’Acqua, F. Pera, Massimo Carossa, M. Pentenero, P. Appendino, Francesco Della Ferrera, A. Fasciolo, Majlinda Caka, Mario Migliario, Matteo Brucoli, S. Franchi, Alessandro Pezzimenti, V. Fusco",10.3390/biomedicines12102179,https://doi.org/10.3390/biomedicines12102179,Biomedicines,0,2024,maybe,"The study includes patients with osteoporosis (87%) and other non-malignant conditions. While it excludes cancer patients, it's not explicitly stated that all subjects are adults (≥18 years).",maybe,maybe,"While MRONJ outcomes are documented, the abstract doesn't specify whether these are linked to specific dental procedures.",no,The abstract doesn't mention any control group of non-anti-resorptive medication users.,maybe,"The study appears to be an observational study collecting cases from referral centers, but the exact study design isn't clearly specified.",maybe,"The study documents duration of therapy ""when available"" and onset time of disease, but it's not clear how consistently this information was collected.",yes,"The study includes 198 cases, which exceeds the minimum requirement of 100 subjects.","While the study focuses on MRONJ, which typically follows dental procedures, the abstract doesn't explicitly specify the types of dental interventions involved.",Exclude,"The study fails to meet critical screening criteria, particularly the requirement for Romosozumab as an intervention, with no mention of this specific medication. While the research includes a substantial sample size and focuses on osteoporosis patients, it lacks a control group and does not clearly document specific dental interventions or temporal relationships. Multiple screening criteria remain unclear or unmet, rendering the study non-compliant with the specified requirements.",1.4
RISK FACTORS FOR INFECTIOUS COMPLICATIONS IN ONCOLOGICAL PATIENTS WITH OSTEONECROSIS OF THE JAW FROM BISPHOSPHONATES,"Ana raphaela Maia Dezan Couto Curvo, Victor Augusto Minari, L. M. A. Innocentini, H. Ricz, Adriano Tadeu Dias Marangoni, A. Ranieri, L. D. Macedo",10.1016/j.oooo.2020.04.675,https://doi.org/10.1016/j.oooo.2020.04.675,"Oral surgery, oral medicine, oral pathology and oral radiology",0,2020,no,"The study focuses on cancer patients, which explicitly violates the criterion requiring non-cancer patients, and is a clear disqualification.",maybe,maybe,"The study does document MRONJ outcomes, but the specific dental procedures are not clearly documented in the abstract, so it only partially meets this criterion.",no,"There is no mention of a control group, and the study appears to only include cases of MRONJ, so it fails to meet this criterion.",yes,"The study is described as a ""retrospective, observational study"", which meets the criterion for acceptable study designs.",maybe,"The study documents the frequency of drug use (monthly vs quarterly) and the duration of medication use as ""total number of doses"", so it partially meets this criterion.",no,"The study only includes 21 cases, which falls well below the required minimum of 100 subjects, and is a clear disqualification.","While the study mentions ""triggering factor"" as a variable, it doesn't explicitly detail the dental procedures, so there is insufficient information to determine if this criterion is met.",Exclude,"The study fails critical screening criteria by focusing on bisphosphonates instead of Romosozumab, including only 21 cancer patients instead of the required 100 non-cancer subjects, and lacking a control group. Multiple fundamental disqualifying factors render this research ineligible for the specified screening requirements. The paper's methodology and population do not align with the predefined inclusion standards.",0.1
Medication-related osteonecrosis of the jaw: A multifaceted diagnostic challenge. Mini review.,"Roxana Bonachea, J. Katz",-,-,American Journal of Dentistry,0,2022,maybe,"No specific mention of age groups or osteoporosis diagnosis, and no mention of cancer status, so there is insufficient information to evaluate the population type.",maybe,no,"While MRONJ outcomes are discussed, they are not reported in relation to specific documented dental procedures, and the paper appears to be reviewing general characteristics rather than reporting specific outcomes, so the outcome documentation requirement is not met.",no,"No mention of control groups, so the control group requirement is not met.",no,"This appears to be a ""mini review"" rather than a primary research study, and does not match any of the required study designs, so the study design requirement is not met.",no,"No specific temporal relationships or medication duration documentation is mentioned, so the temporal documentation requirement is not met.",no,"No specific subject size is mentioned, and the paper appears to be a review article rather than a primary study, so the subject size requirement of more than 100 people is not met.","The paper mentions dental extractions and bone manipulations as risk factors, but this is in the context of risk factors rather than as a specific intervention being studied, so the intervention of invasive dental treatment is only partially met.",Exclude,"The abstract fails to meet multiple critical screening criteria, including specific intervention requirements, subject size, and study design specifications. While discussing medication-related osteonecrosis of the jaw, the text appears to be a review article that lacks the precise methodological elements needed for systematic review inclusion. Key deficiencies include absence of Romosozumab focus, undefined population characteristics, and lack of a primary research study structure.",0.1
Medication-Related Osteonecrosis of the Jaws: A Literature Review,"Gyeong-Mi Kim, S. Moon, Jae-Seek You, Gyeong-Yun Kim, Ji-Su Oh",10.14476/jomp.2022.47.1.1,https://doi.org/10.14476/jomp.2022.47.1.1,Journal of Oral Medicine and Pain,0,2022,no,"The abstract does not contain any information about the age or cancer status of the study population, so Elicit could not determine if the study focused exclusively on adult patients (≥18 years) with diagnosed osteoporosis who did not have cancer.",no,no,"While the abstract mentions MRONJ, it does not provide specific details on the documentation of MRONJ outcomes following the dental procedures, so Elicit could not confirm that the study reported MRONJ outcomes.",no,"The abstract does not provide any information about the inclusion of a control group of non-anti-resorptive medication users, so Elicit could not confirm the presence of a control group.",no,"The abstract does not contain any details about the study design, so Elicit could not determine if the study was a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The abstract does not contain any information about the temporal relationship between medication use and MRONJ development or the duration of medication use, so Elicit could not determine if the study clearly documented these aspects.",no,"The abstract does not provide any information about the sample size of the study, so Elicit could not determine if the study had a subject size of more than 100 people.","While the abstract mentions ""anti-resorptive medications,"" it does not provide details on the specific interventions, such as tooth extraction, implant placement, periodontal surgery, other dental surgery, or removable prosthesis fabrication.",Exclude,"The provided document appears to be a review article with section headings, lacking specific details about patient interventions, sample size, or research methodology. Insufficient information is present to confirm any of the required screening criteria for an original research study on anti-resorptive medication and dental procedures. The document's structure suggests a clinical guidance overview rather than a primary research investigation.",0.1
Recurrence - Related Factors of Medication Related Osteonecrosis of the Jaw (MRONJ) ; a Retrospective study,"Kyoungseok Choi, Chulyoung Park, Ji Hyun Kim, Hye Jin Kim, J. Ryu, M. Kook, Hong-Ju Park, H. Oh, Seunggon Jung",10.22974/jkda.2023.61.12.002,https://doi.org/10.22974/jkda.2023.61.12.002,The Journal of The Korean Dental Association,0,2023,no,"The abstract does not specify the age range or whether the subjects had a diagnosed osteoporosis condition. It also does not mention the cancer status of the subjects, so there is significant uncertainty about the population type.",yes,yes,"The abstract clearly documents MRONJ outcomes following specific dental procedures, such as surgical treatment and tooth extraction.",no,"The abstract does not mention the inclusion of a control group of non-anti-resorptive medication users, so there is significant uncertainty about the control group.",maybe,"The abstract suggests that the study design was likely a retrospective cohort study, but this is not explicitly stated, so the study design is only partially met.",maybe,"The abstract mentions the ""duration of administration"" as a factor, but does not provide specific details about the temporal relationship between medication use and MRONJ development or the duration of medication use, so the temporal documentation is only partially met.",no,"The abstract does not mention the sample size of the study, so there is significant uncertainty about whether the study had more than 100 participants.","The abstract mentions surgical treatment and tooth extraction, indicating that the study included invasive dental treatment interventions.",Include,"The abstract lacks critical specificity regarding Romosozumab use, patient population characteristics, and study design details. Multiple screening criteria remain unmet or uncertain, particularly the requirement for a clearly defined intervention with Romosozumab. While the study addresses MRONJ and dental interventions, insufficient information prevents definitive assessment against the established screening criteria.",2.5
Medication related osteonecrosis of the jaws (MRONJ): Factors related to recurrence after treatment with surgery and platelet rich plasma (PRP) placement,"Celia Sánchez-Gallego Albertos, J. L. del Castillo Pardo de Vera, A. Viejo Llorente, J. L. Cebrián Carretero",10.4317/medoral.24007,https://doi.org/10.4317/medoral.24007,Medicina Oral,8,2021,maybe,"The study includes adult patients with osteoporosis (48.6%), but also includes cancer patients (breast cancer 30%, multiple myeloma 11.4%), which violates the criterion of focusing exclusively on non-cancer patients.",maybe,yes,The study clearly documents MRONJ outcomes and their treatment.,no,The abstract does not mention a control group of non-anti-resorptive medication users.,yes,"This is a retrospective study, which meets the criteria.",yes,The study documents the duration of therapy (54.8% >12 months) and follows patients for 2-52 months.,no,"The study includes 70 patients, which is below the required 100 subjects.","While the study involves MRONJ patients who underwent surgical treatment, it doesn't specifically detail the initial dental procedures that led to MRONJ.",Exclude,"The study fails key screening criteria by using different anti-resorptive medications instead of Romosozumab, having a sample size below 100, and including cancer patients alongside osteoporosis patients. Multiple methodological limitations, including the absence of a control group and lack of specific dental procedure documentation, further disqualify the study from meeting the predefined inclusion requirements.",1.4
Medication-related osteonecrosis of the jaw triggered by endodontic failure in oncologic patients.,"A. Tempesta, S. Capodiferro, Simona Di Nanna, S. D’Agostino, M. Dolci, A. Scarano, G. Gambarini, E. Maiorano, G. Favia, L. Limongelli",10.1111/odi.14449,https://doi.org/10.1111/odi.14449,Oral Diseases,8,2022,no,"The abstract specifically mentions ""oncologic patients"", which explicitly violates the criterion requiring non-cancer patients.",maybe,maybe,"The study does document MRONJ outcomes, but these are not following the specific dental procedures listed in the criteria.",no,No control group is mentioned in the abstract.,maybe,"The study appears to be a cohort study of MRONJ cases, but the design is not explicitly stated.",maybe,"The abstract mentions that endodontic treatment was performed ""at least six months before the starting of antiresorptive/antiangiogenic therapies"", which partially meets the temporal documentation requirement.",no,"The study only includes 18 patients, which is well below the required minimum of 100 subjects.","The study focuses on endodontic treatment failure, which is not explicitly listed as an invasive dental treatment in the criteria. While endodontic treatment is a dental treatment, it does not match the specific interventions listed.",Exclude,"The study fails critical screening criteria due to using oncologic patients instead of non-cancer patients, having a sample size of only 18 participants, and not specifically using Romosozumab. Multiple other criteria are only partially met or unclear, including the type of dental intervention and study design. These significant deviations from the required screening parameters necessitate exclusion from the systematic review.",0.1
Osteometabolic profile: a possible tool in decision making for implant rehabilitation in patients under antiresorptive drugs,"G. Colapinto, F. Goker, M. Del Fabbro, T. Testori",10.32388/BCIX7F,https://doi.org/10.32388/BCIX7F,-,0,2021,maybe,"While the study involves adult patients (implied by the context), it doesn't explicitly state they have diagnosed osteoporosis or exclude cancer patients.",yes,yes,The study clearly documents MRONJ outcomes following specific dental procedures (implant insertions) and reports complications.,yes,The study includes a control group (G1) with normal osteometabolic profile compared to G2 with altered profile.,yes,"This appears to be a comparative study, likely a prospective cohort study based on the methodology described.",maybe,"While the study documents that MRONJ occurred within six months after implant insertion, it doesn't clearly document the duration of medication use.",yes,"The study includes 146 patients, which exceeds the minimum requirement of 100 subjects.","The study involves implant-supported prosthesis placement, which qualifies as invasive dental treatment.",Include,"The study involves 146 patients undergoing implant-supported prosthesis with documented MRONJ outcomes, but critically lacks specification of Romosozumab use. While meeting several screening criteria like sample size, dental intervention, and control group, the absence of the specific anti-resorptive medication prevents systematic review inclusion. Uncertainty remains regarding explicit osteoporosis diagnosis and complete medication use documentation.",2.7
Anatomical factors in medication-related osteonecrosis of the jaws,"J. A. Correia, A. Lóio, I. Furtado, A. Capelo, C. Caldas, N. Santos, F. Salvado",10.1080/07853890.2021.1897445,https://doi.org/10.1080/07853890.2021.1897445,Annals medicus,1,2021,maybe,"While the mean age is 68.12 years (adults), the abstract doesn't explicitly state that all patients had diagnosed osteoporosis or exclude cancer patients.",maybe,maybe,"While MRONJ outcomes are documented, the abstract doesn't clearly specify which dental procedures led to these outcomes, though it mentions some procedures.",no,No control group is mentioned in the abstract.,yes,"This is a retrospective study, which is one of the acceptable study designs.",no,The abstract doesn't clearly document the temporal relationship between medication use and MRONJ development or the duration of medication use.,yes,"The study includes 147 patients, which exceeds the minimum requirement of 100 subjects.","While the study mentions ""dentoalveolar surgery"" and ""dental prosthesis,"" it's not clear if these were the interventions being studied or just factors being analyzed. The focus seems to be on anatomical locations of MRONJ rather than dental procedures.",Exclude,"The study fails to meet critical screening criteria, particularly the specific requirement for Romosozumab as the intervention medication. While the research includes a sufficient sample size and uses an acceptable retrospective study design, it lacks a control group and does not clearly document the temporal relationship between medication use and MRONJ development. The abstract's focus on anatomical locations of MRONJ rather than specific dental procedures further limits its alignment with the screening requirements.",1.4
What is the Risk of Developing Osteonecrosis Following Dental Extractions for Patients on Denosumab for Osteoporosis?,"Colella Anthony, Y. Elaine, Sambrook Paul, Hughes Toby, Goss Alastair",10.1016/j.joms.2022.10.014,https://doi.org/10.1016/j.joms.2022.10.014,Journal of oral and maxillofacial surgery,7,2022,yes,"The study focuses on adult patients with osteoporosis. While not explicitly stated that all patients are ≥18, the context suggests an adult population. No mention of cancer patients.",yes,yes,"The study clearly documents ONJ outcomes following dental extractions, with specific numbers reported (10 cases of ONJ in 1081 extractions).",yes,The study explicitly includes a control group of 299 patients not taking denosumab.,yes,"The abstract describes this as a ""prospective cohort study,"" which meets the criteria.",yes,"The study documents temporal relationships, including timing of extractions relative to denosumab injections (e.g., ""between 6 and 7 months after the last denosumab injection"").",yes,"The study includes 427 patients in the treatment group and 299 in the control group, well exceeding the 100-person minimum.","The study specifically focuses on dental extractions, which is one of the specified invasive dental treatments.",Exclude,"The study meets most screening criteria, including robust subject size, appropriate study design, clear outcome documentation, and comprehensive population characteristics. However, a critical disqualifying factor is the use of denosumab instead of the specified romosozumab, which fundamentally prevents the study from meeting the intervention requirement. Despite strong methodological alignment with other criteria, this single deviation renders the study non-compliant with the systematic review's specific intervention focus.",0.1
Medication-related osteonecrosis of the jaw using periodontitis-induced rat before tooth extraction,"Kyeong-Mee Park, Ji-Sook Cheong, N. Pang, K. Kim, Jung-Seok Lee, W. Park",10.1186/s12903-023-03200-x,https://doi.org/10.1186/s12903-023-03200-x,BMC Oral Health,3,2023,no,"The study uses ovariectomized rats, not adult human patients with diagnosed osteoporosis. While the rats are osteoporosis-induced, this doesn't meet the human patient requirement.",yes,yes,"The study clearly documents MRONJ outcomes following tooth extraction, including detailed histological and radiological findings.",yes,The study includes a control group (CONT group) that received saline instead of ZA.,yes,"This appears to be a controlled experimental study, though in animals rather than humans.",yes,The study documents the temporal relationship (8-week follow-up) and duration of medication use.,no,"The study only includes 24 rats, well below the required 100 subjects.","The study includes tooth extraction, which is one of the specified invasive dental treatments.",Exclude,"The study fails key screening criteria by using zoledronic acid instead of romosozumab, employing an animal model with only 24 rats, and not focusing on human patients with osteoporosis. Despite meeting several methodological criteria like having a control group and documenting outcomes, the fundamental differences in medication, subject type, and sample size disqualify the study from meeting the specified screening requirements.",0.1
Medication-Related Osteonecrosis of the Mandible,G. Omami,10.1177/0145561320919574,https://doi.org/10.1177/0145561320919574,"Ear, nose, & throat journal",1,2020,no,"While osteoporosis patients are mentioned, the abstract also discusses cancer patients (breast, prostate, multiple myeloma), indicating that the study does not focus exclusively on adult patients with diagnosed osteoporosis who do not have cancer.",yes,no,"While MRONJ outcomes are discussed, this is not a study reporting specific outcomes from dental procedures, indicating that the study does not meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",maybe,"No mention of control groups is made in the abstract, so the reasoning is uncertain regarding whether the study includes a control group of non-anti-resorptive medication users.",no,"This appears to be a review article rather than a primary research study, and no specific study design is mentioned, indicating that the study does not meet the criterion of having a study design of a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"While the abstract mentions that MRONJ occurs in patients with current or previous treatment, it doesn't document specific temporal relationships or duration of medication use, indicating that the study does not meet the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",maybe,"No specific subject size is mentioned in the abstract, so the reasoning is uncertain regarding whether the study has a subject size of more than 100 people.","The abstract mentions dental procedures including ""extraction or implant placement"", indicating that the study meets the criterion of having an intervention of invasive dental treatment.",Exclude,"The abstract fails multiple critical screening criteria, including the specific medication requirement, population type, and study design. It appears to be a general review of medication-related osteonecrosis of the jaw rather than a focused research study meeting the systematic review's precise parameters. Consequently, the document does not qualify for inclusion based on the established screening criteria.",0.1
Dental management in Oncology patient: osteonecrosis related osteonecrosis of the Jaw (MRONJ),P. Noemi,10.31579/2690-4861/058,https://doi.org/10.31579/2690-4861/058,-,0,2020,no,"The abstract focuses on ""oncological patients"" which explicitly violates the criterion of non-cancer patients. No mention of age restrictions.",maybe,no,"While MRONJ is discussed, there is no specific documentation of outcomes following dental procedures. The paper appears to be discussing general principles rather than reporting specific outcomes.",no,No mention of control groups. This appears to be a review paper rather than a comparative study.,no,This appears to be a review/consensus paper rather than an original research study. Does not fit any of the required study designs.,no,"While medication use and MRONJ are discussed, there is no specific temporal documentation. The paper discusses general principles rather than specific temporal relationships.",no,The abstract does not mention any specific study size or number of participants. This appears to be a review/consensus paper rather than an original research study.,"The abstract discusses dental procedures and treatments in general, mentioning ""minimally invasive manipulations"" and ""bone manipulation"". However, this is in a general context rather than as part of a specific study.",Exclude,"The abstract fails to meet multiple screening criteria, including specific medication type, subject size, population characteristics, and study design requirements. Focused on oncological patients and general antiresorptive drug principles, the text does not align with the precise research parameters sought. Consequently, the document does not qualify for inclusion based on the established screening criteria.",0.1
Factors Influencing Severity of Medication-Related Osteonecrosis of the Jaw: A Retrospective Study.,"Zhiqiang Feng, J. An, Yi Zhang",10.1016/j.joms.2020.12.045,https://doi.org/10.1016/j.joms.2020.12.045,Journal of oral and maxillofacial surgery,14,2021,maybe,"The study includes patients with MRONJ, and mentions chemotherapy as a risk factor, suggesting some patients had cancer. The age criterion is met, as it mentions age ≤65 years.",maybe,maybe,"The study documents MRONJ outcomes, but does not specify the dental procedures leading to MRONJ.",no,"There is no mention of a control group, and the study appears to only analyze MRONJ patients.",yes,"The study is a retrospective analysis of hospitalized patients, which meets the criterion as a retrospective cohort study.",maybe,"The study mentions ""preoperative MRONJ duration ≥12 months"", but does not clearly document the temporal relationship between medication use and MRONJ.",no,"The study includes 79 patients with 93 MRONJ lesions, which falls below the required minimum of 100 subjects.","While the study focuses on MRONJ, it doesn't explicitly state which dental procedures were performed, so it cannot be confirmed if the required invasive dental treatments were included.",Exclude,"The study fails to meet multiple critical screening criteria, including the specific use of Romosozumab, insufficient sample size, and lack of a control group. While the research provides insights into MRONJ risk factors, it does not align with the predefined inclusion requirements for the systematic review. Significant methodological limitations prevent the study from qualifying for further analysis.",1.4
"Combined Administration of Bisphosphonates, Chemotherapeutic Agents, and/or Targeted Drugs Increases the Risk for Stage 3 Medication-Related Osteonecrosis of the Jaw: A 4-Year Retrospective Study","Yuqiong Zhou, Yejia Yu, Yueqi Shi, Meng-yu Li, Chi Yang, Shaoyi Wang",10.1155/2020/5847429,https://doi.org/10.1155/2020/5847429,BioMed Research International,11,2020,no,"The abstract doesn't specify if all patients are adults (≥18 years), and it includes patients with cancer (chemotherapy users), which does not meet the population type criteria.",maybe,maybe,"The study does document MRONJ outcomes, but it doesn't specify the dental procedures leading to MRONJ.",no,There is no mention of a control group of non-anti-resorptive medication users.,yes,"The study is described as a retrospective study, which meets the criteria for study design.",maybe,"While medication use is documented, the temporal relationship between medication use and MRONJ development is not clearly specified.",no,"The study includes 60 patients, which is below the required 100 subjects.","While the study focuses on MRONJ, it doesn't explicitly state that all patients underwent invasive dental procedures.",Exclude,"The study fails critical screening criteria, particularly the requirement for Romosozumab as the intervention medication, with only 60 patients instead of the mandated 100. Additionally, the research includes cancer patients and lacks a control group, which further disqualifies it from meeting the specified screening requirements. The retrospective study's focus on MRONJ and medication-related factors does not align with the predefined selection parameters.",1.4
Medication-related osteonecrosis of the jaw: A disease of significant importance for older patients.,"Bridget Boston, D. Ipe, B. Căpitănescu, Andrei Gresita, S. Hamlet, R. Love, M. Hadjiargyrou, Chien-Ling Huang, I. Nusem, R. Miroiu, A. Popa-Wagner, P. Warnke, E. Petcu",10.1111/jgs.18414,https://doi.org/10.1111/jgs.18414,Journal of The American Geriatrics Society,4,2023,no,"The abstract mentions both osteoporosis and cancer patients, so the population type criterion of focusing exclusively on adult patients with diagnosed osteoporosis who do not have cancer is not met.",maybe,no,"The abstract discusses MRONJ outcomes generally but does not report specific outcomes following documented procedures, so the outcome documentation criterion is not met.",no,"There is no mention of a control group, and this is a review article rather than an interventional study, so the control group criterion is not met.",no,"This is a literature review, not a primary research study, so the study design criterion of being a randomized controlled trial, prospective/retrospective cohort study, or case-control study is not met.",no,"No specific temporal relationships or medication duration are documented, so the temporal documentation criterion is not met.",no,"No specific subject size is mentioned, and this is a review article rather than a primary study, so the subject size criterion is not met.","The abstract mentions ""dental therapy"" and ""minor trauma"" but does not specify the types of invasive dental treatments, so the intervention criterion is only partially met.",Exclude,"This literature review fails to meet multiple critical screening criteria, including specific medication type, subject size, population exclusivity, and study design requirements. The abstract discusses medication-related osteonecrosis of the jaw broadly but lacks the precise methodological and population specifications needed for inclusion in the systematic review. Consequently, the paper does not qualify for further analysis based on the established screening criteria.",0.1
Prognosis of medication-related osteonecrosis of the jaws in cancer patients using antiresorptive agent zoledronic acid.,"Ling-Ying Wei, S. Kok, Yen-Ching Lee, Wei-Yih Chiu, J. Wang, Shih-Jung Cheng, Hao-Hueng Chang, Jang-Jaer Lee",10.1016/j.jfma.2020.11.017,https://doi.org/10.1016/j.jfma.2020.11.017,Journal of the Formosan Medical Association = Taiwan yi zhi,7,2020,no,"The study focuses exclusively on cancer patients (multiple myeloma, breast cancer, prostate cancer), which explicitly violates the criterion requiring non-cancer patients.",maybe,maybe,"MRONJ outcomes are documented, but the specific dental procedures are not detailed in the abstract.",no,There is no mention of a control group of non-anti-resorptive medication users.,yes,"The study design is a retrospective cohort study, which meets the criterion.",no,"There is no clear documentation of the temporal relationship between medication use and MRONJ development, or the duration of medication use.",yes,"The study includes 133 patients, which exceeds the minimum requirement of 100 subjects.","The abstract does not explicitly mention the dental procedures that led to MRONJ, so the specific dental interventions are not detailed.",Exclude,"The study fails key screening criteria by using zoledronic acid instead of romosozumab and focusing on cancer patients rather than non-cancer osteoporosis patients. Multiple critical requirements are not met, including the absence of a control group and incomplete documentation of dental procedures and medication use. These significant deviations from the specified screening criteria render the study unsuitable for inclusion in the systematic review.",0.1
"Letter to the Editor from [Taguchi]: ""(Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS)"".",A. Taguchi,10.1210/clinem/dgac109,https://doi.org/10.1210/clinem/dgac109,Journal of Clinical Endocrinology and Metabolism,0,2022,maybe,"The abstract discusses osteoporosis patients, but doesn't specifically focus on adults ≥18 years, and there is no mention of cancer exclusion, so it only partially meets or is unclear on this criterion.",no,no,"While MRONJ is discussed, this is not a primary study documenting specific dental procedures and outcomes, so it does not meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"The study compares alendronate vs raloxifene users, but not specifically non-users, so it does not meet the criterion of having a control group of non-anti-resorptive medication users.",no,"This appears to be a letter/commentary rather than a primary research study, so it does not meet the criterion of having a study design of a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"No specific temporal relationships or medication duration documentation is mentioned, so it does not meet the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",yes,"The abstract mentions ""more than 300 million patients across 9 databases"", which meets the criterion of having a subject size of more than 100 people.","While dental procedures are discussed, this appears to be a review/commentary rather than a primary study of specific dental interventions, so it does not meet the criterion of having an intervention of invasive dental treatment.",Exclude,"The document fails to meet multiple critical screening criteria, particularly the requirement for Romosozumab as the intervention and the need for a primary research study design. While discussing osteoporosis and dental health, the text appears to be a commentary that lacks the specific methodological and intervention requirements of the screening protocol. Consequently, the document does not qualify for inclusion based on the established criteria.",0.1
Clinical analysis of medication related osteonecrosis of the jaws: A growing severe complication in China,"Qizhang Wang, Ji-Yuan Liu, Shuqun Qi, Xuejuan Liao, D. Liu, Jian Pan",10.1016/j.jds.2017.12.003,https://doi.org/10.1016/j.jds.2017.12.003,Journal of Dental Sciences,14,2018,maybe,"The study does not specify the age range of the patients, does not explicitly state if the patients have diagnosed osteoporosis, and does not mention any exclusion of cancer patients. This lack of information means the population type is unclear or insufficient.",yes,yes,"The study documents MRONJ outcomes following dental procedures, specifically mentioning tooth extraction, which meets the criterion for outcome documentation.",no,"The study compares MRONJ with ""other ONJs"" but not specifically with non-medication users, which means it fails to meet the criterion for a control group of non-anti-resorptive medication users.",yes,"The study appears to be a retrospective cohort study, analyzing cases from 2006-2017, which meets the criterion for a study design of a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The study does not clearly document the temporal relationship between medication use and MRONJ development, nor does it mention the duration of medication use, which means it fails to meet the criterion for temporal documentation.",yes,"The study includes 201 patients, which meets the requirement for a subject size of more than 100 people.","The study mentions tooth extraction as a risk factor, which meets the criterion for an intervention of invasive dental treatment.",Include,"The study fails to meet critical screening criteria, particularly the specific requirement for Romosozumab intervention, and lacks clear documentation of medication use and patient population characteristics. While the research includes a sufficient sample size and examines medication-related osteonecrosis, it does not provide the precise details needed to satisfy the comprehensive screening requirements. Multiple key criteria remain unmet, rendering the study unsuitable for inclusion based on the predefined screening parameters.",2.5
"Comment on ""Medication-Related Osteonecrosis of the Jaw (MRONJ)"" by Elie M. Ferneini in the Section ""Simply Put: JOMS Information for Patients"".","A. Bedogni, V. Fusco, O. D. Fede, G. Bettini, V. Panzarella, R. Mauceri, G. Saia, G. Campisi",10.1016/j.joms.2021.09.021,https://doi.org/10.1016/j.joms.2021.09.021,Journal of oral and maxillofacial surgery,4,2021,no,"The abstract mentions patients with osteoporosis and cancer, indicating that the study is not exclusively focused on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",maybe,no,"While MRONJ is discussed, the abstract does not provide any specific documentation of MRONJ outcomes following dental procedures.",maybe,"The abstract does not mention any control groups, so it cannot be determined if the study includes a control group of non-anti-resorptive medication users.",no,"The abstract indicates that this is a letter to the editor or commentary, rather than a primary research study with a randomized controlled trial, prospective/retrospective cohort study, or case-control study design.",no,"The abstract does not mention any temporal relationships between medication use and MRONJ development, or the duration of medication use.",maybe,"No information about the sample size is provided in the abstract, so it cannot be determined if the study meets the requirement of having more than 100 subjects.","While MRONJ is discussed, no specific dental procedures are described in the abstract, so it cannot be determined if the study includes an intervention of invasive dental treatment.",Exclude,"The document fails to meet multiple critical screening criteria, including specific intervention requirements, study design, and population type. It appears to be a commentary or letter about medication-related osteonecrosis of the jaw rather than a primary research study, lacking the necessary details for inclusion. The text does not provide sufficient information to satisfy the comprehensive screening requirements.",0.1
What Do Prescribers of Bone Modifying Agents Know about Medication-Related Osteonecrosis of the Jaw? Is Current Prevention Enough?,"M. Golu, I. Pașcanu, C. Togănel, C. Petrovan, A. Coșarcă, Despina Luciana Bereczki Temistocle, A. Ormenișan",10.3390/app12189224,https://doi.org/10.3390/app12189224,Applied Sciences,2,2022,no,"The abstract mentions both osteoporosis and cancer patients, and does not focus exclusively on adult osteoporosis patients without cancer. Therefore, the study does not meet the criterion of focusing on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",no,no,"While MRONJ is discussed, this is not a study documenting specific outcomes following dental procedures. Therefore, the study does not meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"No control group is mentioned, and this is a survey study rather than a comparative clinical study. Therefore, the study does not meet the criterion of including a control group of non-anti-resorptive medication users.",no,"This is a survey study of prescribers using a questionnaire, and does not match any of the required study designs (RCT, cohort, or case-control). Therefore, the study does not meet the criterion of having a study design of a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"No temporal relationships or medication durations are documented. Therefore, the study does not meet the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",maybe,"The abstract does not mention any specific subject size, so it is unclear whether the study meets the criterion of having a subject size of more than 100 people.","While dental surgery is mentioned as a risk factor, this is not an interventional study examining specific dental procedures. Therefore, the study does not meet the criterion of having an intervention of invasive dental treatment.",Exclude,"This survey study of prescribers' knowledge about medication-related osteonecrosis of the jaw fails to meet the systematic review's screening criteria, including specific requirements for patient population, intervention type, study design, and outcome documentation. The research does not focus on Romosozumab, lacks a clinical intervention, and does not examine patient outcomes in the manner specified by the screening protocol.",0.1
Risk factors associated with prognosis of patients with medication‐related osteonecrosis of the jaw,"Yoshiaki Tadokoro, T. Hasegawa, D. Takeda, Aki Murakami, Nanae Yatagai, Satomi Arimoro, E. Iwata, Izumi Saito, Junya Kusumoto, M. Akashi",10.1002/hed.27574,https://doi.org/10.1002/hed.27574,Head and Neck,1,2023,maybe,"The abstract does not provide any information about the age groups or osteoporosis diagnosis of the study population, nor does it mention the cancer status of the participants.",maybe,maybe,"The abstract mentions MRONJ as an outcome, but does not provide any specific documentation of the dental procedures that were performed.",maybe,The abstract does not mention the inclusion of a control group of non-anti-resorptive medication users.,maybe,"The study design is not explicitly stated in the abstract, but it appears to be an observational study looking at risk factors, rather than a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"The abstract does not provide any information about the temporal relationship between medication use and MRONJ development, or the duration of medication use.",maybe,"No information is provided about the sample size of the study, so it is uncertain whether the study has a subject size of more than 100 people.","The abstract does not mention any specific invasive dental treatments, such as tooth extraction, implant placement, periodontal surgery, or removable prosthesis fabrication.",Exclude,"The abstract lacks specific details about Romosozumab, dental interventions, patient population, and study design, making it impossible to definitively confirm most screening criteria. Critical information is missing, particularly regarding the specific medication, patient characteristics, and intervention details required by the screening protocol. The broad focus on medication-related osteonecrosis of the jaw suggests the study does not align with the targeted research parameters.",1.4
10-Year Institutional Retrospective Case-Control Study of Medication-Related Osteonecrosis of the Jaw,"Pardis Barati Mahvar, Amna Imran, R. Enciso, Andrew Sanapanya, M. Khalifeh, P. Sedghizadeh, Laurel Henderson",10.1080/19424396.2019.12220864,https://doi.org/10.1080/19424396.2019.12220864,Journal - California Dental Association,0,2019,no,"The abstract does not provide any explicit mention of the age or osteoporosis diagnosis of the patients, nor does it mention their cancer status, so it is uncertain whether this criterion is met.",no,maybe,"MRONJ outcomes are documented, but the specific dental procedures are not mentioned, so the criterion is only partially met.",maybe,"The study includes 615 non-MRONJ patients taking ART, which partially meets the criterion of having a control group, but it is unclear if they are non-ART users.",yes,"The study is explicitly stated as a ""retrospective case-control study"", which meets the criterion of having a study design that is either a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"The study mentions a ""10-year period"", but it does not clearly document the temporal relationship between medication use and MRONJ development or the duration of medication use, so the criterion is only partially met.",yes,"The study includes 223 MRONJ patients and 615 non-MRONJ patients, for a total sample size of 838 patients, which meets the criterion of more than 100 people.","The abstract does not explicitly mention specific dental procedures, so it is uncertain whether this criterion is met.",Exclude,"The study fails to meet the critical criterion of specifying Romosozumab as the antiresorptive medication, rendering it potentially ineligible for inclusion. Multiple screening criteria remain uncertain or only partially satisfied, including specific dental procedures, population characteristics, and temporal documentation of medication use. The retrospective case-control design and sample size are the only clearly met screening requirements.",1.4
CURATIVE RATES OF MEDICATION-RELATED OSTEONECROSIS OF THE JAW FOLLOWING APPLICATION OF THE SICMF-SIPMO SURGICAL TREATMENT ALGORITHM,"G. Bettini, G. Saia, E. Perra, L. Tognin, Piero Franco, G. Bedogni, A. Bedogni",10.32388/LVB61W,https://doi.org/10.32388/LVB61W,Qeios,3,2021,no,"The study includes both cancer and osteoporosis patients, and is not exclusively focused on adult osteoporosis patients without cancer.",no,no,"The study documents MRONJ outcomes, but not in relation to dental procedures. Instead, it focuses on treatment outcomes of existing MRONJ.",no,There is no mention of a control group of non-anti-resorptive medication users.,yes,"The study is described as a ""10-years longitudinal cohort study"", which meets the criterion for study design.",no,There is no clear documentation of the temporal relationship between medication use and MRONJ development.,no,"The study includes 70 patients with 75 operated jaw sites, which is below the required 100 subjects.","The study focuses on treatment of MRONJ rather than dental procedures leading to MRONJ, so it does not meet the criterion of studying invasive dental treatment.",Exclude,"The study fails multiple critical screening criteria, including lack of specificity to Romosozumab, insufficient subject size, and inclusion of cancer patients. While the research design meets some methodological standards, it fundamentally examines MRONJ treatment outcomes rather than dental procedures leading to MRONJ in osteoporosis patients. Consequently, the abstract does not align with the systematic review's targeted research parameters.",0.1
Major considerations of maxillary/mandible osteonecrosis caused by bisphosphonates in the dental implant scenario: a systematic review,"Nathalia Silva Tamarindo, Luiza Beran Gubolin, Victoria Luisa Lopes Bordon, Andreia Borges Scriboni",10.54448/mdnt24s408,https://doi.org/10.54448/mdnt24s408,MedNEXT Journal of Medical and Health Sciences,0,2024,maybe,"The abstract mentions osteoporosis patients, but does not explicitly state that the study focuses exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",maybe,maybe,"The abstract mentions MRONJ outcomes and discusses dental procedures (implants), which partially meets the criterion for reporting MRONJ outcomes following specific, documented dental procedures.",maybe,The abstract does not mention the inclusion of a control group of non-anti-resorptive medication users.,no,"The abstract indicates that this is a systematic review, not a primary study, and therefore does not meet the criterion for a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The abstract does not clearly document the temporal relationship between medication use and MRONJ development, or the duration of medication use.",maybe,"The abstract does not specify the number of subjects in the included studies, so the subject size is uncertain.","The abstract mentions dental implants and ""invasive practices"", which partially meets the criterion for invasive dental treatment.",Exclude,"The systematic review fails critical screening criteria by focusing on bisphosphonates instead of Romosozumab and being a review rather than a primary research study. Multiple screening requirements remain unmet or uncertain, including subject size, population type, control group, and temporal documentation of medication use and outcomes. The study's methodology and focus do not align with the specified screening requirements.",0.1
An Update on Medication Related Osteonecrosis of the Jaw: 18 years of Experience,"Vickas Agarwal, T. Schlieve",-,-,-,1,2021,maybe,"The abstract does not mention adult patients or osteoporosis diagnosis, and does not mention cancer exclusion, so it is unclear if the population type meets the criteria.",maybe,maybe,"While MRONJ is discussed, the abstract does not provide specific documentation of outcomes following dental procedures.",maybe,"The abstract does not mention control groups, so it is unclear if a control group of non-anti-resorptive medication users is included.",no,"The abstract appears to be a review or position paper discussing case reports and series, rather than a primary research study with the required design types.",maybe,"The abstract does not clearly document the temporal relationship between medication use and MRONJ development, or the duration of medication use.",no,"The abstract mentions ""99 cases"" which is below the required 100 subjects.","While the abstract discusses MRONJ, it does not specifically detail the types of dental procedures, so it is unclear if the intervention includes invasive dental treatment.",Exclude,"The abstract fails critical screening criteria by discussing bisphosphonates instead of Romosozumab, presenting a sample size below 100, and appearing to be a review rather than a primary research study. Multiple key requirements are not met, including specific intervention details, population characteristics, and study design specifications. Consequently, the abstract does not align with the predefined screening criteria and would be excluded from further consideration.",0.1
Medication-related osteonecrosis of the jaw in patients with bone metastases from solid tumors: analysis of the Istituto Oncologico Veneto case series,"Selma Ahcene-Djaballah, S. zovato, C. Bacci, G. Bettini, M. Maruzzo, F. Di Sarra, A. M. Ferrara, A. Brunello, V. Guarneri, E. Lamberti, C. Falci, V. Zagonel",10.32388/4AKYSB,https://doi.org/10.32388/4AKYSB,Qeios,0,2021,no,"The study focuses on patients with solid tumors, which explicitly violates the criterion requiring patients without cancer. This is a critical failure.",maybe,maybe,"MRONJ outcomes are mentioned, but the abstract doesn't specify whether these are documented following specific dental procedures.",no,No mention of a control group of non-BAA users.,yes,"The study is described as a ""retrospective study"" which meets the criteria for acceptable study designs.",maybe,"The abstract mentions ""time to onset (TTO)"" which suggests temporal documentation, but it's unclear if duration of medication use is documented.",yes,"The study includes 1211 patients, which clearly exceeds the minimum requirement of 100.","While dental prevention is mentioned, the abstract doesn't explicitly state whether invasive dental treatments were performed. This is unclear from the abstract.",Exclude,"The study fails critical screening criteria by focusing on bone antiresorptive agents for cancer patients rather than Romosozumab for osteoporosis patients. While the study has a large sample size and appropriate study design, the fundamental mismatch in medication type and patient population disqualifies it from the systematic review. Key exclusion factors include the wrong medication and patient population, rendering the study non-compliant with the specified screening requirements.",0.1
Platelet-Rich Plasma in the Prevention and Treatment of Medication-Related Osteonecrosis of the Jaw: A Systematic Review and Meta-Analysis.,Marwan H Aljohani,10.1097/SCS.0000000000010664,https://doi.org/10.1097/SCS.0000000000010664,The Journal of craniofacial surgery (Print),0,2024,maybe,"The abstract does not specify the age range or osteoporosis diagnosis of the population, and there is no mention of cancer status, so the population details are uncertain.",maybe,maybe,"While MRONJ outcomes are documented, the specific dental procedures leading to MRONJ are not detailed, so the outcome documentation is only partially met.",no,"The study compares PRF treatment vs. conventional medical treatments, which is not the required control group of non-anti-resorptive users.",no,"This is a systematic review and meta-analysis, not a primary study, so it does not meet the required study design criteria.",no,"There is no clear documentation of the temporal relationship between medication use and MRONJ development, or the duration of medication use.",yes,"The study includes 480 participants across 11 articles, which meets the requirement of more than 100 subjects.","The abstract discusses MRONJ treatment but does not specify the dental procedures that led to MRONJ, so the intervention details are uncertain.",Exclude,"The systematic review fails to meet critical screening criteria, particularly the requirement for Romosozumab intervention, with the study instead focusing on bisphosphonates and PRF treatment. Multiple key elements are missing or misaligned, including population specifics, control group composition, and temporal documentation of medication use. The study design as a systematic review and meta-analysis further disqualifies it from meeting the established screening requirements.",0.1
Medication-related osteonecrosis of the jaw: An institution’s experience,"M. Altay, A. Radu, S. Pack, N. Yıldırımyan, Andres Flores-Hidalgo, D. Baur, F. Quereshy",10.1080/08869634.2018.1528711,https://doi.org/10.1080/08869634.2018.1528711,Cranio : the journal of craniomandibular practice,6,2018,maybe,"The age range of 40-90 years indicates the study focuses on adult patients (≥18), but there is no mention of cancer status.",no,no,"While MRONJ outcomes are documented, they are not linked to specific dental procedures, and the focus is on surgical treatment of MRONJ rather than initial dental procedures.",no,There is no mention of a control group.,no,"The study appears to be a retrospective case series, which does not meet the required study design types.",no,"There is no clear documentation of the temporal relationship between medication use and MRONJ, and the duration of medication use is not mentioned.",no,"The study includes only 21 patients, which falls well below the required 100+ subjects.","The abstract focuses on surgical treatment of MRONJ rather than the dental procedures that led to MRONJ, and does not clearly document the initial dental procedures.",Exclude,"The study fails to meet multiple critical screening criteria, including the specific anti-resorptive medication, required subject size, and appropriate study design. With only 21 patients and a focus on surgical treatment of MRONJ rather than initial dental procedures, the research does not align with the predefined screening requirements. Key information about medication type, control group, and temporal documentation is missing, rendering the study non-compliant with the established criteria.",0.1
Medication-related osteonecrosis of the jaw: Evidence for infection versus oversuppression.,"K. Fleisher, F. Muggia, R. Glickman",10.1200/JCO.2019.37.15_SUPPL.E18268,https://doi.org/10.1200/JCO.2019.37.15_SUPPL.E18268,Journal of Clinical Oncology,0,2019,maybe,"The study includes both cancer patients (40) and osteoporosis patients (14). The abstract doesn't specify if all patients were ≥18 years, though this is likely given the context.",maybe,maybe,"While MRONJ outcomes are documented, they're not clearly linked to specific dental procedures as required.",no,No control group of non-anti-resorptive medication users is mentioned.,yes,"The study is described as a ""retrospective cohort study"" which meets the criteria.",maybe,"The abstract mentions ""duration of perioperative antiresorptive therapy"" but doesn't clearly document the temporal relationship between medication use and MRONJ development.",no,"The study includes only 54 patients (59 lesions), which is below the required 100 subjects.","While the study involves surgical management of MRONJ, it's not clear if these were specifically following dental procedures. The abstract focuses on treatment of existing MRONJ rather than dental procedures leading to MRONJ.",Exclude,"The study fails to meet multiple critical screening criteria, including the specific requirement for Romosozumab intervention and a subject size of over 100 patients. While the research involves antiresorptive therapy and MRONJ, it includes a mixed population of cancer and osteoporosis patients, lacks a control group, and does not clearly document the temporal relationship between medication use and MRONJ development. The retrospective cohort design partially meets some criteria, but significant methodological limitations prevent full compliance with the screening requirements.",1.4
Genetic and pharmacogenomic aspects of the medication related osteonecrosis of the jaw (MRONJ): a quality research umbrella review,Roberto Sacco,10.37766/inplasy2022.3.0002,https://doi.org/10.37766/inplasy2022.3.0002,-,0,2022,no,"Elicit could not determine the characteristics of the study population, as the provided abstract was incomplete and did not contain any information about the patients.",no,no,"Elicit could not determine if the study reported MRONJ outcomes following specific dental procedures, as the provided abstract was incomplete and did not contain any information about the outcomes.",no,"Elicit could not determine if the study included a control group of non-anti-resorptive medication users, as the provided abstract was incomplete and did not contain any information about the study design.",no,"Elicit could not determine the study design, as the provided abstract was incomplete and did not contain any information about the methodology.",no,"Elicit could not determine if the study clearly documented the temporal relationship between medication use and MRONJ development, as the provided abstract was incomplete and did not contain any information about the temporal aspects of the study.",no,"Elicit could not determine the sample size of the study, as the provided abstract was incomplete and did not contain any information about the number of subjects.","Elicit could not determine if the study involved invasive dental treatments, as the provided abstract was incomplete and did not contain any information about the interventions.",Exclude,"Insufficient information exists to assess the screening criteria due to an incomplete or malformed abstract containing only ""Review question"". Without substantive content, it is impossible to determine compliance with any of the specified research parameters. No meaningful evaluation can be conducted based on the provided text.",0.1
Risk factors for medication-related osteonecrosis of the jaws in menopausal women,"Jocarla Campos Serafim, Gustavo Azevedo Pitol, Ester Victorino Coser, B. Albergaria, S. C. Kano, T. Velloso",10.20396/bjos.v23i00.8668457,https://doi.org/10.20396/bjos.v23i00.8668457,Brazilian Journal of Oral Sciences,0,2024,yes,The study includes adult patients with osteoporosis and does not mention any cancer patients.,yes,yes,"The study evaluates MRONJ risk factors and mentions specific dental procedures (extractions, periodontal disease).",no,The study does not mention a control group of non-anti-resorptive medication users.,yes,"The study appears to be a retrospective cohort study, which meets the acceptable study design criteria.",no,"The study does not clearly document the temporal relationship between medication use and MRONJ, and the duration of medication use is not mentioned.",no,"The study included only 50 patients, which fails to meet the minimum requirement of 100 subjects.","The study mentions tooth extraction and periodontal disease, which are relevant dental interventions.",Exclude,"The study fails critical screening criteria by using bisphosphonates instead of Romosozumab and having a sample size of only 50 patients, which is significantly below the required 100 subjects. Additionally, the research lacks a control group and does not provide comprehensive temporal documentation of medication use and MRONJ development, rendering it unsuitable for the systematic review.",0.1
"Anti-resorptive medications and periodontitis: critical appraisal, clinical management and ONJ risk","L. Barbato, L. Landi, Nicola Discepoli, G. Oteri, A. Carrassi, N. M. Sforza, F. Cairo",10.57582/ijbf.240401.016,https://doi.org/10.57582/ijbf.240401.016,International Journal of Bone Fragility,0,2024,maybe,"The study focuses on osteo-metabolic patients with osteoporosis, and there is no mention of cancer patients, which partially meets the criterion of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer. However, the age criterion is not specified.",yes,no,"While MRONJ is discussed, this is a review paper rather than a primary study documenting specific outcomes, so it fails to meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"There is no mention of a control group in the abstract, so the study fails to meet the criterion of including a control group of non-anti-resorptive medication users.",no,"This appears to be a narrative review rather than an original research study, so it fails to meet the criterion of having a study design of either a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"While the paper discusses different treatment durations (e.g., ""less than three years""), this is in the context of a review rather than primary documentation, so it fails to meet the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",maybe,"The abstract does not mention any specific sample size, so it is uncertain whether the study meets the criterion of having a subject size of more than 100 people.","The abstract discusses periodontal treatment including both non-surgical and surgical interventions, which meets the criterion of the subject having an intervention of invasive dental treatment.",Exclude,"This narrative review fails to meet multiple critical screening criteria, including the specific intervention of Romosozumab, lack of a control group, and absence of a primary research design. The paper discusses anti-resorptive medications and periodontitis but does not constitute an original research study with the required methodological elements for systematic review inclusion.",0.1
Risk Factors and Indices of Osteomyelitis of the Jaw in Osteoporosis Patients: Results from a Hospital-Based Cohort Study in Japan,"T. Yamazaki, M. Yamori, Shiro Tanaka, Keiichi Yamamoto, Eriko Sumi, Megumi Nishimoto-Sano, K. Asai, Katsu Takahashi, T. Nakayama, K. Bessho",10.1371/journal.pone.0079376,https://doi.org/10.1371/journal.pone.0079376,PLoS ONE,5,2013,maybe,"The study includes osteoporosis patients, but also includes those with cancer (mentions chemotherapy). The age criterion (≥18) is not explicitly stated.",maybe,no,"The study focuses on OMJ (osteomyelitis of the jaw) rather than MRONJ (medication-related osteonecrosis of the jaw). While related, these are distinct conditions.",maybe,"While the study is a retrospective cohort study, it is not clear if there is a specific control group of non-BP users.",yes,"The study is described as a retrospective cohort study, which meets the criteria.",maybe,"While the study examines risk factors, it is not clear if it documents the temporal relationship between medication use and jaw condition development.",maybe,"The abstract does not specify the total number of subjects, so it is unclear if the study has a subject size of more than 100 people.","While the study examines OMJ (osteomyelitis of the jaw), it does not explicitly state whether this occurred after specific dental procedures. The focus seems to be on risk factors rather than dental interventions.",Exclude,"The study focuses on bisphosphonates and osteomyelitis of the jaw, which fundamentally differs from the specified screening criteria involving Romosozumab and medication-related osteonecrosis of the jaw. Critical mismatches include the medication type, patient population, and outcome measure, rendering the study non-compliant with the established screening requirements. Multiple key criteria were not met, particularly the core intervention and outcome specifications.",1.4
Choosing the Right Partner for Medication Related Osteonecrosis of the Jaw: What Central European Dentists Know,"E. Bruckmoser, Miriam Palaoro, Lukas Latzko, D. Schnabl, S. Neururer, J. Laimer",10.3390/ijerph18094466,https://doi.org/10.3390/ijerph18094466,International Journal of Environmental Research and Public Health,9,2021,no,"The study focuses on dentists' knowledge, not patients, and there is no mention of osteoporosis patients, so it does not meet the criterion of focusing exclusively on adult patients with diagnosed osteoporosis who do not have cancer.",no,no,"The study does not document actual MRONJ outcomes, only discussing knowledge about MRONJ, so it does not meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"No control group is mentioned, and this is not applicable as this is a survey study, so it does not meet the criterion of including a control group of non-anti-resorptive medication users.",no,"This is a survey study, which does not match any of the required study designs (RCT, cohort, or case-control), so it does not meet the criterion of having a study design of a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The study does not document the temporal relationship between medication use and MRONJ development or the duration of medication use, so it does not meet the criterion of clearly documenting both the temporal relationship and the duration of medication use.",no,"The study has 1,197 valid replies from dentists, but this is a survey of dentists, not patients, so it does not meet the criterion of having a subject size of more than 100 people.","While dental procedures are mentioned, this is a survey about knowledge and management, not a study of actual dental procedures, so it does not meet the criterion of having an intervention of invasive dental treatment.",Exclude,"This survey study of dentists' knowledge about medication-related osteonecrosis of the jaw fails to meet multiple critical screening criteria, including specific intervention type, patient population, study design, and outcome documentation. The research does not involve patients, lacks a control group, and does not examine actual dental procedures or MRONJ outcomes, rendering it ineligible for the systematic review.",0.1
"The risk of osteonecrosis of the jaw (ONJ) and adverse outcomes in patients using antiresorptive drugs undergoing orthodontic treatment, A protocol for a systematic review","Julian Woolley, O. Akintola, J. Yates, M. Calasans-Maia, J. Calasans-Maia, R. Sacco",10.37766/inplasy2020.7.0124,https://doi.org/10.37766/inplasy2020.7.0124,-,0,2020,no,"Elicit could not determine if the study focused exclusively on adult patients (≥18 years) with diagnosed osteoporosis who did not have cancer, as the provided abstract was incomplete and did not contain any information about the study population.",no,no,"While the title mentioned ONJ, Elicit could not determine if the study reported specific, documented dental procedures and MRONJ outcomes, as the provided abstract was incomplete and did not contain any information about the study outcomes.",no,"Elicit could not determine if the study included a control group of non-anti-resorptive medication users, as the provided abstract was incomplete and did not contain any information about the study design or control group.",no,"Elicit could not determine the study design, as the provided abstract was incomplete and did not contain any information about the study methodology.",no,"Elicit could not determine if the study clearly documented the temporal relationship between medication use and MRONJ development, as well as the duration of medication use, as the provided abstract was incomplete and did not contain any information about the study's temporal documentation.",no,"Elicit could not determine the subject size of the study, as the provided abstract was incomplete and did not contain any information about the number of participants.","Elicit could not determine if the study included invasive dental treatments, as the provided abstract was incomplete and did not contain any information about the interventions.",Exclude,"An incomplete abstract fragment prevents comprehensive assessment of the screening criteria, with insufficient information to determine study characteristics related to medication, patient population, intervention, and outcomes. Critical details about subject size, control group, study design, and specific dental procedures are missing, rendering a definitive screening determination impossible without the complete abstract.",0.1
Risk factors for dental findings of the development of medication-related osteonecrosis of the jaw: Investigation of 3734 teeth in cancer patients receiving high dose antiresorptive agents,"M. Otsuru, Yoshinari Fujiki, S. Soutome, Norio Nakamura, Taro Miyoshi, T. Naruse, Mizuho Ohnuma, Y. Hotokezaka, S. Rokutanda, M. Umeda",10.1016/j.jds.2023.04.026,https://doi.org/10.1016/j.jds.2023.04.026,Journal of Dental Sciences,3,2023,maybe,"There is no explicit mention of the age or osteoporosis diagnosis of the study population, and no mention of cancer status, so the reasoning is uncertain.",yes,yes,"The abstract mentions MRONJ outcomes and dental procedures, and specifically focuses on the relationship between dental findings and MRONJ development, indicating the study meets this criterion.",maybe,"There is no mention of a control group of non-anti-resorptive medication users, so the reasoning is uncertain.",maybe,"The study design is not explicitly stated, and while it appears to be an observational study, the specific type is unclear, so the reasoning is uncertain.",maybe,"The abstract mentions ""prior to"" administration of ARAs, suggesting the study documents the temporal relationship between medication use and MRONJ development, but the duration of medication use is not clearly documented, so the reasoning is partially met.",maybe,"No information is provided about the sample size of the study, so the reasoning is uncertain.","The abstract mentions tooth extraction and ""invasive dental treatment of the bone"", indicating the study includes an intervention of invasive dental treatment.",Exclude,"The abstract lacks specificity about Romosozumab, which is a critical screening requirement, and provides insufficient details about study design, population characteristics, and sample size. While the study addresses medication-related osteonecrosis of the jaw and dental procedures, it fails to meet key screening criteria, particularly the precise intervention specification. Multiple screening elements remain uncertain or unmet, significantly reducing the likelihood of study inclusion.",1.4
Preventive dental management of osteonecrosis of the jaws related to zoledronic acid treatment.,"JA Coello-Suanzes, V. Rollón-Ugalde, A. Castaño-Seiquer, E. Lledo-Villar, J. Herce-López, P. Infante-Cossio, Á. Rollón-Mayordomo",10.1111/odi.12842,https://doi.org/10.1111/odi.12842,Oral Diseases,9,2018,no,"The study specifically focuses on cancer patients, which is explicitly excluded in the screening criteria.",yes,yes,"The study clearly documents BRONJ outcomes following dental procedures, particularly extractions.",maybe,"While the study has two groups (A and B), these are not control groups in the sense of comparing anti-resorptive medication users vs. non-users. Instead, they compare timing of dental treatment relative to medication initiation.",yes,This appears to be a prospective cohort study with clear comparison groups.,yes,"The study documents temporal relationships between medication use and BRONJ development, with clear follow-up periods and timing of dental interventions.",yes,"The study includes 255 patients, which is well above the minimum requirement of 100.","The study includes dental extractions and other dental treatments, which meet the criteria for invasive dental procedures.",Exclude,"The study fails key screening criteria by using zoledronic acid instead of romosozumab and focusing on cancer patients rather than non-cancer osteoporosis patients. Despite meeting several methodological requirements like adequate sample size and clear outcome documentation, the fundamental misalignment with core inclusion criteria necessitates exclusion from the systematic review.",0.1
Incidence of osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases from solid tumors or multiple myeloma: Results from three phase III trials.,"A. Lipton, F. Saad, C. V. Van Poznak, Janet E Brown, A. Stopeck, K. Fizazi, D. Henry, N. Shore, I. Diel, K. Tonkin, R. De Boer, Huei Wang, A. Braun",10.1200/JCO.2013.31.15_SUPPL.9640,https://doi.org/10.1200/JCO.2013.31.15_SUPPL.9640,-,7,2013,no,"The study focuses on patients with metastatic bone disease (MBD) from solid tumors or multiple myeloma, not osteoporosis patients, which is another critical mismatch.",maybe,maybe,"While ONJ outcomes are reported (3.8-4.7% incidence), the specific dental procedures leading to ONJ are not detailed in the abstract.",yes,The study includes a control group comparing denosumab vs ZA.,yes,"These are phase 3 clinical trials, which are randomized controlled trials.",yes,The study documents temporal relationships and duration of treatment (approximately 5 years).,yes,"The study includes 5,677 patients, well above the 100-person minimum.","The abstract doesn't explicitly mention dental procedures. While ONJ is discussed, specific dental interventions are not detailed.",Exclude,"The study focuses on denosumab and zoledronic acid in cancer patients with metastatic bone disease, which critically differs from the required romosozumab intervention in osteoporosis patients. Despite meeting several methodological criteria like large sample size and robust study design, the fundamental mismatch in medication type and patient population necessitates exclusion from the systematic review.",0.1
Clinical significance of drug cessation on medication-related osteonecrosis of the jaw in patients with osteoporosis,"K. R. Mustakim, M. Eo, J. Lee, M. Seo, S. Kim",10.5125/jkaoms.2023.49.2.75,https://doi.org/10.5125/jkaoms.2023.49.2.75,Journal of the Korean Association of Oral and Maxillofacial Surgeons,4,2023,maybe,"The study focuses on osteoporosis patients, but doesn't explicitly state they are all adults (≥18 years) or confirm absence of cancer patients.",yes,yes,The study clearly documents MRONJ outcomes following surgical interventions.,yes,"The study compares BP suspension vs. non-suspension groups, effectively creating a control group.",yes,"While not explicitly stated, this appears to be a retrospective cohort study analyzing patients treated from 2012 to 2020.",yes,The study documents temporal relationships through follow-up periods and timing of BP suspension relative to surgery.,no,"The study only includes 24 patients, which is well below the required minimum of 100 subjects.","The study involves surgical interventions and mentions ""surgery"" multiple times, though specific procedures aren't detailed in the abstract.",Exclude,"The study fails key screening criteria by using bisphosphonates instead of Romosozumab and having a sample size of only 24 patients, which is significantly below the required 100 subjects. Despite meeting several other criteria like documenting MRONJ outcomes and including a control group, the fundamental mismatches in medication type and sample size render the study non-compliant with the specified screening requirements.",1.4
Quantitative proteomics in medication-related osteonecrosis of the jaw: a proof-of-concept study.,"A. Lorenzo-Pouso, S. Bravo, Javier Carballo, María del Pilar Chantada-Vázquez, J. Bagan, L. Bagán, C. Chamorro-Petronacci, Mercedes Conde-Amboage, R. López-López, A. García-García, M. Pérez‐Sayáns",10.1111/odi.14201,https://doi.org/10.1111/odi.14201,Oral Diseases,10,2022,maybe,"The abstract does not provide explicit information about the age or osteoporosis diagnosis of the subjects, nor does it mention their cancer status, so there is insufficient information to determine if the population type meets the criterion.",no,no,"While the study examines MRONJ, there is no documentation of specific dental procedures, as the focus is on biomarkers rather than procedure outcomes.",yes,"The study includes both BMA consumers and healthy controls, which meets the criterion of having a control group of non-anti-resorptive medication users.",yes,"The study is explicitly stated as a case-control study, which meets the criterion of having a study design that is either a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The abstract does not mention the temporal relationship between medication use and MRONJ development or the duration of medication use, so there is no documentation of this information.",no,"The study includes only 38 samples total (18 MRONJ patients, 10 BMA consumers, 10 controls), which is less than the required 100 subjects.","There is no mention of dental procedures or interventions in the study, as it focuses on salivary proteome analysis rather than invasive dental treatment.",Exclude,"The study fails to meet multiple critical screening criteria, including specific intervention type, sample size, and dental procedure documentation. While the research explores medication-related osteonecrosis of the jaw through a case-control design, it lacks the precise focus on Romosozumab, dental interventions, and comprehensive outcome tracking required by the systematic review protocol. The biomarker-focused study does not align with the core requirements of the screening criteria.",1.4
Medication‐related osteonecrosis of the jaw and successful implant treatment in a patient on high‐dose antiresorptive medication: A case report,"C. Ottesen, S. W. M. Andersen, S. S. Jensen, T. Kofod, K. Gotfredsen",10.1002/cre2.620,https://doi.org/10.1002/cre2.620,Clinical and Experimental Dental Research,7,2022,no,"The abstract specifically mentions ""patient with cancer"", which explicitly violates the criterion requiring non-cancer patients.",yes,maybe,"The abstract mentions MRONJ outcomes following dental procedures, but as a case report, the documentation may be limited.",no,"As a case report, there is no control group mentioned.",no,"This is a case report, which is not one of the accepted study designs (RCT, cohort, or case-control).",maybe,The abstract does not clearly document the temporal relationship or duration of medication use.,no,"This is a case report, which by definition involves a single patient, clearly failing the requirement for a subject size of more than 100 people.","The abstract mentions dental implant treatment, which qualifies as invasive dental treatment.",Exclude,"The case report fails multiple critical screening criteria, including using an unspecified antiresorptive medication, involving a single patient with cancer, and lacking a control group. These fundamental deviations from the required study parameters render the paper ineligible for inclusion, particularly given the strict requirements for medication type, population characteristics, and study design.",0.1
Anti-angiogenic drug aggravates the degree of anti-resorptive drug-based medication-related osteonecrosis of the jaw by impairing the proliferation and migration function of gingival fibroblasts,"Ningrui Zhao, Qingxiang Li, Yifei Wang, Qiao Qiao, Hongyuan Huang, C. Guo, Y. Guo",10.1186/s12903-023-03034-7,https://doi.org/10.1186/s12903-023-03034-7,BMC Oral Health,9,2023,no,"The study specifically focuses on cancer patients, which is explicitly excluded in the screening criteria.",yes,yes,The study clearly documents MRONJ outcomes following tooth extraction procedures.,yes,"The study includes control groups, comparing different drug regimens and including a control group in the mouse model.",yes,"While not explicitly stated, the study appears to be a prospective cohort study with experimental components.",maybe,"While the study documents the relationship between medication use and MRONJ, the duration of medication use is not clearly specified in the abstract.",maybe,"The abstract does not specify the total number of human subjects, so the subject size is unclear.","The study includes tooth extraction as an intervention, which meets this criterion.",Exclude,"The study fails key screening criteria by focusing on zoledronate instead of romosozumab and examining cancer patients rather than non-cancer osteoporosis patients. Despite meeting some criteria like invasive dental treatment and outcome documentation, the fundamental misalignment with core inclusion requirements necessitates exclusion from the systematic review.",0.1
Latest findings of treatment and prevention of medication-related osteonecrosis of the jaw : Results of multicenter clinical trials,M. Umeda,10.5794/jjoms.66.52,https://doi.org/10.5794/jjoms.66.52,Japanese Journal of Oral & Maxillofacial Surgery,0,2020,maybe,"The abstract does not specify the age range or whether patients have cancer, so the information about the population type is unclear.",yes,yes,"The abstract discusses MRONJ outcomes following dental procedures, particularly focusing on surgical treatment and tooth extraction, meeting this criterion.",no,The abstract does not mention any control group of non-anti-resorptive medication users.,maybe,"While the abstract mentions ""multicenter clinical trials,"" the specific study design is not clearly stated.",maybe,"The abstract discusses the relationship between medication use and MRONJ, including drug holidays, but the specific duration of medication use is not clearly documented.",maybe,"The abstract mentions ""multicenter clinical trials"" but does not specify the number of subjects, so the information about the subject size is unclear.","The abstract discusses tooth extraction and other dental treatments, meeting this criterion.",Include,"The abstract discusses medication-related osteonecrosis of the jaw treatment but lacks specificity regarding key screening criteria, particularly the use of Romosozumab. Critical information about subject size, population characteristics, control group, and study design is missing or unclear. While the text provides insights into MRONJ management, it does not comprehensively meet the predefined screening requirements.",2.5
Medication‐related to osteonecrosis of the jaw affect dental implant success? A systematic review,"M. D. P. R. Sanchez, Lamis Meorin Nogueira, R. M. Pinheiro, M. Haddad, Diana Lucia Bettin Yanez, Francy Osorio, J. Gale",10.1111/clr.478_13509,https://doi.org/10.1111/clr.478_13509,Clinical Oral Implants Research,0,2019,maybe,The abstract doesn't explicitly specify the age of patients or whether they have osteoporosis. It only mentions patients receiving antiresorptive medications.,yes,yes,The study clearly documents MRONJ outcomes following dental implant procedures.,maybe,The abstract doesn't mention whether the included studies had control groups of non-anti-resorptive medication users.,no,"This is a systematic review, not a primary research study of the specified designs (RCT, cohort, or case-control).",maybe,"The abstract mentions a mean interval of 42 months between implant placement and MRONJ development, but doesn't clearly document the duration of medication use.",maybe,"The abstract mentions 106 cases of osteonecrosis across 8 studies, but this is a meta-analysis rather than a single study with >100 subjects.","The study specifically focuses on dental implants, which is one of the specified invasive dental treatments.",Exclude,"The systematic review focuses on bisphosphonates and dental implants, which fundamentally differs from the specified screening criteria involving Romosozumab. Critical misalignments include the wrong medication type, study design, and unclear population characteristics, rendering the paper unsuitable for inclusion in the systematic review. Multiple screening criteria were not met, particularly the core requirement of studying Romosozumab in osteoporosis patients.",1.4
THE ROLE OF CONSERVATIVE MANAGEMENT IN PATIENTS WITH MEDICATION-RELATED OSTEONECROSIS OF JAW: A MEMORIAL SLOAN KETTERING CANCER CENTER EXPERIENCE,"A. Pischek, Annu Singh, D. Shem, J. Randazzo, S. Yom, J. Huryn, C. Estilo",10.1016/j.oooo.2021.08.051,https://doi.org/10.1016/j.oooo.2021.08.051,"Oral surgery, oral medicine, oral pathology and oral radiology",0,2022,no,"The study specifically focuses on oncologic patients (breast cancer, multiple myeloma), which violates the criterion of excluding cancer patients.",maybe,maybe,"While MRONJ outcomes are documented, the specific dental procedures leading to MRONJ are not clearly detailed in the abstract.",no,No control group of non-anti-resorptive medication users is mentioned.,yes,"This is a retrospective cohort study, which meets the criteria for study design.",yes,"The study clearly documents temporal relationships, including median time to MRONJ onset (28 months) and duration of medication use.",yes,"The study includes 110 patients, which exceeds the minimum requirement of 100 subjects.","While the study discusses MRONJ, it doesn't explicitly state whether the cases were triggered by dental procedures. The abstract mentions ""spontaneous MRONJ"" in 47% of cases, so the documentation of invasive dental treatment is unclear.",Exclude,"The study fails key screening criteria by focusing on cancer patients using pamidronate, zoledronic acid, and denosumab instead of Romosozumab, and lacks a control group of non-anti-resorptive medication users. While the study meets some criteria like subject size and study design, critical disqualifying factors prevent its inclusion in the systematic review. The absence of clear documentation of dental interventions and the focus on oncologic patients further support exclusion.",0.1
Prognosis of Medication-Related Osteonecrosis of the Jaw with Surgical Treatment,"E. Kobayashi, Haruka Takahashi, Kensuke Igarashi, Hiroki Katagiri, M. Haga-Tsujimura, I. Ogura, K. Nakahara, A. Tanaka",10.2485/jhtb.31.39,https://doi.org/10.2485/jhtb.31.39,Journal of Hard Tissue Biology,0,2022,no,"The study includes both osteoporosis patients (40) and cancer patients (46), and does not focus exclusively on adult osteoporosis patients without cancer, which violates this criterion.",maybe,maybe,"The study reports MRONJ outcomes following surgical treatment, but it does not specify the dental procedures that led to MRONJ.",no,There is no mention of a control group of non-anti-resorptive medication users.,yes,"The study is described as a retrospective study, which meets the criterion for acceptable study designs.",no,"There is no clear documentation of the temporal relationship between medication use and MRONJ, and the duration of medication use is not mentioned.",yes,"The study includes 86 patients (40 osteoporosis + 46 cancer), which meets the minimum requirement of more than 100 subjects.","The study focuses on surgical treatment of MRONJ, but it does not specify the dental procedures that led to MRONJ.",Exclude,"The study fails to meet several critical screening criteria, including the specific use of Romosozumab, exclusive focus on adult osteoporosis patients, and presence of a control group. While the study includes a sufficient sample size and uses an acceptable retrospective design, significant methodological limitations prevent it from satisfying the comprehensive screening requirements. The mixed patient population and lack of detailed temporal documentation further compromise its alignment with the specified criteria.",1.4
Prediction of medication-related osteonecrosis of the jaws using machine learning methods from estrogen receptor 1 polymorphisms and clinical information,"Seo-Yong Choi, Jin-Woo Kim, Sang-Hyeon Oh, Seung-min Cheon, Jeong Yee, Sun-Jong Kim, H. Gwak, J. Chung",10.3389/fmed.2023.1140620,https://doi.org/10.3389/fmed.2023.1140620,Frontiers in Medicine,2,2023,maybe,"The study focuses on women with osteoporosis, and there's no mention of cancer patients. However, the age range isn't fully specified, though it mentions age ≥72 as a risk factor.",no,no,"While MRONJ outcomes are documented, the specific dental procedures leading to these outcomes aren't detailed in the abstract.",no,The abstract doesn't mention a control group of non-anti-resorptive medication users. The study appears to only include bisphosphonate users.,no,"While this appears to be an observational study, the specific design (whether prospective/retrospective cohort or case-control) isn't explicitly stated.",maybe,"The study mentions treatment duration (≥48 months) as a risk factor, but the temporal relationship between medication use and MRONJ development isn't clearly documented in the abstract.",yes,"The study includes 125 patients, which exceeds the minimum requirement of 100.","The abstract doesn't explicitly mention specific dental procedures, and while MRONJ is discussed, the specific dental interventions leading to it are not detailed.",Exclude,"The study focuses on bisphosphonates in osteoporotic women, which fundamentally differs from the specified Romosozumab intervention, rendering it non-compliant with the primary screening criterion. While the research meets some secondary requirements like sample size, critical methodological elements such as control group composition and specific dental procedure documentation remain unclear. The medication type mismatch represents a decisive exclusion factor from the intended screening parameters.",1.4
Antiresorptive medication in oncology: the clinical and dental profile of patients in a reference center,"V. C. Ferreira, A. Kemp, J. Vendruscolo, L. Sassi, J. Schussel",10.5125/jkaoms.2021.47.1.20,https://doi.org/10.5125/jkaoms.2021.47.1.20,Journal of the Korean Association of Oral and Maxillofacial Surgeons,0,2021,no,"The study focuses on cancer patients, which explicitly violates the criterion requiring non-cancer patients.",maybe,maybe,"The study reports MRONJ outcomes (9 patients developed osteonecrosis), but doesn't clearly document specific dental procedures leading to MRONJ.",no,No mention of a control group of non-anti-resorptive medication users.,no,"The study is described as an ""observational cross-sectional study"", which does not meet the required study design types.",no,"No clear documentation of temporal relationship between medication use and MRONJ, and no mention of duration of medication use.",no,"The study includes 90 patients, which is below the required 100.","While dental procedures are mentioned, the abstract doesn't clearly specify which invasive dental treatments were performed.",Exclude,"The study fails critical screening criteria by focusing on cancer patients using zoledronic acid instead of Romosozumab, with a sample size below 100 and an inappropriate study design. Multiple key requirements are not met, including population type, intervention specifics, and control group composition, rendering the study unsuitable for the systematic review.",0.1
Pathological events in 55 patients with advanced Medications-related osteonecrosis of the Jaws (MRONJ),"A. Pizzo, M. Frontera, G. Ghidini, M. Meleti, M. Manfredi, P. Vescovi",10.3389/conf.fphys.2019.27.00060,https://doi.org/10.3389/conf.fphys.2019.27.00060,Frontiers in Physiology,0,2019,maybe,"The study includes both oncological (76%) and non-oncological (24%) patients, and the age range is 35-87 years (adults). This partially meets the criterion of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",yes,yes,"The study clearly documents MRONJ outcomes following specific dental procedures, meeting this criterion.",no,"There is no mention of a control group in the study, indicating that it fails this criterion.",yes,"The study is described as a ""retrospective study"", which meets the criterion of having a study design that is either a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"While the study documents the time period of the study (2004-2017), it does not clearly document the temporal relationship between medication use and MRONJ development, partially meeting this criterion.",no,"The study includes 55 patients, which is below the required 100 subjects.","The study mentions various dental procedures including extractions, implants, and prosthetic treatments, indicating that it meets the criterion of having an intervention of invasive dental treatment.",Exclude,"The study fails critical screening criteria, particularly the requirement for Romosozumab intervention, with a sample size of only 55 patients and inclusion of cancer patients. While documenting dental procedures and MRONJ outcomes, the research lacks a control group and does not meet the specified population and intervention requirements. Multiple methodological limitations significantly reduce the study's alignment with the predefined screening criteria.",1.4
Characteristics of patients with osteonecrosis of the jaw with oral versus intravenous bisphosphonate treatment,"Seung-hun Lee, So-Young Choi, M. Bae, T. Kwon",10.1186/s40902-021-00310-w,https://doi.org/10.1186/s40902-021-00310-w,Maxillofacial plastic and reconstructive surgery,4,2021,maybe,"The study includes both osteoporosis patients and cancer patients. The abstract specifically mentions both groups and even compares them, which doesn't meet the criterion of focusing exclusively on non-cancer patients with osteoporosis.",maybe,yes,The study clearly documents MRONJ outcomes and mentions surgical treatments.,no,The abstract doesn't mention any control group of non-anti-resorptive medication users. The comparison is between oral and IV BP groups.,yes,"It's described as a retrospective study, which meets the criteria for acceptable study designs.",yes,The study documents duration of medication use (31.4 months for IV BP vs 53.1 months for oral BP) and appears to track temporal relationships.,yes,"The study includes 278 patients, well above the 100-person minimum requirement.","While the study discusses MRONJ, it doesn't explicitly state which dental procedures were performed. However, it mentions ""number of surgeries"" suggesting some dental interventions were involved.",Exclude,"The study fails key screening criteria by focusing on bisphosphonates instead of Romosozumab and including cancer patients alongside osteoporosis patients. While the study meets some methodological requirements like sample size and study design, critical exclusion criteria related to medication type and population specificity prevent its inclusion in the systematic review.",1.4
Risk reduction strategies for patients at risk of medication-related osteonecrosis of the jaws undergoing dental extractions: a systematic review,"T. Halai, R. Sacco, V. Mercadante, J. Eyeson, S. Fedele",10.37766/inplasy2021.6.0064,https://doi.org/10.37766/inplasy2021.6.0064,-,0,2021,no,"Elicit was unable to determine if the study focused exclusively on adult patients (≥18 years) with diagnosed osteoporosis who did not have cancer, as the provided abstract did not contain any information about the study population.",no,no,"Elicit was unable to assess whether the study reported MRONJ outcomes following specific, documented dental procedures, as the provided abstract did not contain any information about the outcomes measured.",no,"Elicit was unable to assess whether the study included a control group of non-anti-resorptive medication users, as the provided abstract did not contain any information about the study design or control group.",no,"Elicit was unable to determine the study design, as the provided abstract did not contain any information about the study methodology.",no,"Elicit was unable to determine if the study clearly documented both the temporal relationship between medication use and MRONJ development and the duration of medication use, as the provided abstract did not contain any information about the temporal aspects of the study.",no,"Elicit was unable to determine if the study had a subject size of more than 100 people, as the provided abstract did not contain any information about the sample size.","Elicit was unable to assess whether the subjects had an intervention of invasive dental treatment, including tooth extraction, implant placement, periodontal surgery, other dental surgery, or removable prosthesis fabrication, as the provided abstract did not contain any information about the intervention.",Exclude,"No substantive information is available to assess the screening criteria, as only a ""Review question"" text exists without any actual abstract content. Without details about study population, intervention, design, or outcomes, it is impossible to determine compliance with the specified screening requirements.",0.1
Comparison of the Effect of Oral Versus Intravenous Bisphosphonate Administration on Osteoclastogenesis in Advanced-Stage Medication-Related Osteonecrosis of the Jaw Patients,"Hye-Won Kim, Min-woo Lee, Jung-Hwan Lee, M. Kim",10.3390/jcm10132988,https://doi.org/10.3390/jcm10132988,Journal of Clinical Medicine,2,2021,maybe,"The study mentions osteoporosis patients and specifically excludes cancer patients, but doesn't explicitly state all subjects are ≥18 years.",maybe,maybe,"While MRONJ outcomes are documented, it's not clear if these are following specific dental procedures as required.",no,The study compares two groups of BP users (oral vs. IV) but doesn't include a control group of non-anti-resorptive medication users.,yes,"The study is described as a retrospective study, which meets the criteria for acceptable study designs.",maybe,The abstract doesn't clearly document the temporal relationship between medication use and MRONJ development or the duration of medication use.,no,"The study only includes 20 subjects total (10 oral BP and 10 IV BP), which is well below the required 100+ subjects.","While the study involves patients who underwent surgery for MRONJ treatment, it's not clear if this was the initial dental intervention or just the treatment of existing MRONJ.",Exclude,"The study fails key screening criteria by using bisphosphonates instead of Romosozumab, having a sample size of only 20 patients, and lacking a control group of non-medication users. Critical methodological limitations include insufficient subject numbers, wrong medication type, and unclear documentation of dental procedures and temporal relationships. These fundamental deviations from the specified screening requirements render the study unsuitable for inclusion in the systematic review.",0.1
Potential role of comprehensive dental care in preventing medication related osteonecrosis of the jaw (MRONJ): a single centre study,"Kamila Alblazi, Syed Nabil, Nor Rafeah Tumian, S. S. M. Yunus, R. Ramli",10.1186/s12903-024-05081-0,https://doi.org/10.1186/s12903-024-05081-0,BMC Oral Health,0,2024,maybe,"There is no specific mention of age groups or osteoporosis diagnosis, and no mention of cancer exclusion, so it is uncertain whether the study focuses exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",maybe,maybe,"The abstract mentions MRONJ outcomes and dental procedures, which partially meets the criterion of reporting MRONJ outcomes following specific, documented dental procedures, but the details are limited.",maybe,"There is no mention of control groups, so it is uncertain whether the study includes a control group of non-anti-resorptive medication users.",maybe,"The study design is not explicitly stated, and it appears to be an observational study, but this cannot be confirmed, so it is uncertain whether the study design is a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"There is no clear documentation of the temporal relationship between medication use and MRONJ development, or the duration of medication use, so it is uncertain whether the study clearly documents these aspects.",maybe,"No information is provided about the sample size, so it cannot be determined if the study meets the requirement of having more than 100 subjects.","The abstract mentions dental extraction and ""comprehensive dental care"", which partially meets the criterion of having an intervention of invasive dental treatment, but the details are limited.",Exclude,"The abstract lacks specificity regarding Romosozumab, failing a critical screening criterion, and provides insufficient details about study design, population characteristics, and intervention specifics. Multiple key screening requirements remain unaddressed or uncertain, significantly reducing the likelihood of study inclusion. The broad focus on antiresorptive drugs and dental care prevents a clear alignment with the targeted research parameters.",1.4
Inhibition of HMGB1/RAGE Signaling Reduces the Incidence of Medication‐Related Osteonecrosis of the Jaw (MRONJ) in Mice,"I. Gkouveris, D. Hadaya, Naseim Elzakra, A. Soundia, O. Bezouglaia, S. Dry, F. Pirih, T. Aghaloo, S. Tetradis",10.1002/jbmr.4637,https://doi.org/10.1002/jbmr.4637,Journal of Bone and Mineral Research,7,2022,no,"The study is conducted in mice, not adult human patients, and there is no mention of an osteoporosis diagnosis.",no,no,"The study documents MRONJ outcomes, but these are in an experimental model, not clinical procedures.",yes,The study includes a vehicle (control) group.,no,"This is an experimental animal study, which does not match the required study designs (RCT, cohort, or case-control).",no,"The study documents the temporal relationship (1, 2, and 4 weeks), but this is in an experimental model, not a clinical context.",no,"The study is conducted in mice, not humans, and there is no mention of the sample size.","The study uses ""ligature-induced experimental periodontitis"", which is an experimental model rather than actual clinical dental procedures.",Exclude,"This mouse model study investigating molecular mechanisms of medication-related osteonecrosis fails to meet multiple critical screening criteria, including the use of romosozumab, human subject population, and clinical dental intervention. The experimental design fundamentally differs from the required clinical research parameters, rendering it unsuitable for the systematic review.",0.1
A Study of Oral Health Parameters and the Properties and Composition of Saliva in Oncological Patients with and without Medication-Related Osteonecrosis of the Jaw Who Take Bisphosphonates,"Hanna Sobczak-Jaskow, B. Kochańska, B. Drogoszewska",10.3390/medicina59061073,https://doi.org/10.3390/medicina59061073,Medicina,4,2023,no,"The study specifically focuses on oncological patients, which is explicitly excluded in the criteria (must NOT have cancer).",no,maybe,"While MRONJ outcomes are documented, the abstract doesn't clearly indicate that these were specifically following documented dental procedures.",yes,The study includes a control group of 32 persons without oncological history and without antiresorptive therapy.,yes,"The study is described as a retrospective case-control study, which meets the criteria.",maybe,"The study mentions cumulative BP dose and its relationship to MRONJ, but doesn't clearly document the temporal relationship between medication use and MRONJ development.",no,"The study includes 49 patients total (29 with MRONJ + 20 without), plus 32 controls, which is below the required 100 subjects.","While the study examines oral cavity status and includes dental parameters, it doesn't explicitly state that subjects underwent invasive dental treatments. The focus seems to be on examining existing oral conditions rather than tracking outcomes of specific dental procedures.",Exclude,"The study fails key screening criteria by focusing on bisphosphonates instead of Romosozumab, including oncological patients, and having a sample size below 100 participants. Critical methodological misalignments with the specified inclusion criteria render this research ineligible for the systematic review. Multiple fundamental screening requirements were not met, necessitating exclusion from further analysis.",0.1
The role of interdisciplinary cooperation in the prevention of medication-related osteonecrosis of the jaw (MRONJ),"Monika Teślak, Izabela Chlebus, Iwona Ordyniec-Kwaśnica",10.31373/ejtcm/120581,https://doi.org/10.31373/ejtcm/120581,-,0,2020,maybe,"The abstract does not provide any clear indication of the patient age or osteoporosis diagnosis, nor does it mention the cancer status of the patients.",no,no,The abstract mentions osteonecrosis of the jaw but does not specify the documentation of outcomes following specific dental procedures.,no,The abstract does not mention the inclusion of a control group of non-anti-resorptive medication users.,no,"The abstract indicates that the study appears to be a case series, which does not meet the required study design criteria of a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The abstract does not provide any clear documentation of the temporal relationship between medication use and MRONJ development, nor the duration of medication use.",no,"The abstract only mentions a case series of 36 patients, which is less than the required subject size of more than 100 people.","The abstract does not provide any specific mention of invasive dental treatments, only referring to ""surgical treatment"" in general terms.",Exclude,"The abstract fails to meet multiple critical screening criteria, including the specific medication requirement, subject size, and study design. Key deficiencies include discussing bisphosphonates instead of Romosozumab, presenting a small case series of 36 patients, and lacking clear documentation of dental interventions, control groups, and temporal relationships. These fundamental shortcomings render the study ineligible for the systematic review.",0.1
Impact of Antiresorptive Agents on Maxillary Bones: a Narrative Literature Review,"Maria Luiza da Silva Matos, Pedro Henrique Bastos de OIiveira, A. Sanches, Tila Fortuna Costa Freire, J. Dantas, M. Carrera",10.17921/2447-8938.2021v23n4p268-276,https://doi.org/10.17921/2447-8938.2021v23n4p268-276,Journal of Health Science,0,2021,maybe,"The paper mentions patients with bone metastases and hormonal deficiency, but does not specify age groups or exclude cancer patients. Therefore, it is unclear whether the study meets the criterion of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",maybe,no,"The paper discusses MRONJ outcomes in general, but does not report specific outcomes from documented procedures. Therefore, it fails to meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures (extractions, periodontal surgery, implants, or prosthetic treatments).",no,"As a narrative review, the paper does not include a control group of non-anti-resorptive medication users. Therefore, it fails to meet this criterion.",no,"The paper is a narrative literature review, and not a randomized controlled trial, prospective/retrospective cohort study, or case-control study. Therefore, it fails to meet the criterion of having a study design that is either a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The paper does not document the temporal relationship between medication use and MRONJ development, or the duration of medication use. Therefore, it fails to meet the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development, and the duration of medication use.",maybe,"The paper is a narrative literature review of 33 studies, and no specific subject size is mentioned. Therefore, it is unclear whether the study meets the criterion of having a subject size of more than 100 people.","The paper discusses dental procedures and MRONJ in general, and mentions conservative, surgical, and adjuvant therapy. Therefore, it partially meets the criterion of having an intervention of invasive dental treatment, including tooth extraction, implant placement, periodontal surgery, other dental surgery, or removable prosthesis fabrication.",Exclude,"This narrative literature review fails to meet multiple critical screening criteria, including specific intervention requirements, study design, and outcome documentation. The paper discusses anti-resorptive drugs and MRONJ in general, but lacks the precise methodological and population specifications needed for systematic review inclusion. Consequently, the study does not qualify for further analysis under the established screening criteria.",0.1
"Medication-Related Osteonecrosis of the Jaw: A Cross-Sectional Survey among Urologists in Switzerland, Germany, and Austria","Salvatore Calderaro, K. Bausch, Céline Tourbier, C. Wetterauer, F. Thieringer, B. Berg",10.3390/jcm12020638,https://doi.org/10.3390/jcm12020638,Journal of Clinical Medicine,3,2023,no,"The study focuses on urologists treating cancer patients (prostate cancer), which does not meet the criterion of focusing exclusively on adult patients with diagnosed osteoporosis who do not have cancer.",no,no,"While MRONJ is discussed, this is not a study documenting specific outcomes following dental procedures. Therefore, the study does not meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"No control group is mentioned in the abstract, so the study does not meet the criterion of including a control group of non-anti-resorptive medication users.",no,"This is a postal survey study of urologists, which does not match the required study designs of randomized controlled trials, prospective/retrospective cohort studies, or case-control studies.",no,"The abstract does not provide any information on the temporal relationship between medication use and MRONJ development or the duration of medication use. Therefore, the study does not meet the criterion of clearly documenting both the temporal relationship and the duration of medication use.",maybe,"The study surveyed 176 urologists, but this is not the patient population size. The abstract does not provide information on the actual patient numbers, so it is unclear whether the study meets the criterion of having a subject size of more than 100 people.","While dental procedures are mentioned, this is a survey of urologists about their practices, not a study directly examining invasive dental treatments. Therefore, the study does not meet the criterion of having an intervention of invasive dental treatment.",Exclude,"This study fails to meet multiple critical screening criteria, including the specific intervention of Romosozumab, patient population type, and required study design. The research is a survey of urologists about medication-related osteonecrosis of the jaw, focusing on cancer patients, which fundamentally differs from the targeted research parameters. Consequently, the abstract does not qualify for inclusion based on the predefined screening requirements.",0.1
Periodontitis and peri-implantitis,Reena Wadia,10.1038/s41415-020-1444-7,https://doi.org/10.1038/s41415-020-1444-7,British Dental Journal,1,2020,maybe,"While the study involves adult patients with MRONJ, it doesn't explicitly state they have diagnosed osteoporosis or exclude cancer patients, so the population type is unclear.",yes,yes,The study clearly documents MRONJ outcomes following specific dental procedures (implant-related treatments).,no,No control group is mentioned in the abstract.,maybe,"The study is described as a retrospective case series, which is not one of the specified acceptable study designs.",maybe,"While the study mentions monitoring and prevention, it doesn't clearly document the temporal relationship between medication use and MRONJ development or the duration of medication use.",no,"The study only includes 15 patients, which is well below the required 100 subjects.","The study focuses on peri-implant MRONJ and includes implant removal and other surgical treatments, which meets the requirement for invasive dental treatment.",Exclude,"The study fails to meet multiple critical screening criteria, including the specific requirement for Romosozumab medication, with a sample size of only 15 patients instead of the required 100. Significant methodological limitations include the absence of a control group, unclear population characteristics, and a study design that does not align with the specified research parameters.",1.4
IJOMS Vol 18-4_11.indd,"SO Okada, Naohisa Hirahara",-,-,-,0,2020,maybe,The abstract does not mention the age groups or cancer status of the patient population.,maybe,maybe,"While MRONJ is discussed, the abstract does not provide details on the specific dental procedures and outcomes.",maybe,The abstract does not mention the inclusion of a control group of non-anti-resorptive medication users.,no,"The abstract indicates that this appears to be a review article rather than an original research study, and does not describe a clear study design.",maybe,"The abstract mentions ""long interval use"" of the medication, but does not provide specific temporal documentation of the relationship between medication use and MRONJ development, or the duration of medication use.",maybe,No information is provided about the sample size of the study.,"While the abstract discusses MRONJ, it does not specify which dental procedures were involved.",Exclude,"The abstract fails to meet critical screening criteria, particularly lacking specific details about Romosozumab intervention and study design. Multiple key requirements remain unaddressed, including subject size, population type, control group, and outcome documentation. The text appears to be a review article about bisphosphonates rather than an original research study focused on the specified screening parameters.",1.4
Incidence and treatment of MR-ONJ in a cohort of oncological patients.,"G. Setti, G. Garuti, Francesco Diamante, U. Consolo, P. Bellini",10.32388/O4EIE8,https://doi.org/10.32388/O4EIE8,Qeios,0,2021,no,"The study focuses on ""onco-hematological"" patients, which indicates these are cancer patients. The screening criteria specifically exclude cancer patients.",yes,yes,"The study reports MRONJ outcomes following dental procedures, though specific procedures aren't detailed in the abstract.",maybe,The abstract doesn't explicitly mention a control group of non-anti-resorptive medication users.,yes,"This appears to be a prospective cohort study with a defined timeframe and follow-up, which meets the study design criteria.",yes,"The study documents temporal relationships and duration of medication use, with clear timeframes (2007-2016 and 2020-2021 periods).",yes,"The study includes 313 patients total, which is well above the 100-person threshold specified in the screening criteria.","The abstract mentions dental evaluation and treatment, including surgical therapy, which indicates the study includes invasive dental treatment interventions.",Exclude,"The study focuses on cancer patients receiving antiresorptive drugs, which immediately disqualifies it from meeting the screening criteria requiring non-cancer patients with osteoporosis. While the research includes a substantial patient population and documents dental interventions and MRONJ outcomes, the fundamental population type and medication specificity do not align with the predefined screening requirements.",1.4
Antiresorptive agent-related osteonecrosis of the jaw risk in cancer patients before bone-modifying agent therapy: A retrospective study of 511 patients.,"C. Kanno, Momoyo Kojima, Yu Tezuka, Sadanoshin Yaginuma, Yoshiaki Kanaya, T. Kaneko",10.1016/j.bone.2023.116892,https://doi.org/10.1016/j.bone.2023.116892,Bone,1,2023,no,"The study focuses on cancer patients receiving BMAs, not adult patients with diagnosed osteoporosis without cancer.",yes,yes,The study clearly documents ARONJ outcomes following tooth extraction procedures.,yes,The study includes a control group (non-extraction group) with 376 patients.,yes,"This is a retrospective cohort study, which meets the criteria.",maybe,"While the study documents the temporal relationship between tooth extraction and ARONJ development, it doesn't clearly specify the duration of BMA use.",yes,"The study includes 511 patients, which is well above the 100-person threshold.","The study specifically focuses on tooth extraction, which is one of the specified invasive dental treatments.",Exclude,"The study fails to meet key screening criteria due to its focus on cancer patients receiving bone-modifying agents, rather than osteoporosis patients using Romosozumab. While methodologically sound with a large sample size and clear documentation of dental procedures and outcomes, the fundamental population and intervention type do not align with the specified review requirements. Critical mismatches in patient population and medication type prevent the study from qualifying for inclusion.",1.4
A primary prevention strategy: oral hygiene and correct lifestyles  among patients at risk of developing drug-related osteonecrosis of the Jaw,"Giovanna Mosaico, C. Casu",10.32388/BGMWYJ,https://doi.org/10.32388/BGMWYJ,Qeios,1,2021,no,"The abstract mentions both osteoporosis and cancer patients, and does not specify age restrictions, so it is not focused exclusively on non-cancer patients.",maybe,no,"While MRONJ is discussed, it's not in the context of a specific study, and there is no specific documentation of outcomes following procedures.",no,"There is no mention of control groups, and this appears to be a review article rather than a comparative study.",no,"This appears to be a review article or treatise, not a RCT, cohort study, or case-control study.",no,"While medication use is discussed generally, there's no specific temporal documentation, and no specific duration of medication use is mentioned.",no,"The abstract does not mention any specific study size, and this is a review/treatise rather than a primary research study.","The abstract discusses dental procedures and surgery in general terms, mentioning tooth extraction and dental prostheses, but this is in a general context, not as part of a specific study.",Exclude,"The abstract describes a review article about medication-related osteonecrosis of the jaw, which fundamentally fails to meet multiple critical screening criteria, including the specific intervention of Romosozumab, study design requirements, and population specifications. Key deficiencies include the absence of a primary research study design, lack of a defined subject population, and no documentation of specific intervention outcomes or temporal relationships. Consequently, this paper does not qualify for inclusion in the systematic review.",0.1
"Differences Between Medication-Related Osteonecrosis of the Jaw Caused by Bisphosphonates and Denosumab: Histological, Molecular Biological, and Clinical Studies","Taro Miyoshi, M. Otsuru, Kota Morishita, K. Omori, Kei-ichiro Miura, S. Hayashida, S. Rokutanda, Yuki Matsushita, Masahiro Umeda, Tomohiro Yamada",10.7759/cureus.62855,https://doi.org/10.7759/cureus.62855,Cureus,2,2024,maybe,"The abstract doesn't specify the age range of patients or explicitly state whether they have cancer, which is a significant information gap.",maybe,maybe,"While MRONJ outcomes are documented, the specific dental procedures leading to these outcomes are not clearly detailed in the abstract.",no,The study compares BP vs DMB users but doesn't mention a control group of non-anti-resorptive medication users.,yes,"The study includes a retrospective analysis component, which meets the acceptable study design criteria.",maybe,The abstract doesn't provide clear information about the temporal relationship between medication use and MRONJ development or the duration of medication use.,yes,"The study includes 298 patients in the retrospective analysis, which exceeds the minimum requirement of 100 subjects.","While the study discusses MRONJ, which typically follows dental procedures, the abstract doesn't explicitly state which dental procedures were performed, creating uncertainty.",Exclude,"The study focuses on bisphosphonates and denosumab, not Romosozumab, which immediately disqualifies it from meeting the primary intervention criterion. While the research includes a substantial patient sample and employs a retrospective design, critical screening requirements are not met, particularly the specific medication and control group specifications. Multiple screening criteria remain unclear or unmet, rendering the study non-compliant with the established screening protocol.",1.4
Denosumab-Related Osteonecrosis of the Jaw: a five year monocentric retrospective study of Ancona General Hospital,"L. Togni, M. Mascitti, A. Tesei, V. Zavaglia, A. Nori, A. Santarelli",10.32388/J240O0,https://doi.org/10.32388/J240O0,Qeios,0,2021,no,"The study explicitly includes oncological patients, which violates the ""no cancer"" requirement. It also does not specify if all patients had diagnosed osteoporosis.",maybe,maybe,"While MRONJ outcomes are documented, the specific dental procedures leading to these outcomes are not clearly detailed in the abstract.",no,No control group is mentioned in the abstract.,yes,"The study is described as a retrospective study, which meets the criteria.",maybe,"While the study period is specified (2014-2018), the abstract does not clearly indicate how medication use and MRONJ development were temporally documented.",maybe,"The abstract does not specify the total number of cases studied, so the subject size is unclear.","While the study is conducted in a Department of Special and Surgical Stomatology, it does not explicitly state which dental procedures were performed, so the intervention is unclear.",Exclude,"The study focuses on Denosumab-related osteonecrosis of the jaw, which fundamentally differs from the specified Romosozumab intervention, and includes oncological patients, thus failing key screening criteria. Multiple critical requirements are not met, including the absence of a control group, unclear subject size, and inclusion of cancer patients, rendering the study non-compliant with the predefined screening parameters.",0.1
MRONJ ASSOCIATED WITH DENTAL INFECTION AND SECONDARY INVOLVEMENT OF THE NEARBY IMPLANT: A CASE REPORT,"Stefania Nespoli, E. Audino, S. Negrini, Francesco Daleffe, M. Mensi, L. Visconti, A. Castellani, S. Salgarello",10.32388/U22PV1.3,https://doi.org/10.32388/U22PV1.3,Qeios,0,2021,maybe,"The abstract does not specify the age or osteoporosis diagnosis of the patients, and it mentions both skeletal and oncological diseases, which makes it unclear whether the study focuses exclusively on adult patients with diagnosed osteoporosis who do not have cancer.",yes,yes,"The abstract does document MRONJ outcomes following specific dental procedures, which meets this criterion.",no,"No control group is mentioned in the abstract, so the study does not meet this criterion.",no,"This is a case report, which does not meet the criterion of being a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The abstract does not clearly document the temporal relationship between medication use and MRONJ development or the duration of medication use, so it fails this criterion.",no,"This is a case report with a single patient, which does not meet the criterion of having a subject size of more than 100 people.","The abstract mentions tooth extraction and implant placement, which are considered invasive dental treatments and meet this criterion.",Exclude,"This case report fails multiple critical screening criteria, including the use of Romosozumab, minimum subject size, and appropriate study design. The single-patient case study lacks a control group, does not clearly document temporal medication relationships, and does not exclusively focus on adult osteoporosis patients without cancer. Consequently, the paper does not meet the systematic review's fundamental requirements for inclusion.",0.1
Identification of Potentially Pathogenic Variants Associated with Recurrence in Medication-Related Osteonecrosis of the Jaw (MRONJ) Patients Using Whole-Exome Sequencing,"Songmi Kim, Seyoung Mun, Wonseok Shin, Kyudong Han, Moon-Young Kim",10.3390/jcm11082145,https://doi.org/10.3390/jcm11082145,Journal of Clinical Medicine,5,2022,maybe,"While the abstract mentions postmenopausal osteoporosis patients, it also includes cancer patients and doesn't specify age requirements. The population appears to be mixed.",maybe,maybe,"While MRONJ is documented, the specific dental procedures leading to MRONJ are not clearly documented for all subjects.",no,No control group is mentioned in the abstract.,no,"This appears to be a genetic variant study using whole-exome sequencing, not a randomized controlled trial, cohort study, or case-control study.",no,The abstract does not document the temporal relationship between medication use and MRONJ development or the duration of medication use.,no,"The study only includes 10 MRONJ patients, which is well below the required minimum of 100 subjects.","The abstract mentions tooth extraction and dental trauma as causes of MRONJ, but doesn't clearly document specific dental procedures for all subjects.",Exclude,"The study fails critical screening criteria by focusing on bisphosphonates instead of Romosozumab, having a sample size of only 10 patients, and lacking a control group. Multiple methodological limitations, including an inappropriate study design and incomplete documentation of dental procedures and medication use, render the research unsuitable for the systematic review. The genetic variant study does not meet the required clinical research parameters for inclusion.",0.1
Incidence and Risk of Anti-Resorptive Agent-Related Osteonecrosis of the Jaw after Tooth Extraction: A Retrospective Study,"R. Shimizu, S. Sukegawa, Yuka Sukegawa, K. Hasegawa, S. Ono, Tomoya Nakamura, Ai Fujimura, Ayaka Fujisawa, K. Nakano, Kiyofumi Takabatake, Hotaka Kawai, H. Nagatsuka, Y. Furuki",10.3390/healthcare10071332,https://doi.org/10.3390/healthcare10071332,Healthcare,1,2022,maybe,"While the study includes patients with bone metastases, osteoporosis, and multiple myeloma, it's not clear if it focuses exclusively on adult patients with diagnosed osteoporosis without cancer. The inclusion of patients with bone metastases and multiple myeloma suggests this criterion is likely not met.",yes,yes,The study clearly documents ARONJ outcomes following tooth extraction procedures.,no,The abstract does not mention a control group of non-anti-resorptive medication users. The study appears to only analyze patients undergoing BMA therapy.,yes,"This is a retrospective cohort study, which meets the criteria for study design.",maybe,"While the study period is mentioned (March 2014 to January 2022), the abstract doesn't clearly specify how the temporal relationship between medication use and ARONJ development was documented, nor the duration of medication use.",yes,"The study includes 302 patients with 505 target sites, which is well above the 100-person threshold specified in the criteria.","The study specifically focuses on tooth extraction, which is one of the specified invasive dental treatments.",Exclude,"The study fails to meet critical screening criteria, particularly the requirement for Romosozumab as the intervention, and likely includes patients with cancer beyond the specified population. While the research demonstrates a robust sample size and focuses on dental procedures, key methodological requirements are not satisfied, rendering the study non-compliant with the predefined screening parameters.",1.4
"Risk factors for medication-related osteonecrosis of the jaws: a case-control study in Queensland, Australia",K. McGowan,-,-,-,0,2019,maybe,"While the study includes adult patients, it's not explicitly stated that all patients are ≥18 years. Additionally, the abstract mentions ""39 different systemic diseases"" but doesn't specify whether cancer patients were included or excluded.",yes,yes,"The study clearly documents MRONJ outcomes following specific dental procedures, including extractions and other dental treatments.",yes,"The study explicitly mentions using ""disease-free controls"" matched to cases according to sex, age, primary disease, and antiresorptive type, dose, and duration.",yes,"The study includes case-control studies, which is one of the accepted study designs.",yes,"The study documents temporal relationships between medication use and MRONJ development, including duration of medication use and timing of dental procedures.",yes,"The study includes 4106 cases of MRONJ, which is well above the 100-person threshold.","The study explicitly mentions dental extractions, fillings, and dentures as interventions, and specifically notes that ""Cases averaged approximately one extraction and one filling per year.""",Include,"The study involves a large sample size of 4106 MRONJ cases and includes comprehensive dental and medical risk factor analysis, with a robust case-control design and clear documentation of dental interventions and outcomes. However, the research does not specifically focus on Romosozumab, which is a critical screening requirement, and there are uncertainties regarding the precise patient population characteristics. These limitations suggest the study would likely not meet the systematic review's inclusion criteria.",2.7
Medication-related osteonecrosis of the jaw: Osteoclast profile in comparison with osteoradionecrosis of the jaw and osteomyelitis of the jaw.,"Vy Tran Ngoc Thuy, R. Chaisuparat",10.1111/jop.13202,https://doi.org/10.1111/jop.13202,Journal of Oral Pathology & Medicine,1,2021,maybe,"There is no explicit mention of patient age or osteoporosis diagnosis, and no mention of cancer status.",no,no,"While MRONJ is studied, there is no documentation of specific dental procedures. The focus is on histological findings rather than procedure outcomes.",no,"The study includes control groups (normal jaw bone, osteoradionecrosis, osteomyelitis), but not specifically non-anti-resorptive medication users.",yes,"The study appears to be a case-control study comparing different conditions, which meets the criterion for study design.",no,"There is no documentation of the temporal relationship between medication use and MRONJ, and no mention of medication duration.",no,"The study only includes 38 subjects total (11 MRONJ cases), which is less than the required 100 people.",There is no mention of dental procedures or treatments in the study. The focus is on histological analysis of jaw bone.,Exclude,"The study fails to meet multiple critical screening criteria, including specific medication intervention, subject size, and documentation of dental procedures. While the research provides insights into osteoclast morphology in MRONJ, it does not align with the required parameters for inclusion, particularly regarding Romosozumab use and comprehensive clinical documentation. The histological analysis, though scientifically valuable, does not satisfy the predefined screening requirements.",1.4
Diagnosis and management of antiresorptive-related osteonecrosis of the jaw.,S. Ruggiero,-,-,General dentistry,1,2013,maybe,"The abstract does not specify the age range or osteoporosis diagnosis, and there is no mention of cancer exclusion, so the reasoning is uncertain on this criterion.",maybe,maybe,"The abstract discusses jaw necrosis outcomes and mentions ""stage-specific management strategies"", so it partially meets this criterion.",maybe,"The abstract does not mention any control groups, so the reasoning is uncertain on this criterion.",no,"The abstract mentions ""multiple retrospective, prospective, and case-controlled studies"", but it appears to be a review rather than a primary study, so it fails this criterion.",maybe,"The abstract mentions ""duration of exposure"" as a risk factor, so it partially meets this criterion.",maybe,"No specific subject size is mentioned in the abstract, so the reasoning is uncertain on this criterion.","The abstract mentions ""dentoalveolar trauma"" and discusses dental procedures, so it partially meets this criterion.",Include,"The abstract fails to meet several critical screening criteria, including specific intervention with Romosozumab, clear subject size, and definitive study design. While discussing antiresorptive medications and jaw necrosis, the text appears to be a general review lacking the precise details required for inclusion in the targeted research parameters. Multiple key screening elements remain unaddressed or uncertain, preventing straightforward qualification.",2.5
Bisphosphonate application and volumetric effects on MRONJ lesions.,"Max-Philipp Lentzen, Johannes Buller, Maximilian Riekert, A. Grandoch, M. Kreppel, J. Zöller, M. Zirk",10.1016/j.jcms.2021.01.014,https://doi.org/10.1016/j.jcms.2021.01.014,Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,5,2021,maybe,"The study includes both adults (50-93 years) and cancer patients, which partially meets the criterion of focusing exclusively on adult patients with diagnosed osteoporosis who do not have cancer.",no,maybe,"The study documents MRONJ outcomes, but does not specify the dental procedures leading to MRONJ.",no,There is no mention of a control group of non-anti-resorptive medication users in the study.,no,"The study appears to be a retrospective analysis of CT images, but the specific study design (randomized controlled trial, prospective/retrospective cohort study, or case-control study) is not clearly specified.",no,"There is no clear documentation of the temporal relationship between medication use and MRONJ development, and no mention of the duration of medication use.",no,"The study includes 66 patients, which is less than the required subject size of more than 100 people.","There is no mention of dental procedures or treatments in the study, and the focus is on analyzing existing MRONJ lesions rather than invasive dental treatment.",Exclude,"The study fails to meet multiple critical screening criteria, including the specific requirement for Romosozumab intervention, insufficient sample size, and lack of focus on invasive dental treatments. While examining medication-related osteonecrosis of the jaw, the research does not align with the predefined methodological and population specifications. Consequently, the abstract does not qualify for inclusion based on the established screening requirements.",1.4
Rodents as an animal model for studying tooth extraction-related medication-related osteonecrosis of the jaw: assessment of outcomes.,"Henrique Hadad, Henrique R. Matheus, Sara I. Pai, F. Souza, F. Guastaldi",10.1016/j.archoralbio.2023.105875,https://doi.org/10.1016/j.archoralbio.2023.105875,Archives of Oral Biology,3,2023,no,"The study is conducted on rodent animal models, not human patients, which is a clear failure of a critical criterion.",yes,no,"While MRONJ outcomes are documented, this is in animal models, not human patients, so it does not meet the criterion as specified.",maybe,"While the study likely includes controls (as it's an animal model study), it's not relevant since this is not a human study, so the criterion cannot be properly evaluated.",no,"This appears to be a review of animal studies, not a primary clinical study, so it does not meet the required study design criteria.",no,"While temporal relationships are likely documented, this is in animal models, not human patients, so it does not meet the criterion as specified.",maybe,"The abstract discusses 118 studies but does not specify the subject size per study, so it cannot be confirmed if this criterion is met.","The study focuses on tooth extraction, which meets the criterion for invasive dental treatment.",Exclude,"The study fails critical screening criteria by using rodent animal models instead of human patients and examining zoledronic acid and alendronate rather than romosozumab. Multiple key requirements are not met, including population type, intervention medication, and study design, rendering the research ineligible for inclusion in the review.",0.1
MON-513 Osteonecrosis after Successful Osseointegrated Dental Implantation,"Paul Belany, C. Zachariadou, Se Aguirre, A. Salvador, Js Yu, Jr Kalmar, S. Rotenberg, Steven W. Ing",10.1210/JS.2019-MON-513,https://doi.org/10.1210/JS.2019-MON-513,Journal of the Endocrine Society,0,2019,maybe,"The patient is an adult (77 years) with osteoporosis, but the abstract also mentions hyperparathyroidism. The patient does not have cancer.",yes,yes,The study clearly documents MRONJ outcomes following specific dental procedures (implant placement and removal).,no,"As a case report, there is no control group of non-anti-resorptive medication users.",no,"This is a case report, which does not meet the required study designs (RCT, cohort, or case-control).",yes,"The study clearly documents the temporal relationship between medication use and MRONJ development, including the duration of medication use (8 years of uninterrupted antiresorptive therapy).",no,"This is a case report of a single patient (77-year-old woman), far below the required 100+ subjects.","The study involves dental implant placement and subsequent removal, which qualifies as invasive dental treatment.",Exclude,"This case report fails key screening criteria, primarily due to using ibandronate and denosumab instead of romosozumab, and being a single-patient study rather than a larger research design. Despite documenting detailed MRONJ outcomes and temporal medication relationships, the study does not meet fundamental requirements for subject size, control group, and study design.",0.1
What Affects Healing Rates in Patients Treated for Medication-Related Osteonecrosis of the Jaw? The Role of Operative Therapy and Other Clinical Factors.,"M. Fujimori, Y. Toriyabe, Noriyuki Sakakibara, Masanori Nojima, Shujiroh Makino",10.1016/j.joms.2024.06.176,https://doi.org/10.1016/j.joms.2024.06.176,Journal of oral and maxillofacial surgery,1,2024,no,The abstract does not specify whether the subjects are adults with diagnosed osteoporosis or if they have cancer.,no,maybe,"The abstract mentions MRONJ outcomes and ""operative therapy,"" but does not provide specific details about the dental procedures involved.",no,The abstract does not mention a control group of non-anti-resorptive medication users.,no,The study design is not explicitly stated in the abstract.,no,The abstract does not provide any information about the temporal relationship between medication use and MRONJ development or the duration of medication use.,no,"The abstract does not mention the number of subjects involved in the study, so the subject size cannot be determined.","While the abstract mentions ""operative therapy,"" it does not specify the types of dental procedures involved, such as tooth extraction, implant placement, periodontal surgery, or removable prosthesis fabrication.",Exclude,"The abstract lacks critical details about medication type, subject demographics, intervention specifics, and study design, making it impossible to confirm compliance with the comprehensive screening criteria. Insufficient information prevents verification of key requirements such as patient population, control group, and precise dental treatment interventions. Multiple essential screening elements remain unaddressed, rendering the abstract inadequate for inclusion assessment.",1.4
Optical bone density as a prognostic risk factor for the development of medication-related osteonecrosis of the jaw in patients with bone metastases,"N. Vinogradova, L. Solomatina, M. Kharitonova, K. L'vov, D. Borzunov",10.18019/1028-4427-2020-26-4-539-543,https://doi.org/10.18019/1028-4427-2020-26-4-539-543,-,2,2020,maybe,"Adult patients are implied but not explicitly stated, and there is no mention of cancer status.",maybe,maybe,"MRONJ outcomes are documented, but the specific dental procedures are not detailed.",no,There is no mention of a control group.,yes,"The study design is a retrospective analysis, which meets the criterion.",no,"There is no clear documentation of the temporal relationship between medication use and MRONJ development, or the duration of medication use.",no,"The study includes 52 patients, which is less than the required 100 subjects.","While the study is about MRONJ, it does not explicitly state which dental procedures were performed.",Exclude,"The study fails critical screening criteria, particularly the requirement for Romosozumab as the intervention, with only 52 patients instead of the mandated 100+ subjects. Multiple key elements are missing, including a control group, clear documentation of dental procedures, and temporal relationship of medication use, rendering the study non-compliant with the systematic review requirements.",0.1
"Dentists’ Awareness of Medication-Related Osteonecrosis of the Jaw (Risk Factors, Drugs, and Prevention) in the Republic of Croatia","Sven Bival, Lucija Šimović, Anamarija Blažun, L. Bergman, D. Vražić, M. Granić",10.15644/asc57/2/3,https://doi.org/10.15644/asc57/2/3,Acta Stomatologica Croatica,1,2023,no,"The study population consists of doctors, not patients, and there is no mention of osteoporosis patients. Therefore, it does not meet the criterion of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",no,no,"While MRONJ is discussed, it is in the context of doctors' knowledge, and the study does not document any actual MRONJ outcomes following specific dental procedures.",no,"The study does not include a control group of non-anti-resorptive medication users, as it is a survey study of doctors' knowledge and not an interventional study.",no,"The study design is a survey study of doctors' knowledge, which does not match any of the required study designs (RCT, cohort, or case-control).",no,"The study does not document any temporal relationships between medication use and MRONJ development, or the duration of medication use.",no,"The study includes 458 dental medicine doctors (DDMs), not patients, and therefore does not meet the criterion of having a subject size of more than 100 people.","This is a survey study of doctors' knowledge, and does not involve any actual invasive dental treatments, such as tooth extraction, implant placement, periodontal surgery, or removable prosthesis fabrication. Therefore, it does not meet the criterion of having an intervention of invasive dental treatment.",Exclude,"This survey study of dental doctors' knowledge about antiresorptive medications fails to meet any of the specified screening criteria, including patient population, intervention type, study design, and outcome documentation. The research focuses on doctors' understanding of medication-related osteonecrosis of the jaw rather than a clinical investigation of patients receiving specific treatments. Consequently, the study does not align with the systematic review's requirements for inclusion.",0.1
Update on Medication Related Osteonecrosis of the Jaws,B. Boyd,10.32481/djph.2023.04.009,https://doi.org/10.32481/djph.2023.04.009,Delaware journal of public health,1,2023,no,"The abstract mentions patients with osteoporosis, but also includes cancer patients, so the population type criterion of focusing exclusively on adult patients with diagnosed osteoporosis who do not have cancer is not met.",maybe,maybe,"While the abstract discusses ONJ/MRONJ, it does not provide any specific documentation of outcomes following dental procedures, so it is not possible to determine if the outcome documentation criterion is met.",maybe,"The abstract does not mention any control groups, so it is not possible to determine if the control group criterion is met.",no,"The abstract appears to be a review or commentary rather than a primary research study, and no specific study design is mentioned, so the study design criterion is not met.",maybe,"The abstract does not mention any specific temporal relationships or duration of medication use, so it is not possible to determine if the temporal documentation criterion is met.",maybe,"The abstract does not provide any information about the study size or number of participants, so it is not possible to determine if the subject size criterion of more than 100 people is met.","While the abstract discusses ONJ/MRONJ, it does not specify which dental procedures were involved, so it is not possible to determine if the intervention criterion of invasive dental treatment is met.",Exclude,"The abstract fails to meet multiple critical screening criteria, including specific intervention requirements, population type, and study design. It appears to be a general review about osteonecrosis of the jaws rather than a focused research study, lacking the precise details needed to satisfy the predefined screening parameters. Consequently, the document does not qualify for inclusion based on the established criteria.",0.1
Medication-related osteonecrosis of jaws revisited through the bone inherited disorders: what do we know?,"M. Fénelon, J. Fricain",10.1051/MBCB/2021015,https://doi.org/10.1051/MBCB/2021015,Journal of Oral Medicine and Oral Surgery,0,2021,maybe,"The abstract does not provide any specific information about patient age or osteoporosis diagnosis, nor does it mention cancer status, so it cannot be confirmed if the population type criterion is met.",maybe,maybe,"While MRONJ is mentioned, there is no specific documentation of outcomes following dental procedures, so it is too vague to confirm if this criterion is met.",maybe,"The abstract does not mention any control groups, so it cannot be confirmed if this criterion is met.",maybe,"The abstract does not specify the study design, so it cannot be determined if it meets the criterion of being a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"The abstract does not provide any information about the temporal relationship between medication use and MRONJ development or the duration of medication use, so it cannot be confirmed if this criterion is met.",maybe,"No information is provided about the sample size, so it cannot be determined if the study meets the requirement of having more than 100 subjects.","While the abstract mentions ""bone complications"" in oral surgery patients, it does not specifically detail the types of dental procedures, so it is too vague to confirm if the intervention meets the criterion of invasive dental treatment.",Exclude,"The abstract fails to meet critical screening criteria, particularly the requirement for Romosozumab as the intervention medication. Insufficient details are provided about study design, population characteristics, and specific dental procedures, rendering most screening criteria unverifiable. The focus on Bisphosphonates and Denosumab instead of the specified medication fundamentally disqualifies the study from meeting the established screening requirements.",0.1
[ALGORITHM FOR TREATMENT PATIENTS WITH MEDICAL OSTEONEKROSIS OF JAWS BY CORRECTING ORAL MICROBIOTAL DISORDERS].,"T. Ivanyushko, K. Polyakov, L. Arazashvili, A. Simonova",-,-,Georgian medical news,0,2021,no,"The patients are adults (55-76 years), but they have cancer (mentions ""tumor metastasis""), which fails the criterion requiring non-cancer patients.",no,maybe,"The study documents MRONJ outcomes, but it does not clearly specify the dental procedures leading to MRONJ, so it only partially meets this criterion.",maybe,"The study includes 10 healthy individuals as controls, but these are not specifically non-anti-resorptive medication users, so it only partially meets this criterion.",yes,"The study appears to be a prospective cohort study, which meets this criterion.",maybe,"The study mentions monthly IV administration and documents 6-month follow-up, which partially meets this criterion.",no,"The study includes only 22 patients with MRONJ and 10 healthy controls, which falls well below the required 100+ subjects, and is another clear disqualification.","The study mentions surgical treatment but does not specify if it is dental. The focus seems to be on cancer treatment and subsequent MRONJ, so it does not clearly meet this criterion.",Exclude,"The study fails key screening criteria due to using Zometa instead of Romosozumab, having a small sample size of 32 participants, and including cancer patients. Multiple methodological limitations, including unclear dental intervention specifics and non-compliance with population and intervention requirements, render the study unsuitable for systematic review inclusion.",0.1
A clinical retrospective study of implant as a risk factor for medication-related osteonecrosis of the jaw: surgery vs loading?,"Yong-Dae Kwon, Hyunmi Jo, Jae-eun Kim, Jooyoung Ohe",10.1186/s40902-023-00398-2,https://doi.org/10.1186/s40902-023-00398-2,Maxillofacial plastic and reconstructive surgery,4,2023,maybe,"While the study mentions ""older patients,"" it doesn't explicitly state that all patients are ≥18 years or confirm osteoporosis diagnosis. However, the context suggests these are adult patients.",yes,yes,The study clearly documents MRONJ outcomes following specific dental procedures (implant placement) and includes detailed radiological documentation.,no,The abstract doesn't mention any control group of non-anti-resorptive medication users.,maybe,"The study design isn't explicitly stated, though it appears to be a retrospective case series based on the methodology described.",yes,The study documents both the temporal relationship (51.03 months following implant placement) and duration of medication use (61.37 months average).,no,"The study includes only 33 patients, which is well below the required minimum of 100 subjects.","The study focuses on dental implant placement, which is explicitly mentioned as one of the qualifying invasive dental treatments.",Exclude,"The study fails key screening criteria due to using bisphosphonates instead of Romosozumab, having a small sample size of 33 patients, and lacking a control group. Despite documenting dental implant-related MRONJ outcomes with detailed temporal and radiological analysis, the fundamental methodological limitations prevent the study from meeting the specified inclusion requirements.",1.4
The Importance of Dental Screening Prior to Commencing Anti-Resorptive Therapy for Treatment of Cancer: A Case Report and Discussion.,"Fiona McDonnell, C. Steel",10.1177/205016841800700307,https://doi.org/10.1177/205016841800700307,Primary Dental Journal,2,2018,no,"The patient has metastatic breast cancer, which explicitly violates the criterion of ""no cancer"".",yes,yes,"The study does document MRONJ outcomes following dental procedures, which meets this criterion.",no,"As a case report, there is no control group, which means this criterion is not met.",no,"This is a case report, which is not one of the accepted study designs.",maybe,"While the abstract mentions ""concurrent use"" of anti-resorptive therapies, it doesn't clearly document the temporal relationship or duration of medication use, so this criterion is not clearly met.",no,"This is a case report of a single patient, which clearly fails the requirement of more than 100 subjects.","The abstract mentions tooth extraction and dental treatment, which meets the criterion of invasive dental treatment.",Exclude,"This case report fails multiple critical screening criteria, including using an unspecified anti-resorptive medication, involving a cancer patient, and lacking a control group. The single-patient study design and absence of clear temporal documentation further disqualify it from meeting the systematic review requirements. Multiple fundamental screening criteria were not satisfied, rendering the paper unsuitable for inclusion.",0.1
Different Presentation and Outcomes in the Surgical Treatment of Advanced MRONJ in Oncological and Nononcological Patients Taking or Not Corticosteroid Therapy,"P. Garzino Demo, Alessandro Bojino, F. Roccia, M. Malandrino, Stefan Cocis, G. Ramieri",10.1155/2021/7855497,https://doi.org/10.1155/2021/7855497,BioMed Research International,2,2021,no,"The study includes both oncological and non-oncological patients, and the age range is not specified. It also includes cancer patients, which is explicitly excluded in the criteria.",maybe,maybe,"The study documents MRONJ outcomes and treatment, but it doesn't clearly document the specific dental procedures leading to MRONJ.",no,"There is no mention of a control group, and the study appears to only analyze MRONJ patients.",yes,"The study is clearly stated as a retrospective study, which meets this criterion.",maybe,"The abstract mentions ""time of administration"" but doesn't clearly document the temporal relationships, and the duration of medication use is not specified.",no,"The study includes 64 patients, which is below the required 100 subjects.","The abstract doesn't explicitly state the dental procedures that led to MRONJ, and while it discusses surgical treatment of MRONJ, it doesn't specify the initial dental interventions.",Exclude,"The study fails key screening criteria by including patients with various antiresorptive medications instead of Romosozumab, having fewer than 100 subjects, and incorporating cancer patients. Multiple critical requirements were not met, including the lack of a control group and insufficient documentation of dental procedures and medication use. These deficiencies render the study unsuitable for inclusion in the systematic review.",0.1
Medication-Related Osteonecrosis of Jaw,Jang-Jaer Lee,10.1142/9789811220814_0010,https://doi.org/10.1142/9789811220814_0010,Osteoporosis of the Spine,0,2021,no,"The abstract mentions osteoporosis but does not specify age groups or cancer status, so it cannot be confirmed if the study meets the criterion of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",no,no,"While MRONJ is discussed, there is no indication of specific documented dental procedures, so it cannot be confirmed if the study meets the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"No information is provided about study groups or controls, so it cannot be confirmed if the study meets the criterion of including a control group of non-anti-resorptive medication users.",no,"This appears to be a book chapter rather than a primary research study, so it does not meet the study design criteria of being a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"No information is provided about the temporal relationship between medication use and MRONJ development or the duration of medication use, so it cannot be confirmed if the study meets the criterion of clearly documenting both the temporal relationship and the duration of medication use.",no,"No information is provided about the sample size, so it cannot be confirmed if the study meets the requirement of having more than 100 subjects.","While the abstract discusses MRONJ, it does not specify which dental procedures are included, so it cannot be confirmed if the study meets the criterion of having an intervention of invasive dental treatment.",Exclude,"This book chapter lacks critical details required by the screening criteria, including specific medication type, subject size, intervention details, and study design. Multiple key requirements remain unaddressed, rendering the document insufficient for meeting the comprehensive screening standards. The abstract appears to be a general review rather than a primary research study with the necessary methodological and procedural specifications.",1.4
Dentoalveolar surgery and Prevention of Medication-related Osteonecrosis of the Jaw (MR-ONJ) in patients treated with Bisphosphonates: our experience.,"F. Lonardi, G. Capocasale, F. Zotti, Riccardo Nocini, Annarita Signoriello, G. Panozzo, M. Albanese",10.32388/6CCLYF,https://doi.org/10.32388/6CCLYF,Qeios,0,2021,maybe,"While the study includes patients with osteometabolic conditions, it also includes cancer patients, which is explicitly excluded in the criteria. The abstract doesn't specify age restrictions.",yes,yes,"The study focuses on MRONJ outcomes following dental procedures, particularly extractions, which meets the outcome documentation criteria.",maybe,"The abstract doesn't mention whether there is a control group of non-bisphosphonate users, so this is unclear.",maybe,"While it appears to be an observational study of their experience, the specific study design isn't clearly stated.",maybe,"While the study mentions duration of treatment as a risk factor, it's not clear if they specifically document the temporal relationship between medication use and MRONJ development.",maybe,"The abstract doesn't specify the number of subjects involved in their one-year experience, so the subject size is unclear.","The study focuses on dentoalveolar surgery, including tooth extraction and other dental procedures, which meets the intervention criteria.",Exclude,"The study focuses on bisphosphonates rather than Romosozumab, which immediately disqualifies it from meeting the primary intervention criterion. Additionally, the research includes cancer patients and lacks clear documentation of several key methodological elements, further compromising its alignment with the specified screening requirements. Multiple critical screening criteria are not met, rendering the study unsuitable for inclusion.",1.4
Medication Related Osteonecrosis of the Jaw: A Conservative Approach,"D. Rushing, A. Arango, Adam Wandell",10.1016/j.joms.2022.07.063,https://doi.org/10.1016/j.joms.2022.07.063,Journal of oral and maxillofacial surgery,0,2022,no,"The abstract mentions both osteoporosis and cancer patients, and is not exclusively focused on adult osteoporosis patients without cancer, so it fails to meet the criterion of focusing on the specified population type.",maybe,maybe,"While MRONJ is discussed, specific dental procedures and outcomes are not detailed in the abstract, so it is uncertain whether the study reports MRONJ outcomes following specific, documented dental procedures.",maybe,"There is no mention of control groups in the abstract, so it is uncertain whether the study includes a control group of non-anti-resorptive medication users.",no,"The paper appears to be a review paper discussing epidemiologic studies and guidelines, rather than a primary research study with the specified study designs, so it fails to meet the criterion of having a randomized controlled trial, prospective/retrospective cohort study, or case-control study design.",maybe,"No specific temporal relationships or medication duration are discussed in the abstract, so it is uncertain whether the study clearly documents both the temporal relationship between medication use and MRONJ development and the duration of medication use.",maybe,"No specific subject size is mentioned in the abstract, only general incidence rates are provided, so it is uncertain whether the study meets the criterion of having a subject size of more than 100 people.","While the abstract discusses MRONJ, it does not specifically describe dental procedures, and the paper appears to be more of a review/guidelines paper rather than a study of invasive dental treatment, so it is uncertain whether the intervention meets the criterion of including invasive dental treatment.",Exclude,"The abstract fails to meet multiple critical screening criteria, including specific medication type, population focus, and study design. It appears to be a review or guidelines document rather than a primary research study, lacking the required specificity for inclusion. The paper does not provide sufficient details to satisfy the comprehensive screening requirements.",1.4
Prevention of Medication-related Osteonecrosis of the Jaw (MR-ONJ) after dentoalveolar surgery in cancer patients: one year experience.,"G. Capocasale, F. Lonardi, Annarita Signoriello, G. Panozzo, F. Zotti, Riccardo Nocini, M. Albanese",10.32388/TTPEZS,https://doi.org/10.32388/TTPEZS,Qeios,0,2021,no,"The study focuses on cancer patients, which explicitly violates the criterion requiring non-cancer patients.",yes,yes,"The study reports on MRONJ outcomes following dental procedures, which meets this criterion.",no,"There is no mention of a control group, so it cannot be confirmed if this criterion is met.",yes,"The study is described as a ""retrospective analysis"", which meets the criterion for a retrospective cohort study.",maybe,"The study mentions a one-year follow-up, but does not clearly document the temporal relationship between medication use and MRONJ development.",no,"The study only includes 15 patients, which is well below the required minimum of 100 subjects.","The study mentions tooth extraction and ""surgical procedures"", which meets the criterion for invasive dental treatment.",Exclude,"The study fails critical screening criteria due to its small sample size of 15 patients, focus on cancer patients instead of non-cancer patients, and lack of specificity regarding the anti-resorptive medication. Multiple key requirements were not met, including the need for a larger population, a non-cancer patient group, and clear documentation of medication type and temporal relationships. These fundamental deviations disqualify the study from meeting the established screening criteria.",0.1
Comparative Analysis of the Oral Microbiome of Medication-Related Osteonecrosis of the Jaw Patients,Jun-Young Kim,10.1016/j.joms.2023.08.053,https://doi.org/10.1016/j.joms.2023.08.053,Journal of oral and maxillofacial surgery,0,2023,no,"The abstract mentions osteoporosis patients but also includes those with ""skeletal complications associated with osseous metastasis, and multiple myeloma"", so the population is not exclusively focused on adult patients with diagnosed osteoporosis who do not have cancer.",no,no,"While MRONJ is the focus, the abstract does not mention any specific dental procedures, so the study does not report MRONJ outcomes following specific, documented dental procedures.",yes,"The abstract mentions ""healthy and MRONJ disease groups"", suggesting the inclusion of a control group of non-anti-resorptive medication users.",maybe,"The abstract indicates that the study appears to be a comparative analysis study, but it is not clearly specified if it is a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The abstract does not mention any temporal relationships or duration of medication use, so the study does not clearly document both the temporal relationship between medication use and MRONJ development and the duration of medication use.",maybe,"The abstract does not mention the sample size, so it is uncertain whether the study has a subject size of more than 100 people.","The abstract does not mention any specific dental procedures or treatments, so the intervention does not meet the criterion of invasive dental treatment.",Exclude,"The abstract describes a microbiological study on MRONJ that fails to meet multiple critical screening criteria, including specific medication type, population exclusivity, and documentation of dental procedures. Key deficiencies include lack of focus on Romosozumab, inclusion of cancer patients, and absence of detailed temporal and procedural documentation. The study's fundamental research approach diverges significantly from the required systematic review parameters.",1.4
Long-Term Risk of Medication-Related Osteonecrosis of the Jaw (MRONJ) After Bisphosphonates and/or Denosumab in Metastatic Breast Cancer Patients,"V. Fusco, Costanza Massarino, M. Rossi, A. Gambino, A. Maconi, P. Arduino",10.32388/mb953f.2,https://doi.org/10.32388/mb953f.2,Qeios,0,2024,no,"The study focuses on cancer patients (breast cancer with bone metastases), which explicitly violates the criterion requiring non-cancer patients.",no,no,"While MRONJ outcomes are documented, there is no mention of specific dental procedures, so this criterion is not met.",no,"There is no mention of a control group of non-anti-resorptive medication users, so it cannot be confirmed that this criterion is met.",yes,"The study is described as a ""retrospective multicenter study"", which would qualify as a retrospective cohort study, and this criterion is met.",maybe,"The study does document temporal relationships and duration (mentions 6-year cumulative incidence), but this is irrelevant given the other disqualifying factors.",maybe,"While the subject size is not explicitly stated, the study is described as a multicenter study across all breast centers in Tyrol, suggesting it likely has more than 100 patients. However, this is moot given the intervention mismatch.","The abstract does not mention any dental procedures or interventions, which is a critical missing element.",Exclude,"The study focuses on cancer patients receiving bisphosphonates and denosumab, which fundamentally conflicts with the screening criteria requiring non-cancer patients and Romosozumab intervention. Multiple critical screening requirements are unmet, including population type, medication, and dental intervention specifics, rendering the study ineligible for inclusion.",0.1
Onset of MRONJ in Breast Cancer Patients after Switching from Low to High Dose of Bone Modifying Agents Due to Bone Metastases Development: A Single Center Retrospective Cohort Study,"R. Mauceri, Martina Coppini, G. Campisi",10.3390/oral2040026,https://doi.org/10.3390/oral2040026,Oral,2,2022,no,"The study focuses on breast cancer patients, not osteoporosis patients, and all patients have cancer. This indicates that the population type does not meet the requirement of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",no,maybe,"MRONJ outcomes are documented, but the specific dental procedures are not detailed. This suggests that the study may not fully meet the requirement of reporting MRONJ outcomes following specific, documented dental procedures.",no,There is no mention of a control group in the study.,yes,"The study is described as a retrospective study, which meets the requirement for a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",yes,"The study provides clear documentation of medication duration and MRONJ development, including specific timing for medication use and MRONJ onset. This indicates that the study meets the requirement of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",no,"The study only includes 14 patients, which is well below the required 100+ subjects.","While the study is about MRONJ, it doesn't explicitly describe the dental procedures performed, only mentioning ""prevention"" and monitoring. This suggests that the intervention may not include the required invasive dental treatment.",Exclude,"The study fails critical screening criteria due to its focus on breast cancer patients using bone modifying agents, with a sample size of only 14 participants, which does not meet the required 100+ subjects. Additionally, the research does not involve Romosozumab, lacks a control group, and does not exclusively study osteoporosis patients, rendering it ineligible for the systematic review.",0.1
“Prevalence of late stage in 507 Medication-related osteonecrosis of the jaws (MRONJ) sites: comparison between cancer and osteometabolic patients.”,G. Ghidini,10.32388/9yp1ev,https://doi.org/10.32388/9yp1ev,Qeios,0,-,maybe,"The study includes both cancer and non-cancer patients, and the non-cancer patients (Group B) are only 100 patients. The age criteria are not specified.",no,maybe,"MRONJ outcomes are documented, but the specific dental procedures leading to MRONJ are not detailed.",no,"There is no mention of a control group of non-anti-resorptive medication users. The study compares cancer vs non-cancer patients, not medication users vs non-users.",yes,"The study is clearly stated as a retrospective study, which meets the acceptable study design criteria.",no,"There is no clear documentation of the temporal relationship between medication use and MRONJ, and the duration of medication use is not mentioned.",yes,"The study includes 394 patients (507 sites), which clearly exceeds the minimum requirement of 100 subjects.","While MRONJ is discussed, the abstract doesn't specify which dental procedures were performed, which is a significant missing element.",Exclude,"The study fails to meet several critical screening criteria, including specific anti-resorptive medication identification, control group composition, and detailed documentation of dental procedures and medication use. While the study includes a substantial patient population and uses an acceptable retrospective design, significant gaps exist in key methodological requirements. The mixed patient population and lack of precise intervention details further compromise its alignment with the specified screening criteria.",1.4
Examination of certain single-nucleotide polymorphisms of interleukins 1A and 1B in medication-related osteonecrosis of the jaw - An ambirectional cohort study.,"Szófia Szentpéteri, János Kósa, Huba Donat Juhasz, György Deák, Z. Németh, P. Lakatos, M. Vaszilkó",10.1016/j.jcms.2024.06.007,https://doi.org/10.1016/j.jcms.2024.06.007,Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,2,2024,no,"There is no explicit mention of the age range or osteoporosis diagnosis of the subjects, and no mention of cancer status, so there is insufficient information to confirm this criterion.",maybe,maybe,"The study reports MRONJ outcomes and mentions surgical therapy, but the specific dental procedures are not documented, so it only partially meets this criterion.",yes,"The study includes 59 healthy controls, which meets this criterion.",yes,"The study appears to be a case-control study, with 91 patients and 59 controls, which meets this criterion.",no,"There is no clear documentation of the temporal relationship between medication use and MRONJ, and the duration of medication use is not mentioned, so this criterion is not met.",yes,"The study includes 91 patients with MRONJ and 59 controls, for a total of 150 subjects, which meets the requirement of more than 100 people.","The study mentions that ""surgical therapy was required in 79 cases"", but the specific dental procedures are not detailed, so it only partially meets this criterion.",Include,"The study lacks critical specification of Romosozumab as the anti-resorptive medication, which fundamentally disqualifies it from meeting the primary screening criteria. While the research includes a control group and adequate sample size, it fails to provide essential details about medication type, specific dental procedures, and patient population characteristics. The absence of key information prevents the study from satisfying the comprehensive screening requirements.",2.7
Improving Knowledge of MRONJ Risk Among Singapore Dental Practitioners Using an Educational Lecture With an Incorporated Quiz,"L. Gani, S. Chionh",10.1210/jendso/bvab048.534,https://doi.org/10.1210/jendso/bvab048.534,Journal of the Endocrine Society,0,2021,no,"The study focuses on dental professionals, not patients, and does not mention adult patients with osteoporosis, so it does not meet the criterion of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",no,no,"The study does not document any actual MRONJ outcomes, and only discusses dental professionals' knowledge and attitudes about MRONJ, so it does not meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"The study does not mention a control group, and the study design is an educational intervention survey, so it does not meet the criterion of including a control group of non-anti-resorptive medication users.",no,"The study design is an educational intervention study with pre/post surveys, which does not match the required study designs of randomized controlled trial, prospective/retrospective cohort study, or case-control study, so it does not meet the criterion of having a study design that is either a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The study does not document any temporal relationships or medication duration, so it does not meet the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",no,"The study has 126 responses from dental professionals, which is not a study of patients, so it does not meet the criterion of having a subject size of more than 100 people.","While the study discusses invasive dental treatments, it is from the perspective of dental practitioners' willingness to perform them, and does not study actual dental procedures and outcomes, so it does not meet the criterion of having an intervention of invasive dental treatment.",Exclude,"This study of dental professionals' knowledge about osteoporosis treatment fails to meet multiple critical screening criteria, including specific medication type, patient population, intervention details, and outcome documentation. The research focuses on educational survey responses rather than a clinical study of patients, rendering it incompatible with the systematic review's requirements. Consequently, the abstract does not qualify for inclusion based on the predefined screening criteria.",0.1
Prevalence of late stage in 507 Medication-related osteonecrosis of the jaws (MRONJ) sites: comparison between cancer and osteometabolic patients,"G. Ghidini, P. De Francesco, M. Frontera, M. Manfredi, M. Meleti, P. Vescovi",10.32388/9YP1EV.2,https://doi.org/10.32388/9YP1EV.2,-,0,2021,maybe,"The study includes both cancer and non-cancer patients, and non-cancer patients (Group B) are specifically mentioned as having osteometabolic conditions. However, it's not explicitly stated that all non-cancer patients have diagnosed osteoporosis.",maybe,maybe,"MRONJ outcomes are documented, but the specific dental procedures leading to MRONJ are not mentioned in the abstract.",no,No control group of non-anti-resorptive medication users is mentioned. The study only compares cancer vs non-cancer patients.,yes,"The study is clearly stated as a retrospective study, which meets the acceptable study design criteria.",no,No clear documentation of the temporal relationship or duration of medication use is provided. The study period is mentioned (2004-2021) but not individual patient timelines.,yes,"The study includes 394 patients with 507 MRONJ sites, which clearly exceeds the minimum requirement of 100 subjects.","While MRONJ is mentioned, the abstract doesn't specify which dental procedures were performed. This information is missing but could potentially be in the full text.",Include,"The study fails to meet several critical screening criteria, including specific use of Romosozumab, presence of a control group, and clear documentation of dental procedures and medication duration. While the study includes a large patient population and uses an acceptable retrospective design, significant gaps exist in meeting the comprehensive screening requirements. The mixed patient population and lack of precise intervention details further compromise its potential for inclusion.",2.5
DENOSUMAB-RELATED OSTEONECROSIS OF THE MANDIBLE AFTER A SINGLE DOSE — A CASE REPORT,"K. Papadimitriou, I. Melakopoulos",10.1016/j.ijom.2023.10.406,https://doi.org/10.1016/j.ijom.2023.10.406,International Journal of Oral & Maxillofacial Surgery,1,2024,maybe,"The abstract mentions ""osteoporotic patients"" but doesn't specify the age range or explicitly exclude cancer patients, so the population type is only partially met.",no,maybe,"ONJ/MRONJ outcomes are discussed, but specific dental procedures aren't detailed, so the outcome documentation is only partially met.",no,"The abstract doesn't mention control groups, so the control group criterion is unclear.",no,"The abstract appears to be discussing multiple studies but doesn't specify their design types, so the study design is unclear.",maybe,"The abstract mentions timing in relation to single dose and bisphosphonate history, but doesn't clearly document the duration of medication use, so the temporal documentation is only partially met.",no,"The abstract mentions ""63 cases"" in one study but doesn't provide the total sample size for the main study being discussed, so the subject size is unclear.","While ONJ is discussed, the abstract doesn't explicitly state whether dental procedures were performed, so the intervention is unclear.",Exclude,"The abstract discusses denosumab-related osteonecrosis of the jaw, which fundamentally differs from the specified romosozumab intervention, rendering the study non-compliant with the primary screening criterion. Multiple other screening requirements remain unclear or partially met, further complicating potential inclusion. The critical medication mismatch represents an absolute disqualifying factor for the study.",0.1
Treatment of Medication-Related Osteonecrosis of the Jaws without Segmental Resections: A Case Series,"Tito Lúcio Fernandes, Bruno Viezzer Fernandes, Gilson Cesar Nobre Franco",10.12659/AJCR.942980,https://doi.org/10.12659/AJCR.942980,The American journal of case reports,1,2024,maybe,"The study includes adult females (58-85 years) with osteoporosis, but also includes 2 patients with breast cancer, which should be excluded according to the criteria.",yes,yes,The study clearly documents MRONJ outcomes following specific dental procedures.,no,No control group is mentioned in the abstract.,no,"This is a case series, which is not one of the accepted study designs (RCT, cohort, or case-control).",maybe,"While the abstract mentions treatment and follow-up periods (5 and 18.3 months), it doesn't clearly document the temporal relationship between medication use and MRONJ development.",no,"The study includes only 11 patients, well below the required 100+ subjects.","The abstract mentions tooth extraction and prosthetic trauma as triggers, and includes dental procedures like debridement and implant removal, which meets the intervention criterion.",Exclude,"The case series fails to meet multiple critical screening criteria, including the use of Romosozumab, insufficient sample size, and inappropriate study design. Key disqualifying factors include the use of different anti-resorptive medications, a small patient cohort of 11, and the inclusion of cancer patients, which deviate significantly from the specified inclusion requirements.",0.1
Mandibular and palatal tori exposed by trauma are risk factors for medication-related osteonecrosis of the jaws: a report from the Copenhagen ONJ cohort,M. Schiødt,10.1016/j.oooo.2019.07.046,https://doi.org/10.1016/j.oooo.2019.07.046,-,1,2020,maybe,"While the study includes adult patients with osteoporosis (10 cases), it also includes cancer patients (16 cases) and patients with no systemic diseases (3 cases). The study is not exclusively focused on non-cancer osteoporosis patients.",yes,yes,The study clearly documents MRONJ outcomes following specific dental procedures.,no,The abstract does not mention any control group of non-anti-resorptive medication users.,yes,"The study appears to be a retrospective cohort study (Copenhagen ONJ Cohort), which meets the requirement for a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"While the study documents the temporal relationship between trauma and MRONJ development, it's not entirely clear about the duration of medication use, though it mentions ""duration of antiresorptive treatment was recorded.""",yes,"The study includes 391 patients total, with 29 having tori-related MRONJ, which exceeds the minimum requirement of 100 subjects.","The study includes various dental procedures such as tooth extraction, denture-related procedures, and other dental interventions, which meet the requirement for invasive dental treatment.",Exclude,"The study fails to meet critical screening criteria, particularly the requirement for Romosozumab as the intervention medication. While the research includes a substantial patient cohort and documents dental procedures related to medication-related osteonecrosis, the absence of the specified anti-resorptive medication and lack of a control group render it unsuitable for inclusion. The mixed patient population and incomplete temporal documentation further compromise its alignment with the screening requirements.",1.4
Assessment of Awareness and Knowledge of Medication Related Osteonecrosis of Jaw among Dental Students at a Tertiary Hospital in Eastern Nepal,"S. Keshwar, D. Sarraf, Ashish Shrestha, M. Jaisani, Sushmita Shrestha",10.3126/jcmsn.v17i1.29260,https://doi.org/10.3126/jcmsn.v17i1.29260,Journal of College of Medical Sciences-Nepal,1,2021,no,"The study population consists of dental students, not osteoporosis patients. Therefore, the study does not meet the criterion of focusing exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",no,no,"The study focuses on knowledge assessment, not actual MRONJ outcomes. Therefore, the study does not meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"No control group is mentioned in the study. Therefore, the study does not meet the criterion of including a control group of non-anti-resorptive medication users.",no,"The study has a cross-sectional study design, which is not one of the specified study designs (RCT, cohort, or case-control). Therefore, the study does not meet the criterion of having a study design of either a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The study does not document the temporal relationship between medication use and MRONJ development or the duration of medication use. Therefore, the study does not meet the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use.",no,"The study has 191 participants, but these are dental students, not patients. Therefore, the study does not meet the criterion of having a subject size of more than 100 people.","While the study mentions invasive dental treatments, it is in the context of knowledge assessment, not actual treatment outcomes. Therefore, the study does not meet the criterion of having an intervention of invasive dental treatment.",Exclude,"This study of dental students' knowledge about medication-related osteonecrosis of the jaw fails to meet any of the specified screening criteria, as it does not involve patients, Romosozumab treatment, invasive dental procedures, or MRONJ outcomes. The research is a cross-sectional knowledge assessment study that fundamentally differs from the required clinical research parameters.",0.1
Genetic Background of Medication-Related Osteonecrosis of the Jaw: Current Evidence and Future Perspectives,"Bence Bojtor, B. Balla, M. Vaszilkó, Szófia Szentpéteri, Zsuzsanna Putz, J. Kósa, P. Lakatos",10.3390/ijms251910488,https://doi.org/10.3390/ijms251910488,International Journal of Molecular Sciences,0,2024,maybe,"No specific mention of adult patients or osteoporosis diagnosis, and no mention of cancer exclusion, so it is uncertain whether this criterion is met.",no,no,"While MRONJ is the focus, specific dental procedures and outcomes are not documented, so it fails this criterion.",no,"No mention of control groups, so it fails this criterion.",no,"This appears to be a review article about genetic factors in MRONJ, rather than a primary research study with any of the specified designs, so it fails this criterion.",no,"No mention of temporal relationships or medication duration, so it fails this criterion.",maybe,"No mention of sample size in the abstract, so it is uncertain whether this criterion is met.","While MRONJ is discussed, specific dental procedures are not detailed, and only ""inflammation"" is mentioned as a factor, so it fails this criterion.",Exclude,"The abstract fails to meet multiple critical screening criteria, including specific intervention details, study design requirements, and outcome documentation. Lacking precise information about Romosozumab, dental procedures, patient population, and control groups, the text appears to be a genetic review rather than a targeted research study addressing the specified screening parameters.",0.1
Cumulative incidence and risk factors for medication-related osteonecrosis of the jaw during long-term prostate cancer management,"M. Tani, K. Hatano, Akihiro Yoshimura, Y. Horibe, Yutong Liu, N. Sassi, Toshiki Oka, Yohei Okuda, A. Yamamoto, T. Uemura, G. Yamamichi, Y. Ishizuya, Y. Yamamoto, Taigo Kato, A. Kawashima, Norio Nonomura",10.1038/s41598-024-64440-7,https://doi.org/10.1038/s41598-024-64440-7,Scientific Reports,0,2024,no,"The study focuses exclusively on prostate cancer patients with bone metastases, not osteoporosis patients without cancer, which is a critical mismatch with the inclusion criteria.",maybe,maybe,"While MRONJ outcomes are documented, the specific dental procedures leading to these outcomes are not mentioned in the abstract.",no,The abstract doesn't mention a control group of non-BMA users. The comparison is between different types of BMA (denosumab vs zoledronic acid).,yes,"While not explicitly stated, this appears to be a retrospective cohort study based on the follow-up period and analysis described.",yes,The study documents temporal relationships with median follow-up of 19 months and reports cumulative incidence rates over time.,yes,"The study includes 179 patients, which exceeds the minimum requirement of 100.","While MRONJ is discussed, the abstract doesn't explicitly mention the types of dental procedures that led to MRONJ, which is a significant limitation.",Exclude,"The study focuses on bone-modifying agents in prostate cancer patients, which fundamentally differs from the required criteria of Romosozumab treatment for osteoporosis patients. Critical screening criteria were not met, including medication type, patient population, and control group composition. Multiple core requirements were unambiguously unmet, rendering the study ineligible for inclusion.",0.1
MEDICATION-RELATED OSTEONECROSIS OF THE JAWS DUE TO ADJUVANT OR HIGH DOSE ANTIRESORPTIVE TREATMENT,"S. Andersen, T. Kofod",10.1016/j.ijom.2023.10.135,https://doi.org/10.1016/j.ijom.2023.10.135,International Journal of Oral & Maxillofacial Surgery,0,2024,maybe,"The abstract mentions ""patients with MRONJ"" but does not specify the age or cancer status of the population, so it is uncertain whether the study focuses exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",maybe,maybe,"The study focuses on MRONJ outcomes, which likely includes documentation of specific dental procedures, but this is not explicitly stated, so it is uncertain whether the study reports MRONJ outcomes following specific, documented dental procedures.",maybe,"The abstract does not mention a control group, so it is uncertain whether the study includes a control group of non-anti-resorptive medication users.",yes,"The abstract indicates that the study appears to be a cohort study (""Copenhagen ONJ Cohort""), which meets the criterion for study design.",maybe,"The abstract does not mention any explicit documentation of the temporal relationship between medication use and MRONJ development or the duration of medication use, so it is uncertain whether the study clearly documents these aspects.",maybe,"The abstract mentions a cohort study from 2005-2021, which likely includes a large number of subjects, but the exact size is not specified, so it is uncertain whether the study has more than 100 subjects.","The study focuses on MRONJ cases, which likely includes dental procedures, but the specific dental interventions are not explicitly stated, so it is uncertain whether the study includes the required invasive dental treatments.",Exclude,"The abstract fails to meet the critical screening criterion of focusing specifically on Romosozumab, instead discussing general antiresorptive treatment. Multiple other screening criteria remain uncertain due to limited information, including subject size, population characteristics, and specific dental interventions. The study's broad approach to medication-related osteonecrosis of the jaws prevents definitive alignment with the detailed screening requirements.",1.4
SURGICAL TREATMENT OF MEDICATION RELATED OSTEONECROSIS OF THE JAW USING PRF,"E. Tzaferi, Mary-Eleni Zouloumi, Athina Tzatzaki, Christos Gkanidis, L. Zouloumis",10.54936/haoms231p20,https://doi.org/10.54936/haoms231p20,Hellenic Archives of Oral &amp; Maxillofacial Surgery,0,2022,no,"The patient is 76 years old, which meets the adult requirement. However, the patient has cancer (renal cell carcinoma), which fails the criterion of no cancer patients.",no,maybe,"MRONJ outcomes are documented, but the temporal relationship to dental procedures is not clearly documented.",no,"This is a case report with no control group, which fails to meet the criterion of including a control group of non-anti-resorptive medication users.",no,"This is a case report, which does not meet the required study designs of randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"The duration of medication use is mentioned (1 year), but the relationship to dental procedures is not clearly documented.",no,"This is a single case report with only 1 subject, which fails to meet the minimum requirement of 100 subjects.","While dental treatment is mentioned, it's not clear if the patient had any invasive dental procedures before MRONJ development. The treatment described is for MRONJ itself, not a preventive dental intervention.",Exclude,"The case report fails multiple critical screening criteria, including using denosumab instead of romosozumab, having a sample size of only one patient, and involving a cancer patient. These fundamental deviations from the required study parameters render the paper ineligible for inclusion in the systematic review. The study design, lack of a control group, and absence of clear documentation of dental procedures further disqualify it from meeting the established screening requirements.",0.1
Multiple myeloma masquerading as medication-related osteonecrosis of the jaw: a case study,"Y. Danskin, Dalal Alhajji, S. Yom, C. Estilo",10.1016/j.oooo.2019.07.032,https://doi.org/10.1016/j.oooo.2019.07.032,-,0,2020,no,"The patient has multiple myeloma (cancer), which explicitly violates the criterion requiring non-cancer patients.",maybe,no,"While MRONJ is discussed, the case actually turned out to be bone metastasis, so the outcome documentation is present but not for the intended condition.",no,"As a case report, there is no control group, so it fails to meet this criterion.",no,"This is a case report, which does not meet the required study design types (RCT, cohort, or case-control).",maybe,"The paper does document medication use (28 doses from 2013-2016), but this is irrelevant given the other disqualifying factors.",no,"This is a single case report of one patient, which fails to meet the minimum requirement of 100 subjects.","The paper mentions removal of a fixed partial denture (FPD) and subsequent treatment, but it's not clearly described as a planned invasive procedure.",Exclude,"The case report fails multiple critical screening criteria, including using the wrong medication (zoledronic acid instead of Romosozumab), involving a cancer patient, and being a single case study rather than a larger research design. These fundamental deviations from the required parameters render the paper unsuitable for inclusion in the systematic review.",0.1
"Difficult management of severe Medication-Related Osteonecrosis of the Jaws in a denosumab treated osteoporotic patient, a case report.","Silvia Arrigoni, V. Martini, R. Bonacina",10.32388/R75CTY,https://doi.org/10.32388/R75CTY,Qeios,0,2021,maybe,"While the patient has osteoporosis and appears to be an adult, the abstract doesn't explicitly confirm age ≥18 or rule out cancer.",yes,yes,"The study clearly documents MRONJ outcomes following implant placement, including staging and temporal progression.",no,"As a case report, there is no control group mentioned.",no,"This is a case report, which is not one of the accepted study designs (RCT, cohort, or case-control).",yes,The abstract clearly documents the temporal relationship (3 months after implant placement) and timing of medication use (6 months after last injection).,no,"This is a single case report, not meeting the minimum requirement of 100 subjects.","The study involves implant placement, which is explicitly mentioned as one of the qualifying dental interventions.",Exclude,"The case report fails key screening criteria by using denosumab instead of romosozumab, presenting a single patient case rather than a study with over 100 subjects, and lacking a control group. Despite documenting dental intervention and MRONJ outcomes, the study design does not meet the required methodological standards for inclusion in the systematic review.",0.1
Osteoclast profile of medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis,"Christian Gross, Manuel Weber, Kay Creutzburg, Patrick Möbius, R. Preidl, K. Amann, F. Wehrhan",10.1186/s12967-017-1230-8,https://doi.org/10.1186/s12967-017-1230-8,Journal of Translational Medicine,0,2017,no,"The age of patients is not specified, and there is no mention of cancer status, so it cannot be confirmed if the population meets the criteria.",no,no,"While MRONJ is documented, specific dental procedures are not detailed, so the study does not meet this criterion.",maybe,"The study includes a control group (n=10), but this control group is not specifically for non-anti-resorptive medication users.",yes,"The study is a retrospective analysis of tissue specimens, which meets the criteria as a retrospective study.",no,"There is no documentation of the temporal relationship or duration of medication use, so the study does not meet this criterion.",no,"The study includes 70 patients total, which does not meet the minimum requirement of 100 subjects.","The abstract does not specify the dental procedures that led to MRONJ, and while MRONJ typically follows dental procedures, this is not explicitly documented.",Exclude,"The study focuses on bisphosphonate-related MRONJ, which immediately disqualifies it from the review due to the specified requirement for Romosozumab. Additionally, the sample size of 70 patients falls short of the required 100 subjects, and critical documentation of dental procedures, temporal medication use, and patient population characteristics are missing. These fundamental deviations from the screening criteria render the study unsuitable for inclusion.",0.1
384. Denosumab-Related Osteonecrosis of the Jaw: an Emergent and Potentially Complex Bone and Joint Infection,"Romain Bricca, F. Valour, Conrad Anne, E. Braun, P. Jaby, Jean-Thomas Bachelet, Pierre Breton, Arnaud Gleizal, F. Laurent, C. Chidiac, T. Ferry",10.1093/ofid/ofz360.457,https://doi.org/10.1093/ofid/ofz360.457,Open Forum Infectious Diseases,0,2019,maybe,"While the study includes adult patients (median age 71), it primarily focuses on patients with cancer (83% had metastatic cancer), which is explicitly excluded in the criteria.",yes,yes,"The study clearly documents MRONJ outcomes following dental procedures, including detailed documentation of the cases and their management.",no,No control group of non-anti-resorptive medication users is mentioned in the abstract.,yes,"This is a retrospective observational cohort study, which meets the acceptable study design criteria.",maybe,"While the study documents some temporal aspects (median follow-up of 6 months), it's not entirely clear about the duration of medication use before MRONJ development.",no,"The study only includes 12 patients, well below the required minimum of 100 subjects.","The abstract mentions dental surgical procedures and specifically notes that 7 patients (58%) had dental surgical procedures before DRONJ, which meets the criteria for invasive dental treatment.",Exclude,"The study fails to meet multiple critical screening criteria, including using the wrong medication (denosumab instead of romosozumab), having an insufficient sample size of only 12 patients, and primarily focusing on cancer patients. These fundamental mismatches with the predefined inclusion criteria render the study ineligible for the systematic review.",0.1
This Month in JAAD Case Reports: May 2022 Medication-related Osteonecrosis of the Jaw.,Brett Sloan,10.1016/j.jaad.2022.02.004,https://doi.org/10.1016/j.jaad.2022.02.004,Journal of American Academy of Dermatology,0,2022,no,"The abstract indicates that the study includes both cancer patients and those with metabolic bone disease, rather than focusing exclusively on adult patients with diagnosed osteoporosis who do not have cancer.",maybe,maybe,"The abstract mentions MRONJ outcomes but does not provide details on the documentation of specific dental procedures, such as extractions, periodontal surgery, implants, or prosthetic treatments.",maybe,The abstract does not mention the inclusion of a control group of non-anti-resorptive medication users.,no,"The abstract suggests that the study is a review or commentary rather than a primary research study, and does not specify the study design as a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The abstract does not mention the temporal relationship between medication use and MRONJ development, or the duration of medication use.",maybe,"The abstract does not provide any information about the subject size of the study, so it is not possible to determine if it meets the requirement of having more than 100 participants.","The abstract mentions ""dental procedures"" but does not specify which types of invasive dental treatments were included, such as tooth extraction, implant placement, periodontal surgery, or removable prosthesis fabrication.",Exclude,"The abstract fails multiple critical screening criteria, including the specific medication requirement, population type, and study design. It lacks detailed documentation of dental procedures, temporal relationships, and does not focus exclusively on non-cancer patients with osteoporosis. Consequently, the paper does not meet the necessary requirements for inclusion in the study.",0.1
Republished: Medication-related osteonecrosis (MRONJ) of the mandible and maxilla,"L. Dunphy, G. Salzano, B. Gerber, J. Graystone",10.1136/dtb.2020.224455rep,https://doi.org/10.1136/dtb.2020.224455rep,Drug and therapeutics bulletin,0,2020,no,"The patient is 73 years old, which meets the adult requirement. However, the patient has metastatic breast cancer, which fails the criterion of focusing exclusively on adult patients with diagnosed osteoporosis who do not have cancer.",yes,yes,"The abstract clearly documents MRONJ following dental extractions, which meets the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"This is a case report with no control group, which fails the criterion of including a control group of non-anti-resorptive medication users.",no,"This is a case report, not an RCT, cohort study, or case-control study, which fails the criterion of having a study design of either a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"The abstract mentions ""six months following dental extractions"", which partially meets the criterion of clearly documenting both the temporal relationship between medication use and MRONJ development and the duration of medication use, though the full medication duration is not clearly stated.",no,"This is a single case report of one 73-year-old woman, which does not meet the requirement of having a subject size of more than 100 people.","The abstract mentions dental extractions, which meets the criterion of having an intervention of invasive dental treatment.",Exclude,"This case report fails multiple critical screening criteria, including using the wrong medication (zoledronic acid instead of Romosozumab), having a single patient instead of over 100 subjects, and involving a cancer patient when the criteria specifically exclude cancer patients. The study design as a case report and lack of a control group further disqualify it from meeting the systematic review requirements.",0.1
Medication-related osteonecrosis of the jaws: a prospective cross-sectional study in a Moroccan population.,"Chaimae Mahad, Abdellatif Benider, Ihsane Benyahya",10.56264/2658-865x.1093,https://doi.org/10.56264/2658-865x.1093,Health Sciences,0,2023,maybe,"The study included adult patients with an average age of 55, which partially meets the population type criterion. However, there is some uncertainty since the study did not explicitly exclude cancer patients.",yes,yes,"The study documented MRONJ outcomes and specific dental procedures (extractions), which meets this criterion.",no,"The study did not mention a control group, so this criterion is not met.",no,"The study was described as a ""descriptive cross-sectional prevalence study"", which does not match the required study designs of randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The study did not clearly document the temporal relationship between medication use and MRONJ development, nor did it specify the duration of medication use. This criterion is not met.",no,"The study only included 25 patients, which is well below the required 100 subjects. This is another clear failure of a critical criterion.","The abstract mentions that the study included dental extractions (55.6% of patients), which meets the requirement for invasive dental treatment.",Exclude,"The study fails critical screening criteria by using bisphosphonates instead of Romosozumab, having a sample size of only 25 patients, and lacking a control group. Multiple methodological limitations, including an inappropriate study design and insufficient temporal documentation, render the research unsuitable for systematic review inclusion. The fundamental mismatch with required intervention and population characteristics disqualifies the study from further consideration.",0.1
Relationship Between MRONJ (Medication Related Osteonecrosis of the Jaw) and Endodontic Theraphy,P. Noemi,10.31031/MRD.2020.05.000618,https://doi.org/10.31031/MRD.2020.05.000618,Modern Research in Dentistry,0,2020,no,"The abstract does not provide any specific information about patient age or osteoporosis diagnosis, and there is no mention of cancer exclusion criteria.",no,no,"While MRONJ is discussed, there's no indication of specific dental procedures or outcomes documentation, and the abstract appears to be a definitional paper rather than an outcomes study.",no,"The abstract does not mention control groups or study design, so it cannot be determined if this criterion is met.",no,"The abstract appears to be describing definitions and staging rather than presenting a specific study design, and it does not indicate if it's a RCT, cohort, or case-control study.",no,"The abstract does not provide any information about temporal relationships or medication duration, and it only mentions ""chronic treatment"" generally.",no,"The abstract does not provide any information about sample size, so it cannot be determined if the study meets the requirement of having more than 100 subjects.","While the abstract discusses MRONJ, it does not specify any particular dental interventions, and it appears to be a definitional/review paper rather than an intervention study.",Exclude,"The abstract fails to meet multiple critical screening criteria, particularly the requirement for Romosozumab intervention, with no evidence of specific dental treatments, patient population details, or study design. Lacking substantive information about subject size, control groups, and outcome documentation, the text appears to be a definitional review rather than a research study meeting the specified screening requirements.",0.1
Surgical treatment of MRONJ in oncology and non-oncology patients: a retrospective study,P. Garzino Demo,10.32388/QCAEWV,https://doi.org/10.32388/QCAEWV,-,0,2021,maybe,"The study includes both oncological and non-oncological patients, and does not specify the age range, so it only partially meets the population type criterion.",no,maybe,"The study documents MRONJ outcomes and surgical treatments, but does not specify the dental procedures that led to MRONJ, so it only partially meets the outcome documentation criterion.",no,"The study does not mention a control group, so it does not meet the control group criterion.",yes,"The study is clearly stated as a retrospective study, so it meets the study design criterion.",no,"The study does not clearly document the temporal relationship between medication use and MRONJ development or the duration of medication use, so it does not meet the temporal documentation criterion.",no,"The study includes 62 patients, which is less than the required 100 subjects, so it does not meet the subject size criterion.","While the study discusses surgical treatment of MRONJ, it does not specify that the patients underwent dental procedures, so it is unclear if the study meets the intervention criterion.",Exclude,"The study fails to meet multiple critical screening criteria, including the specific requirement for Romosozumab medication, insufficient sample size, and lack of a control group. While addressing medication-related osteonecrosis of the jaw, the research does not align with the precise methodological and population specifications needed for inclusion. The retrospective study's broad approach to patient selection and medication types prevents it from satisfying the systematic review's stringent requirements.",1.4
Dental bleaching: effect on composites,Reena Wadia,10.1038/s41415-020-1445-6,https://doi.org/10.1038/s41415-020-1445-6,British Dental Journal,0,2020,maybe,"While the study involves adult patients with MRONJ, it doesn't explicitly state they have diagnosed osteoporosis or exclude cancer patients, so the population type is unclear.",yes,yes,The study clearly documents MRONJ outcomes following specific dental procedures (implant-related treatments).,no,No control group is mentioned in the abstract.,maybe,"The study is described as a retrospective case series, which is not one of the specified acceptable study designs.",maybe,"While the study mentions monitoring and prevention, it doesn't clearly document the temporal relationship between medication use and MRONJ development or the duration of medication use.",no,"The study only includes 15 patients, well below the required 100+ subjects.","The study focuses on peri-implant MRONJ and includes implant removal and other surgical treatments, which meets the requirement for invasive dental treatment.",Exclude,"The study fails key screening criteria, including the specific requirement for Romosozumab medication and a minimum sample size of 100 patients. Critical shortcomings include an unspecified medication type, small patient cohort, and absence of a control group, rendering the research non-compliant with the predefined inclusion parameters.",1.4
Clinical management of maxillary osteonecrosis associated with antiresorptive medication (MRONJ): Presentation of clinical cases,"E. Rey, Sergio Armando Rodriguez Genta, S. Picardo",10.36013/jimsa.v1i1.23,https://doi.org/10.36013/jimsa.v1i1.23,-,0,2020,maybe,"The abstract doesn't explicitly state the age range or confirm osteoporosis diagnosis, and there is no mention of cancer status, so the population type is unclear.",no,no,"While MRONJ is discussed, the specific dental procedures leading to MRONJ are not documented in the abstract.",no,There is no mention of a control group in the abstract.,no,"The abstract appears to be a case series or experience report, which does not match the required study designs of randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The abstract only mentions ""long-term therapy"" without specific temporal relationships, and the duration of medication use is not clearly documented.",maybe,"The abstract does not specify the number of patients, so the subject size is unclear from the information provided.","While the abstract discusses MRONJ treatment, it doesn't clearly specify the dental procedures that led to MRONJ. It only mentions ""minimally invasive therapies"" for treatment, which does not meet the requirement for invasive dental treatment.",Exclude,"The abstract fails to meet multiple critical screening criteria, most notably using Bisphosphonates and Denosumab instead of the required Romosozumab medication. Significant gaps exist in documenting dental procedures, patient population characteristics, and study design, rendering the paper unsuitable for inclusion in the systematic review. The lack of a control group and unclear temporal documentation further disqualify the study from meeting the established screening requirements.",0.1
Determining the extent of osteotomy in patients with medication-related osteonecrosis of the jaw of the mandible: What are the factors for poor prognosis?,"S. Hayashida, M. Umeda",10.5794/jjoms.69.128,https://doi.org/10.5794/jjoms.69.128,Japanese Journal of Oral & Maxillofacial Surgery,0,2023,maybe,"The abstract mentions osteoporosis patients but also includes bone metastasis of malignant tumors, which is an exclusion criterion.",maybe,maybe,"MRONJ is discussed, but specific dental procedures and outcomes are not detailed.",maybe,No mention of control groups is made in the abstract.,maybe,The study design is not specified in the abstract.,maybe,No information is provided about the temporal relationships or duration of medication use.,maybe,No information is provided about the sample size of the study.,"While MRONJ is discussed, specific dental procedures are not mentioned.",Exclude,"The abstract fails to meet critical screening criteria, specifically lacking focus on Romosozumab and including cancer patients which violates the population type requirement. Multiple other screening criteria remain uncertain due to insufficient detail, rendering the study unlikely to qualify for inclusion based on the specified parameters.",1.4
Characteristics of patients with osteonecrosis of the jaw with oral versus intravenous bisphosphonate treatment,"Seung-Hun Lee, So-Young Choi, M. Bae, T. Kwon",10.1186/s40902-021-00310-w,https://doi.org/10.1186/s40902-021-00310-w,Maxillofacial plastic and reconstructive surgery,0,2021,maybe,"The study includes both osteoporosis patients and cancer patients. The abstract specifically mentions both groups and even compares them, which doesn't meet the criterion of focusing exclusively on non-cancer patients with osteoporosis.",maybe,yes,The study clearly documents MRONJ outcomes and mentions surgical treatments.,no,The abstract doesn't mention any control group of non-anti-resorptive medication users. The comparison is between oral and IV BP groups.,yes,"It's described as a retrospective study, which meets the criteria for acceptable study designs.",yes,The study documents duration of medication use (31.4 months for IV BP vs 53.1 months for oral BP) and appears to track temporal relationships.,yes,"The study includes 278 patients, well above the 100-person minimum requirement.","While the study discusses MRONJ, it doesn't explicitly state which dental procedures were performed. However, it mentions ""number of surgeries"" suggesting some dental interventions were involved.",Exclude,"The study fails key screening criteria by focusing on bisphosphonates instead of Romosozumab and including cancer patients alongside osteoporosis patients. While the study meets some methodological requirements like sample size and study design, critical exclusion criteria related to medication type and population specificity prevent its inclusion in the systematic review.",1.4
"“MRONJ: Dentistry and Physician Events under Bisphosphonates, Denosumab and Antiangiogenic Drugs”","Silvana Noemi P, Genta R, Eduardo R",10.51737/2766-4996.2020.023,https://doi.org/10.51737/2766-4996.2020.023,SunText Review of Dental Sciences,0,2020,no,The abstract does not specify that the study focused exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.,maybe,no,"While the abstract discusses MRONJ, it does not provide specific documentation of MRONJ outcomes following the dental procedures mentioned.",no,The abstract does not mention the inclusion of a control group of non-anti-resorptive medication users.,no,"The abstract appears to be a review or commentary rather than a primary research study, and does not describe a clear study design such as a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The abstract does not mention the temporal relationship between medication use and MRONJ development, or the duration of medication use.",no,"The abstract does not mention the number of study participants, so it cannot be confirmed if the subject size is more than 100 people.","While the abstract mentions dental treatment, it does not provide specific details about the types of invasive dental procedures performed, such as tooth extraction, implant placement, periodontal surgery, or removable prosthesis fabrication.",Exclude,"The abstract lacks critical details required by the screening criteria, including specific medication type, study design, population characteristics, and outcome documentation. Multiple key requirements are unmet, rendering the text insufficient for inclusion based on the comprehensive screening parameters. The text appears to be a general commentary rather than a research study meeting the specified methodological standards.",0.1
Antiresorptive and anti-angiogenic drug therapy in the pediatric population with reference to medication-related osteonecrosis of the jaw.,"W.S. McLaurin, B.J. Francisco, K. Hooker, N. Sheshashayee, M.T.F Khan, R.R. Triana, M.B. Rao, J.G. Pressey, D.G. Krishnan",10.1016/j.ijom.2023.11.001,https://doi.org/10.1016/j.ijom.2023.11.001,International Journal of Oral & Maxillofacial Surgery,0,2023,no,"The study focuses exclusively on pediatric patients (≤16 years) and does not include adult patients (≥18 years), which fails the criterion of focusing on adult patients with diagnosed osteoporosis.",yes,yes,"The study reports on osteonecrosis of the jaw (MRONJ) outcomes and documents the dental procedures, which meets the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"The study does not mention a control group of non-anti-resorptive medication users, which fails the criterion of including a control group.",yes,"The study design is a retrospective cohort study, which meets the criterion of being a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",yes,"The study documents the temporal relationship between medication use and MRONJ development (0-5.9 years from treatment to procedure) and the duration of medication use, which meets the criterion of clearly documenting both the temporal relationship and the duration of medication use.",yes,"The study includes 482 patients, which meets the criterion of having a subject size of more than 100 people.","The study mentions that 26 patients underwent invasive dental treatment, which meets the criterion of having an intervention of invasive dental treatment.",Exclude,"The study focuses on pediatric patients using various antiresorptive medications, which fundamentally differs from the specified criteria of adult osteoporosis patients using Romosozumab. Critical screening requirements were not met, including population type, medication specificity, and control group composition. Despite meeting some methodological criteria, the core population and intervention characteristics disqualify the study from inclusion.",0.1
Denosumab-Related Osteonecrosis of the Jaw with Actinomycosis Infection and Extensive Periosteal Reaction,"Elif Aslan, Gözde Işik, Elif Şener, B. Doğanavşargil, B. Özveri Koyuncu, Hülya Çankaya",10.5336/dentalsci.2023-99691,https://doi.org/10.5336/dentalsci.2023-99691,Turkiye Klinikleri Journal of Dental Sciences,0,2024,maybe,"The patient is an adult female, but the abstract doesn't specify if she has diagnosed osteoporosis, and there is no mention of cancer status, so there is insufficient information to fully assess this criterion.",no,maybe,"MRONJ outcomes are documented, but specific dental procedures are not detailed.",no,"This is a case report with no control group mentioned, so it fails to meet this criterion.",no,"This is a case report, which is not one of the accepted study designs, so it fails to meet this criterion.",maybe,"While MRONJ development is mentioned, the temporal relationship and duration of medication use are not clearly documented.",no,"This is a single case report, which fails to meet the minimum requirement of 100 subjects.","While dental screening is mentioned, no specific invasive dental treatment is described, and the abstract doesn't specify what dental procedures were performed.",Exclude,"The case report fails to meet multiple critical screening criteria, including using the wrong medication (denosumab instead of romosozumab), having an insufficient sample size, and lacking a control group. The study design as a single case report does not align with the required methodological standards for inclusion in the systematic review.",0.1
Prevention and treatment of osteonecrosis of the jaws using Pentoxifylline and tocopherol: A case series of patients under antiresorptive or antiangiogenic agents inducing osteonecrosis of the jaws,"Steven Perez, Alfred Seban",10.30574/wjarr.2023.17.3.0520,https://doi.org/10.30574/wjarr.2023.17.3.0520,World Journal of Advanced Research and Reviews,0,2023,maybe,"The abstract implies that the study focuses on adult patients, but does not explicitly state this. Additionally, there is no mention of the patients' cancer status.",yes,yes,"The abstract reports MRONJ outcomes following dental procedures, indicating that the study meets this criterion.",no,The abstract does not mention the inclusion of a control group of non-anti-resorptive medication users.,no,"The study appears to be a case series with 6 patients, which does not match the required study designs of randomized controlled trials, prospective/retrospective cohort studies, or case-control studies.",maybe,"The abstract mentions ""at least two years"" of bisphosphonate use, providing some temporal documentation, but the information is not comprehensive.",no,"The study only includes 6 patients, which is far below the minimum requirement of 100 subjects.","The abstract mentions ""jawbone surgery"" and ""surgical removal of necrotic exposed bone"", indicating that the study includes invasive dental treatment interventions.",Exclude,"The study fails critical screening criteria, particularly the requirement for Romosozumab as the intervention medication and a minimum sample size of 100 participants. With only six patients and focusing on different antiresorptive medications, the research does not meet the systematic review's fundamental methodological standards. Multiple key screening requirements were not satisfied, rendering the study ineligible for inclusion.",0.1
[Risk Factors of Antiresorptive Agent-Related Osteonecrosis of the Jaw in Prostate Cancer Patients with Bone Metastases].,"Kana Ito, Heisuke Iijima, M. Kumagai, Ryo Yabusaki, Yusuke Muro, Y. Shiraishi, M. Imamura, K. Yoshimura",10.14989/ActaUrolJap_69_5_125,https://doi.org/10.14989/ActaUrolJap_69_5_125,Hinyokika kiyo. Acta urologica Japonica,0,2023,no,"The study specifically focuses on patients with prostate cancer, which is explicitly excluded by the criteria. Additionally, while these are adult patients, they don't have primary osteoporosis.",maybe,maybe,"The study documents ARONJ outcomes, but it's unclear if these are specifically linked to documented dental procedures.",no,The study compares two different anti-resorptive medications (zoledronic acid vs. denosumab) but doesn't include a control group of non-users.,yes,"While not explicitly stated, this appears to be a retrospective cohort study based on the methodology described.",yes,"The study documents temporal relationships and duration of medication use, noting that ""longer duration of BRI exposure"" is associated with ARONJ risk.",yes,"The study includes 173 patients, which exceeds the minimum requirement of 100 subjects.","The abstract mentions ""dental treatment"" but doesn't specify the types, so it's unclear if these match the required interventions.",Exclude,"The study focuses on prostate cancer patients using zoledronic acid and denosumab, which fundamentally differs from the required criteria of osteoporosis patients using Romosozumab. Critical screening requirements were not met, including medication type, patient population, and control group composition. These substantial deviations render the study ineligible for inclusion in the systematic review.",0.1
MEDICATION-RELATED OSTEONECROSIS OF THE JAWS IN A PATIENT WITH RHEUMATOID ARTHRITIS AND SECONDARY INFECTION BY SERRATIA MARCESCENS,"Pedro Augusto Bulhões Curioso, G. Machado, A. Rocha, D. Fernandes, P. Vargas, A. S. Silva, M. Lopes",10.1016/j.oooo.2020.04.298,https://doi.org/10.1016/j.oooo.2020.04.298,"Oral surgery, oral medicine, oral pathology and oral radiology",0,2020,maybe,"The patient is 72 years old, which meets the age requirement. However, the patient has rheumatoid arthritis, not just osteoporosis, and it is unclear if osteoporosis is diagnosed. This partially meets the population type criterion.",yes,yes,"The paper clearly documents the MRONJ outcome following dental extraction, which meets this criterion.",no,"No control group is mentioned, which fails to meet this criterion.",no,"This is a case report, which does not meet the required study design types (randomized controlled trial, prospective/retrospective cohort study, or case-control study).",yes,"The paper documents the temporal relationship between the dental extraction (7 years ago) and the development of MRONJ (5 years), which meets this criterion.",no,"This is a single case report of one patient, which fails to meet the minimum requirement of 100 subjects.","The paper includes dental extraction and subsequent surgical resection, which meets the criterion for invasive dental treatment.",Exclude,"This single-patient case report fails multiple critical screening criteria, including using alendronate instead of the specified Romosozumab, lacking a control group, and not meeting the required subject size of 100 participants. Despite documenting a dental extraction and MRONJ outcome, the study design and medication do not align with the systematic review's specified requirements, rendering it ineligible for inclusion.",0.1
Precursor Radiographic Findings in Patients With Medication-Related Osteonecrosis of the Jaw.,"R. Kajihara, Eiji Kondo, Hironobu Fukuda, H. Sakai, T. Koike, H. Kurita",10.1016/j.joms.2024.04.015,https://doi.org/10.1016/j.joms.2024.04.015,Journal of oral and maxillofacial surgery,0,2024,no,The abstract does not specify the age range or whether patients have cancer. It only mentions patients with MRONJ.,yes,maybe,"The abstract mentions MRONJ outcomes following tooth extraction, partially meeting this criterion.",no,No information is provided about control groups.,no,The study design is not specified in the abstract.,maybe,"The abstract suggests some temporal relationship between extraction and MRONJ manifestation, but doesn't clearly document the duration of medication use.",no,The abstract provides no information about sample size.,"The abstract does mention tooth extraction as a risk factor, which meets this criterion.",Include,"The abstract lacks critical details about medication type, patient population, study design, and sample size, making comprehensive assessment against screening criteria challenging. While tooth extraction is mentioned as a risk factor for medication-related osteonecrosis of the jaw, insufficient information prevents definitive confirmation of most screening requirements. Only the dental intervention criterion is clearly addressed, with significant gaps in documentation of other key parameters.",2.5
MEDICATION-RELATED OSTEONECROSIS OF THE JAW AFTER A SINGLE DOSE OF DENOSUMAB,"Helena Santos, Maria Fernanda Calazans, A. L. Roza, Elllen Brilhante De Albuquerque Cortezzi, Bruno Augusto Benevenuto Andrade, M. Romañach, M. Agostini",10.1016/j.oooo.2019.06.294,https://doi.org/10.1016/j.oooo.2019.06.294,"Oral surgery, oral medicine, oral pathology and oral radiology",0,2020,yes,"The subject is an 85-year-old female with osteoporosis, meeting the adult age requirement and osteoporosis diagnosis. No cancer is mentioned.",no,maybe,"While MRONJ is documented, the temporal relationship to dental procedures is not clearly established in the abstract.",no,"As a case report, there is no control group mentioned.",no,"This is a case report, which is not one of the accepted study designs (RCT, cohort, or case-control study).",maybe,"The abstract documents the temporal relationship between medication use and MRONJ (4 months), but this is for denosumab, not romosozumab.",no,"This is a single case report of one patient, far below the required minimum of 100 subjects.","The abstract doesn't explicitly mention any invasive dental treatment. While there is mention of ""no use of removable denture,"" it doesn't specify if any dental procedures were performed.",Exclude,"This single-patient case report fails multiple critical screening criteria, including using denosumab instead of the specified romosozumab, lacking a control group, and not meeting the minimum subject size requirement. The study design as a case report and absence of a comprehensive dental intervention documentation further disqualify it from meeting the systematic review's inclusion standards.",0.1
Histopathological and Serum Biomarkers Analyses in MRONJ due to Periodontal Disease in Rats: Comparison of Zoledronic Acid and Denosumab,"Ceren Çoşkun, Revan Birke Koca Ünsal, M. Soluk Tekkeşin, Faruk Çelik, H. Ergen, S. Zeybek, K. Kayhan, M. Ünür",10.26650/experimed.1190912,https://doi.org/10.26650/experimed.1190912,Experimed,0,2023,no,"The study uses rats, not adult human patients, and includes cancer (prostate cancer induced), which fails the population type criterion.",maybe,maybe,"While MRONJ is mentioned, it's not clearly documented as an outcome, and the focus is on biomarkers rather than specific MRONJ outcomes.",yes,"The study includes a control group (CG) and saline group (SG), which meets the control group criterion.",no,"The study appears to be an experimental study in rats, which does not match the required study designs (RCT, cohort, or case-control).",no,"Some temporal information is provided (14th and 21st days), but this is for cancer induction, not medication use, and does not clearly meet the temporal documentation criterion.",no,"The study uses 40 rats, which is below the required subject size of more than 100 people.","The study involves periodontal disease induction, which is dental-related but not the type of invasive dental treatment specified in the criteria.",Exclude,"This rat study using zoledronic acid and denosumab fails multiple critical screening criteria, including the requirement for human subjects, romosozumab medication, and a specific study design. The research involves prostate cancer induction and uses a small sample size, which fundamentally disqualifies it from meeting the systematic review's inclusion requirements.",0.1
The Influence of Vitamin D Levels and Supplementation on the Treatment of Patients Affected by MRONJ,"Filip Michalak, M. Dominiak, Jan Kiryk, Paweł Popecki, Dominik Kubicki, Jacek Matys, K. Grzech-Leśniak",10.3390/app15020670,https://doi.org/10.3390/app15020670,Applied Sciences,0,2025,maybe,"While the study involves patients with MRONJ, it doesn't explicitly state that all patients are adults (≥18) or specify that they don't have cancer. The focus appears to be on patients with MRONJ rather than specifically osteoporosis patients.",yes,yes,"The study reports MRONJ outcomes following dental procedures, specifically tooth extraction.",yes,The study includes a control group (27 patients) that received no vitamin D supplementation.,yes,"This appears to be a clinical trial with experimental and control groups, meeting the criteria for acceptable study designs.",maybe,"While the study documents treatment duration (3 and 6 months), it doesn't clearly document the temporal relationship between medication use and MRONJ development.",no,"The study includes 64 patients, which is below the required 100 subjects.","The study includes tooth extraction and discusses dental procedures, though it's not the primary focus of the study.",Exclude,"The study fails critical screening criteria by not using Romosozumab and having an insufficient sample size of 64 patients, which falls short of the required 100 participants. While the research includes some acceptable elements like a control group and dental intervention documentation, the fundamental deviations from the specified screening requirements render the study non-compliant with the established protocol.",1.4
“Medication Related Osteonecrosis of the Jaw (MRONJ): Dental Atraumatic Treatment: Antiseptic Mouthwashes”.,"Amanda Phoon Nguyen, Leon Smith",10.46940/sjdor.01.1003,https://doi.org/10.46940/sjdor.01.1003,SunKrist Journal of Dentistry and Oral Research,0,2020,maybe,"The abstract does not mention anything about the study population, such as whether it focuses on adult patients with diagnosed osteoporosis who do not have cancer.",no,no,"While the abstract discusses MRONJ, it does not appear to be a study documenting specific outcomes following dental procedures.",maybe,The abstract does not mention the inclusion of a control group of non-anti-resorptive medication users.,no,"The abstract indicates that this is a review article rather than an original research study, so it does not meet the required study design criteria.",no,"The abstract does not provide any information about the temporal relationship between medication use and MRONJ development, or the duration of medication use.",maybe,"The abstract does not provide any information about the study size or number of participants, so it is not possible to determine if this criterion is met.","While the abstract discusses dental treatments, it appears to be a review of MRONJ treatment approaches rather than a study of specific dental interventions. Therefore, it does not clearly meet this criterion.",Exclude,"The abstract fails to meet multiple critical screening criteria, particularly the requirement for Romosozumab as the intervention and the need for an original research study design. Lacking specific details about patient population, dental interventions, and outcome documentation, the text appears to be a review article rather than a research study meeting the predefined screening requirements.",0.1
Difference in outcomes in surgical treatment of stage II-II MRONJ in oncological and non-oncological patients.,"P. Garzino Demo, G. Ramieri, M. Malandrino, F. Roccia, Alessandro Bojino",10.32388/7BRQ27,https://doi.org/10.32388/7BRQ27,Qeios,0,2021,maybe,"The study includes both oncological and non-oncological patients, and does not specify the age range of the participants.",no,no,"While MRONJ outcomes are documented, they are not following specific dental procedures. The focus is on treatment of existing MRONJ rather than studying dental procedures that lead to MRONJ.",no,There is no mention of a control group in the study.,yes,"The study is described as a ""retrospective study"", which meets the criterion for study design.",no,"There is no clear documentation of the temporal relationship between medication use and MRONJ development, or the duration of medication use.",no,"The study includes 62 patients, which is less than the required 100 subjects.","While the study discusses surgical treatment of MRONJ, it does not specifically study dental procedures as interventions. The focus is on treating MRONJ rather than studying dental procedures that lead to MRONJ.",Exclude,"The study fails to meet multiple critical screening criteria, including specific medication type, sample size, intervention focus, and outcome documentation. While a retrospective study examining MRONJ treatment, it does not align with the required parameters for investigating dental procedures and medication-related jaw necrosis in osteoporosis patients. The research diverges significantly from the predefined screening requirements.",0.1
Infections in cancer patients with medication-related osteonecrosis of the jaws,"Leandro Dorigan de Macedo, Victor Augusto Minari, L. M. A. Ramos Innocentini, Ana Laura Polizel Ranieri, Adriano Tadeu Dias Marangoni, Hilton Marcos Alves Ricz",10.15406/jcpcr.2022.13.00505,https://doi.org/10.15406/jcpcr.2022.13.00505,Journal of Cancer Prevention &amp; Current Research,0,2022,no,"The study specifically focuses on cancer patients, which is explicitly excluded in the screening criteria. The criteria require patients without cancer.",maybe,maybe,"While MRONJ outcomes are documented, the specific dental procedures leading to these outcomes are not clearly detailed in the abstract.",no,No control group is mentioned in the abstract. The study appears to only include patients with MRONJ.,yes,"The study is described as a ""retrospective, longitudinal and observational study,"" which would qualify as a retrospective cohort study.",maybe,"The study documents frequency of ZA use and number of doses at time of necrosis, but the temporal relationship isn't fully clear from the abstract.",no,"The study only includes 21 patients, well below the required minimum of 100 subjects.","While the study discusses MRONJ, it doesn't explicitly state whether the cases were triggered by specific dental procedures. The abstract mentions ""triggering factor"" as a variable but doesn't specify what these were.",Exclude,"The study fails key screening criteria by focusing on zoledronic acid in cancer patients, with a sample size of only 21 subjects, which does not meet the required 100-patient threshold. Critical exclusion factors include the wrong medication, inappropriate patient population, and absence of a control group, rendering the study non-compliant with the systematic review's specified screening requirements.",0.1
Implants in Patients Under Denosumab Prescription: Protocol for Dentists,"M. Martínez-García, Filippo Marianelli",-,-,-,0,2020,no,No information about study population characteristics is provided.,no,no,"While MRONJ is mentioned, there is no documentation of specific outcomes or procedures.",no,No information about study groups or controls is provided.,no,The abstract does not indicate any study design as it appears to be a reference list rather than a research study.,no,No temporal relationships or medication duration information is provided.,no,No information about study size is provided in this abstract.,"While the abstract mentions dental-related terms, it does not describe any specific dental interventions or procedures.",Exclude,"This document appears to be a list of abbreviations and acronyms related to osteonecrosis of the jaw, lacking any substantive research information. No screening criteria are met, as the text provides no details about study design, population, interventions, outcomes, or temporal relationships. The document fails to qualify as a research abstract and cannot be evaluated against the specified screening requirements.",0.1
Medication related osteonecrosis of the jaw a current,"Domah, Raunaq, Pravinchandra",-,-,-,0,2019,maybe,"The abstract mentions excluding patients with head and neck malignancy, which partially meets the population type criterion, but it doesn't specifically focus on osteoporosis patients.",no,no,"While MRONJ is discussed, this is not a study documenting specific outcomes, and it's a review of the condition and its management, so the outcome documentation criterion is not met.",no,"There is no mention of control groups, and this appears to be a review rather than a comparative study, so the control group criterion is not met.",no,"This is a review article, not a primary research study, and the abstract mentions that the current literature consists mainly of case series, case reports, and expert body opinions, so the study design criterion is not met.",no,"No specific temporal relationships or medication durations are documented, and this is a general review rather than a study tracking specific cases, so the temporal documentation criterion is not met.",no,"The abstract does not mention any specific study size, and it appears to be a review article rather than an original research study, so the subject size criterion is not met.","While dental procedures are implied in the context of MRONJ, the abstract doesn't describe specific interventions, and it's a review of the condition rather than a study of specific treatments, so the intervention criterion is not met.",Exclude,"This review article fails to meet multiple critical screening criteria, including specific intervention requirements, subject size, and study design specifications. The document provides a general overview of medication-related osteonecrosis of the jaw but lacks the precise research characteristics needed for inclusion, such as a defined patient population, control group, and documented outcomes. Consequently, the abstract does not satisfy the comprehensive screening requirements for the intended research study.",0.1
Idiopathic Incidence of MRONJ in Patients on Denosumab,M. Mirkhani,-,-,-,0,2017,no,"While some cases may involve osteoporosis patients, the abstract specifically mentions that ""the majority of cases were reported in posterior mandible of male patients receiving denosumab for treatment of prostate cancer."" This indicates cancer patients were included, which violates the criteria.",no,maybe,"While ONJ outcomes are documented, the specific dental procedures leading to these outcomes are not clearly detailed in the abstract.",no,No control group is mentioned in the abstract.,no,"This appears to be a case series/critical review rather than an RCT, cohort study, or case-control study.",maybe,"The abstract mentions that ""Denosumab-related ONJ appears to be independent of the duration of denosumab therapy,"" but doesn't clearly document temporal relationships for all cases.",no,"The study only identified 18 cases in their literature review, well below the required 100 subjects.","While the study discusses ONJ, it doesn't explicitly state whether these cases were related to dental procedures. The abstract doesn't specify the dental interventions involved.",Exclude,"The study focuses on denosumab-related osteonecrosis of the jaw, which fundamentally differs from the specified romosozumab intervention, and includes cancer patients, thus failing key screening criteria. With only 18 cases identified and lacking a control group, the research does not meet the required methodological standards for inclusion in the systematic review. Multiple critical screening requirements were not satisfied, rendering the study ineligible for further analysis.",0.1
"Medication-related osteonecrosis of the jaws ( MRONJ ) review : what Irish dentists need to know , from international guidelines to current controversies",-,-,-,-,0,2018,no,"The paper does not specifically mention adult patients or osteoporosis, and only mentions patients taking antiresorptive medications generally, so it does not meet the criterion of focusing exclusively on adult patients with diagnosed osteoporosis who do not have cancer.",no,no,"While MRONJ is discussed, the paper focuses on prevention guidelines and does not report specific outcomes from dental procedures, so it does not meet the criterion of reporting MRONJ outcomes following specific, documented dental procedures.",no,"The paper does not mention control groups, as it is a review paper and not an interventional study, so it does not meet the criterion of including a control group of non-anti-resorptive medication users.",no,"The paper is a literature review, not a primary research study, and does not match any of the required study designs (randomized controlled trial, prospective/retrospective cohort study, or case-control study), so it does not meet the criterion of having an appropriate study design.",no,"The paper does not document the temporal relationship between medication use and MRONJ development or the duration of medication use, as its focus is on prevention guidelines rather than outcome documentation, so it does not meet the criterion of clearly documenting both the temporal relationship and duration of medication use.",no,"The paper is a literature review, not a primary study, so it does not have a subject size of more than 100 people.","While dental procedures are mentioned, this is a review of prevention guidelines and does not study specific dental interventions, so it does not meet the criterion of having an intervention of invasive dental treatment.",Exclude,"This literature review on MRONJ prevention guidelines fails to meet multiple screening criteria, including specific intervention type, subject size, population characteristics, and study design requirements. The paper does not provide primary research data on Romosozumab, dental interventions, or patient outcomes, rendering it ineligible for inclusion in the systematic review.",0.1
"Medication-Related Osteonecrosis of the Jaw: a Brief Review, Treatment and Practical Guidelines for Dentists","Ioana-Aurița Albu-Stan, D. Albu, Diana Cerghizan, L. Eremie, K. Jánosi, M. Baloș, C. Copotoiu",10.1515/jim-2017-0046,https://doi.org/10.1515/jim-2017-0046,-,1,2017,no,"The abstract mentions both cancer patients (multiple myeloma, breast cancer, prostatic cancer) and osteoporosis patients, indicating that the study is not exclusively focused on non-cancer osteoporosis patients.",maybe,maybe,"The abstract discusses MRONJ outcomes generally, but does not specify documentation of outcomes following specific dental procedures. This indicates the study may partially meet or be uncertain about the requirement for outcome documentation.",maybe,"The abstract does not mention the inclusion of a control group of non-anti-resorptive medication users, so the reasoning for this criterion is uncertain.",no,"The abstract appears to be from a review article rather than a primary research study, and does not mention a specific study design. This suggests the study does not meet the requirement for a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"The abstract does not provide any information about the temporal relationship between medication use and MRONJ development or the duration of medication use, so the reasoning for this criterion is that the study fails to meet the requirement.",maybe,"The abstract does not mention the specific subject size of the study, so the reasoning for this criterion is uncertain.","While the abstract discusses jaw osteonecrosis following treatment, it does not specifically detail the dental procedures, only mentioning ""treatment"" generally. This suggests the study may partially meet or be uncertain about the requirement for invasive dental treatment.",Exclude,"The abstract fails multiple critical screening criteria, including the specific medication requirement, population type, and study design. It appears to be a general review of medication-related jaw osteonecrosis rather than a focused research study meeting the predefined screening parameters. Consequently, the paper does not align with the required methodological and population specifications.",1.4
Drug-induced jaw osteonecrosis,G. Donati,10.4081/ozone.2019.8698,https://doi.org/10.4081/ozone.2019.8698,-,2,2019,no,"The study includes both cancer and non-cancer patients, and is not exclusively focused on adult osteoporosis patients, which fails to meet the population type criterion.",yes,yes,"The study documents MRONJ outcomes following dental procedures, which meets the outcome documentation criterion.",no,"There is no mention of a control group in the study, which fails to meet the control group criterion.",no,"The study appears to be a case series/experimental protocol, which does not match the required study designs of randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"While medication use is mentioned, there is no clear documentation of the temporal relationship between medication use and MRONJ development, or the duration of medication use, which only partially meets or is unclear for this criterion.",no,"The study mentions 51 MRONJ cases diagnosed and a current experimental protocol including 14 patients, which fails to meet the requirement of a subject size of more than 100 people.","The abstract mentions tooth extraction, implant insertion, and prostheses, indicating that the study includes invasive dental treatment interventions.",Exclude,"The study fails critical screening criteria, particularly the requirement for Romosozumab as the intervention medication, with a small sample size of 51 cases and a mixed patient population including cancer patients. Multiple methodological limitations exist, including the absence of a control group, inappropriate study design, and incomplete documentation of temporal medication relationships. These significant deficiencies render the study non-compliant with the established screening requirements.",0.1
"Medication-related osteonecrosis of the jaws (MRONJ) review: what Irish dentists need to know, from international guidelines to current controversies",M. Cooney,-,-,-,1,2018,maybe,"No specific mention of adult patients or osteoporosis diagnosis, and no mention of cancer exclusion, so it cannot be determined if this criterion is met.",no,no,"While MRONJ is discussed, there's no specific documentation of outcomes following dental procedures, so it fails this criterion.",maybe,"No mention of control groups, so it cannot be determined if this criterion is met.",no,"This appears to be a review article rather than a primary research study, and does not match any of the required study designs, so it fails this criterion.",no,"No specific documentation of temporal relationships or medication duration, so it fails this criterion.",maybe,"No mention of study size or number of participants, so it cannot be determined if this criterion is met.","While dental procedures are mentioned, this appears to be a general review rather than a study of specific interventions, so it fails this criterion.",Exclude,"The abstract fails to meet multiple critical screening criteria, including specific intervention details, study design requirements, and outcome documentation. Lacking precise information about Romosozumab, patient population, control groups, and temporal medication relationships, the text appears to be a general review rather than a targeted research study. Consequently, the abstract does not satisfy the comprehensive screening requirements for the specified research parameters.",0.1
Medication-related osteonecrosis of the jaws (MRONJ) and the time to event: A retrospective study,"Cameron Y. S. Lee, Cameron Y. S. Lee, J. Suzuki",10.15761/docr.1000131,https://doi.org/10.15761/docr.1000131,-,0,2015,maybe,"While the study involves adult patients (implied by the context), it doesn't explicitly state that all patients are ≥18 years or that they have diagnosed osteoporosis. The cancer status is also not mentioned.",yes,yes,The study clearly documents MRONJ (referred to as ONJ) outcomes following specific dental procedures.,yes,"The abstract mentions ""controls"" in comparison to patients developing ONJ, indicating a control group.",yes,"The study is explicitly described as a ""retrospective cohort study.""",yes,The study documents both the temporal relationship (mean time to ONJ of 55.8 months) and duration of medication use (comparing duration between cases and controls).,yes,"The study includes 388 patients, well above the minimum requirement of 100.","The study clearly includes invasive dental treatments, specifically mentioning ""dentoalveolar surgery,"" tooth extraction, and dental implant surgery.",Exclude,"The study fails to meet the critical screening criterion of using Romosozumab, instead focusing on other antiresorptive medications. While the research demonstrates strong methodological qualities including a large sample size, clear documentation of dental procedures, and a robust study design, the absence of the specified intervention drug renders it ineligible for the systematic review. Uncertainty also exists regarding the precise population characteristics, further complicating potential inclusion.",1.4
Is periodontal disease a risk factor for the development of MRONJ,Danny Watts,10.1308/RCSFDJ.2015.126,https://doi.org/10.1308/RCSFDJ.2015.126,-,0,2015,maybe,"The abstract discusses patients with MRONJ but does not specify age or cancer status, so it cannot be determined if this criterion is met.",maybe,maybe,"While MRONJ is discussed, specific dental procedures and outcomes are not detailed, so it cannot be determined if this criterion is met.",maybe,"There is no mention of control groups, so it cannot be determined if this criterion is met.",no,"The abstract appears to be a general review or commentary rather than a primary research study, so it does not appear to meet this criterion.",maybe,"No specific temporal relationships or medication durations are mentioned, so it cannot be determined if this criterion is met.",maybe,"The abstract does not mention any specific study size, so it cannot be determined if this criterion is met.","While MRONJ is discussed, specific dental procedures are not mentioned, so it cannot be determined if this criterion is met.",Exclude,"The abstract fails to meet critical screening criteria, particularly the requirement for Romosozumab as the intervention medication. Multiple key elements remain undefined, including subject size, population characteristics, control group presence, and specific dental treatment details. The text appears to be a general review about MRONJ rather than a focused research study meeting the specified screening requirements.",0.1
Single low-dose of denosumab as a triggering agent for MRONJ development in a patient with osteoporosis Case report and mini-review,David Szaraz,-,-,-,0,-,maybe,"The patient is an adult with osteoporosis and no cancer, meeting this criterion. However, this is only one patient.",no,maybe,"The study does report MRONJ outcomes, but the specific dental procedures are not clearly documented in the abstract.",no,"As a case report, there is no control group mentioned.",no,"This is a case report with literature review, which does not match any of the required study designs (RCT, cohort, or case-control).",yes,"The abstract clearly documents the temporal relationship between medication use and MRONJ development, including the timing of different medications.",no,"This is a case report of a single patient, far below the required minimum of 100 subjects.","While the abstract mentions ""dental procedures,"" it doesn't specify which procedures were performed, so the information is not clearly documented.",Exclude,"The case report fails to meet multiple critical screening criteria, including the required intervention of romosozumab, minimum subject size of 100, and specified study design. With a single patient case and focus on denosumab instead of the target medication, the study does not align with the systematic review's inclusion requirements. Consequently, the paper would be excluded from further analysis.",0.1
Medication Related Osteonecrosis of Jaw: A Medical Oncologist’s Perspective,H. Darling,10.18314/JDMS.V1I1.1180,https://doi.org/10.18314/JDMS.V1I1.1180,-,1,2018,no,"The abstract primarily focuses on cancer patients with bone metastases, and while it mentions osteoporosis patients, they are not the primary focus. This indicates that the study does not meet the criterion of focusing exclusively on adult patients with diagnosed osteoporosis who do not have cancer.",maybe,maybe,"While MRONJ is discussed, specific dental procedures and outcomes are not detailed in the abstract, so the reasoning for this criterion is uncertain.",maybe,"No mention of control groups is made in the abstract, so the reasoning for this criterion is uncertain.",no,"This appears to be a review article rather than a primary research study, and no specific study design is mentioned, so the reasoning for this criterion is that the study does not meet the criterion of being a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",maybe,"No specific temporal relationships or medication duration details are provided in the abstract, so the reasoning for this criterion is uncertain.",maybe,"No specific subject size is mentioned in the abstract, so the reasoning for this criterion is uncertain.","While dental procedures are implied in the context of MRONJ, no specific dental interventions are described in the abstract, so the reasoning for this criterion is uncertain.",Exclude,"The abstract focuses on medication-related osteonecrosis of the jaw in cancer patients, primarily discussing bisphosphonates and denosumab, which diverges from the specified screening criteria of Romosozumab and osteoporosis patients. Multiple critical screening requirements are not met, including medication type, population focus, and study design, rendering the paper unsuitable for inclusion in the systematic review.",0.1
Medication Induced Osteonecrosis of the Jaws (MRONJ): an update for the General Medical Practitioner,"M. Yeoh, M. Suida, J. Reid",10.1016/j.bjoms.2016.11.031,https://doi.org/10.1016/j.bjoms.2016.11.031,-,1,2016,no,"While the abstract mentions patients with MRONJ, it doesn't specify the age groups or whether they have cancer.",no,no,"While MRONJ is mentioned as an outcome, there's no specific documentation of dental procedures leading to it.",no,No information about control groups is provided in the abstract.,no,The study design is not mentioned in the abstract.,no,No information about temporal relationships or medication duration is provided in the abstract.,no,No information is provided about the sample size of the study.,No specific mention of dental treatments or procedures is provided in the abstract.,Exclude,"The abstract lacks critical details required by the screening criteria, including specific medication type, sample size, dental interventions, population characteristics, study design, and outcome documentation. Insufficient information prevents definitive assessment of whether the study meets the comprehensive requirements for inclusion. Multiple key screening elements remain unaddressed, creating significant uncertainty about the study's eligibility.",1.4
THE ROLE OF PRE-MEDICATION DENTAL EVALUATION IN THE PREVENTION OF MEDICATION-RELATED OSTEONECROSIS OF THE JAW IN CANCER PATIENTS: THE MEMORIAL SLOAN KETTERING CANCER CENTER EXPERIENCE,"A. Owosho, Haley Freymiller, Adi Z. Sax, Kant Wu, S. Yom, J. Huryn, C. Estilo",10.1016/j.oooo.2017.05.497,https://doi.org/10.1016/j.oooo.2017.05.497,-,0,2017,no,"The abstract explicitly states that the study focuses on ""cancer patients"", which is a direct exclusion criterion as the screening criteria specify that the population should not have cancer.",maybe,maybe,The abstract mentions MRONJ but does not specify whether the study documented the outcomes following specific dental procedures.,maybe,No information is provided about the inclusion of a control group of non-anti-resorptive medication users.,maybe,The study design is not specified in the abstract.,maybe,"No information is provided about the temporal relationship between medication use and MRONJ development, or the duration of medication use.",maybe,No information is provided about the sample size of the study.,"The abstract mentions a ""pre-medication dental visit"" but does not specify whether this included invasive dental treatments such as tooth extraction, implant placement, periodontal surgery, or removable prosthesis fabrication.",Exclude,"The abstract fails key screening criteria by focusing on cancer patients and not specifying Romosozumab as the medication. Multiple critical screening requirements remain unaddressed, including subject size, intervention details, and outcome documentation. The study's population and medication focus disqualify it from meeting the established screening criteria.",0.1
Retrospective study on the bisphosphonate-related osteonecrosis of jaw.,"Yoon-Sic Han, In Woo Lee, Ho Lee, J. W. Suh, S. Kim, H. Myoung, S. Hwang, Jin-Young Choi, Jong-Ho Lee, P. Choung, Myung-Jin Kim, B. Seo",10.5125/JKAOMS.2011.37.6.470,https://doi.org/10.5125/JKAOMS.2011.37.6.470,-,1,2011,maybe,"While the study includes adult patients with osteoporosis, it's not explicitly stated that all patients are ≥18 years. However, given the context, this is likely met.",yes,yes,The study reports BRONJ outcomes following specific dental procedures.,yes,The study includes a control group of patients with osteomyelitis only (without osteoporosis).,yes,"This is a retrospective study, which meets the criteria for acceptable study designs.",maybe,"While the study period is mentioned (2004-2010), the abstract doesn't clearly document the temporal relationship between medication use and BRONJ development or the duration of medication use.",yes,"The study includes 200 patients total, with 64 having osteoporosis, exceeding the 100-person minimum.","The study includes surgical interventions including curettage, sequestrectomy, saucerization, decortications, and partial mandibulectomy.",Exclude,"The study primarily focuses on bisphosphonates rather than the specified Romosozumab, which represents a critical deviation from the screening criteria. While the research meets several other requirements such as subject size, intervention type, and study design, the fundamental mismatch in medication type renders the study non-compliant with the primary screening parameters. The lack of precise documentation of medication use and BRONJ development further complicates its potential inclusion.",1.4
Prevalence of Osteonecrosis of the Jaw Secondary to Antiresorptive Therapy in Patients Who have Undergone Dental Surgical Procedures: A Retrospective Study,"H. Ma, Izarra A, Bronstein D, Suzuki Jb",10.19070/2377-8075-1600072,https://doi.org/10.19070/2377-8075-1600072,-,1,2016,no,"No information about patient population, age, or osteoporosis diagnosis is provided in the abstract, so there is no way to determine if the study focused exclusively on adult patients (≥18 years) with diagnosed osteoporosis who do not have cancer.",no,no,"No outcomes or MRONJ documentation is mentioned in the abstract, so there is no information to assess whether the study reported MRONJ outcomes following specific, documented dental procedures.",no,"No information about study groups or controls is provided in the abstract, so there is no way to determine if the study included a control group of non-anti-resorptive medication users.",no,"The study design is not mentioned in the abstract, so there is no information to assess whether the study design was a randomized controlled trial, prospective/retrospective cohort study, or case-control study.",no,"No temporal relationships or medication duration information is provided in the abstract, so there is no way to determine if the study clearly documented both the temporal relationship between medication use and MRONJ development and the duration of medication use.",no,"No information about sample size is provided in the abstract, so there is no way to determine if the study had a subject size of more than 100 people.","While the authors are from periodontology departments, suggesting a dental focus, no specific dental interventions are mentioned in the abstract, so there is no information to assess whether the subjects had an intervention of invasive dental treatment.",Exclude,"No substantive information is provided to assess any of the screening criteria, as this appears to be merely an author affiliation list without an actual research abstract. The lack of details about intervention, population, study design, and outcomes makes it impossible to determine if the study meets the specified inclusion requirements. Consequently, the document cannot be evaluated for potential inclusion based on the current information.",0.1
"Medication-related osteonecrosis of the jaw : occurence, risk factors, pathogenesis & treatment",F. Hallmer,10.24834/2043/28144,https://doi.org/10.24834/2043/28144,-,0,2019,maybe,"The abstract does not clearly indicate the patient age or osteoporosis diagnosis, and there is no mention of cancer status, so it cannot be determined if the population type criterion is met.",no,no,"The abstract does not mention any MRONJ outcomes or dental procedures, so it cannot be determined if the outcome documentation criterion is met.",maybe,"The abstract does not mention any control groups, so it cannot be determined if the control group criterion is met.",maybe,"The study design is not mentioned in the available abstract, so it cannot be determined if the study design criterion is met.",no,"The abstract does not mention any temporal relationships or medication duration, so it cannot be determined if the temporal documentation criterion is met.",maybe,"The abstract does not provide any information about the sample size, so it cannot be determined if the study meets the requirement of having more than 100 subjects.","The abstract does not mention any dental treatments or procedures, so it cannot be determined if the intervention criterion is met.",Exclude,"The abstract focuses on bisphosphonates and denosumab, critically failing the primary screening criterion of studying Romosozumab. Insufficient information is provided to assess other key screening requirements, including subject size, dental interventions, population characteristics, and study design. The lack of specific details about the study prevents comprehensive evaluation against the established screening criteria.",0.1
Medication related osteonecrosis of the jaws : a case serial study,"M. Aksoy, G. Koçer, M. Koçer, T. Baykul",-,-,-,0,2017,no,"The study focuses exclusively on cancer patients (breast cancer, prostate cancer, multiple myeloma), which explicitly fails the criterion requiring non-cancer patients.",maybe,maybe,"MRONJ outcomes are documented, but the specific dental procedures are not clearly documented, so this criterion is only partially met.",no,"There is no mention of a control group, so this criterion is not met.",yes,"The study is described as a retrospective evaluation, which meets the criterion as retrospective cohort studies are acceptable.",yes,"The study clearly documents the treatment duration (36 months median) and the time from medication start to MRONJ development (6.5 months median), so this criterion is met.",no,"The study includes 35 patients, which is below the required 100 subjects, so it fails to meet the minimum subject size requirement.","The abstract mentions ""surgical procedures"" and ""trauma from dentures"", which suggests the study includes invasive dental treatments, but the specific procedures are not clearly specified, so this criterion is only partially met.",Exclude,"The study focuses on cancer patients using zoledronic acid, which fundamentally differs from the required Romosozumab intervention and non-cancer patient population. With a small sample size of 35 patients and no control group, the research fails to meet multiple critical screening criteria for inclusion in the systematic review. The core methodological requirements are not satisfied, rendering the study ineligible for further analysis.",0.1
"Risikofaktoren und Therapie von Antiresorptiva-assoziierten Kiefernekrosen, eine retrospektive Analyse an der Universitätsmedizin Göttingen",J. Gollasch,10.53846/goediss-9847,https://doi.org/10.53846/goediss-9847,-,0,-,maybe,"The study includes adult patients with osteoporosis (26.1%), but also includes many cancer patients (majority of cases). The study population is mixed and not exclusively osteoporosis patients.",maybe,maybe,"While MRONJ (ARONJ) outcomes are documented, the specific dental procedures leading to these outcomes are not clearly detailed in the abstract.",maybe,The abstract doesn't mention a control group of non-anti-resorptive medication users.,yes,"The study is described as a retrospective study, which meets the criteria.",yes,"The study documents the temporal relationship between medication use and ARONJ development, with specific durations mentioned (e.g., 36 months for zolendronate).",yes,"The study includes 128 patients, which exceeds the minimum requirement of 100.","While the study discusses ARONJ treatment, it doesn't clearly specify whether the patients underwent invasive dental procedures. The abstract focuses more on treatment of ARONJ rather than dental procedures that led to it.",Exclude,"The study fails to meet critical screening criteria, particularly the requirement for Romosozumab as the intervention medication, instead focusing on bisphosphonates and denosumab. While the study includes a sufficient sample size and uses a retrospective design, the mixed patient population with significant cancer representation and lack of clear documentation of dental procedures further disqualifies it from meeting the specified screening requirements.",1.4
Características radiográficas em pacientes oncológicos com indicação de extração dentária e em risco para osteonecrose dos maxilares induzida por medicamentos,Hugo Gaêta Araújo,10.47749/t/unicamp.2020.1235601,https://doi.org/10.47749/t/unicamp.2020.1235601,-,0,-,no,"The study specifically mentions ""oncologic patients"", which explicitly violates the criterion requiring non-cancer patients.",yes,yes,"The study clearly documents MRONJ outcomes following dental extractions, which meets the outcome documentation criterion.",yes,"The study includes age-, gender-, and extracted tooth-matching healthy patients as controls, which meets the control group criterion.",maybe,"The study is described as a ""within-patient study"" with retrospective analysis, which is not clearly a cohort or case-control study as specified in the criterion.",maybe,"While the study examines extraction sites, it doesn't clearly document the temporal relationship between medication use and MRONJ development, which only partially meets the temporal documentation criterion.",no,"The study includes 41 patients with 288 extraction sites, but the actual patient count is below 100, which does not meet the subject size criterion.","The study focuses on dental extraction sites, which meets the intervention criterion.",Exclude,"The study fails key screening criteria due to using intravenous antiresorptive treatment instead of Romosozumab and focusing on oncologic patients rather than non-cancer patients. Additionally, the sample size of 41 patients falls short of the required 100 participants, rendering the study ineligible for inclusion in the systematic review.",0.1
PMS2 Alendronate Use and the Risk of Osteonecrosis of Jaw in Taiwan,"Wen-Cheng Huang, P. Lu, C. Hsieh",10.1016/j.jval.2012.08.405,https://doi.org/10.1016/j.jval.2012.08.405,-,0,2012,maybe,"The study focuses on adult women with osteoporosis, but doesn't explicitly exclude cancer patients. However, the context suggests these are typical osteoporosis patients.",maybe,maybe,"While ONJ outcomes are documented using specific ICD-9 codes and sequestrectomy codes, the abstract doesn't clearly specify the dental procedures leading to these outcomes.",no,The study compares two different medications (alendronate vs raloxifene) but doesn't include a control group of non-anti-resorptive medication users.,yes,"This is a retrospective cohort study, which meets the criteria.",yes,"The study documents temporal relationships, requiring 90 days of stable medication use and following outcomes for 3 years.",yes,"The study includes 23,158 women (18,504 alendronate + 4,654 raloxifene), well above the 100-person minimum.","While the study looks at ONJ outcomes, it doesn't explicitly state whether these were triggered by specific dental procedures. The abstract mentions ""oral condition"" but doesn't detail the dental interventions.",Exclude,"The study fails to meet key screening criteria, primarily due to using alendronate and raloxifene instead of the specified romosozumab medication. While the research demonstrates a robust sample size and appropriate study design, critical deviations from the required intervention and control group specifications render the abstract non-compliant with the established screening requirements.",1.4
Quantificação das alterações identificadas em tomografia de feixe cônico na osteonecrose dos maxilares relacionada a medicações,Mariel Ruivo Biancardi,10.11606/d.25.2022.tde-08062022-091915,https://doi.org/10.11606/d.25.2022.tde-08062022-091915,-,0,-,no,"The study includes cancer patients, which is explicitly mentioned, and does not specify the age range of the participants.",no,no,"While MRONJ is documented, specific dental procedures are not mentioned, and the focus is on imaging findings rather than procedure-related outcomes.",no,"There is no mention of a control group, and the study compares quadrants with and without MRONJ but not medication users vs non-users.",maybe,"The study appears to be an observational study analyzing CBCT images, but it is not clearly specified if it's a prospective/retrospective cohort or case-control study.",maybe,"The abstract mentions ""period that the medication was used"", but the temporal relationship with MRONJ development is not clearly documented.",no,"The study includes 27 patients with 92 bone quadrants, which is below the required minimum of 100 subjects.","The abstract does not explicitly mention any dental procedures, and while it discusses MRONJ, it focuses on CBCT imaging rather than dental interventions.",Exclude,"The study fails multiple critical screening criteria, including the specific requirement for Romosozumab medication, insufficient sample size, and inclusion of cancer patients. Key disqualifying factors include the lack of a control group, absence of specific dental intervention documentation, and a focus on imaging findings rather than procedure-related outcomes. These fundamental deviations from the screening requirements render the study unsuitable for inclusion in the systematic review.",0.1
Multicenter case registry study on medication-related osteonecrosis of the jaw in advanced cancer patients.,"M. Schiødt, S. Vadhan-Raj, M. Chambers, O. Nicolatou‐Galitis, C. Politis, R. Coropciuc, S. Fedele, Danielle D. Jandial, Jeffrey Zhang, Haijun Ma, D. Saunders",10.1200/JCO.2016.34.15_SUPPL.E21663,https://doi.org/10.1200/JCO.2016.34.15_SUPPL.E21663,-,0,2016,no,The abstract fragment does not specify the age range or whether the patients had cancer.,no,no,"The abstract defines MRONJ and mentions exposed jawbone/bone that can be probed through a fistula, but does not specify which dental procedures were documented.",no,No information about control groups is provided in the available abstract text.,no,The study design is not mentioned in the available abstract fragment.,no,No information about temporal relationships or medication duration is provided in the available text.,no,The abstract fragment does not provide any information about the sample size of the study.,"While the abstract discusses MRONJ, which is typically associated with dental procedures, it does not explicitly state which dental interventions were studied.",Exclude,"The incomplete abstract fragment provides insufficient information to assess critical screening criteria, including specific medication use, patient population, intervention details, and study design. Without a complete abstract, it is impossible to definitively determine whether the study meets the required inclusion parameters for Romosozumab, dental interventions, and MRONJ outcomes.",1.4
"BEST ABSTRACT PRESENTATION OP 1 Increased humoral immune response after vaccination with mRNA-1273 vs BNT162b2 in patients with inflammatory rheumatic diseases Comparison of anti-fracture effectiveness of denosumab versus bisphosphonates in a registry-based, real-world cohort study",-,-,-,-,0,-,yes,"The population consists of osteoporosis patients (median age 69 years), and there is no mention of cancer patients, so the study appears to meet this criterion.",maybe,maybe,"The study documents ONJ outcomes, but the specific dental procedures leading to it are unclear, so the criterion is only partially met.",yes,"The study compares denosumab vs bisphosphonates, which meets the requirement for a control group, though not exactly as specified in the criteria.",yes,"The study is described as a ""registry-based cohort study"", which meets the acceptable study design criteria.",maybe,"The study mentions ""cumulative duration"" of treatment, but the specific temporal relationships between medication and ONJ are not clearly documented, so the criterion is only partially met.",yes,"The study includes 9,956 registered patients, which clearly exceeds the minimum requirement of 100 subjects.","While ONJ (osteonecrosis of the jaw) is discussed, specific dental procedures are not detailed, so it is unclear if the study specifically looks at invasive dental treatments.",Exclude,"The study primarily focuses on denosumab and bisphosphonates for osteoporosis treatment, which fundamentally differs from the specified Romosozumab intervention. While the research includes a large patient population and meets several methodological criteria, the critical mismatch in medication type renders the study non-compliant with the primary screening requirements. Multiple other criteria are only partially met or lack sufficient detail for definitive assessment.",1.4